id,claim,sentence,evidence,role
0,"1,000 genomes project enables mapping of genetic sequence variation consisting of rare variants with larger penetrance effects than common variants.","Genome-wide association studies (GWAS) have now identified at least 2,000 common variants that appear associated with common diseases or related traits (http://www.genome.gov/gwastudies), hundreds of which have been convincingly replicated.",False,BACKGROUND
1,"1,000 genomes project enables mapping of genetic sequence variation consisting of rare variants with larger penetrance effects than common variants.","It is generally thought that the associated markers reflect the effect of a nearby common (minor allele frequency >0.05) causal site, which is associated with the marker, leading to extensive resequencing efforts to find causal sites.",False,BACKGROUND
2,"1,000 genomes project enables mapping of genetic sequence variation consisting of rare variants with larger penetrance effects than common variants.","We propose as an alternative explanation that variants much less common than the associated one may create ""synthetic associations"" by occurring, stochastically, more often in association with one of the alleles at the common site versus the other allele.",True,BACKGROUND
3,"1,000 genomes project enables mapping of genetic sequence variation consisting of rare variants with larger penetrance effects than common variants.","Although synthetic associations are an obvious theoretical possibility, they have never been systematically explored as a possible explanation for GWAS findings.",False,BACKGROUND
4,"1,000 genomes project enables mapping of genetic sequence variation consisting of rare variants with larger penetrance effects than common variants.","Here, we use simple computer simulations to show the conditions under which such synthetic associations will arise and how they may be recognized.",False,BACKGROUND
5,"1,000 genomes project enables mapping of genetic sequence variation consisting of rare variants with larger penetrance effects than common variants.","We show that they are not only possible, but inevitable, and that under simple but reasonable genetic models, they are likely to account for or contribute to many of the recently identified signals reported in genome-wide association studies.",True,RESULTS
6,"1,000 genomes project enables mapping of genetic sequence variation consisting of rare variants with larger penetrance effects than common variants.","We also illustrate the behavior of synthetic associations in real datasets by showing that rare causal mutations responsible for both hearing loss and sickle cell anemia create genome-wide significant synthetic associations, in the latter case extending over a 2.5-Mb interval encompassing scores of ""blocks"" of associated variants.",False,RESULTS
7,"1,000 genomes project enables mapping of genetic sequence variation consisting of rare variants with larger penetrance effects than common variants.","In conclusion, uncommon or rare genetic variants can easily create synthetic associations that are credited to common variants, and this possibility requires careful consideration in the interpretation and follow up of GWAS signals.",True,RESULTS
8,1/2000 in UK have abnormal PrP positivity.,"OBJECTIVES To carry out a further survey of archived appendix samples to understand better the differences between existing estimates of the prevalence of subclinical infection with prions after the bovine spongiform encephalopathy epizootic and to see whether a broader birth cohort was affected, and to understand better the implications for the management of blood and blood products and for the handling of surgical instruments.   
",False,OBJECTIVE
9,1/2000 in UK have abnormal PrP positivity.,"DESIGN Irreversibly unlinked and anonymised large scale survey of archived appendix samples.   
",False,METHODS
10,1/2000 in UK have abnormal PrP positivity.,"SETTING Archived appendix samples from the pathology departments of 41 UK hospitals participating in the earlier survey, and additional hospitals in regions with lower levels of participation in that survey.   ",False,METHODS
11,1/2000 in UK have abnormal PrP positivity.,"SAMPLE 32,441 archived appendix samples fixed in formalin and embedded in paraffin and tested for the presence of abnormal prion protein (PrP).   
",False,METHODS
12,1/2000 in UK have abnormal PrP positivity.,"RESULTS Of the 32,441 appendix samples 16 were positive for abnormal PrP, indicating an overall prevalence of 493 per million population (95% confidence interval 282 to 801 per million).",True,RESULTS
13,1/2000 in UK have abnormal PrP positivity.,"The prevalence in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per million) and was similar in both sexes and across the three broad geographical areas sampled.",False,RESULTS
14,1/2000 in UK have abnormal PrP positivity.,"Genetic testing of the positive specimens for the genotype at PRNP codon 129 revealed a high proportion that were valine homozygous compared with the frequency in the normal population, and in stark contrast with confirmed clinical cases of vCJD, all of which were methionine homozygous at PRNP codon 129.   
",False,RESULTS
15,1/2000 in UK have abnormal PrP positivity.,"CONCLUSIONS This study corroborates previous studies and suggests a high prevalence of infection with abnormal PrP, indicating vCJD carrier status in the population compared with the 177 vCJD cases to date.",False,CONCLUSIONS
16,1/2000 in UK have abnormal PrP positivity.,These findings have important implications for the management of blood and blood products and for the handling of surgical instruments.,False,CONCLUSIONS
17,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,BACKGROUND The heritable haemoglobinopathy alpha(+)-thalassaemia is caused by the reduced synthesis of alpha-globin chains that form part of normal adult haemoglobin (Hb).,False,OBJECTIVE
18,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,Individuals homozygous for alpha(+)-thalassaemia have microcytosis and an increased erythrocyte count.,True,OBJECTIVE
19,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"Alpha(+)-thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count.",False,OBJECTIVE
20,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"We tested the hypothesis that the erythrocyte indices associated with alpha(+)-thalassaemia homozygosity provide a haematological benefit during acute malaria.   
",False,OBJECTIVE
21,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,METHODS AND FINDINGS Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by alpha(+)-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease.,False,METHODS
22,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,We observed a reduction in median erythrocyte count of approximately 1.5 x 10(12)/l in all children with acute falciparum malaria relative to values in community children (p < 0.001).,False,RESULTS
23,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count.,False,RESULTS
24,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,This model predicted that children homozygous for alpha(+)-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 x 10(12)/l as a result of the reduced mean cell Hb in homozygous alpha(+)-thalassaemia.,False,RESULTS
25,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"In addition, children homozygous for alpha(+)-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA.",False,RESULTS
26,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"We estimated that the haematological profile in children homozygous for alpha(+)-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24-1.12, p = 0.09).   
",True,RESULTS
27,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,CONCLUSIONS The increased erythrocyte count and microcytosis in children homozygous for alpha(+)-thalassaemia may contribute substantially to their protection against SMA.,True,CONCLUSIONS
28,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum.,False,CONCLUSIONS
29,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,"This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia.",False,CONCLUSIONS
30,A high microerythrocyte count raises vulnerability to severe anemia in homozygous alpha (+)- thalassemia trait subjects.,Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.,False,CONCLUSIONS
31,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.","OBJECTIVES To carry out a further survey of archived appendix samples to understand better the differences between existing estimates of the prevalence of subclinical infection with prions after the bovine spongiform encephalopathy epizootic and to see whether a broader birth cohort was affected, and to understand better the implications for the management of blood and blood products and for the handling of surgical instruments.   
",False,OBJECTIVE
32,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.","DESIGN Irreversibly unlinked and anonymised large scale survey of archived appendix samples.   
",False,METHODS
33,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.","SETTING Archived appendix samples from the pathology departments of 41 UK hospitals participating in the earlier survey, and additional hospitals in regions with lower levels of participation in that survey.   ",False,METHODS
34,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.","SAMPLE 32,441 archived appendix samples fixed in formalin and embedded in paraffin and tested for the presence of abnormal prion protein (PrP).   
",False,METHODS
35,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.","RESULTS Of the 32,441 appendix samples 16 were positive for abnormal PrP, indicating an overall prevalence of 493 per million population (95% confidence interval 282 to 801 per million).",True,RESULTS
36,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.","The prevalence in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per million) and was similar in both sexes and across the three broad geographical areas sampled.",False,RESULTS
37,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.","Genetic testing of the positive specimens for the genotype at PRNP codon 129 revealed a high proportion that were valine homozygous compared with the frequency in the normal population, and in stark contrast with confirmed clinical cases of vCJD, all of which were methionine homozygous at PRNP codon 129.   
",False,RESULTS
38,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.","CONCLUSIONS This study corroborates previous studies and suggests a high prevalence of infection with abnormal PrP, indicating vCJD carrier status in the population compared with the 177 vCJD cases to date.",False,CONCLUSIONS
39,"A total of 1,000 people in the UK are asymptomatic carriers of vCJD infection.",These findings have important implications for the management of blood and blood products and for the handling of surgical instruments.,False,CONCLUSIONS
40,ADAR1 binds to Dicer to cleave pre-miRNA.,Adenosine deaminases acting on RNA (ADARs) are involved in RNA editing that converts adenosine residues to inosine specifically in double-stranded RNAs.,False,BACKGROUND
41,ADAR1 binds to Dicer to cleave pre-miRNA.,"In this study, we investigated the interaction of the RNA editing mechanism with the RNA interference (RNAi) machinery and found that ADAR1 forms a complex with Dicer through direct protein-protein interaction.",True,BACKGROUND
42,ADAR1 binds to Dicer to cleave pre-miRNA.,"Most importantly, ADAR1 increases the maximum rate (Vmax) of pre-microRNA (miRNA) cleavage by Dicer and facilitates loading of miRNA onto RNA-induced silencing complexes, identifying a new role of ADAR1 in miRNA processing and RNAi mechanisms.",True,RESULTS
43,ADAR1 binds to Dicer to cleave pre-miRNA.,"ADAR1 differentiates its functions in RNA editing and RNAi by the formation of either ADAR1/ADAR1 homodimer or Dicer/ADAR1 heterodimer complexes, respectively.",False,CONCLUSIONS
44,ADAR1 binds to Dicer to cleave pre-miRNA.,"As expected, the expression of miRNAs is globally inhibited in ADAR1(-/-) mouse embryos, which, in turn, alters the expression of their target genes and might contribute to their embryonic lethal phenotype.",False,CONCLUSIONS
45,AIRE is expressed in some skin tumors.,Expression of the intermediate filament protein keratin 17 (K17) is robustly upregulated in inflammatory skin diseases and in many tumors originating in stratified and pseudostratified epithelia.,False,BACKGROUND
46,AIRE is expressed in some skin tumors.,"We report that autoimmune regulator (Aire), a transcriptional regulator, is inducibly expressed in human and mouse tumor keratinocytes in a K17-dependent manner and is required for timely onset of Gli2-induced skin tumorigenesis in mice.",True,BACKGROUND
47,AIRE is expressed in some skin tumors.,"The induction of Aire mRNA in keratinocytes depends on a functional interaction between K17 and the heterogeneous nuclear ribonucleoprotein hnRNP K. Further, K17 colocalizes with Aire protein in the nucleus of tumor-prone keratinocytes, and each factor is bound to a specific promoter region featuring an NF-κB consensus sequence in a relevant subset of K17- and Aire-dependent proinflammatory genes.",False,RESULTS
48,AIRE is expressed in some skin tumors.,"These findings provide radically new insight into keratin intermediate filament and Aire function, along with a molecular basis for the K17-dependent amplification of inflammatory and immune responses in diseased epithelia.",False,RESULTS
49,ALDH1 expression is associated with better breast cancer outcomes.,Application of stem cell biology to breast cancer research has been limited by the lack of simple methods for identification and isolation of normal and malignant stem cells.,False,BACKGROUND
50,ALDH1 expression is associated with better breast cancer outcomes.,"Utilizing in vitro and in vivo experimental systems, we show that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties.",False,BACKGROUND
51,ALDH1 expression is associated with better breast cancer outcomes.,These cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model.,False,BACKGROUND
52,ALDH1 expression is associated with better breast cancer outcomes.,"In breast carcinomas, high ALDH activity identifies the tumorigenic cell fraction, capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor.",False,BACKGROUND
53,ALDH1 expression is associated with better breast cancer outcomes.,"In a series of 577 breast carcinomas, expression of ALDH1 detected by immunostaining correlated with poor prognosis.",True,BACKGROUND
54,ALDH1 expression is associated with better breast cancer outcomes.,These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts.,False,BACKGROUND
55,ALDH1 expression is associated with poorer prognosis in breast cancer.,Application of stem cell biology to breast cancer research has been limited by the lack of simple methods for identification and isolation of normal and malignant stem cells.,False,BACKGROUND
56,ALDH1 expression is associated with poorer prognosis in breast cancer.,"Utilizing in vitro and in vivo experimental systems, we show that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties.",False,BACKGROUND
57,ALDH1 expression is associated with poorer prognosis in breast cancer.,These cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model.,False,BACKGROUND
58,ALDH1 expression is associated with poorer prognosis in breast cancer.,"In breast carcinomas, high ALDH activity identifies the tumorigenic cell fraction, capable of self-renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor.",False,BACKGROUND
59,ALDH1 expression is associated with poorer prognosis in breast cancer.,"In a series of 577 breast carcinomas, expression of ALDH1 detected by immunostaining correlated with poor prognosis.",True,BACKGROUND
60,ALDH1 expression is associated with poorer prognosis in breast cancer.,These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts.,False,BACKGROUND
61,AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.,"Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in a number of organs, including the lungs1.",False,BACKGROUND
62,AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.,Cellular metabolism regulates tissue repair and remodelling responses to injury2-4.,False,BACKGROUND
63,AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.,AMPK is a critical sensor of cellular bioenergetics and controls the switch from anabolic to catabolic metabolism5.,False,BACKGROUND
64,AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.,"However, the role of AMPK in fibrosis is not well understood.",False,BACKGROUND
65,AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.,"Here, we demonstrate that in humans with idiopathic pulmonary fibrosis (IPF) and in an experimental mouse model of lung fibrosis, AMPK activity is lower in fibrotic regions associated with metabolically active and apoptosis-resistant myofibroblasts.",False,RESULTS
66,AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.,"Pharmacological activation of AMPK in myofibroblasts from lungs of humans with IPF display lower fibrotic activity, along with enhanced mitochondrial biogenesis and normalization of sensitivity to apoptosis.",True,RESULTS
67,AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.,"In a bleomycin model of lung fibrosis in mice, metformin therapeutically accelerates the resolution of well-established fibrosis in an AMPK-dependent manner.",True,CONCLUSIONS
68,AMP-activated protein kinase (AMPK) activation increases inflammation-related fibrosis in the lungs.,"These studies implicate deficient AMPK activation in non-resolving, pathologic fibrotic processes, and support a role for metformin (or other AMPK activators) to reverse established fibrosis by facilitating deactivation and apoptosis of myofibroblasts.",True,CONCLUSIONS
69,APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.,"Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.",False,BACKGROUND
70,APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.,"Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-β (Aβ) peptides, and that they displayed GABAergic neuron degeneration.",True,BACKGROUND
71,APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.,"ApoE4 increased Aβ production in human, but not in mouse, neurons.",False,RESULTS
72,APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.,"Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.",False,RESULTS
73,APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.,"Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.",False,RESULTS
74,APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation causing GABA neuron degeneration.,"Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.",False,CONCLUSIONS
75,"APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.","Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems.",False,BACKGROUND
76,"APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.","Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-β (Aβ) peptides, and that they displayed GABAergic neuron degeneration.",True,BACKGROUND
77,"APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.","ApoE4 increased Aβ production in human, but not in mouse, neurons.",False,RESULTS
78,"APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.","Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4.",False,RESULTS
79,"APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.","Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4.",False,RESULTS
80,"APOE4 expression in iPSC-derived neurons increases AlphaBeta production and tau phosphorylation, delaying GABA neuron degeneration.","Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.",False,CONCLUSIONS
81,Activation of PPM1D suppresses p53 function.,Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect.,False,BACKGROUND
82,Activation of PPM1D suppresses p53 function.,"To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSGs) and 12 thalamic gliomas.",False,METHODS
83,Activation of PPM1D suppresses p53 function.,We also performed targeted mutational analysis of an additional 24 such tumors and genome-wide methylation profiling of 45 gliomas.,False,METHODS
84,Activation of PPM1D suppresses p53 function.,"This study led to the discovery of tumor-specific mutations in PPM1D, encoding wild-type p53-induced protein phosphatase 1D (WIP1), in 37.5% of the BSGs that harbored hallmark H3F3A mutations encoding p.",False,RESULTS
85,Activation of PPM1D suppresses p53 function.,Lys27Met substitutions.,False,RESULTS
86,Activation of PPM1D suppresses p53 function.,PPM1D mutations were mutually exclusive with TP53 mutations in BSG and attenuated p53 activation in vitro.,True,RESULTS
87,Activation of PPM1D suppresses p53 function.,PPM1D mutations were truncating alterations in exon 6 that enhanced the ability of PPM1D to suppress the activation of the DNA damage response checkpoint protein CHK2.,True,CONCLUSIONS
88,Activation of PPM1D suppresses p53 function.,These results define PPM1D as a frequent target of somatic mutation and as a potential therapeutic target in brainstem gliomas.,False,CONCLUSIONS
89,Activation of PPM1D suppresses p53 function.,Improved sequencing technologies offer unprecedented opportunities for investigating the role of rare genetic variation in common disease.,False,BACKGROUND
90,Activation of PPM1D suppresses p53 function.,"However, there are considerable challenges with respect to study design, data analysis and replication.",False,BACKGROUND
91,Activation of PPM1D suppresses p53 function.,"Using pooled next-generation sequencing of 507 genes implicated in the repair of DNA in 1,150 samples, an analytical strategy focused on protein-truncating variants (PTVs) and a large-scale sequencing case–control replication experiment in 13,642 individuals, here we show that rare PTVs in the p53-inducible protein phosphatase PPM1D are associated with predisposition to breast cancer and ovarian cancer.",False,METHODS
92,Activation of PPM1D suppresses p53 function.,"PPM1D PTV mutations were present in 25 out of 7,781 cases versus 1 out of 5,861 controls (P = 1.12 × 10−5), including 18 mutations in 6,912 individuals with breast cancer (P = 2.42 × 10−4) and 12 mutations in 1,121 individuals with ovarian cancer (P = 3.10 × 10−9).",False,RESULTS
93,Activation of PPM1D suppresses p53 function.,"Notably, all of the identified PPM1D PTVs were mosaic in lymphocyte DNA and clustered within a 370-base-pair region in the final exon of the gene, carboxy-terminal to the phosphatase catalytic domain.",False,RESULTS
94,Activation of PPM1D suppresses p53 function.,"Functional studies demonstrate that the mutations result in enhanced suppression of p53 in response to ionizing radiation exposure, suggesting that the mutant alleles encode hyperactive PPM1D isoforms.",True,CONCLUSIONS
95,Activation of PPM1D suppresses p53 function.,"Thus, although the mutations cause premature protein truncation, they do not result in the simple loss-of-function effect typically associated with this class of variant, but instead probably have a gain-of-function effect.",False,CONCLUSIONS
96,Activation of PPM1D suppresses p53 function.,Our results have implications for the detection and management of breast and ovarian cancer risk.,False,CONCLUSIONS
97,Activation of PPM1D suppresses p53 function.,"More generally, these data provide new insights into the role of rare and of mosaic genetic variants in common conditions, and the use of sequencing in their identification.",False,CONCLUSIONS
98,All hematopoietic stem cells segregate their chromosomes randomly.,Stem cells are proposed to segregate chromosomes asymmetrically during self-renewing divisions so that older (‘immortal’) DNA strands are retained in daughter stem cells whereas newly synthesized strands segregate to differentiating cells.,False,BACKGROUND
99,All hematopoietic stem cells segregate their chromosomes randomly.,"Stem cells are also proposed to retain DNA labels, such as 5-bromo-2-deoxyuridine (BrdU), either because they segregate chromosomes asymmetrically or because they divide slowly.",False,BACKGROUND
100,All hematopoietic stem cells segregate their chromosomes randomly.,"However, the purity of stem cells among BrdU-label-retaining cells has not been documented in any tissue, and the ‘immortal strand hypothesis’ has not been tested in a system with definitive stem cell markers.",False,BACKGROUND
101,All hematopoietic stem cells segregate their chromosomes randomly.,"Here we tested these hypotheses in haematopoietic stem cells (HSCs), which can be highly purified using well characterized markers.",False,BACKGROUND
102,All hematopoietic stem cells segregate their chromosomes randomly.,"We administered BrdU to newborn mice, mice treated with cyclophosphamide and granulocyte colony-stimulating factor, and normal adult mice for 4 to 10 days, followed by 70 days without BrdU. In each case, less than 6% of HSCs retained BrdU and less than 0.5% of all BrdU-retaining haematopoietic cells were HSCs, revealing that BrdU has poor specificity and poor sensitivity as an HSC marker.",False,METHODS
103,All hematopoietic stem cells segregate their chromosomes randomly.,Sequential administration of 5-chloro-2-deoxyuridine and 5-iodo-2-deoxyuridine indicated that all HSCs segregate their chromosomes randomly.,True,RESULTS
104,All hematopoietic stem cells segregate their chromosomes randomly.,Division of individual HSCs in culture revealed no asymmetric segregation of the label.,False,RESULTS
105,All hematopoietic stem cells segregate their chromosomes randomly.,"Thus, HSCs cannot be identified on the basis of BrdU-label retention and do not retain older DNA strands during division, indicating that these are not general properties of stem cells.",False,RESULTS
106,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,Angiotensin converting enzyme (ACE) inhibitors are now one of the most frequently used classes of antihypertensive drugs.,False,BACKGROUND
107,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,"Beyond their utility in the management of hypertension, their use has been extended to the long-term management of patients with congestive heart failure (CHF), as well as diabetic and nondiabetic nephropathies.",False,BACKGROUND
108,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,"Although ACE inhibitor therapy usually improves renal blood flow (RBF) and sodium excretion rates in CHF and reduces the rate of progressive renal injury in chronic renal disease, its use can also be associated with a syndrome of “functional renal insufficiency” and/or hyperkalemia.",True,BACKGROUND
109,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,"This form of acute renal failure (ARF) most commonly develops shortly after initiation of ACE inhibitor therapy but can be observed after months or years of therapy, even in the absence of prior ill effects.",False,BACKGROUND
110,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,ARF is most likely to occur when renal perfusion pressure cannot be sustained because of substantial decreases in mean arterial pressure (MAP) or when glomerular filtration rate (GFR) is highly angiotensin II (Ang II) dependent.,False,BACKGROUND
111,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,Conditions that predict an adverse hemodynamic effect of ACE inhibitors in patients with CHF are preexisting hypotension and low cardiac filling pressures.,False,BACKGROUND
112,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,"The GFR is especially dependent on Ang II during extracellular fluid (ECF) volume depletion, high-grade bilateral renal artery stenosis, or stenosis of a dominant or single kidney, as in a renal transplant recipient.",False,BACKGROUND
113,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,"Understanding the pathophysiological mechanisms and the common risk factors for ACE inhibitor–induced functional ARF is critical, because preventive strategies for ARF exist, and if effectively used, they may permit use of these compounds in a less restricted fashion.  ",True,BACKGROUND
114,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,"Under normal physiological conditions, renal autoregulation adjusts renal vascular resistance, so that RBF and GFR remain constant over a wide range of MAPs.1 The intrinsic renal autoregulation mechanism is adjusted by Ang II and the sympathetic nervous system.",False,BACKGROUND
115,Angiotensin converting enzyme inhibitors are associated with increased risk for functional renal insufficiency.,When renal perfusion pressure falls (as in …,False,BACKGROUND
116,Anthrax spores can be disposed of easily after they are dispersed.,"CONTEXT Bioterrorist attacks involving letters and mail-handling systems in Washington, DC, resulted in Bacillus anthracis (anthrax) spore contamination in the Hart Senate Office Building and other facilities in the US Capitol's vicinity.   
",False,BACKGROUND
117,Anthrax spores can be disposed of easily after they are dispersed.,"OBJECTIVE To provide information about the nature and extent of indoor secondary aerosolization of B anthracis spores.   
",False,OBJECTIVE
118,Anthrax spores can be disposed of easily after they are dispersed.,"DESIGN Stationary and personal air samples, surface dust, and swab samples were collected under semiquiescent (minimal activities) and then simulated active office conditions to estimate secondary aerosolization of B anthracis spores.",False,METHODS
119,Anthrax spores can be disposed of easily after they are dispersed.,"Nominal size characteristics, airborne concentrations, and surface contamination of B anthracis particles (colony-forming units) were evaluated.   
",False,METHODS
120,Anthrax spores can be disposed of easily after they are dispersed.,"RESULTS Viable B anthracis spores reaerosolized under semiquiescent conditions, with a marked increase in reaerosolization during simulated active office conditions.",False,RESULTS
121,Anthrax spores can be disposed of easily after they are dispersed.,Increases were observed for B anthracis collected on open sheep blood agar plates (P<.001) and personal air monitors (P =.01) during active office conditions.,False,RESULTS
122,Anthrax spores can be disposed of easily after they are dispersed.,More than 80% of the B anthracis particles collected on stationary monitors were within an alveolar respirable size range of 0.95 to 3.5 micro m.   CONCLUSIONS Bacillus anthracis spores used in a recent terrorist incident reaerosolized under common office activities.,True,CONCLUSIONS
123,Anthrax spores can be disposed of easily after they are dispersed.,"These findings have important implications for appropriate respiratory protection, remediation, and reoccupancy of contaminated office environments.",False,CONCLUSIONS
124,Antibiotic induced alterations in the gut microbiome reduce resistance against Clostridium difficile,"Antibiotics can have significant and long-lasting effects on the gastrointestinal tract microbiota, reducing colonization resistance against pathogens including Clostridium difficile.",True,BACKGROUND
125,Antibiotic induced alterations in the gut microbiome reduce resistance against Clostridium difficile,Here we show that antibiotic treatment induces substantial changes in the gut microbial community and in the metabolome of mice susceptible to C. difficile infection.,False,BACKGROUND
126,Antibiotic induced alterations in the gut microbiome reduce resistance against Clostridium difficile,"Levels of secondary bile acids, glucose, free fatty acids and dipeptides decrease, whereas those of primary bile acids and sugar alcohols increase, reflecting the modified metabolic activity of the altered gut microbiome.",False,RESULTS
127,Antibiotic induced alterations in the gut microbiome reduce resistance against Clostridium difficile,"In vitro and ex vivo analyses demonstrate that C. difficile can exploit specific metabolites that become more abundant in the mouse gut after antibiotics, including the primary bile acid taurocholate for germination, and carbon sources such as mannitol, fructose, sorbitol, raffinose and stachyose for growth.",False,RESULTS
128,Antibiotic induced alterations in the gut microbiome reduce resistance against Clostridium difficile,Our results indicate that antibiotic-mediated alteration of the gut microbiome converts the global metabolic profile to one that favours C. difficile germination and growth.,True,CONCLUSIONS
129,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,"BACKGROUND Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa.",False,BACKGROUND
130,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,"In 2010, there were an estimated 1.1 million incident cases of tuberculosis among the 34 million people living with HIV worldwide.",False,BACKGROUND
131,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,Antiretroviral therapy has substantial potential to prevent HIV-associated tuberculosis.,False,BACKGROUND
132,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,"We conducted a systematic review of studies that analysed the impact of antiretroviral therapy on the incidence of tuberculosis in adults with HIV infection.   
",False,BACKGROUND
133,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,"METHODS AND FINDINGS PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically searched.",False,METHODS
134,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,"Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in developing countries.",False,METHODS
135,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,"For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy initiation: (1) less than 200 cells/µl, (2) 200 to 350 cells/µl, (3) greater than 350 cells/µl, and (4) any CD4 count.",False,METHODS
136,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,Eleven studies met the inclusion criteria.,False,RESULTS
137,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,"Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all baseline CD4 count categories: (1) less than 200 cells/µl (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2) 200 to 350 cells/µl (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/µl (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4 count (HR 0.35, 95% CI 0.28 to 0.44).",True,RESULTS
138,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,"There was no evidence of hazard ratio modification with respect to baseline CD4 count category (p = 0.20).   
",False,RESULTS
139,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,CONCLUSIONS Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4 count strata.,True,CONCLUSIONS
140,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control the HIV-associated tuberculosis syndemic.   ,False,CONCLUSIONS
141,Antiretroviral therapy reduces rates of tuberculosis across a broad range of CD4 strata.,REVIEW REGISTRATION International Prospective Register of Systematic Reviews CRD42011001209 Please see later in the article for the Editors' Summary.,False,CONCLUSIONS
142,Articles published in open access format are less likely to be cited than traditional journals.,PLoS Biology publishes today a research article by Gunther Eysenbach that is not about biology.,False,none
143,Articles published in open access format are less likely to be cited than traditional journals.,It is about citations.,False,none
144,Articles published in open access format are less likely to be cited than traditional journals.,It provides robust evidence that open-access articles (OA articles) are more immediately recognized and cited than non-OA articles.,True,BACKGROUND
145,Articles published in open access format are less likely to be cited than traditional journals.,"As such, it adds objective support to the belief we have always held that open-access publication speeds up scientific dialog between researchers and, consequently, should be extended to the whole scientific literature as quickly as possible.",False,BACKGROUND
146,Articles published in open access format are less likely to be cited than traditional journals.,It is therefore fitting that we publish such a paper.    ,False,BACKGROUND
147,Articles published in open access format are less likely to be cited than traditional journals.,We have long argued that papers freely available in a journal will be more often read and cited than those behind a subscription barrier.,False,BACKGROUND
148,Articles published in open access format are less likely to be cited than traditional journals.,"However, solid evidence to support or refute such a claim has been surprisingly hard to find.",False,BACKGROUND
149,Articles published in open access format are less likely to be cited than traditional journals.,"Since most open-access journals are new, comparisons of the effects of open access with established subscription-based journals are easily confounded by age and reputation.",False,BACKGROUND
150,Articles published in open access format are less likely to be cited than traditional journals.,"In the current study, Eysenbach compared citations compiled by Thomson Scientific (formerly Thomson ISI) to individual articles published between June 2004 and December 2004 in the same journal—namely, Proceedings of the National Academy of Sciences (PNAS), which announced its open-access option for authors on June 8 of that year, with an associated publication charge of US$1,000.",False,BACKGROUND
151,Articles published in open access format are less likely to be cited than traditional journals.,Non-OA articles in PNAS are subject to a six-month “toll-access” delay before the article becomes publicly available.,False,BACKGROUND
152,Articles published in open access format are less likely to be cited than traditional journals.,"The results of this natural experiment are clear: in the 4 to 16 months following publication, OA articles gained a significant citation advantage over non-OA articles during the same period.",True,BACKGROUND
153,Articles published in open access format are less likely to be cited than traditional journals.,They are twice as likely to be cited 4 to 10 months after publication and almost three times as likely between 10 and 16 months.,True,BACKGROUND
154,Articles published in open access format are less likely to be cited than traditional journals.,"Given that PNAS delays open access for only six months, the disparity between OA and non-OA articles in journals where the delay is longer or where articles remain “toll-access” is likely to be even greater.    ",False,BACKGROUND
155,Articles published in open access format are less likely to be cited than traditional journals.,Eysenbach also looked at the impact of self-archiving non-OA articles.,False,CONCLUSIONS
156,Articles published in open access format are less likely to be cited than traditional journals.,"One route to open access, it is argued, is for authors to archive their published articles on their own Web sites or in institutional repositories, although this does not include an explicit business model to cover the cost of peer-review and publishing.",False,CONCLUSIONS
157,Articles published in open access format are less likely to be cited than traditional journals.,The analysis revealed that self-archived articles are also cited less often than OA articles from the same journal.    ,False,CONCLUSIONS
158,Articles published in open access format are less likely to be cited than traditional journals.,"Yes, you're right; we do have a strong and vested interest in publishing results that so obviously endorse our existence.",False,CONCLUSIONS
159,Articles published in open access format are less likely to be cited than traditional journals.,"Moreover, the author of the article is also an editor of an open-access journal.",False,CONCLUSIONS
160,Articles published in open access format are less likely to be cited than traditional journals.,But sometimes a potential conflict of interest can actually help to ensure rigor.,False,CONCLUSIONS
161,Articles published in open access format are less likely to be cited than traditional journals.,"In this case, we have an acute interest in ensuring that the article meets the same, if not higher, standards as any other research article we publish.",False,CONCLUSIONS
162,Articles published in open access format are less likely to be cited than traditional journals.,"Not only must the conclusions provide a significant advance for the field, but the study must be technically sound, with appropriate evidence to support those conclusions.",False,CONCLUSIONS
163,Articles published in open access format are less likely to be cited than traditional journals.,"As with all our research articles, we consulted throughout the evaluation process with an academic editor with appropriate expertise—in this case, Carol Tenopir, professor of information sciences at the University of Tennessee (Knoxville, Tennessee, United States).",False,CONCLUSIONS
164,Articles published in open access format are less likely to be cited than traditional journals.,"The article was reviewed by two experts in bibliometric analyses and information science, and an experienced research biologist with expertise in statistics.",False,CONCLUSIONS
165,Articles published in open access format are less likely to be cited than traditional journals.,"They all enthusiastically supported publication, although one understandably questioned the suitability of PLoS Biology as the publication venue.    ",False,CONCLUSIONS
166,Articles published in open access format are less likely to be cited than traditional journals.,We have no intention of making PLoS Biology a regular home for bibliometric studies (even when about open access).,False,CONCLUSIONS
167,Articles published in open access format are less likely to be cited than traditional journals.,What makes this study worth publishing in PLoS Biology is not only the relative strength of evidence supporting the claim but also the extent to which many (especially other publishers) have anticipated such an analysis.,False,CONCLUSIONS
168,Articles published in open access format are less likely to be cited than traditional journals.,"As far as we are aware, no other study has compared OA and non-OA articles from the same journal and controlled for so many potentially confounding factors.",False,CONCLUSIONS
169,Articles published in open access format are less likely to be cited than traditional journals.,"Eysenbach's multivariate analysis took into account the number of days since publication, number of authors, article type, country of the corresponding author, funding type, subject area, submission track ( PNAS has three different ways that authors can submit a paper), and the previous citation record of the first and last authors.",False,CONCLUSIONS
170,Articles published in open access format are less likely to be cited than traditional journals.,He even administered a supplementary questionnaire to assess whether authors choosing the OA option in PNAS chose to do so for only their most important research (they didn't).,False,CONCLUSIONS
171,Articles published in open access format are less likely to be cited than traditional journals.,As Ian Rowlands from the Centre for Publishing at University College London—and one of the reviewers who agreed to be identified in this article—said at the start of his review:          “Many (most) of the papers and presentations I have read/seen on this topic have completely failed to address the kinds of confounding issues that are so convincingly tackled here.,False,CONCLUSIONS
172,Articles published in open access format are less likely to be cited than traditional journals.,"For that reason alone, this paper deserves to be published and alerted to the widest possible audience.",False,CONCLUSIONS
173,Articles published in open access format are less likely to be cited than traditional journals.,"”          In addition to providing evidence for the immediate advantage of open access, Eysenbach's analysis also highlights several potential challenges to its long-term future.",False,CONCLUSIONS
174,Articles published in open access format are less likely to be cited than traditional journals.,"Although a limited dataset, the citation history of the first and last authors differed between those who chose the open-access option and those who did not.",False,CONCLUSIONS
175,Articles published in open access format are less likely to be cited than traditional journals.,"In the group that chose open access, last authors tended to have a “stronger” previous citation record, whereas this situation was reversed among the group that declined the open-access option—here, it was the first authors who tended to be stronger.",False,CONCLUSIONS
176,Articles published in open access format are less likely to be cited than traditional journals.,"This may reflect varying attitudes of authors at different stages of their career, a stronger influence from the leader of a particular group, or an age- or career-related difference in the ability to pay the publication charge (e.g., [ 1]).",False,CONCLUSIONS
177,Articles published in open access format are less likely to be cited than traditional journals.,"Indeed, access to appropriate funds may also be a reason why a lower proportion of authors from European countries tended to choose the open-access option.",False,CONCLUSIONS
178,Articles published in open access format are less likely to be cited than traditional journals.,"In many of these countries, funds for page charges—and, by extension, open-access publication fees—are often not included within research grants.    ",False,CONCLUSIONS
179,Articles published in open access format are less likely to be cited than traditional journals.,PNAS was one of the first journals to offer an open-access option to its authors.,False,CONCLUSIONS
180,Articles published in open access format are less likely to be cited than traditional journals.,"However, such hybrid journals are increasing: Blackwell, Springer, and Oxford University Press now provide this option as well.",False,CONCLUSIONS
181,Articles published in open access format are less likely to be cited than traditional journals.,This means that similar experiments can be replicated.,False,CONCLUSIONS
182,Articles published in open access format are less likely to be cited than traditional journals.,"Moreover, although the evidence from the current analysis argues most strongly for a time advantage in citation for OA articles, a study over longer periods will reveal whether this translates into a sustained increase in the number of citations.",True,CONCLUSIONS
183,Articles published in open access format are less likely to be cited than traditional journals.,"In the meantime, open-access advocates should be emboldened by tangible evidence for what has seemed obvious all along.",False,CONCLUSIONS
184,Articles published in open access format are more likely to be cited than traditional journals.,PLoS Biology publishes today a research article by Gunther Eysenbach that is not about biology.,False,none
185,Articles published in open access format are more likely to be cited than traditional journals.,It is about citations.,False,none
186,Articles published in open access format are more likely to be cited than traditional journals.,It provides robust evidence that open-access articles (OA articles) are more immediately recognized and cited than non-OA articles.,True,BACKGROUND
187,Articles published in open access format are more likely to be cited than traditional journals.,"As such, it adds objective support to the belief we have always held that open-access publication speeds up scientific dialog between researchers and, consequently, should be extended to the whole scientific literature as quickly as possible.",False,BACKGROUND
188,Articles published in open access format are more likely to be cited than traditional journals.,It is therefore fitting that we publish such a paper.    ,False,BACKGROUND
189,Articles published in open access format are more likely to be cited than traditional journals.,We have long argued that papers freely available in a journal will be more often read and cited than those behind a subscription barrier.,False,BACKGROUND
190,Articles published in open access format are more likely to be cited than traditional journals.,"However, solid evidence to support or refute such a claim has been surprisingly hard to find.",False,BACKGROUND
191,Articles published in open access format are more likely to be cited than traditional journals.,"Since most open-access journals are new, comparisons of the effects of open access with established subscription-based journals are easily confounded by age and reputation.",False,BACKGROUND
192,Articles published in open access format are more likely to be cited than traditional journals.,"In the current study, Eysenbach compared citations compiled by Thomson Scientific (formerly Thomson ISI) to individual articles published between June 2004 and December 2004 in the same journal—namely, Proceedings of the National Academy of Sciences (PNAS), which announced its open-access option for authors on June 8 of that year, with an associated publication charge of US$1,000.",False,BACKGROUND
193,Articles published in open access format are more likely to be cited than traditional journals.,Non-OA articles in PNAS are subject to a six-month “toll-access” delay before the article becomes publicly available.,False,BACKGROUND
194,Articles published in open access format are more likely to be cited than traditional journals.,"The results of this natural experiment are clear: in the 4 to 16 months following publication, OA articles gained a significant citation advantage over non-OA articles during the same period.",True,BACKGROUND
195,Articles published in open access format are more likely to be cited than traditional journals.,They are twice as likely to be cited 4 to 10 months after publication and almost three times as likely between 10 and 16 months.,True,BACKGROUND
196,Articles published in open access format are more likely to be cited than traditional journals.,"Given that PNAS delays open access for only six months, the disparity between OA and non-OA articles in journals where the delay is longer or where articles remain “toll-access” is likely to be even greater.    ",False,BACKGROUND
197,Articles published in open access format are more likely to be cited than traditional journals.,Eysenbach also looked at the impact of self-archiving non-OA articles.,False,CONCLUSIONS
198,Articles published in open access format are more likely to be cited than traditional journals.,"One route to open access, it is argued, is for authors to archive their published articles on their own Web sites or in institutional repositories, although this does not include an explicit business model to cover the cost of peer-review and publishing.",False,CONCLUSIONS
199,Articles published in open access format are more likely to be cited than traditional journals.,The analysis revealed that self-archived articles are also cited less often than OA articles from the same journal.    ,False,CONCLUSIONS
200,Articles published in open access format are more likely to be cited than traditional journals.,"Yes, you're right; we do have a strong and vested interest in publishing results that so obviously endorse our existence.",False,CONCLUSIONS
201,Articles published in open access format are more likely to be cited than traditional journals.,"Moreover, the author of the article is also an editor of an open-access journal.",False,CONCLUSIONS
202,Articles published in open access format are more likely to be cited than traditional journals.,But sometimes a potential conflict of interest can actually help to ensure rigor.,False,CONCLUSIONS
203,Articles published in open access format are more likely to be cited than traditional journals.,"In this case, we have an acute interest in ensuring that the article meets the same, if not higher, standards as any other research article we publish.",False,CONCLUSIONS
204,Articles published in open access format are more likely to be cited than traditional journals.,"Not only must the conclusions provide a significant advance for the field, but the study must be technically sound, with appropriate evidence to support those conclusions.",False,CONCLUSIONS
205,Articles published in open access format are more likely to be cited than traditional journals.,"As with all our research articles, we consulted throughout the evaluation process with an academic editor with appropriate expertise—in this case, Carol Tenopir, professor of information sciences at the University of Tennessee (Knoxville, Tennessee, United States).",False,CONCLUSIONS
206,Articles published in open access format are more likely to be cited than traditional journals.,"The article was reviewed by two experts in bibliometric analyses and information science, and an experienced research biologist with expertise in statistics.",False,CONCLUSIONS
207,Articles published in open access format are more likely to be cited than traditional journals.,"They all enthusiastically supported publication, although one understandably questioned the suitability of PLoS Biology as the publication venue.    ",False,CONCLUSIONS
208,Articles published in open access format are more likely to be cited than traditional journals.,We have no intention of making PLoS Biology a regular home for bibliometric studies (even when about open access).,False,CONCLUSIONS
209,Articles published in open access format are more likely to be cited than traditional journals.,What makes this study worth publishing in PLoS Biology is not only the relative strength of evidence supporting the claim but also the extent to which many (especially other publishers) have anticipated such an analysis.,False,CONCLUSIONS
210,Articles published in open access format are more likely to be cited than traditional journals.,"As far as we are aware, no other study has compared OA and non-OA articles from the same journal and controlled for so many potentially confounding factors.",False,CONCLUSIONS
211,Articles published in open access format are more likely to be cited than traditional journals.,"Eysenbach's multivariate analysis took into account the number of days since publication, number of authors, article type, country of the corresponding author, funding type, subject area, submission track ( PNAS has three different ways that authors can submit a paper), and the previous citation record of the first and last authors.",False,CONCLUSIONS
212,Articles published in open access format are more likely to be cited than traditional journals.,He even administered a supplementary questionnaire to assess whether authors choosing the OA option in PNAS chose to do so for only their most important research (they didn't).,False,CONCLUSIONS
213,Articles published in open access format are more likely to be cited than traditional journals.,As Ian Rowlands from the Centre for Publishing at University College London—and one of the reviewers who agreed to be identified in this article—said at the start of his review:          “Many (most) of the papers and presentations I have read/seen on this topic have completely failed to address the kinds of confounding issues that are so convincingly tackled here.,False,CONCLUSIONS
214,Articles published in open access format are more likely to be cited than traditional journals.,"For that reason alone, this paper deserves to be published and alerted to the widest possible audience.",False,CONCLUSIONS
215,Articles published in open access format are more likely to be cited than traditional journals.,"”          In addition to providing evidence for the immediate advantage of open access, Eysenbach's analysis also highlights several potential challenges to its long-term future.",False,CONCLUSIONS
216,Articles published in open access format are more likely to be cited than traditional journals.,"Although a limited dataset, the citation history of the first and last authors differed between those who chose the open-access option and those who did not.",False,CONCLUSIONS
217,Articles published in open access format are more likely to be cited than traditional journals.,"In the group that chose open access, last authors tended to have a “stronger” previous citation record, whereas this situation was reversed among the group that declined the open-access option—here, it was the first authors who tended to be stronger.",False,CONCLUSIONS
218,Articles published in open access format are more likely to be cited than traditional journals.,"This may reflect varying attitudes of authors at different stages of their career, a stronger influence from the leader of a particular group, or an age- or career-related difference in the ability to pay the publication charge (e.g., [ 1]).",False,CONCLUSIONS
219,Articles published in open access format are more likely to be cited than traditional journals.,"Indeed, access to appropriate funds may also be a reason why a lower proportion of authors from European countries tended to choose the open-access option.",False,CONCLUSIONS
220,Articles published in open access format are more likely to be cited than traditional journals.,"In many of these countries, funds for page charges—and, by extension, open-access publication fees—are often not included within research grants.    ",False,CONCLUSIONS
221,Articles published in open access format are more likely to be cited than traditional journals.,PNAS was one of the first journals to offer an open-access option to its authors.,False,CONCLUSIONS
222,Articles published in open access format are more likely to be cited than traditional journals.,"However, such hybrid journals are increasing: Blackwell, Springer, and Oxford University Press now provide this option as well.",False,CONCLUSIONS
223,Articles published in open access format are more likely to be cited than traditional journals.,This means that similar experiments can be replicated.,False,CONCLUSIONS
224,Articles published in open access format are more likely to be cited than traditional journals.,"Moreover, although the evidence from the current analysis argues most strongly for a time advantage in citation for OA articles, a study over longer periods will reveal whether this translates into a sustained increase in the number of citations.",True,CONCLUSIONS
225,Articles published in open access format are more likely to be cited than traditional journals.,"In the meantime, open-access advocates should be emboldened by tangible evidence for what has seemed obvious all along.",False,CONCLUSIONS
226,"Assembly of invadopodia is triggered by focal generation of phosphatidylinositol-3,4-biphosphate and the activation of the nonreceptor tyrosine kinase Src.",Podosomes (also termed invadopodia in cancer cells) are actin-rich adhesion structures with matrix degradation activity that develop in various cell types.,False,BACKGROUND
227,"Assembly of invadopodia is triggered by focal generation of phosphatidylinositol-3,4-biphosphate and the activation of the nonreceptor tyrosine kinase Src.","Despite their significant physiological importance, the molecular mechanism of podosome formation is largely unknown.",False,BACKGROUND
228,"Assembly of invadopodia is triggered by focal generation of phosphatidylinositol-3,4-biphosphate and the activation of the nonreceptor tyrosine kinase Src.","In this study, we investigated the molecular mechanisms of podosome formation.",False,BACKGROUND
229,"Assembly of invadopodia is triggered by focal generation of phosphatidylinositol-3,4-biphosphate and the activation of the nonreceptor tyrosine kinase Src.","The expression of various phosphoinositide-binding domains revealed that the podosomes in Src-transformed NIH3T3 (NIH-src) cells are enriched with PtdIns(3,4)P2, suggesting an important role of this phosphoinositide in podosome formation.",True,METHODS
230,"Assembly of invadopodia is triggered by focal generation of phosphatidylinositol-3,4-biphosphate and the activation of the nonreceptor tyrosine kinase Src.","Live-cell imaging analysis revealed that Src-expression stimulated podosome formation at focal adhesions of NIH3T3 cells after PtdIns(3,4)P2 accumulation.",True,METHODS
231,"Assembly of invadopodia is triggered by focal generation of phosphatidylinositol-3,4-biphosphate and the activation of the nonreceptor tyrosine kinase Src.","The adaptor protein Tks5/FISH, which is essential for podosome formation, was found to form a complex with Grb2 at adhesion sites in an Src-dependent manner.",False,RESULTS
232,"Assembly of invadopodia is triggered by focal generation of phosphatidylinositol-3,4-biphosphate and the activation of the nonreceptor tyrosine kinase Src.","Further, it was found that N-WASP bound all SH3 domains of Tks5/FISH, which facilitated circular podosome formation.",False,RESULTS
233,"Assembly of invadopodia is triggered by focal generation of phosphatidylinositol-3,4-biphosphate and the activation of the nonreceptor tyrosine kinase Src.","These results indicate that augmentation of the N-WASP-Arp2/3 signal was accomplished on the platform of Tks5/FISH-Grb2 complex at focal adhesions, which is stabilized by PtdIns(3,4)P2.",False,CONCLUSIONS
234,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,"OBJECTIVE To assess whether population screening for impaired vision among older people in the community leads to improvements in vision.   
",False,OBJECTIVE
235,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,DESIGN Systematic review of randomised controlled trials of population screening in the community that included any assessment of vision or visual function with at least 6 months' follow up.   ,False,METHODS
236,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,"SUBJECTS Adults aged 65 or over.   
",False,METHODS
237,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,"MAIN OUTCOME MEASURE Proportions with visual impairment in intervention and control groups with any method of assessing visual impairment.   
",False,METHODS
238,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,RESULTS There were no trials that primarily assessed visual screening.,False,METHODS
239,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,Outcome data on vision were available for 3494 people in five trials of multiphasic assessment.,False,METHODS
240,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,"All the trials used self reported measures for vision impairment, both as screening tools and as outcome measures.",False,METHODS
241,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,The inclusion of a visual screening component in the assessment did not result in improvements in self reported visual problems (pooled odds ratio 1.04:95% confidence interval 0.89 to 1.22).,True,RESULTS
242,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,"A small reduction (11%) in the number of older people with self reported visual problems cannot be excluded.   
",False,CONCLUSIONS
243,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,CONCLUSIONS Screening of asymptomatic older people in the community is not justified on present evidence.,True,CONCLUSIONS
244,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,Visual impairment in this age group can usually be reduced with treatment.,False,CONCLUSIONS
245,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,It is unclear why no benefit was seen.,False,CONCLUSIONS
246,Asymptomatic visual impairment screening in elderly populations does not lead to improved vision.,Further work is needed to clarify what interventions are appropriate for older people with unreported impairment of vision.,False,CONCLUSIONS
247,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"UNLABELLED Congruent audiovisual speech enhances our ability to comprehend a speaker, even in noise-free conditions.",True,BACKGROUND
248,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"When incongruent auditory and visual information is presented concurrently, it can hinder a listener's perception and even cause him or her to perceive information that was not presented in either modality.",True,BACKGROUND
249,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"Efforts to investigate the neural basis of these effects have often focused on the special case of discrete audiovisual syllables that are spatially and temporally congruent, with less work done on the case of natural, continuous speech.",False,BACKGROUND
250,Auditory entrainment is strengthened when people see congruent visual and auditory information.,Recent electrophysiological studies have demonstrated that cortical response measures to continuous auditory speech can be easily obtained using multivariate analysis methods.,False,BACKGROUND
251,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"Here, we apply such methods to the case of audiovisual speech and, importantly, present a novel framework for indexing multisensory integration in the context of continuous speech.",False,BACKGROUND
252,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"Specifically, we examine how the temporal and contextual congruency of ongoing audiovisual speech affects the cortical encoding of the speech envelope in humans using electroencephalography.",False,METHODS
253,Auditory entrainment is strengthened when people see congruent visual and auditory information.,We demonstrate that the cortical representation of the speech envelope is enhanced by the presentation of congruent audiovisual speech in noise-free conditions.,True,RESULTS
254,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"Furthermore, we show that this is likely attributable to the contribution of neural generators that are not particularly active during unimodal stimulation and that it is most prominent at the temporal scale corresponding to syllabic rate (2-6 Hz).",False,RESULTS
255,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"Finally, our data suggest that neural entrainment to the speech envelope is inhibited when the auditory and visual streams are incongruent both temporally and contextually.   ",True,RESULTS
256,Auditory entrainment is strengthened when people see congruent visual and auditory information.,SIGNIFICANCE STATEMENT Seeing a speaker's face as he or she talks can greatly help in understanding what the speaker is saying.,True,CONCLUSIONS
257,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"This is because the speaker's facial movements relay information about what the speaker is saying, but also, importantly, when the speaker is saying it.",False,CONCLUSIONS
258,Auditory entrainment is strengthened when people see congruent visual and auditory information.,Studying how the brain uses this timing relationship to combine information from continuous auditory and visual speech has traditionally been methodologically difficult.,False,CONCLUSIONS
259,Auditory entrainment is strengthened when people see congruent visual and auditory information.,Here we introduce a new approach for doing this using relatively inexpensive and noninvasive scalp recordings.,False,CONCLUSIONS
260,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"Specifically, we show that the brain's representation of auditory speech is enhanced when the accompanying visual speech signal shares the same timing.",True,CONCLUSIONS
261,Auditory entrainment is strengthened when people see congruent visual and auditory information.,"Furthermore, we show that this enhancement is most pronounced at a time scale that corresponds to mean syllable length.",False,CONCLUSIONS
262,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"CONTEXT Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging.",False,OBJECTIVE
263,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.   
",False,OBJECTIVE
264,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"OBJECTIVE To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.   
",False,OBJECTIVE
265,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"DESIGN, SETTING, AND PATIENTS One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.   
",False,METHODS
266,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,INTERVENTION Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later.,False,METHODS
267,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs.   
",False,METHODS
268,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"MAIN OUTCOME MEASURES The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events.   
",False,METHODS
269,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,RESULTS Patient and graft survival at 13 to 30 months was similar in all groups.,False,RESULTS
270,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection.",False,RESULTS
271,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02).",False,RESULTS
272,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group.,False,RESULTS
273,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002).",False,RESULTS
274,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02)   CONCLUSION Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.   
",True,CONCLUSIONS
275,Autologous transplantation of mesenchymal stem cells causes a higher rate of opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00658073.,False,CONCLUSIONS
276,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"CONTEXT Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging.",False,OBJECTIVE
277,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.   
",False,OBJECTIVE
278,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"OBJECTIVE To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.   
",False,OBJECTIVE
279,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"DESIGN, SETTING, AND PATIENTS One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.   
",False,METHODS
280,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,INTERVENTION Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later.,False,METHODS
281,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs.   
",False,METHODS
282,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"MAIN OUTCOME MEASURES The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events.   
",False,METHODS
283,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,RESULTS Patient and graft survival at 13 to 30 months was similar in all groups.,False,RESULTS
284,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection.",False,RESULTS
285,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02).",False,RESULTS
286,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group.,False,RESULTS
287,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002).",False,RESULTS
288,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,"Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02)   CONCLUSION Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.   
",True,CONCLUSIONS
289,Autologous transplantation of mesenchymal stem cells causes fewer opportunistic infections than induction therapy with anti-interleukin-2 receptor antibodies.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00658073.,False,CONCLUSIONS
290,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"CONTEXT Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging.",False,OBJECTIVE
291,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.   
",False,OBJECTIVE
292,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"OBJECTIVE To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.   
",False,OBJECTIVE
293,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"DESIGN, SETTING, AND PATIENTS One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.   
",False,METHODS
294,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,INTERVENTION Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later.,False,METHODS
295,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs.   
",False,METHODS
296,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"MAIN OUTCOME MEASURES The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events.   
",False,METHODS
297,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,RESULTS Patient and graft survival at 13 to 30 months was similar in all groups.,False,RESULTS
298,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection.",True,RESULTS
299,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02).",False,RESULTS
300,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group.,False,RESULTS
301,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002).",False,RESULTS
302,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,"Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02)   CONCLUSION Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.   
",True,CONCLUSIONS
303,Autologous transplantation of mesenchymal stem cells has lower rates of rejection than induction therapy with anti-interleukin-2 receptor antibodies.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00658073.,False,CONCLUSIONS
304,Autophagy declines in aged organisms.,"Chaperone-mediated autophagy (CMA), a selective mechanism for degradation of cytosolic proteins in lysosomes, contributes to the removal of altered proteins as part of the cellular quality-control systems.",False,BACKGROUND
305,Autophagy declines in aged organisms.,"We have previously found that CMA activity declines in aged organisms and have proposed that this failure in cellular clearance could contribute to the accumulation of altered proteins, the abnormal cellular homeostasis and, eventually, the functional loss characteristic of aged organisms.",True,BACKGROUND
306,Autophagy declines in aged organisms.,"To determine whether these negative features of aging can be prevented by maintaining efficient autophagic activity until late in life, in this work we have corrected the CMA defect in aged rodents.",False,BACKGROUND
307,Autophagy declines in aged organisms.,"We have generated a double transgenic mouse model in which the amount of the lysosomal receptor for CMA, previously shown to decrease in abundance with age, can be modulated.",False,RESULTS
308,Autophagy declines in aged organisms.,We have analyzed in this model the consequences of preventing the age-dependent decrease in receptor abundance in aged rodents at the cellular and organ levels.,False,CONCLUSIONS
309,Autophagy declines in aged organisms.,"We show here that CMA activity is maintained until advanced ages if the decrease in the receptor abundance is prevented and that preservation of autophagic activity is associated with lower intracellular accumulation of damaged proteins, better ability to handle protein damage and improved organ function.",False,CONCLUSIONS
310,Bariatric surgery has a positive impact on mental health.,IMPORTANCE Bariatric surgery is associated with sustained weight loss and improved physical health status for severely obese individuals.,False,BACKGROUND
311,Bariatric surgery has a positive impact on mental health.,"Mental health conditions may be common among patients seeking bariatric surgery; however, the prevalence of these conditions and whether they are associated with postoperative outcomes remains unknown.   
",False,BACKGROUND
312,Bariatric surgery has a positive impact on mental health.,"OBJECTIVE To determine the prevalence of mental health conditions among bariatric surgery candidates and recipients, to evaluate the association between preoperative mental health conditions and health outcomes following bariatric surgery, and to evaluate the association between surgery and the clinical course of mental health conditions.   
",False,OBJECTIVE
313,Bariatric surgery has a positive impact on mental health.,"DATA SOURCES We searched PubMed, MEDLINE on OVID, and PsycINFO for studies published between January 1988 and November 2015.",False,METHODS
314,Bariatric surgery has a positive impact on mental health.,"Study quality was assessed using an adapted tool for risk of bias; quality of evidence was rated based on GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria.   
",False,METHODS
315,Bariatric surgery has a positive impact on mental health.,"FINDINGS We identified 68 publications meeting inclusion criteria: 59 reporting the prevalence of preoperative mental health conditions (65,363 patients) and 27 reporting associations between preoperative mental health conditions and postoperative outcomes (50,182 patients).",False,RESULTS
316,Bariatric surgery has a positive impact on mental health.,"Among patients seeking and undergoing bariatric surgery, the most common mental health conditions, based on random-effects estimates of prevalence, were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]).",False,RESULTS
317,Bariatric surgery has a positive impact on mental health.,There was conflicting evidence regarding the association between preoperative mental health conditions and postoperative weight loss.,False,RESULTS
318,Bariatric surgery has a positive impact on mental health.,Neither depression nor binge eating disorder was consistently associated with differences in weight outcomes.,False,RESULTS
319,Bariatric surgery has a positive impact on mental health.,"Bariatric surgery was, however, consistently associated with postoperative decreases in the prevalence of depression (7 studies; 8%-74% decrease) and the severity of depressive symptoms (6 studies; 40%-70% decrease).   
",True,RESULTS
320,Bariatric surgery has a positive impact on mental health.,"CONCLUSIONS AND RELEVANCE Mental health conditions are common among bariatric surgery patients-in particular, depression and binge eating disorder.",False,CONCLUSIONS
321,Bariatric surgery has a positive impact on mental health.,There is inconsistent evidence regarding the association between preoperative mental health conditions and postoperative weight loss.,False,CONCLUSIONS
322,Bariatric surgery has a positive impact on mental health.,Moderate-quality evidence supports an association between bariatric surgery and lower rates of depression postoperatively.,True,CONCLUSIONS
323,Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).,"In systemic lupus erythematosus (SLE), self-reactive antibodies can target the kidney (lupus nephritis), leading to functional failure and possible mortality.",False,BACKGROUND
324,Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).,"We report that activation of basophils by autoreactive IgE causes their homing to lymph nodes, promoting T helper type 2 (T(H)2) cell differentiation and enhancing the production of self-reactive antibodies that cause lupus-like nephritis in mice lacking the Src family protein tyrosine kinase Lyn (Lyn(-/-) mice).",True,BACKGROUND
325,Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).,"Individuals with SLE also have elevated serum IgE, self-reactive IgEs and activated basophils that express CD62 ligand (CD62L) and the major histocompatibility complex (MHC) class II molecule human leukocyte antigen-DR (HLA-DR), parameters that are associated with increased disease activity and active lupus nephritis.",True,RESULTS
326,Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).,Basophils were also present in the lymph nodes and spleen of subjects with SLE.,False,RESULTS
327,Basophils counteract disease development in patients with systemic lupus erythematosus (SLE).,"Thus, in Lyn(-/-) mice, basophils and IgE autoantibodies amplify autoantibody production that leads to lupus nephritis, and in individuals with SLE IgE autoantibodies and activated basophils are factors associated with disease activity and nephritis.",True,RESULTS
328,Birth-weight is positively associated with breast cancer.,"BACKGROUND Birth size, perhaps a proxy for prenatal environment, might be a correlate of subsequent breast cancer risk, but findings from epidemiological studies have been inconsistent.",False,BACKGROUND
329,Birth-weight is positively associated with breast cancer.,"We re-analysed individual participant data from published and unpublished studies to obtain more precise estimates of the magnitude and shape of the birth size-breast cancer association.   
",False,BACKGROUND
330,Birth-weight is positively associated with breast cancer.,"METHODS AND FINDINGS Studies were identified through computer-assisted and manual searches, and personal communication with investigators.",False,METHODS
331,Birth-weight is positively associated with breast cancer.,"Individual participant data from 32 studies, comprising 22,058 breast cancer cases, were obtained.",False,METHODS
332,Birth-weight is positively associated with breast cancer.,"Random effect models were used, if appropriate, to combine study-specific estimates of effect.",False,METHODS
333,Birth-weight is positively associated with breast cancer.,"Birth weight was positively associated with breast cancer risk in studies based on birth records (pooled relative risk [RR] per one standard deviation [SD] [= 0.5 kg] increment in birth weight: 1.06; 95% confidence interval [CI] 1.02-1.09) and parental recall when the participants were children (1.02; 95% CI 0.99-1.05), but not in those based on adult self-reports, or maternal recall during the woman's adulthood (0.98; 95% CI 0.95-1.01) (p for heterogeneity between data sources = 0.003).",True,RESULTS
334,Birth-weight is positively associated with breast cancer.,"Relative to women who weighed 3.000-3.499 kg, the risk was 0.96 (CI 0.80-1.16) in those who weighed < 2.500 kg, and 1.12 (95% CI 1.00-1.25) in those who weighed > or = 4.000 kg (p for linear trend = 0.001) in birth record data.",True,RESULTS
335,Birth-weight is positively associated with breast cancer.,"Birth length and head circumference from birth records were also positively associated with breast cancer risk (pooled RR per one SD increment: 1.06 [95% CI 1.03-1.10] and 1.09 [95% CI 1.03-1.15], respectively).",False,RESULTS
336,Birth-weight is positively associated with breast cancer.,Simultaneous adjustment for these three birth size variables showed that length was the strongest independent predictor of risk.,False,RESULTS
337,Birth-weight is positively associated with breast cancer.,The birth size effects did not appear to be confounded or mediated by established breast cancer risk factors and were not modified by age or menopausal status.,False,RESULTS
338,Birth-weight is positively associated with breast cancer.,"The cumulative incidence of breast cancer per 100 women by age 80 y in the study populations was estimated to be 10.0, 10.0, 10.4, and 11.5 in those who were, respectively, in the bottom, second, third, and top fourths of the birth length distribution.   
",False,RESULTS
339,Birth-weight is positively associated with breast cancer.,"CONCLUSIONS This pooled analysis of individual participant data is consistent with birth size, and in particular birth length, being an independent correlate of breast cancer risk in adulthood.",True,CONCLUSIONS
340,Birth-weight is positively associated with breast cancer.,Breast cancer may originate in utero.,False,BACKGROUND
341,Birth-weight is positively associated with breast cancer.,We reviewed the available evidence on the association between birthweight and the risk of breast cancer.,False,BACKGROUND
342,Birth-weight is positively associated with breast cancer.,"To date, 26 research papers addressing this issue have been published.",False,RESULTS
343,Birth-weight is positively associated with breast cancer.,"The majority of studies identified a positive link between birthweight and premenopausal, but not postmenopausal, breast cancer.",True,RESULTS
344,Birth-weight is positively associated with breast cancer.,The relative risk estimate for breast cancer comparing women with high birthweight to women with low birthweight combining all studies including both pre- and postmenopausal breast cancer was 1.23 (95% confidence interval 1.13-1.34).,True,RESULTS
345,Birth-weight is positively associated with breast cancer.,The mechanisms underlying this association likely include elevated levels of growth factors that may increase the number of susceptible stem cells in the mammary gland or initiate tumors through DNA mutations.,False,RESULTS
346,Birth-weight is positively associated with breast cancer.,"Loss of imprinting (LOI) of growth hormone genes relevant for intrauterine growth, such as insulin-like growth factor 2 (IGF2), leads to abnormally high levels of these hormones evidenced by high birthweight.",False,CONCLUSIONS
347,Birth-weight is positively associated with breast cancer.,LOI of IGF2 has also been found in mammary tumor tissue.,False,CONCLUSIONS
348,Birth-weight is positively associated with breast cancer.,The role of environmental factors that stimulate such epigenetic regulation of gene expression remains to be elucidated.,False,CONCLUSIONS
349,Birth-weight is positively associated with breast cancer.,BACKGROUND Emerging evidence suggests an association between female prenatal experience and her subsequent risk of developing breast cancer.,False,OBJECTIVE
350,Birth-weight is positively associated with breast cancer.,"Potential underlying mechanisms include variation in amounts of maternal endogenous sex hormones and growth hormones, germ-cell mutations, formation of cancer stem-cells, and other genetic or epigenetic events.",False,OBJECTIVE
351,Birth-weight is positively associated with breast cancer.,"We reviewed and summarised quantitatively the available data on intrauterine exposures and risk of breast cancer.   
",False,OBJECTIVE
352,Birth-weight is positively associated with breast cancer.,METHODS We systematically searched for studies that assessed association between perinatal factors and risk of breast cancer.,False,METHODS
353,Birth-weight is positively associated with breast cancer.,"We reviewed separately each of the perinatal factors, including birthweight, birth length, parental age at delivery, gestational age, intrauterine exposure to diethylstilbestrol, twin membership, maternal pre-eclampsia or eclampsia, and other factors.   
",False,METHODS
354,Birth-weight is positively associated with breast cancer.,"FINDINGS We identified 57 studies published between Oct 1, 1980, and June 21, 2007.",False,RESULTS
355,Birth-weight is positively associated with breast cancer.,"Increased risk of breast cancer was noted with increased birthweight (relative risk [RR] 1.15 [95% CI 1.09-1.21]), birth length (1.28 [1.11-1.48]), higher maternal age (1.13 [1.02-1.25]), and paternal age (1.12 [1.05-1.19]).",True,RESULTS
356,Birth-weight is positively associated with breast cancer.,Decreased risk of breast cancer was noted for maternal pre-eclampsia and eclampsia (0.48 [0.30-0.78]) and twin membership (0.93 [0.87-1.00]).,False,RESULTS
357,Birth-weight is positively associated with breast cancer.,"No association was noted between risk of breast cancer and gestational age at birth (0.95 [0.71-1.26]) or maternal diethylstilbestrol treatment (1.40 [0.86-2.28]).   
",False,RESULTS
358,Birth-weight is positively associated with breast cancer.,INTERPRETATION The intrauterine environment contributes to the predisposition of women to breast cancer in adulthood.,False,CONCLUSIONS
359,Birth-weight is positively associated with breast cancer.,The in-utero mechanisms responsible for such predisposition need to be elucidated.,False,CONCLUSIONS
360,Birth-weight is positively associated with breast cancer.,"INTRODUCTION Various perinatal factors, including birth weight, birth order, maternal age, gestational age, twin status, and parental smoking, have been postulated to affect breast cancer risk in daughters by altering the hormonal environment of the developing fetal mammary glands.",False,BACKGROUND
361,Birth-weight is positively associated with breast cancer.,"Despite ample biologic plausibility, epidemiologic studies to date have yielded conflicting results.",False,BACKGROUND
362,Birth-weight is positively associated with breast cancer.,"We investigated the associations between perinatal factors and subsequent breast cancer risk through meta-analyses.   
",False,BACKGROUND
363,Birth-weight is positively associated with breast cancer.,"METHODS We reviewed breast cancer studies published from January 1966 to February 2007 that included data on birth weight, birth order, maternal age, gestational age, twin status, and maternal or paternal smoking.",False,METHODS
364,Birth-weight is positively associated with breast cancer.,"Meta-analyses using random effect models were employed to summarize the results.   
",False,METHODS
365,Birth-weight is positively associated with breast cancer.,"RESULTS We found that heavier birth weights were associated with increased breast cancer risk, with studies involving five categories of birth weight identifying odds ratios (ORs) of 1.24 (95% confidence interval [CI] 1.04 to 1.48) for 4,000 g or more and 1.15 (95% CI 1.04 to 1.26) for 3,500 g to 3,999 g, relative to a birth weight of 2,500 to 2,599 g. These studies provided no support for a J-shaped relationship of birthweight to risk.",True,RESULTS
366,Birth-weight is positively associated with breast cancer.,"Support for an association with birthweight was also derived from studies based on three birth weight categories (OR 1.15 [95% CI 1.01 to 1.31] for > or =4,000 g relative to <3,000 g) and two birth weight categories (OR 1.09 [95% CI 1.02 to 1.18] for > or =3,000 g relative to <3,000 g).",False,RESULTS
367,Birth-weight is positively associated with breast cancer.,"Women born to older mothers and twins were also at some increased risk, but the results were heterogeneous across studies and publication years.",False,RESULTS
368,Birth-weight is positively associated with breast cancer.,"Birth order, prematurity, and maternal smoking were unrelated to breast cancer risk.   
",False,CONCLUSIONS
369,Birth-weight is positively associated with breast cancer.,CONCLUSION Our findings provide some support for the hypothesis that in utero exposures reflective of higher endogenous hormone levels could affect risk for development of breast cancer in adulthood.,True,CONCLUSIONS
370,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 leads to increased TDP-43-induced neuronal loss.,"Genetic mutations in TAR DNA-binding protein 43 (TARDBP, also known as TDP-43) cause amyotrophic lateral sclerosis (ALS), and an increase in the presence of TDP-43 (encoded by TARDBP) in the cytoplasm is a prominent histopathological feature of degenerating neurons in various neurodegenerative diseases.",False,BACKGROUND
371,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 leads to increased TDP-43-induced neuronal loss.,"However, the molecular mechanisms by which TDP-43 contributes to ALS pathophysiology remain elusive.",False,BACKGROUND
372,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 leads to increased TDP-43-induced neuronal loss.,Here we have found that TDP-43 accumulates in the mitochondria of neurons in subjects with ALS or frontotemporal dementia (FTD).,False,BACKGROUND
373,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 leads to increased TDP-43-induced neuronal loss.,Disease-associated mutations increase TDP-43 mitochondrial localization.,False,RESULTS
374,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 leads to increased TDP-43-induced neuronal loss.,"In mitochondria, wild-type (WT) and mutant TDP-43 preferentially bind mitochondria-transcribed messenger RNAs (mRNAs) encoding respiratory complex I subunits ND3 and ND6, impair their expression and specifically cause complex I disassembly.",False,RESULTS
375,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 leads to increased TDP-43-induced neuronal loss.,"The suppression of TDP-43 mitochondrial localization abolishes WT and mutant TDP-43-induced mitochondrial dysfunction and neuronal loss, and improves phenotypes of transgenic mutant TDP-43 mice.",True,CONCLUSIONS
376,Blocking the interaction between TDP-43 and respiratory complex I proteins ND3 and ND6 leads to increased TDP-43-induced neuronal loss.,"Thus, our studies link TDP-43 toxicity directly to mitochondrial bioenergetics and propose the targeting of TDP-43 mitochondrial localization as a promising therapeutic approach for neurodegeneration.",False,CONCLUSIONS
377,Bone marrow cells contribute to adult macrophage compartments.,"Despite accumulating evidence suggesting local self-maintenance of tissue macrophages in the steady state, the dogma remains that tissue macrophages derive from monocytes.",False,BACKGROUND
378,Bone marrow cells contribute to adult macrophage compartments.,"Using parabiosis and fate-mapping approaches, we confirmed that monocytes do not show significant contribution to tissue macrophages in the steady state.",False,BACKGROUND
379,Bone marrow cells contribute to adult macrophage compartments.,"Similarly, we found that after depletion of lung macrophages, the majority of repopulation occurred by stochastic cellular proliferation in situ in a macrophage colony-stimulating factor (M-Csf)- and granulocyte macrophage (GM)-CSF-dependent manner but independently of interleukin-4.",False,RESULTS
380,Bone marrow cells contribute to adult macrophage compartments.,"We also found that after bone marrow transplantation, host macrophages retained the capacity to expand when the development of donor macrophages was compromised.",True,RESULTS
381,Bone marrow cells contribute to adult macrophage compartments.,Expansion of host macrophages was functional and prevented the development of alveolar proteinosis in mice transplanted with GM-Csf-receptor-deficient progenitors.,False,CONCLUSIONS
382,Bone marrow cells contribute to adult macrophage compartments.,"Collectively, these results indicate that tissue-resident macrophages and circulating monocytes should be classified as mononuclear phagocyte lineages that are independently maintained in the steady state.",False,CONCLUSIONS
383,Breast cancer development is determined exclusively by genetic factors.,"BACKGROUND Information is scarce about the combined effects on breast cancer incidence of low-penetrance genetic susceptibility polymorphisms and environmental factors (reproductive, behavioural, and anthropometric risk factors for breast cancer).",False,BACKGROUND
384,Breast cancer development is determined exclusively by genetic factors.,"To test for evidence of gene-environment interactions, we compared genotypic relative risks for breast cancer across the other risk factors in a large UK prospective study.   
",False,BACKGROUND
385,Breast cancer development is determined exclusively by genetic factors.,"METHODS We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption).   
",True,METHODS
386,Breast cancer development is determined exclusively by genetic factors.,FINDINGS After allowance for multiple testing none of the 120 comparisons yielded significant evidence of a gene-environment interaction.,False,RESULTS
387,Breast cancer development is determined exclusively by genetic factors.,"By contrast with previous suggestions, there was little evidence that the genotypic relative risks were affected by use of hormone replacement therapy, either overall or for oestrogen-receptor-positive disease.",False,RESULTS
388,Breast cancer development is determined exclusively by genetic factors.,"Only one of the 12 polymorphisms was correlated with any of the ten other risk factors: carriers of the high-risk C allele of MAP3K1-rs889312 were significantly shorter than non-carriers (mean height 162.4 cm [95% CI 162.1-162.7] vs 163.1 cm [162.9-163.2]; p=0.01 after allowance for multiple testing).   
",False,RESULTS
389,Breast cancer development is determined exclusively by genetic factors.,"INTERPRETATION Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.   
",True,CONCLUSIONS
390,Breast cancer development is determined exclusively by genetic factors.,FUNDING Cancer Research UK and the UK Medical Research Council.,False,CONCLUSIONS
391,CHEK2 is not associated with breast cancer.,Background Checkpoint kinase 2 (CHEK2) averts cancer development by promoting cell cycle arrest and activating DNA repair in genetically damaged cells.,False,OBJECTIVE
392,CHEK2 is not associated with breast cancer.,"Previous investigation has established a role for the CHEK2 gene in breast cancer aetiology, but studies have largely been limited to the rare 1100delC mutation.",False,OBJECTIVE
393,CHEK2 is not associated with breast cancer.,Whether common polymorphisms in this gene influence breast cancer risk remains unknown.,False,OBJECTIVE
394,CHEK2 is not associated with breast cancer.,"In this study, we aimed to assess the importance of common CHEK2 variants on population risk for breast cancer by capturing the majority of diversity in the gene using haplotype tagging single nucleotide polymorphisms (tagSNPs).",False,OBJECTIVE
395,CHEK2 is not associated with breast cancer.,Methods and Findings We analyzed 14 common SNPs spanning 52 kilobases (kb) of the CHEK2 gene in 92 Swedish women.,False,METHODS
396,CHEK2 is not associated with breast cancer.,Coverage evaluation indicated that these typed SNPs would efficiently convey association signal also from untyped SNPs in the same region.,False,METHODS
397,CHEK2 is not associated with breast cancer.,Six of the 14 SNPs predicted well both the haplotypic and single SNP variations within CHEK2.,False,RESULTS
398,CHEK2 is not associated with breast cancer.,"We genotyped these six tagSNPs in 1,577 postmenopausal breast cancer cases and 1,513 population controls, but found no convincing association between any common CHEK2 haplotype and breast cancer risk.",True,RESULTS
399,CHEK2 is not associated with breast cancer.,"The 1100delC mutation was rare in our Swedish population—0.7% in cases and 0.4% in controls— with a corresponding odds ratio for carriers versus noncarriers of 2.26 (95% confidence interval, 0.99–5.15).",False,RESULTS
400,CHEK2 is not associated with breast cancer.,Estimates of the population frequency and the odds ratio of 1100delC indicate that our sample is representative of a Northern European population.,False,RESULTS
401,CR is associated with higher methylation age.,"In mammals, caloric restriction consistently results in extended lifespan.",False,BACKGROUND
402,CR is associated with higher methylation age.,"Epigenetic information encoded by DNA methylation is tightly regulated, but shows a striking drift associated with age that includes both gains and losses of DNA methylation at various sites.",True,BACKGROUND
403,CR is associated with higher methylation age.,"Here, we report that epigenetic drift is conserved across species and the rate of drift correlates with lifespan when comparing mice, rhesus monkeys, and humans.",False,BACKGROUND
404,CR is associated with higher methylation age.,Twenty-two to 30-year-old rhesus monkeys exposed to 30% caloric restriction since 7-14 years of age showed attenuation of age-related methylation drift compared to ad libitum-fed controls such that their blood methylation age appeared 7 years younger than their chronologic age.,True,METHODS
405,CR is associated with higher methylation age.,Even more pronounced effects were seen in 2.7-3.2-year-old mice exposed to 40% caloric restriction starting at 0.3 years of age.,True,RESULTS
406,CR is associated with higher methylation age.,The effects of caloric restriction on DNA methylation were detectable across different tissues and correlated with gene expression.,False,RESULTS
407,CR is associated with higher methylation age.,We propose that epigenetic drift is a determinant of lifespan in mammals.,False,CONCLUSIONS
408,CR is associated with higher methylation age.,Caloric restriction has been shown to increase lifespan in mammals.,True,CONCLUSIONS
409,CR is associated with higher methylation age.,"Here, the authors provide evidence that age-related methylation drift correlates with lifespan and that caloric restriction in mice and rhesus monkeys results in attenuation of age-related methylation drift.",True,CONCLUSIONS
410,CX3CR1 on the Th2 cells impairs T cell survival,Allergic asthma is a T helper type 2 (T(H)2)-dominated disease of the lung.,False,BACKGROUND
411,CX3CR1 on the Th2 cells impairs T cell survival,"In people with asthma, a fraction of CD4(+) T cells express the CX3CL1 receptor, CX3CR1, and CX3CL1 expression is increased in airway smooth muscle, lung endothelium and epithelium upon allergen challenge.",False,BACKGROUND
412,CX3CR1 on the Th2 cells impairs T cell survival,Here we found that untreated CX3CR1-deficient mice or wild-type (WT) mice treated with CX3CR1-blocking reagents show reduced lung disease upon allergen sensitization and challenge.,False,BACKGROUND
413,CX3CR1 on the Th2 cells impairs T cell survival,"Transfer of WT CD4(+) T cells into CX3CR1-deficient mice restored the cardinal features of asthma, and CX3CR1-blocking reagents prevented airway inflammation in CX3CR1-deficient recipients injected with WT T(H)2 cells.",False,RESULTS
414,CX3CR1 on the Th2 cells impairs T cell survival,"We found that CX3CR1 signaling promoted T(H)2 survival in the inflamed lungs, and injection of B cell leukemia/lymphoma-2 protein (BCl-2)-transduced CX3CR1-deficient T(H)2 cells into CX3CR1-deficient mice restored asthma.",True,RESULTS
415,CX3CR1 on the Th2 cells impairs T cell survival,CX3CR1-induced survival was also observed for T(H)1 cells upon airway inflammation but not under homeostatic conditions or upon peripheral inflammation.,False,RESULTS
416,CX3CR1 on the Th2 cells impairs T cell survival,"Therefore, CX3CR1 and CX3CL1 may represent attractive therapeutic targets in asthma.",False,CONCLUSIONS
417,CX3CR1 on the Th2 cells promotes T cell survival,Allergic asthma is a T helper type 2 (T(H)2)-dominated disease of the lung.,False,BACKGROUND
418,CX3CR1 on the Th2 cells promotes T cell survival,"In people with asthma, a fraction of CD4(+) T cells express the CX3CL1 receptor, CX3CR1, and CX3CL1 expression is increased in airway smooth muscle, lung endothelium and epithelium upon allergen challenge.",False,BACKGROUND
419,CX3CR1 on the Th2 cells promotes T cell survival,Here we found that untreated CX3CR1-deficient mice or wild-type (WT) mice treated with CX3CR1-blocking reagents show reduced lung disease upon allergen sensitization and challenge.,False,BACKGROUND
420,CX3CR1 on the Th2 cells promotes T cell survival,"Transfer of WT CD4(+) T cells into CX3CR1-deficient mice restored the cardinal features of asthma, and CX3CR1-blocking reagents prevented airway inflammation in CX3CR1-deficient recipients injected with WT T(H)2 cells.",False,RESULTS
421,CX3CR1 on the Th2 cells promotes T cell survival,"We found that CX3CR1 signaling promoted T(H)2 survival in the inflamed lungs, and injection of B cell leukemia/lymphoma-2 protein (BCl-2)-transduced CX3CR1-deficient T(H)2 cells into CX3CR1-deficient mice restored asthma.",True,RESULTS
422,CX3CR1 on the Th2 cells promotes T cell survival,CX3CR1-induced survival was also observed for T(H)1 cells upon airway inflammation but not under homeostatic conditions or upon peripheral inflammation.,False,RESULTS
423,CX3CR1 on the Th2 cells promotes T cell survival,"Therefore, CX3CR1 and CX3CL1 may represent attractive therapeutic targets in asthma.",False,CONCLUSIONS
424,CX3CR1 on the Th2 cells promotes airway inflammation.,Allergic asthma is a T helper type 2 (T(H)2)-dominated disease of the lung.,False,BACKGROUND
425,CX3CR1 on the Th2 cells promotes airway inflammation.,"In people with asthma, a fraction of CD4(+) T cells express the CX3CL1 receptor, CX3CR1, and CX3CL1 expression is increased in airway smooth muscle, lung endothelium and epithelium upon allergen challenge.",False,BACKGROUND
426,CX3CR1 on the Th2 cells promotes airway inflammation.,Here we found that untreated CX3CR1-deficient mice or wild-type (WT) mice treated with CX3CR1-blocking reagents show reduced lung disease upon allergen sensitization and challenge.,True,BACKGROUND
427,CX3CR1 on the Th2 cells promotes airway inflammation.,"Transfer of WT CD4(+) T cells into CX3CR1-deficient mice restored the cardinal features of asthma, and CX3CR1-blocking reagents prevented airway inflammation in CX3CR1-deficient recipients injected with WT T(H)2 cells.",True,RESULTS
428,CX3CR1 on the Th2 cells promotes airway inflammation.,"We found that CX3CR1 signaling promoted T(H)2 survival in the inflamed lungs, and injection of B cell leukemia/lymphoma-2 protein (BCl-2)-transduced CX3CR1-deficient T(H)2 cells into CX3CR1-deficient mice restored asthma.",False,RESULTS
429,CX3CR1 on the Th2 cells promotes airway inflammation.,CX3CR1-induced survival was also observed for T(H)1 cells upon airway inflammation but not under homeostatic conditions or upon peripheral inflammation.,True,RESULTS
430,CX3CR1 on the Th2 cells promotes airway inflammation.,"Therefore, CX3CR1 and CX3CL1 may represent attractive therapeutic targets in asthma.",False,CONCLUSIONS
431,CX3CR1 on the Th2 cells suppresses airway inflammation.,Allergic asthma is a T helper type 2 (T(H)2)-dominated disease of the lung.,False,BACKGROUND
432,CX3CR1 on the Th2 cells suppresses airway inflammation.,"In people with asthma, a fraction of CD4(+) T cells express the CX3CL1 receptor, CX3CR1, and CX3CL1 expression is increased in airway smooth muscle, lung endothelium and epithelium upon allergen challenge.",False,BACKGROUND
433,CX3CR1 on the Th2 cells suppresses airway inflammation.,Here we found that untreated CX3CR1-deficient mice or wild-type (WT) mice treated with CX3CR1-blocking reagents show reduced lung disease upon allergen sensitization and challenge.,True,BACKGROUND
434,CX3CR1 on the Th2 cells suppresses airway inflammation.,"Transfer of WT CD4(+) T cells into CX3CR1-deficient mice restored the cardinal features of asthma, and CX3CR1-blocking reagents prevented airway inflammation in CX3CR1-deficient recipients injected with WT T(H)2 cells.",True,RESULTS
435,CX3CR1 on the Th2 cells suppresses airway inflammation.,"We found that CX3CR1 signaling promoted T(H)2 survival in the inflamed lungs, and injection of B cell leukemia/lymphoma-2 protein (BCl-2)-transduced CX3CR1-deficient T(H)2 cells into CX3CR1-deficient mice restored asthma.",False,RESULTS
436,CX3CR1 on the Th2 cells suppresses airway inflammation.,CX3CR1-induced survival was also observed for T(H)1 cells upon airway inflammation but not under homeostatic conditions or upon peripheral inflammation.,False,RESULTS
437,CX3CR1 on the Th2 cells suppresses airway inflammation.,"Therefore, CX3CR1 and CX3CL1 may represent attractive therapeutic targets in asthma.",False,CONCLUSIONS
438,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,BACKGROUND Alcohol has been reported to be a common and modifiable risk factor for hypertension.,False,BACKGROUND
439,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,"However, observational studies are subject to confounding by other behavioural and sociodemographic factors, while clinical trials are difficult to implement and have limited follow-up time.",False,BACKGROUND
440,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,Mendelian randomization can provide robust evidence on the nature of this association by use of a common polymorphism in aldehyde dehydrogenase 2 (ALDH2) as a surrogate for measuring alcohol consumption.,False,BACKGROUND
441,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,ALDH2 encodes a major enzyme involved in alcohol metabolism.,False,BACKGROUND
442,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,Individuals homozygous for the null variant (*2*2) experience adverse symptoms when drinking alcohol and consequently drink considerably less alcohol than wild-type homozygotes (*1*1) or heterozygotes.,True,BACKGROUND
443,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,"We hypothesise that this polymorphism may influence the risk of hypertension by affecting alcohol drinking behaviour.   
",False,BACKGROUND
444,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,"METHODS AND FINDINGS We carried out fixed effect meta-analyses of the ALDH2 genotype with blood pressure (five studies, n = 7,658) and hypertension (three studies, n = 4,219) using studies identified via systematic review.",False,METHODS
445,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,"In males, we obtained an overall odds ratio of 2.42 (95% confidence interval [CI] 1.66-3.55, p = 4.8 x 10(-6)) for hypertension comparing *1*1 with *2*2 homozygotes and an odds ratio of 1.72 (95% CI 1.17-2.52, p = 0.006) comparing heterozygotes (surrogate for moderate drinkers) with *2*2 homozygotes.",False,RESULTS
446,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,"Systolic blood pressure was 7.44 mmHg (95% CI 5.39-9.49, p = 1.1 x 10(-12)) greater among *1*1 than among *2*2 homozygotes, and 4.24 mmHg (95% CI 2.18-6.31, p = 0.00005) greater among heterozygotes than among *2*2 homozygotes.   
",False,RESULTS
447,Carriers of the alcohol aldehyde dehydrogenase deficiency mutation drink less that non-carries.,CONCLUSIONS These findings support the hypothesis that alcohol intake has a marked effect on blood pressure and the risk of hypertension.,False,CONCLUSIONS
448,Cell autonomous sex determination in somatic cells does not occur in Galliformes.,"In the mammalian model of sex determination, embryos are considered to be sexually indifferent until the transient action of a sex-determining gene initiates gonadal differentiation.",False,BACKGROUND
449,Cell autonomous sex determination in somatic cells does not occur in Galliformes.,"Although this model is thought to apply to all vertebrates, this has yet to be established.",False,BACKGROUND
450,Cell autonomous sex determination in somatic cells does not occur in Galliformes.,"Here we have examined three lateral gynandromorph chickens (a rare, naturally occurring phenomenon in which one side of the animal appears male and the other female) to investigate the sex-determining mechanism in birds.",False,BACKGROUND
451,Cell autonomous sex determination in somatic cells does not occur in Galliformes.,"These studies demonstrated that gynandromorph birds are genuine male:female chimaeras, and indicated that male and female avian somatic cells may have an inherent sex identity.",True,METHODS
452,Cell autonomous sex determination in somatic cells does not occur in Galliformes.,"To test this hypothesis, we transplanted presumptive mesoderm between embryos of reciprocal sexes to generate embryos containing male:female chimaeric gonads.",False,METHODS
453,Cell autonomous sex determination in somatic cells does not occur in Galliformes.,"In contrast to the outcome for mammalian mixed-sex chimaeras, in chicken mixed-sex chimaeras the donor cells were excluded from the functional structures of the host gonad.",False,RESULTS
454,Cell autonomous sex determination in somatic cells does not occur in Galliformes.,"In an example where female tissue was transplanted into a male host, donor cells contributing to the developing testis retained a female identity and expressed a marker of female function.",True,RESULTS
455,Cell autonomous sex determination in somatic cells does not occur in Galliformes.,"Our study demonstrates that avian somatic cells possess an inherent sex identity and that, in birds, sexual differentiation is substantively cell autonomous.",True,CONCLUSIONS
456,Cell autonomous sex determination in somatic cells occurs in Passeriformes.,"In the mammalian model of sex determination, embryos are considered to be sexually indifferent until the transient action of a sex-determining gene initiates gonadal differentiation.",False,BACKGROUND
457,Cell autonomous sex determination in somatic cells occurs in Passeriformes.,"Although this model is thought to apply to all vertebrates, this has yet to be established.",False,BACKGROUND
458,Cell autonomous sex determination in somatic cells occurs in Passeriformes.,"Here we have examined three lateral gynandromorph chickens (a rare, naturally occurring phenomenon in which one side of the animal appears male and the other female) to investigate the sex-determining mechanism in birds.",False,BACKGROUND
459,Cell autonomous sex determination in somatic cells occurs in Passeriformes.,"These studies demonstrated that gynandromorph birds are genuine male:female chimaeras, and indicated that male and female avian somatic cells may have an inherent sex identity.",True,METHODS
460,Cell autonomous sex determination in somatic cells occurs in Passeriformes.,"To test this hypothesis, we transplanted presumptive mesoderm between embryos of reciprocal sexes to generate embryos containing male:female chimaeric gonads.",False,METHODS
461,Cell autonomous sex determination in somatic cells occurs in Passeriformes.,"In contrast to the outcome for mammalian mixed-sex chimaeras, in chicken mixed-sex chimaeras the donor cells were excluded from the functional structures of the host gonad.",False,RESULTS
462,Cell autonomous sex determination in somatic cells occurs in Passeriformes.,"In an example where female tissue was transplanted into a male host, donor cells contributing to the developing testis retained a female identity and expressed a marker of female function.",True,RESULTS
463,Cell autonomous sex determination in somatic cells occurs in Passeriformes.,"Our study demonstrates that avian somatic cells possess an inherent sex identity and that, in birds, sexual differentiation is substantively cell autonomous.",True,CONCLUSIONS
464,Cellular aging closely links to an older appearance.,"OBJECTIVE To determine whether perceived age correlates with survival and important age related phenotypes.   
",False,OBJECTIVE
465,Cellular aging closely links to an older appearance.,"DESIGN Follow-up study, with survival of twins determined up to January 2008, by which time 675 (37%) had died.   
",False,METHODS
466,Cellular aging closely links to an older appearance.,"SETTING Population based twin cohort in Denmark.   
",False,METHODS
467,Cellular aging closely links to an older appearance.,"PARTICIPANTS 20 nurses, 10 young men, and 11 older women (assessors); 1826 twins aged >or=70.   
",False,METHODS
468,Cellular aging closely links to an older appearance.,MAIN OUTCOME MEASURES Assessors: perceived age of twins from photographs.,False,METHODS
469,Cellular aging closely links to an older appearance.,"Twins: physical and cognitive tests and molecular biomarker of ageing (leucocyte telomere length).   
",False,METHODS
470,Cellular aging closely links to an older appearance.,"RESULTS For all three groups of assessors, perceived age was significantly associated with survival, even after adjustment for chronological age, sex, and rearing environment.",False,RESULTS
471,Cellular aging closely links to an older appearance.,Perceived age was still significantly associated with survival after further adjustment for physical and cognitive functioning.,False,RESULTS
472,Cellular aging closely links to an older appearance.,"The likelihood that the older looking twin of the pair died first increased with increasing discordance in perceived age within the twin pair-that is, the bigger the difference in perceived age within the pair, the more likely that the older looking twin died first.",False,RESULTS
473,Cellular aging closely links to an older appearance.,Twin analyses suggested that common genetic factors influence both perceived age and survival.,False,RESULTS
474,Cellular aging closely links to an older appearance.,"Perceived age, controlled for chronological age and sex, also correlated significantly with physical and cognitive functioning as well as with leucocyte telomere length.   
",True,RESULTS
475,Cellular aging closely links to an older appearance.,CONCLUSION Perceived age-which is widely used by clinicians as a general indication of a patient's health-is a robust biomarker of ageing that predicts survival among those aged >or=70 and correlates with important functional and molecular ageing phenotypes.,True,CONCLUSIONS
476,Chenodeosycholic acid treatment increases whole-body energy expenditure.,The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.,False,BACKGROUND
477,Chenodeosycholic acid treatment increases whole-body energy expenditure.,"In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.",True,BACKGROUND
478,Chenodeosycholic acid treatment increases whole-body energy expenditure.,Here we examined the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.,False,BACKGROUND
479,Chenodeosycholic acid treatment increases whole-body energy expenditure.,Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.,True,RESULTS
480,Chenodeosycholic acid treatment increases whole-body energy expenditure.,Whole-body energy expenditure was also increased upon CDCA treatment.,True,RESULTS
481,Chenodeosycholic acid treatment increases whole-body energy expenditure.,"In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.",False,CONCLUSIONS
482,Chenodeosycholic acid treatment increases whole-body energy expenditure.,These findings identify bile acids as a target to activate BAT in humans.,False,CONCLUSIONS
483,Chenodeosycholic acid treatment reduces whole-body energy expenditure.,The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.,False,BACKGROUND
484,Chenodeosycholic acid treatment reduces whole-body energy expenditure.,"In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.",True,BACKGROUND
485,Chenodeosycholic acid treatment reduces whole-body energy expenditure.,Here we examined the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.,False,BACKGROUND
486,Chenodeosycholic acid treatment reduces whole-body energy expenditure.,Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.,True,RESULTS
487,Chenodeosycholic acid treatment reduces whole-body energy expenditure.,Whole-body energy expenditure was also increased upon CDCA treatment.,True,RESULTS
488,Chenodeosycholic acid treatment reduces whole-body energy expenditure.,"In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.",False,CONCLUSIONS
489,Chenodeosycholic acid treatment reduces whole-body energy expenditure.,These findings identify bile acids as a target to activate BAT in humans.,False,CONCLUSIONS
490,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",BACKGROUND Endothelium-dependent modulation of coronary tone is impaired in the collateral-dependent coronary microcirculation.,False,BACKGROUND
491,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","We used a porcine model of chronic coronary occlusion and collateral development to evaluate the hypothesis that exercise training enhances endothelium-mediated relaxation and increases endothelial nitric oxide synthase (ecNOS) mRNA levels of collateral-dependent microvasculature.   
",False,BACKGROUND
492,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","METHODS AND RESULTS Adult female miniature swine were subjected to chronic, progressive ameroid occlusion of the proximal left circumflex coronary artery (LCx); after 2 months, animals were randomly exposed to 16-week exercise-training (EX group; treadmill running) or sedentary (SED group; cage confinement) protocols.",False,METHODS
493,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","After completion of EX or SED programs, coronary arterioles ( approximately 100 microm in diameter) were isolated from collateral-dependent LCx (distal to occlusion) and nonoccluded left anterior descending coronary artery (LAD) regions of each heart.",False,METHODS
494,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",Arterioles were studied by in vitro videomicroscopy or frozen for ecNOS mRNA analysis (RT-PCR techniques).,False,METHODS
495,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",Relaxation to the endothelium-dependent vasodilator bradykinin was decreased (P<0.05) in arterioles isolated from collateral-dependent LCx versus nonoccluded LAD regions of SED animals.,True,RESULTS
496,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","Bradykinin-mediated relaxation, however, was not different in LCx versus LAD arterioles isolated from EX animals.",False,RESULTS
497,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",Nitroprusside-induced relaxation was unaffected by either chronic occlusion or exercise.,False,RESULTS
498,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","Importantly, ecNOS mRNA expression was significantly decreased in arterioles isolated from LCx versus LAD regions of SED animals.",False,RESULTS
499,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","After training, ecNOS mRNA expression was not different between LAD and LCx arterioles.   
",False,RESULTS
500,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","CONCLUSIONS These data indicate that exercise training enhances bradykinin-mediated relaxation of collateral-dependent LCx arterioles isolated after chronic coronary occlusion, most likely because of effects on ecNOS mRNA expression and increased production of NO.",True,CONCLUSIONS
501,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","BACKGROUND The purpose of this study was to test the hypothesis that vasodilator responses of porcine coronary resistance arteries are increased by exercise training.   
",False,OBJECTIVE
502,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",METHODS AND RESULTS Yucatan miniature swine were randomly divided into groups of exercise-trained (ET) and sedentary (SED) control pigs.,False,METHODS
503,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","ET pigs were placed on a progressive treadmill training program lasting 16 to 20 weeks, and SED pigs remained inactive during the same time period.",False,METHODS
504,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","Coronary resistance arteries 64 to 157 microns in diameter were isolated for in vitro evaluation of relaxation responses to the endothelium-independent dilators sodium nitroprusside (1 x 10(-10) to 1 x 10(-4) mol/L) and adenosine (1 x 10(-10) to 1 x 10(-5) mol/L) and to bradykinin (1 x 10(-13) to 3 x 10(-7) mol/L), an endothelium-dependent agent.",False,METHODS
505,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",Relaxation responses to adenosine and sodium nitroprusside were not altered by exercise training.,False,RESULTS
506,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","Endothelium-dependent relaxation to bradykinin was enhanced in coronary resistance arteries from ET pigs (IC50: ET, 0.07 +/-",False,RESULTS
507,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","0.02 nmol/L; SED, 1.59 +/-",False,RESULTS
508,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",0.09 nmol/L).,False,RESULTS
509,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","To determine whether prostanoids and/or the nitric oxide synthase pathway were involved in the ET-induced changes in bradykinin-induced vasodilation, responses to bradykinin were examined in coronary resistance arteries from both ET and SED pigs in the presence of indomethacin and in the presence of nitro-monomethyl L-arginine (L-NMMA).",False,RESULTS
510,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",Both indomethacin and L-NMMA produced significant inhibition of the bradykinin-induced relaxation in vessels from both groups.,False,RESULTS
511,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","Despite decreased bradykinin-induced relaxation after indomethacin, bradykinin-induced vasodilation was still enhanced in vessels from the ET group.",False,RESULTS
512,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.","L-NMMA caused greater inhibition of the bradykinin-induced relaxation in coronary resistance arteries from ET pigs relative to arteries from SED pigs and eliminated the training-induced enhancement of the bradykinin responses.   
",False,CONCLUSIONS
513,"Chronic aerobic exercise alters endothelial function, improving vasodilating mechanisms mediated by NO.",CONCLUSIONS These results suggest that exercise training enhances bradykinin-induced vasodilation through increased endothelium-derived relaxing factor/nitric oxide production by the L-arginine/nitric oxide synthase pathway.,True,CONCLUSIONS
514,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.   
",False,BACKGROUND
515,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.   
",False,OBJECTIVE
516,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites.",False,METHODS
517,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"Five hundred six adult (≥18 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.   
",False,METHODS
518,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.   
",False,METHODS
519,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence.",False,METHODS
520,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.,False,METHODS
521,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"Outcomes were biochemically confirmed.   
",False,METHODS
522,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively).",False,RESULTS
523,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively).",False,RESULTS
524,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively).",True,RESULTS
525,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).   
",False,RESULTS
526,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks.",False,CONCLUSIONS
527,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,Neither outcome was significantly different at 52 weeks.,True,CONCLUSIONS
528,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,"Further research is required to determine the role of combination therapy in smoking cessation.   
",False,CONCLUSIONS
529,Combination nicotine replacement therapies with varenicline or bupropion lead to significantly higher long-term abstinence rates at 52 weeks than varenicline monotherapy.,TRIAL REGISTRATION clinicaltrials.gov Identifier: http://clinicaltrials.gov/show/NCT00935818.,False,CONCLUSIONS
530,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-alpha catalytic subunit (encoded by PIK3CA).,False,BACKGROUND
531,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R).,False,BACKGROUND
532,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"Although the p110-alpha mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models.",False,BACKGROUND
533,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"Furthermore, clinical trials with PI3K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies.",False,BACKGROUND
534,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p110-alpha H1047R.",False,METHODS
535,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"Treatment of these tumors with NVP-BEZ235, a dual pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor in clinical development, led to marked tumor regression as shown by positron emission tomography-computed tomography, magnetic resonance imaging and microscopic examination.",False,RESULTS
536,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to single-agent NVP-BEZ235.",False,RESULTS
537,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these Kras-mutant cancers.",True,RESULTS
538,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and, when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.",True,CONCLUSIONS
539,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"Phosphatidylinositol-3-kinase (PI3K) pathway deregulation is a common event in human cancer, either through inactivation of the tumor suppressor phosphatase and tensin homologue deleted from chromosome 10 or activating mutations of p110-alpha.",False,BACKGROUND
540,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,These hotspot mutations result in oncogenic activity of the enzyme and contribute to therapeutic resistance to the anti-HER2 antibody trastuzumab.,False,BACKGROUND
541,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"The PI3K pathway is, therefore, an attractive target for cancer therapy.",False,BACKGROUND
542,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"We have studied NVP-BEZ235, a dual inhibitor of the PI3K and the downstream mammalian target of rapamycin (mTOR).",False,BACKGROUND
543,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"NVP-BEZ235 inhibited the activation of the downstream effectors Akt, S6 ribosomal protein, and 4EBP1 in breast cancer cells.",False,RESULTS
544,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,The antiproliferative activity of NVP-BEZ235 was superior to the allosteric selective mTOR complex inhibitor everolimus in a panel of 21 cancer cell lines of different origin and mutation status.,False,RESULTS
545,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,The described Akt activation due to mTOR inhibition was prevented by higher doses of NVP-BEZ235.,False,RESULTS
546,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"NVP-BEZ235 reversed the hyperactivation of the PI3K/mTOR pathway caused by the oncogenic mutations of p110-alpha, E545K, and H1047R, and inhibited the proliferation of HER2-amplified BT474 cells exogenously expressing these mutations that render them resistant to trastuzumab.",False,RESULTS
547,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"In trastuzumab-resistant BT474 H1047R breast cancer xenografts, NVP-BEZ235 inhibited PI3K signaling and had potent antitumor activity.",False,RESULTS
548,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"In treated animals, there was complete inhibition of PI3K signaling in the skin at pharmacologically active doses, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies.",False,RESULTS
549,Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.,"In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha.",True,CONCLUSIONS
550,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,The non-enveloped bacilliform viruses are the second group of plant viruses known to possess a genome consisting of circular double-stranded DNA.,False,BACKGROUND
551,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,"We have characterized the viral transcript and determined the complete sequence of the genome of Commelina mellow mottle virus (CoYMV), a member of this group.",False,BACKGROUND
552,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,Analysis of the viral transcript indicates that the virus encodes a single terminally-redundant genome-length plus 120 nucleotide transcript.,False,RESULTS
553,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,"A fraction of the transcripts is polyadenylated, although the majority of the transcript is not polyadenylated.",False,RESULTS
554,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,"Analysis of the genome sequence indicates that the genome is 7489 bp in size and that the transcribed strand contains three open reading frames capable of encoding proteins of 23, 15 and 216 kd.",True,RESULTS
555,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,The function of the 25 and 15 kd proteins is unknown.,False,RESULTS
556,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,"Similarities between the 216 kd polypeptide and the cauliflower mosaic virus coat protein and protease/reverse transcriptase polyprotein suggest that the 216 kd polypeptide is a polyprotein that is proteolytically processed to yield the virion coat protein, a protease, and replicase (reverse transcriptase and ribonuclease H).",False,RESULTS
557,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,Each strand of the CoYMV genome is interrupted by site-specific discontinuities.,False,RESULTS
558,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,"The locations of the 5'-ends of these discontinuities, and the presence and location of a region on the CoYMV transcript capable of annealing with the 3'-end of cytosolic initiator methionine tRNA are consistent with replication by reverse transcription.",False,RESULTS
559,Commelina yellow mottle virus' (ComYMV) genome consists of 7489 baise pairs.,"We have demonstrated that a construct containing 1.3 CoYMV genomes is infective when introduced into Commelina diffusa, the host for CoYMV, using Agrobacterium-mediated infection.",False,CONCLUSIONS
560,Crosstalk between dendritic cells (DCs) and innate lymphoid cells (ILCs) is important in the regulation of intestinal homeostasis.,Mice lacking the transcription factor T-bet in the innate immune system develop microbiota-dependent colitis.,False,BACKGROUND
561,Crosstalk between dendritic cells (DCs) and innate lymphoid cells (ILCs) is important in the regulation of intestinal homeostasis.,"Here, we show that interleukin-17A (IL-17A)-producing IL-7Rα(+) innate lymphoid cells (ILCs) were potent promoters of disease in Tbx21(-/-)Rag2(-/-) ulcerative colitis (TRUC) mice.",False,BACKGROUND
562,Crosstalk between dendritic cells (DCs) and innate lymphoid cells (ILCs) is important in the regulation of intestinal homeostasis.,"TNF-α produced by CD103(-)CD11b(+) dendritic cells synergized with IL-23 to drive IL-17A production by ILCs, demonstrating a previously unrecognized layer of cellular crosstalk between dendritic cells and ILCs.",True,RESULTS
563,Crosstalk between dendritic cells (DCs) and innate lymphoid cells (ILCs) is important in the regulation of intestinal homeostasis.,We have identified Helicobacter typhlonius as a key disease trigger driving excess TNF-α production and promoting colitis in TRUC mice.,False,RESULTS
564,Crosstalk between dendritic cells (DCs) and innate lymphoid cells (ILCs) is important in the regulation of intestinal homeostasis.,"Crucially, T-bet also suppressed the expression of IL-7R, a key molecule involved in controlling intestinal ILC homeostasis.",True,RESULTS
565,Crosstalk between dendritic cells (DCs) and innate lymphoid cells (ILCs) is important in the regulation of intestinal homeostasis.,The importance of IL-7R signaling in TRUC disease was highlighted by the dramatic reduction in intestinal ILCs and attenuated colitis following IL-7R blockade.,True,CONCLUSIONS
566,Crosstalk between dendritic cells (DCs) and innate lymphoid cells (ILCs) is important in the regulation of intestinal homeostasis.,"Taken together, these data demonstrate the mechanism by which T-bet regulates the complex interplay between mucosal dendritic cells, ILCs, and the intestinal microbiota.",True,CONCLUSIONS
567,Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.,"Apoptosis that proceeds via the mitochondrial pathway involves mitochondrial outer membrane permeabilization (MOMP), responsible for the release of cytochrome c and other proteins of the mitochondrial intermembrane space.",True,BACKGROUND
568,Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.,This essential step is controlled and mediated by proteins of the Bcl-2 family.,False,BACKGROUND
569,Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.,"The proapoptotic proteins Bax and Bak are required for MOMP, while the antiapoptotic Bcl-2 proteins, including Bcl-2, Bcl-xL, Mcl-1, and others, prevent MOMP.",False,BACKGROUND
570,Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.,Different proapoptotic BH3-only proteins act to interfere with the function of the antiapoptotic Bcl-2 members and/or activate Bax and Bak.,False,BACKGROUND
571,Cytochrome c is released from the mitochondrial intermembrane space to cytosol during apoptosis.,"Here, we discuss an emerging view, proposed by Certo et al. in this issue of Cancer Cell, on how these interactions result in MOMP and apoptosis.",False,BACKGROUND
572,Deamination of cytidine to uridine on the minus strand of viral DNA results in catastrophic G-to-A mutations in the viral genome.,"Viral replication usually requires that innate intracellular lines of defence be overcome, a task usually accomplished by specialized viral gene products.",False,BACKGROUND
573,Deamination of cytidine to uridine on the minus strand of viral DNA results in catastrophic G-to-A mutations in the viral genome.,"The virion infectivity factor (Vif) protein of human immunodeficiency virus (HIV) is required during the late stages of viral production to counter the antiviral activity of APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; also known as CEM15), a protein expressed notably in human T lymphocytes.",False,BACKGROUND
574,Deamination of cytidine to uridine on the minus strand of viral DNA results in catastrophic G-to-A mutations in the viral genome.,"When produced in the presence of APOBEC3G, vif-defective virus is non-infectious.",False,BACKGROUND
575,Deamination of cytidine to uridine on the minus strand of viral DNA results in catastrophic G-to-A mutations in the viral genome.,"APOBEC3G is closely related to APOBEC1, the central component of an RNA-editing complex that deaminates a cytosine residue in apoB messenger RNA.",True,BACKGROUND
576,Deamination of cytidine to uridine on the minus strand of viral DNA results in catastrophic G-to-A mutations in the viral genome.,"APOBEC family members also have potent DNA mutator activity through dC deamination; however, whether the editing potential of APOBEC3G has any relevance to HIV inhibition is unknown.",False,BACKGROUND
577,Deamination of cytidine to uridine on the minus strand of viral DNA results in catastrophic G-to-A mutations in the viral genome.,"Here, we demonstrate that it does, as APOBEC3G exerts its antiviral effect during reverse transcription to trigger G-to-A hypermutation in the nascent retroviral DNA.",True,BACKGROUND
578,Deamination of cytidine to uridine on the minus strand of viral DNA results in catastrophic G-to-A mutations in the viral genome.,"We also find that APOBEC3G can act on a broad range of retroviruses in addition to HIV, suggesting that hypermutation by editing is a general innate defence mechanism against this important group of pathogens.",False,BACKGROUND
579,Deletion of αvβ8 does not result in a spontaneous inflammatory phenotype.,"Regulatory T (Treg) cells play a pivotal role in suppressing self-harmful T cell responses, but how Treg cells mediate suppression to maintain immune homeostasis and limit responses during inflammation is unclear.",False,BACKGROUND
580,Deletion of αvβ8 does not result in a spontaneous inflammatory phenotype.,"Here we show that effector Treg cells express high amounts of the integrin αvβ8, which enables them to activate latent transforming growth factor-β (TGF-β).",False,BACKGROUND
581,Deletion of αvβ8 does not result in a spontaneous inflammatory phenotype.,"Treg-cell-specific deletion of integrin αvβ8 did not result in a spontaneous inflammatory phenotype, suggesting that this pathway is not important in Treg-cell-mediated maintenance of immune homeostasis.",True,BACKGROUND
582,Deletion of αvβ8 does not result in a spontaneous inflammatory phenotype.,"However, Treg cells lacking expression of integrin αvβ8 were unable to suppress pathogenic T cell responses during active inflammation.",False,BACKGROUND
583,Deletion of αvβ8 does not result in a spontaneous inflammatory phenotype.,"Thus, our results identify a mechanism by which Treg cells suppress exuberant immune responses, highlighting a key role for effector Treg-cell-mediated activation of latent TGF-β in suppression of self-harmful T cell responses during active inflammation.",False,BACKGROUND
584,Dexamethasone decreases risk of postoperative bleeding.,"CONTEXT Dexamethasone is widely used to prevent postoperative nausea and vomiting (PONV) in pediatric tonsillectomy.   
",False,OBJECTIVE
585,Dexamethasone decreases risk of postoperative bleeding.,"OBJECTIVE To assess whether dexamethasone dose-dependently reduces the risk of PONV at 24 hours after tonsillectomy.   
",False,OBJECTIVE
586,Dexamethasone decreases risk of postoperative bleeding.,"DESIGN, SETTING, AND PATIENTS Randomized placebo-controlled trial conducted among 215 children undergoing elective tonsillectomy at a major public teaching hospital in Switzerland from February 2005 to December 2007.   
",False,METHODS
587,Dexamethasone decreases risk of postoperative bleeding.,"INTERVENTIONS Children were randomly assigned to receive dexamethasone (0.05, 0.15, or 0.5 mg/kg) or placebo intravenously after induction of anesthesia.",False,METHODS
588,Dexamethasone decreases risk of postoperative bleeding.,Acetaminophen-codeine and ibuprofen were given as postoperative analgesia.,False,METHODS
589,Dexamethasone decreases risk of postoperative bleeding.,"Follow-up continued until the 10th postoperative day.   
",False,METHODS
590,Dexamethasone decreases risk of postoperative bleeding.,"MAIN OUTCOME MEASURES The primary end point was prevention of PONV at 24 hours; secondary end points were decrease in the need for ibuprofen at 24 hours and evaluation of adverse effects.   
",False,METHODS
591,Dexamethasone decreases risk of postoperative bleeding.,"RESULTS At 24 hours, 24 of 54 participants who received placebo (44%; 95% confidence interval [CI], 31%-59%) had experienced PONV compared with 20 of 53 (38%; 95% CI, 25%-52%), 13 of 54 (24%; 95% CI, 13%-38%), and 6 of 52 (12%; 95% CI, 4%-23%) who received dexamethasone at 0.05, 0.15, and 0.5 mg/kg, respectively (P<.001 for linear trend).",False,RESULTS
592,Dexamethasone decreases risk of postoperative bleeding.,Children who received dexamethasone received significantly less ibuprofen.,False,RESULTS
593,Dexamethasone decreases risk of postoperative bleeding.,There were 26 postoperative bleeding episodes in 22 children.,False,RESULTS
594,Dexamethasone decreases risk of postoperative bleeding.,"Two of 53 (4%; 95% CI, 0.5%-13%)",True,RESULTS
595,Dexamethasone decreases risk of postoperative bleeding.,"children who received placebo had bleeding compared with 6 of 53 (11%; 95% CI, 4%-23%), 2 of 51 (4%; 95% CI, 0.5%-13%), and 12 of 50 (24%; 95% CI, 13%-38%) who received dexamethasone at 0.05, 0.15, and 0.5 mg/kg, respectively (P = .003).",True,RESULTS
596,Dexamethasone decreases risk of postoperative bleeding.,"Dexamethasone, 0.5 mg/kg, was associated with the highest bleeding risk (adjusted relative risk, 6.80; 95% CI, 1.77-16.5).",True,RESULTS
597,Dexamethasone decreases risk of postoperative bleeding.,"Eight children had to undergo emergency reoperation because of bleeding, all of whom had received dexamethasone.",False,RESULTS
598,Dexamethasone decreases risk of postoperative bleeding.,"The trial was stopped early for safety reasons.   
",False,RESULTS
599,Dexamethasone decreases risk of postoperative bleeding.,"CONCLUSION In this study of children undergoing tonsillectomy, dexamethasone decreased the risk of PONV dose dependently but was associated with an increased risk of postoperative bleeding.   
",True,CONCLUSIONS
600,Dexamethasone decreases risk of postoperative bleeding.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00403806.,False,CONCLUSIONS
601,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,"BACKGROUND Although unstable coronary artery disease is the most common reason for admission to a coronary care unit, the long-term prognosis of patients with this diagnosis is unknown.",False,BACKGROUND
602,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,"This is particularly true for patients with diabetes mellitus, who are known to have a high morbidity and mortality after an acute myocardial infarction.   
",False,BACKGROUND
603,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,METHODS AND RESULTS Prospectively collected data from 6 different countries in the Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry were analyzed to determine the 2-year prognosis of diabetic and nondiabetic patients who were hospitalized with unstable angina or non-Q-wave myocardial infarction.,False,METHODS
604,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,"Overall, 1718 of 8013 registry patients (21%) had diabetes.",False,RESULTS
605,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,"Diabetic patients had a higher rate of coronary bypass surgery than nondiabetic patients (23% versus 20%, P:<0.001) but had similar rates of catheterization and angioplasty.",False,RESULTS
606,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,"Diabetes independently predicted mortality (relative risk [RR], 1.57; 95% CI, 1.38 to 1.81; P:<0.001), as well as cardiovascular death, new myocardial infarction, stroke, and new congestive heart failure.",True,RESULTS
607,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,"Moreover, compared with their nondiabetic counterparts, women had a significantly higher risk than men (RR, 1.98; 95% CI, 1.60 to 2.44; and RR, 1.28; 95% CI, 1.06 to 1.56, respectively).",False,RESULTS
608,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,"Interestingly, diabetic patients without prior cardiovascular disease had the same event rates for all outcomes as nondiabetic patients with previous vascular disease.   
",False,RESULTS
609,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,CONCLUSIONS Hospitalization for unstable angina or non-Q-wave myocardial infarction predicts a high 2-year morbidity and mortality; this is especially evident for patients with diabetes.,False,CONCLUSIONS
610,Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.,Diabetic patients with no previous cardiovascular disease have the same long-term morbidity and mortality as nondiabetic patients with established cardiovascular disease after hospitalization for unstable coronary artery disease.,False,CONCLUSIONS
611,Enhanced early production of inflammatory chemokines improves viral control in the lung.,Inflammation induced by recognition of pathogen-associated molecular patterns markedly affects subsequent adaptive responses.,False,BACKGROUND
612,Enhanced early production of inflammatory chemokines improves viral control in the lung.,We asked whether the adaptive immune system can also affect the character and magnitude of innate inflammatory responses.,False,BACKGROUND
613,Enhanced early production of inflammatory chemokines improves viral control in the lung.,"We found that the response of memory, but not naive, CD4+ T cells enhances production of multiple innate inflammatory cytokines and chemokines (IICs) in the lung and that, during influenza infection, this leads to early control of virus.",True,RESULTS
614,Enhanced early production of inflammatory chemokines improves viral control in the lung.,Memory CD4+ T cell–induced IICs and viral control require cognate antigen recognition and are optimal when memory cells are either T helper type 1 (TH1) or TH17 polarized but are independent of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) production and do not require activation of conserved pathogen recognition pathways.,False,RESULTS
615,Enhanced early production of inflammatory chemokines improves viral control in the lung.,This represents a previously undescribed mechanism by which memory CD4+ T cells induce an early innate response that enhances immune protection against pathogens.,False,CONCLUSIONS
616,Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.,Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis]) with histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer immune therapy.,False,BACKGROUND
617,Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.,"Herein, pharmacologic and isoform specificity of HDACis are investigated to guide their addition to a DNMTi, thus devising a new, low-dose, sequential regimen that imparts a robust anti-tumor effect for non-small-cell lung cancer (NSCLC).",False,BACKGROUND
618,Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.,"Using in-vitro-treated NSCLC cell lines, we elucidate an interferon α/β-based transcriptional program with accompanying upregulation of antigen presentation machinery, mediated in part through double-stranded RNA (dsRNA) induction.",False,RESULTS
619,Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.,This is accompanied by suppression of MYC signaling and an increase in the T cell chemoattractant CCL5.,False,RESULTS
620,Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.,Use of this combination treatment schema in mouse models of NSCLC reverses tumor immune evasion and modulates T cell exhaustion state towards memory and effector T cell phenotypes.,True,CONCLUSIONS
621,Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.,"Key correlative science metrics emerge for an upcoming clinical trial, testing enhancement of immune checkpoint therapy for NSCLC.",False,CONCLUSIONS
622,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"OBJECTIVES To determine the incidence and clinical importance of errors in the preparation and administration of intravenous drugs and the stages of the process in which errors occur.   
",False,OBJECTIVE
623,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"DESIGN Prospective ethnographic study using disguised observation.   
",False,METHODS
624,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"PARTICIPANTS Nurses who prepared and administered intravenous drugs.   
",False,METHODS
625,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"SETTING 10 wards in a teaching and non-teaching hospital in the United Kingdom.   
",False,METHODS
626,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"MAIN OUTCOME MEASURES Number, type, and clinical importance of errors.   
",False,METHODS
627,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,RESULTS 249 errors were identified.,False,RESULTS
628,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"At least one error occurred in 212 out of 430 intravenous drug doses (49%, 95% confidence interval 45% to 54%).",False,RESULTS
629,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"Three doses (1%) had potentially severe errors, 126 (29%) potentially moderate errors, and 83 (19%) potentially minor errors.",False,RESULTS
630,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"Most errors occurred when giving bolus doses or making up drugs that required multiple step preparation.   
",True,RESULTS
631,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,CONCLUSIONS The rate of intravenous drug errors was high.,False,CONCLUSIONS
632,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"Although most errors would cause only short term adverse effects, a few could have been serious.",False,CONCLUSIONS
633,Errors in peripheral IV drug administration are most common during bolus administration and multiple-step medicine preparations.,"A combination of reducing the amount of preparation on the ward, training, and technology to administer slow bolus doses would probably have the greatest effect on error rates.",True,CONCLUSIONS
634,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"OBJECTIVE To determine whether higher past exposure to particulate air pollution is associated with prevalent high symptoms of anxiety.   
",False,OBJECTIVE
635,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"DESIGN Observational cohort study.   
",False,METHODS
636,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"SETTING Nurses' Health Study.   
",False,METHODS
637,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"PARTICIPANTS 71,271 women enrolled in the Nurses' Health Study residing throughout the contiguous United States who had valid estimates on exposure to particulate matter for at least one exposure period of interest and data on anxiety symptoms.   
",False,METHODS
638,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"MAIN OUTCOME MEASURES Meaningfully high symptoms of anxiety, defined as a score of 6 points or greater on the phobic anxiety subscale of the Crown-Crisp index, administered in 2004.   
",False,METHODS
639,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"RESULTS The 71,271 eligible women were aged between 57 and 85 years (mean 70 years) at the time of assessment of anxiety symptoms, with a prevalence of high anxiety symptoms of 15%.",False,METHODS
640,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"Exposure to particulate matter was characterized using estimated average exposure to particulate matter <2.5 μm in diameter (PM2.5) and 2.5 to 10 μm in diameter (PM2.5-10) in the one month, three months, six months, one year, and 15 years prior to assessment of anxiety symptoms, and residential distance to the nearest major road two years prior to assessment.",False,METHODS
641,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"Significantly increased odds of high anxiety symptoms were observed with higher exposure to PM2.5 for multiple averaging periods (for example, odds ratio per 10 µg/m(3) increase in prior one month average PM2.5: 1.12, 95% confidence interval 1.06 to 1.19; in prior 12 month average PM2.5: 1.15, 1.06 to 1.26).",True,RESULTS
642,Exposure to fine particulate air pollution is relate to anxiety prevalence.,Models including multiple exposure windows suggested short term averaging periods were more relevant than long term averaging periods.,False,RESULTS
643,Exposure to fine particulate air pollution is relate to anxiety prevalence.,There was no association between anxiety and exposure to PM2.5-10.,False,RESULTS
644,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"Residential proximity to major roads was not related to anxiety symptoms in a dose dependent manner.   
",False,RESULTS
645,Exposure to fine particulate air pollution is relate to anxiety prevalence.,"CONCLUSIONS Exposure to fine particulate matter (PM2.5) was associated with high symptoms of anxiety, with more recent exposures potentially more relevant than more distant exposures.",True,CONCLUSIONS
646,Exposure to fine particulate air pollution is relate to anxiety prevalence.,Research evaluating whether reductions in exposure to ambient PM2.5 would reduce the population level burden of clinically relevant symptoms of anxiety is warranted.,False,CONCLUSIONS
647,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,CONTEXT Exogenous estrogen use may lower risk of dementia in postmenopausal women.,False,BACKGROUND
648,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"A relationship between long-term exposure to endogenous estrogens and incident dementia has been hypothesized but not studied.   
",False,BACKGROUND
649,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"OBJECTIVE To determine whether a longer reproductive period, as an indicator of longer exposure to endogenous estrogens, is associated with lower risk of dementia and Alzheimer disease (AD) in women who have natural menopause.   
",False,OBJECTIVE
650,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"DESIGN AND SETTING The Rotterdam Study, a population-based prospective cohort study conducted in the Netherlands.   
",False,METHODS
651,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"PARTICIPANTS A total of 3601 women aged 55 years or older who did not have dementia at baseline (1990-1993) and had information on age at menarche, age at menopause, and type of menopause.",False,METHODS
652,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"Participants were reexamined in 1993-1994 and 1997-1999 and were continuously monitored for development of dementia.   
",False,METHODS
653,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"MAIN OUTCOME MEASURES Incidence of dementia, based on Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria, and AD, based on National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, compared by quartiles of reproductive period among women with natural menopause.   
",False,METHODS
654,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"RESULTS During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD.",False,RESULTS
655,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"After adjusting for age, dementia was not clearly associated with length of reproductive period.",False,RESULTS
656,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"However, after adjusting for multiple covariates, women with natural menopause and more reproductive years had an increased risk of dementia (adjusted rate ratio [RR] for women with >39 reproductive years [highest quartile] compared with <34 reproductive years [lowest quartile], 1.78; 95% confidence interval [CI], 1.12-2.84).",False,RESULTS
657,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"The adjusted RR per year of increase was 1.04 (95% CI, 1.01-1.08).",False,RESULTS
658,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"For risk of AD, the adjusted RRs were 1.51 (95% CI, 0.91-2.50) and 1.03 (95% CI, 1.00-1.07), respectively.",False,RESULTS
659,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,"Risk of dementia associated with a longer reproductive period was most pronounced in APOE epsilon4 carriers (adjusted RR for >39 reproductive years compared with <34 reproductive years, 4.20 [95% CI, 1.97-8.92] for dementia and 3.42 [95% CI, 1.51-7.75] for AD), whereas in noncarriers, no clear association with dementia or AD was observed.   
",True,RESULTS
660,Female carriers of the Apolipoprotein E4 (APOE4) allele have increased risk for dementia.,CONCLUSION Our findings do not support the hypothesis that a longer reproductive period reduces risk of dementia in women who have natural menopause.,False,CONCLUSIONS
661,FoxO3a activation in neuronal death is mediated by reactive oxygen species (ROS).,The Sir2 deacetylase modulates organismal life-span in various species.,False,BACKGROUND
662,FoxO3a activation in neuronal death is mediated by reactive oxygen species (ROS).,"However, the molecular mechanisms by which Sir2 increases longevity are largely unknown.",False,BACKGROUND
663,FoxO3a activation in neuronal death is mediated by reactive oxygen species (ROS).,"We show that in mammalian cells, the Sir2 homolog SIRT1 appears to control the cellular response to stress by regulating the FOXO family of Forkhead transcription factors, a family of proteins that function as sensors of the insulin signaling pathway and as regulators of organismal longevity.",False,RESULTS
664,FoxO3a activation in neuronal death is mediated by reactive oxygen species (ROS).,"SIRT1 and the FOXO transcription factor FOXO3 formed a complex in cells in response to oxidative stress, and SIRT1 deacetylated FOXO3 in vitro and within cells.",False,RESULTS
665,FoxO3a activation in neuronal death is mediated by reactive oxygen species (ROS).,SIRT1 had a dual effect on FOXO3 function: SIRT1 increased FOXO3's ability to induce cell cycle arrest and resistance to oxidative stress but inhibited FOXO3's ability to induce cell death.,False,CONCLUSIONS
666,FoxO3a activation in neuronal death is mediated by reactive oxygen species (ROS).,"Thus, one way in which members of the Sir2 family of proteins may increase organismal longevity is by tipping FOXO-dependent responses away from apoptosis and toward stress resistance.",True,CONCLUSIONS
667,Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.,Histone levels are tightly regulated to prevent harmful effects such as genomic instability and hypersensitivity to DNA-damaging agents due to the accumulation of these highly basic proteins when DNA replication slows down or stops.,False,BACKGROUND
668,Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.,"Although chromosomal histones are stable, excess (non-chromatin bound) histones are rapidly degraded in a Rad53 (radiation sensitive 53) kinase-dependent manner in Saccharomyces cerevisiae.",True,BACKGROUND
669,Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.,"Here we demonstrate that excess histones associate with Rad53 in vivo and seem to undergo modifications such as tyrosine phosphorylation and polyubiquitylation, before their proteolysis by the proteasome.",True,BACKGROUND
670,Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.,We have identified the Tyr 99 residue of histone H3 as being critical for the efficient ubiquitylation and degradation of this histone.,False,BACKGROUND
671,Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.,"We have also identified the ubiquitin conjugating enzymes (E2) Ubc4 and Ubc5, as well as the ubiquitin ligase (E3) Tom1 (temperature dependent organization in mitotic nucleus 1), as enzymes involved in the ubiquitylation of excess histones.",False,BACKGROUND
672,Free histones are degraded by a Rad53-dependent mechanism once DNA has been replicated.,"Regulated histone proteolysis has major implications for the maintenance of epigenetic marks on chromatin, genomic stability and the packaging of sperm DNA.",False,BACKGROUND
673,GATA-3 is important for hematopoietic stem cell (HSC) function.,Maintaining hematopoietic stem cell (HSC) quiescence is a critical property for the life-long generation of blood cells.,False,BACKGROUND
674,GATA-3 is important for hematopoietic stem cell (HSC) function.,"Approximately 75% of cells in a highly enriched long-term repopulating HSC (LT-HSC) pool (Lin(-)Sca1(+)c-Kit(hi)CD150(+)CD48(-)) are quiescent, with only a small percentage of the LT-HSCs in cycle.",False,BACKGROUND
675,GATA-3 is important for hematopoietic stem cell (HSC) function.,Transcription factor GATA-3 is known to be vital for the development of T cells at multiple stages in the thymus and for Th2 differentiation in the peripheral organs.,False,BACKGROUND
676,GATA-3 is important for hematopoietic stem cell (HSC) function.,"Although it is well documented that GATA-3 is expressed in HSCs, a role for GATA-3 in any prethymic progenitor cell has not been established.",False,BACKGROUND
677,GATA-3 is important for hematopoietic stem cell (HSC) function.,"In the present study, we show that Gata3-null mutant mice generate fewer LT-HSCs and that fewer Gata3-null LT-HSCs are in cycle.",True,BACKGROUND
678,GATA-3 is important for hematopoietic stem cell (HSC) function.,"Furthermore, Gata3 mutant hematopoietic progenitor cells fail to be recruited into an increased cycling state after 5-fluorouracil-induced myelosuppression.",True,BACKGROUND
679,GATA-3 is important for hematopoietic stem cell (HSC) function.,"Therefore, GATA-3 is required for the maintenance of a normal number of LT-HSCs and for their entry into the cell cycle.",True,BACKGROUND
680,Gene expression does not vary appreciably across genetically identical cells.,"Gene expression is a fundamentally stochastic process, with randomness in transcription and translation leading to cell-to-cell variations in mRNA and protein levels.",True,BACKGROUND
681,Gene expression does not vary appreciably across genetically identical cells.,"This variation appears in organisms ranging from microbes to metazoans, and its characteristics depend both on the biophysical parameters governing gene expression and on gene network structure.",False,BACKGROUND
682,Gene expression does not vary appreciably across genetically identical cells.,"Stochastic gene expression has important consequences for cellular function, being beneficial in some contexts and harmful in others.",False,BACKGROUND
683,Gene expression does not vary appreciably across genetically identical cells.,"These situations include the stress response, metabolism, development, the cell cycle, circadian rhythms, and aging.",False,BACKGROUND
684,Gene expression does not vary appreciably across genetically identical cells.,Genetically identical cells sharing an environment can display markedly different phenotypes.,True,BACKGROUND
685,Gene expression does not vary appreciably across genetically identical cells.,"It is often unclear how much of this variation derives from chance, external signals, or attempts by individual cells to exert autonomous phenotypic programs.",False,BACKGROUND
686,Gene expression does not vary appreciably across genetically identical cells.,"By observing thousands of cells for hundreds of consecutive generations under constant conditions, we dissect the stochastic decision between a solitary, motile state and a chained, sessile state in Bacillus subtilis.",False,METHODS
687,Gene expression does not vary appreciably across genetically identical cells.,"We show that the motile state is 'memoryless', exhibiting no autonomous control over the time spent in the state.",False,RESULTS
688,Gene expression does not vary appreciably across genetically identical cells.,"In contrast, the time spent as connected chains of cells is tightly controlled, enforcing coordination among related cells in the multicellular state.",False,RESULTS
689,Gene expression does not vary appreciably across genetically identical cells.,"We show that the three-protein regulatory circuit governing the decision is modular, as initiation and maintenance of chaining are genetically separable functions.",False,CONCLUSIONS
690,Gene expression does not vary appreciably across genetically identical cells.,"As stimulation of the same initiating pathway triggers biofilm formation, we argue that autonomous timing allows a trial commitment to multicellularity that external signals could extend.",False,CONCLUSIONS
691,Glycolysis is one of the primary glycometabolic pathways in cells.,Fast axonal transport (FAT) requires consistent energy over long distances to fuel the molecular motors that transport vesicles.,False,BACKGROUND
692,Glycolysis is one of the primary glycometabolic pathways in cells.,We demonstrate that glycolysis provides ATP for the FAT of vesicles.,True,BACKGROUND
693,Glycolysis is one of the primary glycometabolic pathways in cells.,"Although inhibiting ATP production from mitochondria did not affect vesicles motility, pharmacological or genetic inhibition of the glycolytic enzyme GAPDH reduced transport in cultured neurons and in Drosophila larvae.",False,RESULTS
694,Glycolysis is one of the primary glycometabolic pathways in cells.,GAPDH localizes on vesicles via a huntingtin-dependent mechanism and is transported on fast-moving vesicles within axons.,False,RESULTS
695,Glycolysis is one of the primary glycometabolic pathways in cells.,Purified motile vesicles showed GAPDH enzymatic activity and produced ATP.,False,RESULTS
696,Glycolysis is one of the primary glycometabolic pathways in cells.,"Finally, we show that vesicular GAPDH is necessary and sufficient to provide on-board energy for fast vesicular transport.",False,RESULTS
697,Glycolysis is one of the primary glycometabolic pathways in cells.,"Although detaching GAPDH from vesicles reduced transport, targeting GAPDH to vesicles was sufficient to promote FAT in GAPDH deficient neurons.",False,CONCLUSIONS
698,Glycolysis is one of the primary glycometabolic pathways in cells.,"This specifically localized glycolytic machinery may supply constant energy, independent of mitochondria, for the processive movement of vesicles over long distances in axons.",False,CONCLUSIONS
699,Headaches are not correlated with cognitive impairment.,"OBJECTIVE To evaluate the association of overall and specific headaches with volume of white matter hyperintensities, brain infarcts, and cognition.   
",False,OBJECTIVE
700,Headaches are not correlated with cognitive impairment.,"DESIGN Population based, cross sectional study.   
",False,METHODS
701,Headaches are not correlated with cognitive impairment.,"SETTING Epidemiology of Vascular Ageing study, Nantes, France.   
",False,METHODS
702,Headaches are not correlated with cognitive impairment.,"PARTICIPANTS 780 participants (mean age 69, 58.5% women) with detailed headache assessment.   
",False,METHODS
703,Headaches are not correlated with cognitive impairment.,MAIN OUTCOME MEASURES Brain scans were evaluated for volume of white matter hyperintensities (by fully automated imaging processing) and for classification of infarcts (by visual reading with a standardised assessment grid).,False,METHODS
704,Headaches are not correlated with cognitive impairment.,"Cognitive function was assessed by a battery of tests including the mini-mental state examination.   
",False,METHODS
705,Headaches are not correlated with cognitive impairment.,"RESULTS 163 (20.9%) participants reported a history of severe headache and 116 had migraine, of whom 17 (14.7%) reported aura symptoms.",False,RESULTS
706,Headaches are not correlated with cognitive impairment.,An association was found between any history of severe headache and increasing volume of white matter hyperintensities.,False,RESULTS
707,Headaches are not correlated with cognitive impairment.,"The adjusted odds ratio of being in the highest third for total volume of white matter hyperintensities was 2.0 (95% confidence interval 1.3 to 3.1, P for trend 0.002) for participants with any history of severe headache when compared with participants without severe headache being in the lowest third.",False,RESULTS
708,Headaches are not correlated with cognitive impairment.,The association pattern was similar for all headache types.,False,RESULTS
709,Headaches are not correlated with cognitive impairment.,"Migraine with aura was the only headache type strongly associated with volume of deep white matter hyperintensities (highest third odds ratio 12.4, 1.6 to 99.4, P for trend 0.005) and with brain infarcts (3.4, 1.2 to 9.3).",False,RESULTS
710,Headaches are not correlated with cognitive impairment.,The location of infarcts was predominantly outside the cerebellum and brain stem.,False,RESULTS
711,Headaches are not correlated with cognitive impairment.,"Evidence was lacking for cognitive impairment for any headache type with or without brain lesions.   
",True,RESULTS
712,Headaches are not correlated with cognitive impairment.,"CONCLUSIONS In this population based study, any history of severe headache was associated with an increased volume of white matter hyperintensities.",False,CONCLUSIONS
713,Headaches are not correlated with cognitive impairment.,Migraine with aura was the only headache type associated with brain infarcts.,False,CONCLUSIONS
714,Headaches are not correlated with cognitive impairment.,Evidence that headache of any type by itself or in combination with brain lesions was associated with cognitive impairment was lacking.,False,CONCLUSIONS
715,High cardiopulmonary fitness causes increased mortality rate.,CONTEXT Population surveys indicate that physical activity levels are low in the United States.,False,BACKGROUND
716,High cardiopulmonary fitness causes increased mortality rate.,"One consequence of inactivity, low cardiorespiratory fitness, is an established risk factor for cardiovascular disease (CVD) morbidity and mortality, but the prevalence of cardiorespiratory fitness has not been quantified in representative US population samples.   
",False,BACKGROUND
717,High cardiopulmonary fitness causes increased mortality rate.,"OBJECTIVES To describe the prevalence of low fitness in the US population aged 12 through 49 years and to relate low fitness to CVD risk factors in this population.   
",False,OBJECTIVE
718,High cardiopulmonary fitness causes increased mortality rate.,"DESIGN, SETTING, AND PARTICIPANTS Inception cohort study using data from the cross-sectional nationally representative National Health and Nutrition Examination Survey 1999-2002.",False,METHODS
719,High cardiopulmonary fitness causes increased mortality rate.,Participants were adolescents (aged 12-19 years; n = 3110) and adults (aged 20-49 years; n = 2205) free from previously diagnosed CVD who underwent submaximal graded exercise treadmill testing to achieve at least 75% to 90% of their age-predicted maximum heart rate.,False,METHODS
720,High cardiopulmonary fitness causes increased mortality rate.,"Maximal oxygen consumption (VO2max) was estimated by measuring the heart rate response to reference levels of submaximal work.   
",False,METHODS
721,High cardiopulmonary fitness causes increased mortality rate.,"MAIN OUTCOME MEASURES Low fitness defined using percentile cut points of estimated VO2max from existing external referent populations; anthropometric and other CVD risk factors measured according to standard methods.   
",False,METHODS
722,High cardiopulmonary fitness causes increased mortality rate.,RESULTS Low fitness was identified in 33.6% of adolescents (approximately 7.5 million US adolescents) and 13.9% of adults (approximately 8.5 million US adults); the prevalence was similar in adolescent females (34.4%) and males (32.9%) (P = .40) but was higher in adult females (16.2%) than in males (11.8%) (P = .03).,False,RESULTS
723,High cardiopulmonary fitness causes increased mortality rate.,Non-Hispanic blacks and Mexican Americans were less fit than non-Hispanic whites.,False,RESULTS
724,High cardiopulmonary fitness causes increased mortality rate.,"In all age-sex groups, body mass index and waist circumference were inversely associated with fitness; age- and race-adjusted odds ratios of overweight or obesity (body mass index > or =25) ranged from 2.1 to 3.7 (P<.01 for all), comparing persons with low fitness with those with moderate or high fitness.",False,RESULTS
725,High cardiopulmonary fitness causes increased mortality rate.,"Total cholesterol levels and systolic blood pressure were higher and levels of high-density lipoprotein cholesterol were lower among participants with low vs high fitness.   
",False,CONCLUSIONS
726,High cardiopulmonary fitness causes increased mortality rate.,CONCLUSION Low fitness in adolescents and adults is common in the US population and is associated with an increased prevalence of CVD risk factors.,True,CONCLUSIONS
727,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"IMPORTANCE Exacerbations of respiratory symptoms in chronic obstructive pulmonary disease (COPD) have profound and long-lasting adverse effects on patients.   
",False,BACKGROUND
728,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"OBJECTIVE To test the hypothesis that elevated levels of inflammatory biomarkers in individuals with stable COPD are associated with an increased risk of having exacerbations.   
",False,OBJECTIVE
729,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study examining 61,650 participants with spirometry measurements from the Copenhagen City Heart Study (2001-2003) and the Copenhagen General Population Study (2003-2008).",False,METHODS
730,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"Of these, 6574 had COPD, defined as a ratio between forced expiratory volume in 1 second (FEV1) and forced vital capacity below 0.7.   
",False,METHODS
731,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,MAIN OUTCOMES AND MEASURES Baseline levels of C-reactive protein (CRP) and fibrinogen and leukocyte count were measured in participants at a time when they were not experiencing symptoms of exacerbations.,False,METHODS
732,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,Exacerbations were recorded and defined as short-course treatment with oral corticosteroids alone or in combination with an antibiotic or as a hospital admission due to COPD.,False,METHODS
733,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"Levels of CRP and fibrinogen and leukocyte count were defined as high or low according to cut points of 3 mg/L, 14 μmol/L, and 9 ×10(9)/L, respectively.   
",False,METHODS
734,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"RESULTS During follow-up, 3083 exacerbations were recorded (mean, 0.5/participant).",False,RESULTS
735,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"In the first year of follow-up, multivariable-adjusted odds ratios for having frequent exacerbations were 1.2 (95% CI, 0.7-2.2; 17 events/1000 person-years) for individuals with 1 high biomarker, 1.7 (95% CI, 0.9-3.2; 32 events/1000 person-years) for individuals with 2 high biomarkers, and 3.7 (95% CI, 1.9-7.4; 81 events/1000 person-years) for individuals with 3 high biomarkers compared with individuals who had no elevated biomarkers (9 events/1000 person-years; trend: P = 2 × 10(-5)).",True,RESULTS
736,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"Corresponding hazard ratios using maximum follow-up time were 1.4 (95% CI, 1.1-1.8), 1.6 (95% CI, 1.3-2.2), and 2.5 (95% CI, 1.8-3.4), respectively (trend: P = 1 × 10(-8)).",False,RESULTS
737,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"The addition of inflammatory biomarkers to a basic model including age, sex, FEV1 percent predicted, smoking, use of any inhaled medication, body mass index, history of previous exacerbations, and time since most recent prior exacerbation improved the C statistics from 0.71 to 0.73 (comparison: P = 9 × 10(-5)).",False,RESULTS
738,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"Relative risks were consistent in those with milder COPD, in those with no history of frequent exacerbations, and in the 2 studies separately.",False,RESULTS
739,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"The highest 5-year absolute risks of having frequent exacerbations in those with 3 high biomarkers (vs no high biomarkers) were 62% (vs 24%) for those with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades C-D (n = 558), 98% (vs 64%) in those with a history of frequent exacerbations (n = 127), and 52% (vs 15%) for those with GOLD grades 3-4 (n = 465).   
",False,RESULTS
740,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,"CONCLUSIONS AND RELEVANCE Simultaneously elevated levels of CRP and fibrinogen and leukocyte count in individuals with COPD were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations.",True,CONCLUSIONS
741,High levels of CRP reduces the risk of exacerbations in chronic obstructive pulmonary disease (COPD).,Further investigation is needed to determine the clinical value of these biomarkers for risk stratification.,False,CONCLUSIONS
742,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"OBJECTIVE To obtain summary estimates of the accuracy of a single baseline measurement of the Elecsys Troponin T high-sensitive assay (Roche Diagnostics) for the diagnosis of acute myocardial infarction in patients presenting to the emergency department.   
",False,OBJECTIVE
743,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"DESIGN Systematic review and meta-analysis of diagnostic test accuracy studies.   
",False,METHODS
744,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"DATA SOURCES Medline, Embase, and other relevant electronic databases were searched for papers published between January 2006 and December 2013.   ",False,METHODS
745,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,STUDY SELECTION Studies were included if they evaluated the diagnostic accuracy of a single baseline measurement of Elecsys Troponin T high-sensitive assay for the diagnosis of acute myocardial infarction in patients presenting to the emergency department with suspected acute coronary syndrome.   ,False,METHODS
746,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,STUDY APPRAISAL AND DATA SYNTHESIS The first author screened all titles and abstracts identified through the searches and selected all potentially relevant papers.,False,METHODS
747,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"The screening of the full texts, the data extraction, and the methodological quality assessment, using the adapted QUADAS-2 tool, were conducted independently by two reviewers with disagreements being resolved through discussion or arbitration.",False,METHODS
748,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"If appropriate, meta-analysis was conducted using the hierarchical bivariate model.   
",False,METHODS
749,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,RESULTS Twenty three studies reported the performance of the evaluated assay at presentation.,False,RESULTS
750,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,The results for 14 ng/L and 3-5 ng/L cut-off values were pooled separately.,False,RESULTS
751,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"At 14 ng/L (20 papers), the summary sensitivity was 89.5% (95% confidence interval 86.3% to 92.1%) and the summary specificity was 77.1% (68.7% to 83.7%).",False,RESULTS
752,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"At 3-5 ng/L (six papers), the summary sensitivity was 97.4% (94.9% to 98.7%) and the summary specificity was 42.4% (31.2% to 54.5%).",False,RESULTS
753,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"This means that if 21 of 100 consecutive patients have the target condition (21%, the median prevalence across the studies), 2 (95% confidence interval 2 to 3) of 21 patients with acute myocardial infarction will be missed (false negatives) if 14 ng/L is used as a cut-off value and 18 (13 to 25) of 79 patients without acute myocardial infarction will test positive (false positives).",False,RESULTS
754,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"If the 3-5 ng/L cut-off value is used, <1 (0 to 1) patient with acute myocardial infarction will be missed and 46 (36 to 54) patients without acute myocardial infarction will test positive.   
",False,RESULTS
755,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,CONCLUSIONS The results indicate that a single baseline measurement of the Elecsys Troponin T high-sensitive assay could be used to rule out acute myocardial infarction if lower cut-off values such as 3 ng/L or 5 ng/L are used.,False,CONCLUSIONS
756,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,"However, this method should be part of a comprehensive triage strategy and may not be appropriate for patients who present less than three hours after symptom onset.",True,CONCLUSIONS
757,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,Care must also be exercised because of the higher imprecision of the evaluated assay and the greater effect of lot-to-lot reagent variation at low troponin concentrations.   ,False,CONCLUSIONS
758,High-sensitivity cardiac troponin T (HSCT-T) dosage may not be diagnostic if the onset of symptoms occurs less than 3 hours before acute myocardial injury (AMI).,SYSTEMATIC REVIEW REGISTRATION PROSPERO registration number CRD42013003926.,False,CONCLUSIONS
759,Histone demethylase recruitment and a transient decrease in histone methylation is necessary for ligand-dependent induction of transcription by nuclear receptors.,"Nuclear receptors undergo ligand-dependent conformational changes that are required for corepressor-coactivator exchange, but whether there is an actual requirement for specific epigenetic landmarks to impose ligand dependency for gene activation remains unknown.",False,BACKGROUND
760,Histone demethylase recruitment and a transient decrease in histone methylation is necessary for ligand-dependent induction of transcription by nuclear receptors.,Here we report an unexpected and general strategy that is based on the requirement for specific cohorts of inhibitory histone methyltransferases (HMTs) to impose gene-specific gatekeeper functions that prevent unliganded nuclear receptors and other classes of regulated transcription factors from binding to their target gene promoters and causing constitutive gene activation in the absence of stimulating signals.,False,BACKGROUND
761,Histone demethylase recruitment and a transient decrease in histone methylation is necessary for ligand-dependent induction of transcription by nuclear receptors.,"This strategy, based at least in part on an HMT-dependent inhibitory histone code, imposes a requirement for specific histone demethylases, including LSD1, to permit ligand- and signal-dependent activation of regulated gene expression.",True,BACKGROUND
762,Histone demethylase recruitment and a transient decrease in histone methylation is necessary for ligand-dependent induction of transcription by nuclear receptors.,These events link an inhibitory methylation component of the histone code to a broadly used strategy that circumvents pathological constitutive gene induction by physiologically regulated transcription factors.,False,BACKGROUND
763,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,One hypothesis that couples infection with autoimmune disease is molecular mimicry.,False,BACKGROUND
764,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"Molecular mimicry is characterized by an immune response to an environmental agent that cross-reacts with a host antigen, resulting in disease.",False,BACKGROUND
765,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"This hypothesis has been implicated in the pathogenesis of diabetes, lupus and multiple sclerosis (MS).",False,BACKGROUND
766,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,There is limited direct evidence linking causative agents with pathogenic immune reactions in these diseases.,False,BACKGROUND
767,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"Our study establishes a clear link between viral infection, autoimmunity and neurological disease in humans.",False,BACKGROUND
768,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"As a model for molecular mimicry, we studied patients with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a disease that can be indistinguishable from MS (refs.",False,BACKGROUND
769,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"5,6,7).",False,METHODS
770,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,HAM/TSP patients develop antibodies to neurons.,False,METHODS
771,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,We hypothesized these antibodies would identify a central nervous system (CNS) autoantigen.,False,METHODS
772,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,Immunoglobulin G isolated from HAM/TSP patients identified heterogeneous nuclear ribonuclear protein-A1 (hnRNP-A1) as the autoantigen.,False,RESULTS
773,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"Antibodies to hnRNP-A1 cross-reacted with HTLV-1-tax, the immune response to which is associated with HAM/TSP (refs.",True,RESULTS
774,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"5,9).",False,RESULTS
775,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"Immunoglobulin G specifically stained human Betz cells, whose axons are preferentially damaged.",False,RESULTS
776,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,"Infusion of autoantibodies in brain sections inhibited neuronal firing, indicative of their pathogenic nature.",False,CONCLUSIONS
777,Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) patients produce Immunoglobulin G (IgG) antibodies which cross-react with an immunodominant epitope in Tax.,These data demonstrate the importance of molecular mimicry between an infecting agent and hnRNP-A1 in autoimmune disease of the CNS.,False,CONCLUSIONS
778,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"OBJECTIVE To determine the effects of smoking, plasma lipids, lipoproteins, apolipoproteins, and fibrinogen on the patency of saphenous vein femoropopliteal bypass grafts at one year.   
",False,OBJECTIVE
779,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"DESIGN Prospective study of patients with saphenous vein femoropopliteal bypass grafts entered into a multicentre trial.   
",False,METHODS
780,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"SETTING Surgical wards, outpatient clinics, and home visits coordinated by two tertiary referral centres in London and Birmingham.   
",False,METHODS
781,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"PATIENTS 157 Patients (mean age 66.6 (SD 8.2) years), 113 with patent grafts and 44 with occluded grafts one year after bypass.   
",False,METHODS
782,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"MAIN OUTCOME MEASURE Cumulative percentage patency at one year.   
",False,METHODS
783,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,RESULTS Markers for smoking (blood carboxyhaemoglobin concentration (p less than 0.05) and plasma thiocyanate concentration (p less than 0.01) and plasma concentrations of fibrinogen (p less than 0.001) and apolipoproteins AI (p less than 0.04) and (a) (p less than 0.05) were significantly higher in patients with occluded grafts.,True,RESULTS
784,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,Serum cholesterol concentrations were significantly higher in patients with grafts that remained patent one year after bypass (p less than 0.005).,False,RESULTS
785,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,Analysis of the smoking markers indicated that a quarter of patients (40) were untruthful in their claims to have stopped smoking.,False,RESULTS
786,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"Based on smoking markers, patency of grafts in smokers was significantly lower at one year by life table analysis than in non-smokers (63% v 84%, p less than 0.02).",False,RESULTS
787,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"Patency was significantly higher by life table analysis in patients with a plasma fibrinogen concentration below the median than in those with a concentration above (90% v 57%, p less than 0.0002).",True,RESULTS
788,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"Surprisingly, increased plasma low density lipoprotein cholesterol concentration was significantly associated with improved patency at one year (85%) at values above the median compared with patency (only 68%) at values in the lower half of the range (p less than 0.02).   
",False,RESULTS
789,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,"CONCLUSIONS Plasma fibrinogen concentration was the most important variable predicting graft occlusion, followed by smoking markers.",True,CONCLUSIONS
790,Hyperfibrinogenemia decreases rates of femoropopliteal bypass thrombosis.,A more forceful approach is needed to stop patients smoking; therapeutic measures to improve patency of vein grafts should focus on decreasing plasma fibrinogen concentration rather than serum cholesterol concentration.,True,CONCLUSIONS
791,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"OBJECTIVE To determine the effects of smoking, plasma lipids, lipoproteins, apolipoproteins, and fibrinogen on the patency of saphenous vein femoropopliteal bypass grafts at one year.   
",False,OBJECTIVE
792,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"DESIGN Prospective study of patients with saphenous vein femoropopliteal bypass grafts entered into a multicentre trial.   
",False,METHODS
793,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"SETTING Surgical wards, outpatient clinics, and home visits coordinated by two tertiary referral centres in London and Birmingham.   
",False,METHODS
794,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"PATIENTS 157 Patients (mean age 66.6 (SD 8.2) years), 113 with patent grafts and 44 with occluded grafts one year after bypass.   
",False,METHODS
795,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"MAIN OUTCOME MEASURE Cumulative percentage patency at one year.   
",False,METHODS
796,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,RESULTS Markers for smoking (blood carboxyhaemoglobin concentration (p less than 0.05) and plasma thiocyanate concentration (p less than 0.01) and plasma concentrations of fibrinogen (p less than 0.001) and apolipoproteins AI (p less than 0.04) and (a) (p less than 0.05) were significantly higher in patients with occluded grafts.,True,RESULTS
797,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,Serum cholesterol concentrations were significantly higher in patients with grafts that remained patent one year after bypass (p less than 0.005).,False,RESULTS
798,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,Analysis of the smoking markers indicated that a quarter of patients (40) were untruthful in their claims to have stopped smoking.,False,RESULTS
799,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"Based on smoking markers, patency of grafts in smokers was significantly lower at one year by life table analysis than in non-smokers (63% v 84%, p less than 0.02).",False,RESULTS
800,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"Patency was significantly higher by life table analysis in patients with a plasma fibrinogen concentration below the median than in those with a concentration above (90% v 57%, p less than 0.0002).",True,RESULTS
801,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"Surprisingly, increased plasma low density lipoprotein cholesterol concentration was significantly associated with improved patency at one year (85%) at values above the median compared with patency (only 68%) at values in the lower half of the range (p less than 0.02).   
",False,RESULTS
802,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,"CONCLUSIONS Plasma fibrinogen concentration was the most important variable predicting graft occlusion, followed by smoking markers.",True,CONCLUSIONS
803,Hyperfibrinogenemia increases rates of femoropopliteal bypass thrombosis.,A more forceful approach is needed to stop patients smoking; therapeutic measures to improve patency of vein grafts should focus on decreasing plasma fibrinogen concentration rather than serum cholesterol concentration.,True,CONCLUSIONS
804,Hypocretin neurones induce panicprone state in rats.,"Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks.",False,BACKGROUND
805,Hypocretin neurones induce panicprone state in rats.,In individuals with panic disorder there is evidence of decreased central gamma-aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate.,False,BACKGROUND
806,Hypocretin neurones induce panicprone state in rats.,"In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses.",False,BACKGROUND
807,Hypocretin neurones induce panicprone state in rats.,"The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin), which have a crucial role in arousal, vigilance and central autonomic mobilization, all of which are key components of panic.",False,BACKGROUND
808,Hypocretin neurones induce panicprone state in rats.,"Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses.",True,BACKGROUND
809,Hypocretin neurones induce panicprone state in rats.,"Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety.",False,BACKGROUND
810,Hypocretin neurones induce panicprone state in rats.,"Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder.",False,BACKGROUND
811,Hypoglycemia increases the risk of dementia.,"CONTEXT Although acute hypoglycemia may be associated with cognitive impairment in children with type 1 diabetes, no studies to date have evaluated whether hypoglycemia is a risk factor for dementia in older patients with type 2 diabetes.   
",False,BACKGROUND
812,Hypoglycemia increases the risk of dementia.,"OBJECTIVE To determine if hypoglycemic episodes severe enough to require hospitalization are associated with an increased risk of dementia in a population of older patients with type 2 diabetes followed up for 27 years.   
",False,OBJECTIVE
813,Hypoglycemia increases the risk of dementia.,"DESIGN, SETTING, AND PATIENTS A longitudinal cohort study from 1980-2007 of 16,667 patients with a mean age of 65 years and type 2 diabetes who are members of an integrated health care delivery system in northern California.   
",False,METHODS
814,Hypoglycemia increases the risk of dementia.,MAIN OUTCOME MEASURE Hypoglycemic events from 1980-2002 were collected and reviewed using hospital discharge and emergency department diagnoses.,False,METHODS
815,Hypoglycemia increases the risk of dementia.,"Cohort members with no prior diagnoses of dementia, mild cognitive impairment, or general memory complaints as of January 1, 2003, were followed up for a dementia diagnosis through January 15, 2007.",False,METHODS
816,Hypoglycemia increases the risk of dementia.,"Dementia risk was examined using Cox proportional hazard regression models, adjusted for age, sex, race/ethnicity, education, body mass index, duration of diabetes, 7-year mean glycated hemoglobin, diabetes treatment, duration of insulin use, hyperlipidemia, hypertension, cardiovascular disease, stroke, transient cerebral ischemia, and end-stage renal disease.   
",False,METHODS
817,Hypoglycemia increases the risk of dementia.,RESULTS At least 1 episode of hypoglycemia was diagnosed in 1465 patients (8.8%) and dementia was diagnosed in 1822 patients (11%) during follow-up; 250 patients had both dementia and at least 1 episode of hypoglycemia (16.95%).,False,RESULTS
818,Hypoglycemia increases the risk of dementia.,"Compared with patients with no hypoglycemia, patients with single or multiple episodes had a graded increase in risk with fully adjusted hazard ratios (HRs): for 1 episode (HR, 1.26; 95% confidence interval [CI], 1.10-1.49); 2 episodes (HR, 1.80; 95% CI, 1.37-2.36); and 3 or more episodes (HR, 1.94; 95% CI, 1.42-2.64).",True,RESULTS
819,Hypoglycemia increases the risk of dementia.,"The attributable risk of dementia between individuals with and without a history of hypoglycemia was 2.39% per year (95% CI, 1.72%-3.01%).",False,RESULTS
820,Hypoglycemia increases the risk of dementia.,"Results were not attenuated when medical utilization rates, length of health plan membership, or time since initial diabetes diagnosis were added to the model.",False,RESULTS
821,Hypoglycemia increases the risk of dementia.,"When examining emergency department admissions for hypoglycemia for association with risk of dementia (535 episodes), results were similar (compared with patients with 0 episodes) with fully adjusted HRs: for 1 episode (HR, 1.42; 95% CI, 1.12-1.78) and for 2 or more episodes (HR, 2.36; 95% CI, 1.57-3.55).   
",False,RESULTS
822,Hypoglycemia increases the risk of dementia.,"CONCLUSIONS Among older patients with type 2 diabetes, a history of severe hypoglycemic episodes was associated with a greater risk of dementia.",True,CONCLUSIONS
823,Hypoglycemia increases the risk of dementia.,Whether minor hypoglycemic episodes increase risk of dementia is unknown.,False,CONCLUSIONS
824,Hypothalamic glutamate neurotransmission is crucial to energy balance.,The importance of neuropeptides in the hypothalamus has been experimentally established.,False,BACKGROUND
825,Hypothalamic glutamate neurotransmission is crucial to energy balance.,"Due to difficulties in assessing function in vivo, the roles of the fast-acting neurotransmitters glutamate and GABA are largely unknown.",False,BACKGROUND
826,Hypothalamic glutamate neurotransmission is crucial to energy balance.,"Synaptic vesicular transporters (VGLUTs for glutamate and VGAT for GABA) are required for vesicular uptake and, consequently, synaptic release of neurotransmitters.",False,BACKGROUND
827,Hypothalamic glutamate neurotransmission is crucial to energy balance.,Ventromedial hypothalamic (VMH) neurons are predominantly glutamatergic and express VGLUT2.,False,BACKGROUND
828,Hypothalamic glutamate neurotransmission is crucial to energy balance.,"To evaluate the role of glutamate release from VMH neurons, we generated mice lacking VGLUT2 selectively in SF1 neurons (a major subset of VMH neurons).",False,BACKGROUND
829,Hypothalamic glutamate neurotransmission is crucial to energy balance.,These mice have hypoglycemia during fasting secondary to impaired fasting-induced increases in the glucose-raising pancreatic hormone glucagon and impaired induction in liver of mRNAs encoding PGC-1alpha and the gluconeogenic enzymes PEPCK and G6Pase.,True,RESULTS
830,Hypothalamic glutamate neurotransmission is crucial to energy balance.,"Similarly, these mice have defective counterregulatory responses to insulin-induced hypoglycemia and 2-deoxyglucose (an antimetabolite).",False,RESULTS
831,Hypothalamic glutamate neurotransmission is crucial to energy balance.,"Thus, glutamate release from VMH neurons is an important component of the neurocircuitry that functions to prevent hypoglycemia.",False,RESULTS
832,IRG1 has antiviral effects against neurotropic viruses.,"Although susceptibility of neurons in the brain to microbial infection is a major determinant of clinical outcome, little is known about the molecular factors governing this vulnerability.",False,BACKGROUND
833,IRG1 has antiviral effects against neurotropic viruses.,Here we show that two types of neurons from distinct brain regions showed differential permissivity to replication of several positive-stranded RNA viruses.,False,BACKGROUND
834,IRG1 has antiviral effects against neurotropic viruses.,Granule cell neurons of the cerebellum and cortical neurons from the cerebral cortex have unique innate immune programs that confer differential susceptibility to viral infection ex vivo and in vivo.,False,RESULTS
835,IRG1 has antiviral effects against neurotropic viruses.,"By transducing cortical neurons with genes that were expressed more highly in granule cell neurons, we identified three interferon-stimulated genes (ISGs; Ifi27, Irg1 and Rsad2 (also known as Viperin)) that mediated the antiviral effects against different neurotropic viruses.",True,RESULTS
836,IRG1 has antiviral effects against neurotropic viruses.,"Moreover, we found that the epigenetic state and microRNA (miRNA)-mediated regulation of ISGs correlates with enhanced antiviral response in granule cell neurons.",False,CONCLUSIONS
837,IRG1 has antiviral effects against neurotropic viruses.,"Thus, neurons from evolutionarily distinct brain regions have unique innate immune signatures, which probably contribute to their relative permissiveness to infection.",False,CONCLUSIONS
838,"In adult tissue, most T cells are memory T cells.",It is unclear how the immune response in early life becomes appropriately stimulated to provide protection while also avoiding excessive activation as a result of diverse new antigens.,False,BACKGROUND
839,"In adult tissue, most T cells are memory T cells.",T cells are integral to adaptive immunity; mouse studies indicate that tissue localization of T cell subsets is important for both protective immunity and immunoregulation.,False,BACKGROUND
840,"In adult tissue, most T cells are memory T cells.","In humans, however, the early development and function of T cells in tissues remain unexplored.",False,BACKGROUND
841,"In adult tissue, most T cells are memory T cells.","We present here an analysis of lymphoid and mucosal tissue T cells derived from pediatric organ donors in the first two years of life, as compared to adult organ donors, revealing early compartmentalization of T cell differentiation and regulation.",False,METHODS
842,"In adult tissue, most T cells are memory T cells.","Whereas adult tissues contain a predominance of memory T cells, in pediatric blood and tissues the main subset consists of naive recent thymic emigrants, with effector memory T cells (T(EM)) found only in the lungs and small intestine.",True,RESULTS
843,"In adult tissue, most T cells are memory T cells.","Additionally, regulatory T (T(reg)) cells comprise a high proportion (30-40%) of CD4(+) T cells in pediatric tissues but are present at much lower frequencies (1-10%) in adult tissues.",False,RESULTS
844,"In adult tissue, most T cells are memory T cells.","Pediatric tissue T(reg) cells suppress endogenous T cell activation, and early T cell functionality is confined to the mucosal sites that have the lowest T(reg):T(EM) cell ratios, which suggests control in situ of immune responses in early life.",False,CONCLUSIONS
845,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.",Leukemias and other cancers possess self-renewing stem cells that help to maintain the cancer.,False,BACKGROUND
846,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.",Cancer stem cell eradication is thought to be crucial for successful anticancer therapy.,False,BACKGROUND
847,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.","Using an acute myeloid leukemia (AML) model induced by the leukemia-associated monocytic leukemia zinc finger (MOZ)-TIF2 fusion protein, we show here that AML can be cured by the ablation of leukemia stem cells.",False,BACKGROUND
848,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.","The MOZ fusion proteins MOZ-TIF2 and MOZ-CBP interacted with the transcription factor PU.1 to stimulate the expression of macrophage colony–stimulating factor receptor (CSF1R, also known as M-CSFR, c-FMS or CD115).",False,RESULTS
849,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.",Studies using PU.1-deficient mice showed that PU.1 is essential for the ability of MOZ-TIF2 to establish and maintain AML stem cells.,False,RESULTS
850,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.","Cells expressing high amounts of CSF1R (CSF1Rhigh cells), but not those expressing low amounts of CSF1R (CSF1Rlow cells), showed potent leukemia-initiating activity.",True,RESULTS
851,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.","Using transgenic mice expressing a drug-inducible suicide gene controlled by the CSF1R promoter, we cured AML by ablation of CSF1Rhigh cells.",False,RESULTS
852,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.","Moreover, induction of AML was suppressed in CSF1R-deficient mice and CSF1R inhibitors slowed the progression of MOZ-TIF2–induced leukemia.",True,RESULTS
853,"In mouse models, the loss of CSF1R facilitates MOZ-TIF2-induced leuekmogenesis.","Thus, in this subtype of AML, leukemia stem cells are contained within the CSF1Rhigh cell population, and we suggest that targeting of PU.1-mediated upregulation of CSF1R expression might be a useful therapeutic approach.",True,CONCLUSIONS
854,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.",CONTEXT More than 1.5 million US adults use stimulants and other medications labeled for treatment of attention-deficit/hyperactivity disorder (ADHD).,False,BACKGROUND
855,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","These agents can increase heart rate and blood pressure, raising concerns about their cardiovascular safety.   
",False,BACKGROUND
856,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","OBJECTIVE To examine whether current use of medications prescribed primarily to treat ADHD is associated with increased risk of serious cardiovascular events in young and middle-aged adults.   
",False,OBJECTIVE
857,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","DESIGN, SETTING, AND PARTICIPANTS Retrospective, population-based cohort study using electronic health care records from 4 study sites (OptumInsight Epidemiology, Tennessee Medicaid, Kaiser Permanente California, and the HMO Research Network), starting in 1986 at 1 site and ending in 2005 at all sites, with additional covariate assessment using 2007 survey data.",False,METHODS
858,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","Participants were adults aged 25 through 64 years with dispensed prescriptions for methylphenidate, amphetamine, or atomoxetine at baseline.",False,METHODS
859,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","Each medication user (n = 150,359) was matched to 2 nonusers on study site, birth year, sex, and calendar year (443,198 total users and nonusers).   
",False,METHODS
860,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","MAIN OUTCOME MEASURES Serious cardiovascular events, including myocardial infarction (MI), sudden cardiac death (SCD), or stroke, with comparison between current or new users and remote users to account for potential healthy-user bias.   
",False,METHODS
861,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","RESULTS During 806,182 person-years of follow-up (median, 1.3 years per person), 1357 cases of MI, 296 cases of SCD, and 575 cases of stroke occurred.",False,RESULTS
862,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","There were 107,322 person-years of current use (median, 0.33 years), with a crude incidence per 1000 person-years of 1.34 (95% CI, 1.14-1.57) for MI, 0.30 (95% CI, 0.20-0.42) for SCD, and 0.56 (95% CI, 0.43-0.72) for stroke.",False,RESULTS
863,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","The multivariable-adjusted rate ratio (RR) of serious cardiovascular events for current use vs nonuse of ADHD medications was 0.83 (95% CI, 0.72-0.96).",True,RESULTS
864,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","Among new users of ADHD medications, the adjusted RR was 0.77 (95% CI, 0.63-0.94).",True,RESULTS
865,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","The adjusted RR for current use vs remote use was 1.03 (95% CI, 0.86-1.24); for new use vs remote use, the adjusted RR was 1.02 (95% CI, 0.82-1.28); the upper limit of 1.28 corresponds to an additional 0.19 events per 1000 person-years at ages 25-44 years and 0.77 events per 1000 person-years at ages 45-64 years.   
",False,RESULTS
866,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.","CONCLUSIONS Among young and middle-aged adults, current or new use of ADHD medications, compared with nonuse or remote use, was not associated with an increased risk of serious cardiovascular events.",True,CONCLUSIONS
867,"In young and middle-aged adults, current or remote uses of ADHD medications do not increase the risk of serious cardiovascular events.",Apparent protective associations likely represent healthy-user bias.,False,CONCLUSIONS
868,Incidence of heart failure decreased by 10% in women since 1979.,"CONTEXT The epidemic of heart failure has yet to be fully investigated, and data on incidence, survival, and sex-specific temporal trends in community-based populations are limited.   
",False,BACKGROUND
869,Incidence of heart failure decreased by 10% in women since 1979.,"OBJECTIVE To test the hypothesis that the incidence of heart failure has declined and survival after heart failure diagnosis has improved over time but that secular trends have diverged by sex.   
",False,OBJECTIVE
870,Incidence of heart failure decreased by 10% in women since 1979.,"DESIGN, SETTING, AND PARTICIPANTS Population-based cohort study using the resources of the Rochester Epidemiology Project conducted in Olmsted County, Minnesota.",False,METHODS
871,Incidence of heart failure decreased by 10% in women since 1979.,"Patients were 4537 Olmsted County residents (57% women; mean [SD] age, 74 [14] years) with a diagnosis of heart failure between 1979 and 2000.",False,METHODS
872,Incidence of heart failure decreased by 10% in women since 1979.,"Framingham criteria and clinical criteria were used to validate the diagnosis   MAIN OUTCOME MEASURES Incidence of heart failure and survival after heart failure diagnosis.   
",False,METHODS
873,Incidence of heart failure decreased by 10% in women since 1979.,"RESULTS The incidence of heart failure was higher among men (378/100 000 persons; 95% confidence interval [CI], 361-395 for men; 289/100 000 persons; 95% CI, 277-300 for women) and did not change over time among men or women.",True,RESULTS
874,Incidence of heart failure decreased by 10% in women since 1979.,"After a mean follow-up of 4.2 years (range, 0-23.8 years), 3347 deaths occurred, including 1930 among women and 1417 among men.",False,RESULTS
875,Incidence of heart failure decreased by 10% in women since 1979.,"Survival after heart failure diagnosis was worse among men than women (relative risk, 1.33; 95% CI, 1.24-1.43) but overall improved over time (5-year age-adjusted survival, 43% in 1979-1984 vs 52% in 1996-2000, P<.001).",False,RESULTS
876,Incidence of heart failure decreased by 10% in women since 1979.,"However, men and younger persons experienced larger survival gains, contrasting with less or no improvement for women and elderly persons.   
",False,RESULTS
877,Incidence of heart failure decreased by 10% in women since 1979.,"CONCLUSION In this community-based cohort, the incidence of heart failure has not declined during 2 decades, but survival after onset of heart failure has increased overall, with less improvement among women and elderly persons.",False,CONCLUSIONS
878,Incidence rates of cervical cancer have decreased.,"The number of women dying from cervical cancer in 1997 was 7% lower than in 1996 and has fallen by over 25% since 1992.1 Such rapid change must be at least partly due to cervical screening, although strong cohort effects have caused large fluctuations in cervical mortality in the past.2 We modelled mortality data, taking into account the effects of age and year of birth and looking for trends in time within four age groups to estimate the beneficial effects of cervical screening.  ",True,BACKGROUND
879,Incidence rates of cervical cancer have decreased.,"We obtained mortality data, in 5 year age bands, from death registrations in England and Wales and calculated rates using mid-year population estimates.",False,METHODS
880,Incidence rates of cervical cancer have decreased.,"Mortality since 1993 was adjusted upwards by 4% because of changes in classification of cause of death.3  We modelled the data assuming that the age specific mortality is the product of a smoothly varying age effect, birth cohort effect, and age dependent …",False,METHODS
881,Incidence rates of cervical cancer have decreased.,"OBJECTIVE To describe the efficacy of the Finnish mass screening program for cervical squamous carcinoma and adenocarcinoma, as reflected by changes of incidence and mortality rate.   
",False,OBJECTIVE
882,Incidence rates of cervical cancer have decreased.,METHODS Cervical cancer incidence and mortality data were obtained from the Finnish Cancer Registry.,False,METHODS
883,Incidence rates of cervical cancer have decreased.,"Data were available from the year 1953, when the registry was established.",False,METHODS
884,Incidence rates of cervical cancer have decreased.,The nationwide mass screening program in Finland was started in the mid-1960s.,False,METHODS
885,Incidence rates of cervical cancer have decreased.,A centralized organization administers this program.,False,METHODS
886,Incidence rates of cervical cancer have decreased.,"Women age 30-60 years are notified for screening every 5 years.   
",False,METHODS
887,Incidence rates of cervical cancer have decreased.,RESULTS The mean incidence of cervical carcinoma in the early 1960s was 15.4 per 10(5) woman-years.,True,RESULTS
888,Incidence rates of cervical cancer have decreased.,"In 1991, it was only 2.7 per 10(5) woman-years.",True,RESULTS
889,Incidence rates of cervical cancer have decreased.,The mortality rate has decreased in the same proportion since the mass screening program.,False,RESULTS
890,Incidence rates of cervical cancer have decreased.,"In the early 1960s, the mortality was 6.6 and in 1991 1.4 per 10(5) woman-years.",False,RESULTS
891,Incidence rates of cervical cancer have decreased.,"However, the decrease of the incidence is seen almost exclusively in squamous cell carcinomas.",False,RESULTS
892,Incidence rates of cervical cancer have decreased.,"The mortality caused by adenocarcinoma has decreased in screened birth cohorts, but the incidence rate has remained the same.   
",False,RESULTS
893,Incidence rates of cervical cancer have decreased.,CONCLUSIONS The Finnish mass screening program has been effective and its continuation is of utmost importance.,False,CONCLUSIONS
894,Incidence rates of cervical cancer have decreased.,In the future more attention should be given to glandular cell atypias in cervical smears.,False,CONCLUSIONS
895,Incidence rates of cervical cancer have decreased.,"Thus, it might be possible to decrease the incidence of cervical adenocarcinoma.",False,CONCLUSIONS
896,Incidence rates of cervical cancer have decreased.,"With respect to cervical cancer management, Finland and the Netherlands are comparable in relevant characteristics, e.g., fertility rate, age-of-mother at first birth and a national screening programme for several years.",False,BACKGROUND
897,Incidence rates of cervical cancer have decreased.,The aim of this study is to compare trends in incidence of and mortality from cervical cancer in Finland and the Netherlands in relation to the introduction and intensity of the screening programmes.,False,BACKGROUND
898,Incidence rates of cervical cancer have decreased.,"Therefore, incidence and mortality rates were calculated using the Cancer Registries of Finland and the Netherlands.",False,METHODS
899,Incidence rates of cervical cancer have decreased.,Data on screening intensity were obtained from the Finnish Cancer Registry and the Dutch evaluation centre at ErasmusMC-Rotterdam.,False,METHODS
900,Incidence rates of cervical cancer have decreased.,"Women aged 30-60 have been screened every 5 years, in Finland since 1992 and in the Netherlands since 1996.",False,METHODS
901,Incidence rates of cervical cancer have decreased.,Screening protocols for smear taking and referral to the gynaecologist are comparable.,False,METHODS
902,Incidence rates of cervical cancer have decreased.,Incidence and mortality rates have declined more in Finland.,True,RESULTS
903,Incidence rates of cervical cancer have decreased.,"In 2003, age-adjusted incidence and mortality in Finland were 4.0 and 0.9 and in the Netherlands 4.9 and 1.4 per 100,000 woman-years, respectively.",False,RESULTS
904,Incidence rates of cervical cancer have decreased.,"Excess smear use in the Netherlands was estimated to be 24 per 1,000 women during a 5-year interval compared to 121 in Finland.",False,RESULTS
905,Incidence rates of cervical cancer have decreased.,The decline in mortality in Finland seems to be almost completely related to the screening programme whereas in the Netherlands it was initially considered to be a natural decline.,False,CONCLUSIONS
906,Incidence rates of cervical cancer have decreased.,Differences in risk factors might also play a role: the Netherlands has higher population density and higher percentages of immigrants and (female) smokers.,False,CONCLUSIONS
907,Incidence rates of cervical cancer have decreased.,The greater excess smear use in Finland might also have affected incidence.,False,CONCLUSIONS
908,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,"With respect to cervical cancer management, Finland and the Netherlands are comparable in relevant characteristics, e.g., fertility rate, age-of-mother at first birth and a national screening programme for several years.",False,BACKGROUND
909,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,The aim of this study is to compare trends in incidence of and mortality from cervical cancer in Finland and the Netherlands in relation to the introduction and intensity of the screening programmes.,False,BACKGROUND
910,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,"Therefore, incidence and mortality rates were calculated using the Cancer Registries of Finland and the Netherlands.",False,METHODS
911,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,Data on screening intensity were obtained from the Finnish Cancer Registry and the Dutch evaluation centre at ErasmusMC-Rotterdam.,False,METHODS
912,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,"Women aged 30-60 have been screened every 5 years, in Finland since 1992 and in the Netherlands since 1996.",False,METHODS
913,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,Screening protocols for smear taking and referral to the gynaecologist are comparable.,False,METHODS
914,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,Incidence and mortality rates have declined more in Finland.,True,RESULTS
915,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,"In 2003, age-adjusted incidence and mortality in Finland were 4.0 and 0.9 and in the Netherlands 4.9 and 1.4 per 100,000 woman-years, respectively.",False,RESULTS
916,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,"Excess smear use in the Netherlands was estimated to be 24 per 1,000 women during a 5-year interval compared to 121 in Finland.",False,RESULTS
917,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,The decline in mortality in Finland seems to be almost completely related to the screening programme whereas in the Netherlands it was initially considered to be a natural decline.,True,CONCLUSIONS
918,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,Differences in risk factors might also play a role: the Netherlands has higher population density and higher percentages of immigrants and (female) smokers.,False,CONCLUSIONS
919,Incidence rates of cervical cancer have increased due to nationwide screening programs based primarily on cytology to detect uterine cervical cancer.,The greater excess smear use in Finland might also have affected incidence.,False,CONCLUSIONS
920,Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.,Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease.,False,BACKGROUND
921,Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.,LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules.,False,BACKGROUND
922,Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.,"Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known.",False,BACKGROUND
923,Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.,"Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo.",False,RESULTS
924,Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.,"In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase αTAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport.",True,RESULTS
925,Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.,"In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior.",False,CONCLUSIONS
926,Increased microtubule acetylation repairs LRRK2 Roc-COR domain mutation induced locomotor deficits.,"Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.",False,CONCLUSIONS
927,Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.,Pancreatic ductal adenocarcinoma (PDA) is among the most lethal human cancers in part because it is insensitive to many chemotherapeutic drugs.,False,BACKGROUND
928,Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.,"Studying a mouse model of PDA that is refractory to the clinically used drug gemcitabine, we found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA.",False,BACKGROUND
929,Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.,"We tested whether the delivery and efficacy of gemcitabine in the mice could be improved by coadministration of IPI-926, a drug that depletes tumor-associated stromal tissue by inhibition of the Hedgehog cellular signaling pathway.",True,RESULTS
930,Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.,"The combination therapy produced a transient increase in intratumoral vascular density and intratumoral concentration of gemcitabine, leading to transient stabilization of disease.",True,CONCLUSIONS
931,Increased vessel density along with a reduction in fibrosis decreases the efficacy of chemotherapy treatments.,"Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer.",False,CONCLUSIONS
932,"Inositol lipid 3-phosphatase PTEN converts Ptdlns(3,4)P 2 into phosphatidylinositol 4-phosphate.",The PI3K signaling pathway regulates cell growth and movement and is heavily mutated in cancer.,False,BACKGROUND
933,"Inositol lipid 3-phosphatase PTEN converts Ptdlns(3,4)P 2 into phosphatidylinositol 4-phosphate.","Class I PI3Ks synthesize the lipid messenger PI(3,4,5)P3.",False,BACKGROUND
934,"Inositol lipid 3-phosphatase PTEN converts Ptdlns(3,4)P 2 into phosphatidylinositol 4-phosphate.","PI(3,4,5)P3 can be dephosphorylated by 3- or 5-phosphatases, the latter producing PI(3,4)P2.",False,BACKGROUND
935,"Inositol lipid 3-phosphatase PTEN converts Ptdlns(3,4)P 2 into phosphatidylinositol 4-phosphate.","The PTEN tumor suppressor is thought to function primarily as a PI(3,4,5)P3 3-phosphatase, limiting activation of this pathway.",False,BACKGROUND
936,"Inositol lipid 3-phosphatase PTEN converts Ptdlns(3,4)P 2 into phosphatidylinositol 4-phosphate.","Here we show that PTEN also functions as a PI(3,4)P2 3-phosphatase, both in vitro and in vivo.",True,BACKGROUND
937,"Inositol lipid 3-phosphatase PTEN converts Ptdlns(3,4)P 2 into phosphatidylinositol 4-phosphate.","PTEN is a major PI(3,4)P2 phosphatase in Mcf10a cytosol, and loss of PTEN and INPP4B, a known PI(3,4)P2 4-phosphatase, leads to synergistic accumulation of PI(3,4)P2, which correlated with increased invadopodia in epidermal growth factor (EGF)-stimulated cells.",False,RESULTS
938,"Inositol lipid 3-phosphatase PTEN converts Ptdlns(3,4)P 2 into phosphatidylinositol 4-phosphate.","PTEN deletion increased PI(3,4)P2 levels in a mouse model of prostate cancer, and it inversely correlated with PI(3,4)P2 levels across several EGF-stimulated prostate and breast cancer lines.",False,RESULTS
939,"Inositol lipid 3-phosphatase PTEN converts Ptdlns(3,4)P 2 into phosphatidylinositol 4-phosphate.","These results point to a role for PI(3,4)P2 in the phenotype caused by loss-of-function mutations or deletions in PTEN.",False,CONCLUSIONS
940,Insomnia can be effectively treated with cognitive behavioral therapy.,"CONTEXT Insomnia is a common condition in older adults and is associated with a number of adverse medical, social, and psychological consequences.",False,BACKGROUND
941,Insomnia can be effectively treated with cognitive behavioral therapy.,"Previous research has suggested beneficial outcomes of both psychological and pharmacological treatments, but blinded placebo-controlled trials comparing the effects of these treatments are lacking.   
",False,BACKGROUND
942,Insomnia can be effectively treated with cognitive behavioral therapy.,"OBJECTIVE To examine short- and long-term clinical efficacy of cognitive behavioral therapy (CBT) and pharmacological treatment in older adults experiencing chronic primary insomnia.   
",False,OBJECTIVE
943,Insomnia can be effectively treated with cognitive behavioral therapy.,"DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blinded, placebo-controlled trial of 46 adults (mean age, 60.8 y; 22 women) with chronic primary insomnia conducted between January 2004 and December 2005 in a single Norwegian university-based outpatient clinic for adults and elderly patients.   
",False,METHODS
944,Insomnia can be effectively treated with cognitive behavioral therapy.,"INTERVENTION CBT (sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relaxation; n = 18), sleep medication (7.5-mg zopiclone each night; n = 16), or placebo medication (n = 12).",False,METHODS
945,Insomnia can be effectively treated with cognitive behavioral therapy.,"All treatment duration was 6 weeks, and the 2 active treatments were followed up at 6 months.   
",False,METHODS
946,Insomnia can be effectively treated with cognitive behavioral therapy.,"MAIN OUTCOME MEASURES Ambulant clinical polysomnographic data and sleep diaries were used to determine total wake time, total sleep time, sleep efficiency, and slow-wave sleep (only assessed using polysomnography) on all 3 assessment points.   
",False,METHODS
947,Insomnia can be effectively treated with cognitive behavioral therapy.,RESULTS CBT resulted in improved short- and long-term outcomes compared with zopiclone on 3 out of 4 outcome measures.,True,RESULTS
948,Insomnia can be effectively treated with cognitive behavioral therapy.,"For most outcomes, zopiclone did not differ from placebo.",False,RESULTS
949,Insomnia can be effectively treated with cognitive behavioral therapy.,Participants receiving CBT improved their sleep efficiency from 81.4% at pretreatment to 90.1% at 6-month follow-up compared with a decrease from 82.3% to 81.9% in the zopiclone group.,True,RESULTS
950,Insomnia can be effectively treated with cognitive behavioral therapy.,"Participants in the CBT group spent much more time in slow-wave sleep (stages 3 and 4) compared with those in other groups, and spent less time awake during the night.",True,RESULTS
951,Insomnia can be effectively treated with cognitive behavioral therapy.,"Total sleep time was similar in all 3 groups; at 6 months, patients receiving CBT had better sleep efficiency using polysomnography than those taking zopiclone.   
",False,RESULTS
952,Insomnia can be effectively treated with cognitive behavioral therapy.,"CONCLUSION These results suggest that interventions based on CBT are superior to zopiclone treatment both in short- and long-term management of insomnia in older adults.   
",True,CONCLUSIONS
953,Insomnia can be effectively treated with cognitive behavioral therapy.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00295386.,False,CONCLUSIONS
954,LDL cholesterol has no involvement in the development of cardiovascular disease.,BACKGROUND LDL cholesterol has a causal role in the development of cardiovascular disease.,True,BACKGROUND
955,LDL cholesterol has no involvement in the development of cardiovascular disease.,Improved understanding of the biological mechanisms that underlie the metabolism and regulation of LDL cholesterol might help to identify novel therapeutic targets.,False,BACKGROUND
956,LDL cholesterol has no involvement in the development of cardiovascular disease.,"We therefore did a genome-wide association study of LDL-cholesterol concentrations.   
",False,BACKGROUND
957,LDL cholesterol has no involvement in the development of cardiovascular disease.,"METHODS We used genome-wide association data from up to 11,685 participants with measures of circulating LDL-cholesterol concentrations across five studies, including data for 293 461 autosomal single nucleotide polymorphisms (SNPs) with a minor allele frequency of 5% or more that passed our quality control criteria.",False,METHODS
958,LDL cholesterol has no involvement in the development of cardiovascular disease.,"We also used data from a second genome-wide array in up to 4337 participants from three of these five studies, with data for 290,140 SNPs.",False,METHODS
959,LDL cholesterol has no involvement in the development of cardiovascular disease.,We did replication studies in two independent populations consisting of up to 4979 participants.,False,METHODS
960,LDL cholesterol has no involvement in the development of cardiovascular disease.,"Statistical approaches, including meta-analysis and linkage disequilibrium plots, were used to refine association signals; we analysed pooled data from all seven populations to determine the effect of each SNP on variations in circulating LDL-cholesterol concentrations.   
",False,METHODS
961,LDL cholesterol has no involvement in the development of cardiovascular disease.,"FINDINGS In our initial scan, we found two SNPs (rs599839 [p=1.7x10(-15)] and rs4970834 [p=3.0x10(-11)]) that showed genome-wide statistical association with LDL cholesterol at chromosomal locus 1p13.3.",False,RESULTS
962,LDL cholesterol has no involvement in the development of cardiovascular disease.,The second genome screen found a third statistically associated SNP at the same locus (rs646776 [p=4.3x10(-9)]).,False,RESULTS
963,LDL cholesterol has no involvement in the development of cardiovascular disease.,Meta-analysis of data from all studies showed an association of SNPs rs599839 (combined p=1.2x10(-33)) and rs646776 (p=4.8x10(-20)) with LDL-cholesterol concentrations.,False,RESULTS
964,LDL cholesterol has no involvement in the development of cardiovascular disease.,"SNPs rs599839 and rs646776 both explained around 1% of the variation in circulating LDL-cholesterol concentrations and were associated with about 15% of an SD change in LDL cholesterol per allele, assuming an SD of 1 mmol/L.   INTERPRETATION We found evidence for a novel locus for LDL cholesterol on chromosome 1p13.3.",False,CONCLUSIONS
965,LDL cholesterol has no involvement in the development of cardiovascular disease.,These results potentially provide insight into the biological mechanisms that underlie the regulation of LDL cholesterol and might help in the discovery of novel therapeutic targets for cardiovascular disease.,False,CONCLUSIONS
966,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"CONTEXT A number of countries have implemented a policy of universal leukoreduction of their blood supply, but the potential role of leukoreduction in decreasing postoperative mortality and infection is unclear.   
",False,BACKGROUND
967,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"OBJECTIVE To evaluate clinical outcomes following adoption of a national universal prestorage leukoreduction program for blood transfusions.   
",False,OBJECTIVE
968,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"DESIGN, SETTING, AND POPULATION Retrospective before-and-after cohort study conducted from August 1998 to August 2000 in 23 academic and community hospitals throughout Canada, enrolling 14 786 patients who received red blood cell transfusions following cardiac surgery or repair of hip fracture, or who required intensive care following a surgical intervention or multiple trauma.   
",False,METHODS
969,Leuko-increased blood increases infectious complications in red blood cell transfusion.,INTERVENTION Universal prestorage leukoreduction program introduced by 2 Canadian blood agencies.,False,METHODS
970,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"A total of 6982 patients were enrolled during the control period and 7804 patients were enrolled following prestorage leukoreduction.   
",False,METHODS
971,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"MAIN OUTCOME MEASURES All-cause in-hospital mortality and serious nosocomial infections (pneumonia, bacteremia, septic shock, all surgical site infections) occurring after first transfusion and at least 2 days after index procedure or intensive care unit admission.",False,METHODS
972,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"Secondary outcomes included rates of posttransfusion fever and antibiotic use.   
",False,METHODS
973,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"RESULTS Unadjusted in-hospital mortality rates were significantly lower following the introduction of leukoreduction compared with the control period (6.19% vs 7.03%, respectively; P =.04).",False,RESULTS
974,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"Compared with the control period, the adjusted odds of death following leukoreduction were reduced (odds ratio [OR], 0.87; 95% confidence interval [CI], 0.75-0.99), but serious nosocomial infections did not decrease (adjusted OR, 0.97; 95% CI, 0.87-1.09).",True,RESULTS
975,Leuko-increased blood increases infectious complications in red blood cell transfusion.,"The frequency of posttransfusion fevers decreased significantly following leukoreduction (adjusted OR, 0.86; 95% CI, 0.79-0.94), as did antibiotic use (adjusted OR, 0.90; 95% CI, 0.82-0.99).   
",True,RESULTS
976,Leuko-increased blood increases infectious complications in red blood cell transfusion.,CONCLUSION A national universal leukoreduction program is potentially associated with decreased mortality as well as decreased fever episodes and antibiotic use after red blood cell transfusion in high-risk patients.,True,CONCLUSIONS
977,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"CONTEXT A number of countries have implemented a policy of universal leukoreduction of their blood supply, but the potential role of leukoreduction in decreasing postoperative mortality and infection is unclear.   
",False,BACKGROUND
978,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"OBJECTIVE To evaluate clinical outcomes following adoption of a national universal prestorage leukoreduction program for blood transfusions.   
",False,OBJECTIVE
979,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"DESIGN, SETTING, AND POPULATION Retrospective before-and-after cohort study conducted from August 1998 to August 2000 in 23 academic and community hospitals throughout Canada, enrolling 14 786 patients who received red blood cell transfusions following cardiac surgery or repair of hip fracture, or who required intensive care following a surgical intervention or multiple trauma.   
",False,METHODS
980,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,INTERVENTION Universal prestorage leukoreduction program introduced by 2 Canadian blood agencies.,False,METHODS
981,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"A total of 6982 patients were enrolled during the control period and 7804 patients were enrolled following prestorage leukoreduction.   
",False,METHODS
982,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"MAIN OUTCOME MEASURES All-cause in-hospital mortality and serious nosocomial infections (pneumonia, bacteremia, septic shock, all surgical site infections) occurring after first transfusion and at least 2 days after index procedure or intensive care unit admission.",False,METHODS
983,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"Secondary outcomes included rates of posttransfusion fever and antibiotic use.   
",False,METHODS
984,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"RESULTS Unadjusted in-hospital mortality rates were significantly lower following the introduction of leukoreduction compared with the control period (6.19% vs 7.03%, respectively; P =.04).",False,RESULTS
985,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"Compared with the control period, the adjusted odds of death following leukoreduction were reduced (odds ratio [OR], 0.87; 95% confidence interval [CI], 0.75-0.99), but serious nosocomial infections did not decrease (adjusted OR, 0.97; 95% CI, 0.87-1.09).",True,RESULTS
986,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,"The frequency of posttransfusion fevers decreased significantly following leukoreduction (adjusted OR, 0.86; 95% CI, 0.79-0.94), as did antibiotic use (adjusted OR, 0.90; 95% CI, 0.82-0.99).   
",True,RESULTS
987,Leuko-reduced blood reduces infectious complications in red blood cell transfusion.,CONCLUSION A national universal leukoreduction program is potentially associated with decreased mortality as well as decreased fever episodes and antibiotic use after red blood cell transfusion in high-risk patients.,True,CONCLUSIONS
988,Low nucleosome occupancy correlates with low methylation levels across species.,Dnmt1 epigenetically propagates symmetrical CG methylation in many eukaryotes.,False,BACKGROUND
989,Low nucleosome occupancy correlates with low methylation levels across species.,Their genomes are typically depleted of CG dinucleotides because of imperfect repair of deaminated methylcytosines.,False,BACKGROUND
990,Low nucleosome occupancy correlates with low methylation levels across species.,"Here, we extensively survey diverse species lacking Dnmt1 and show that, surprisingly, symmetrical CG methylation is nonetheless frequently present and catalyzed by a different DNA methyltransferase family, Dnmt5.",False,BACKGROUND
991,Low nucleosome occupancy correlates with low methylation levels across species.,"Numerous Dnmt5-containing organisms that diverged more than a billion years ago exhibit clustered methylation, specifically in nucleosome linkers.",False,BACKGROUND
992,Low nucleosome occupancy correlates with low methylation levels across species.,"Clustered methylation occurs at unprecedented densities and directly disfavors nucleosomes, contributing to nucleosome positioning between clusters.",True,BACKGROUND
993,Low nucleosome occupancy correlates with low methylation levels across species.,Dense methylation is enabled by a regime of genomic sequence evolution that enriches CG dinucleotides and drives the highest CG frequencies known.,False,BACKGROUND
994,Low nucleosome occupancy correlates with low methylation levels across species.,"Species with linker methylation have small, transcriptionally active nuclei that approach the physical limits of chromatin compaction.",False,BACKGROUND
995,Low nucleosome occupancy correlates with low methylation levels across species.,"These features constitute a previously unappreciated genome architecture, in which dense methylation influences nucleosome positions, likely facilitating nuclear processes under extreme spatial constraints.",False,BACKGROUND
996,Lupus-prone mice infected with curliproducing bacteria have higher autoantibody titers compared to controls.,"Research on the human microbiome has established that commensal and pathogenic bacteria can influence obesity, cancer, and autoimmunity through mechanisms mostly unknown.",False,BACKGROUND
997,Lupus-prone mice infected with curliproducing bacteria have higher autoantibody titers compared to controls.,"We found that a component of bacterial biofilms, the amyloid protein curli, irreversibly formed fibers with bacterial DNA during biofilm formation.",False,BACKGROUND
998,Lupus-prone mice infected with curliproducing bacteria have higher autoantibody titers compared to controls.,"This interaction accelerated amyloid polymerization and created potent immunogenic complexes that activated immune cells, including dendritic cells, to produce cytokines such as type I interferons, which are pathogenic in systemic lupus erythematosus (SLE).",False,BACKGROUND
999,Lupus-prone mice infected with curliproducing bacteria have higher autoantibody titers compared to controls.,"When given systemically, curli-DNA composites triggered immune activation and production of autoantibodies in lupus-prone and wild-type mice.",False,BACKGROUND
1000,Lupus-prone mice infected with curliproducing bacteria have higher autoantibody titers compared to controls.,We also found that the infection of lupus-prone mice with curli-producing bacteria triggered higher autoantibody titers compared to curli-deficient bacteria.,True,BACKGROUND
1001,Lupus-prone mice infected with curliproducing bacteria have higher autoantibody titers compared to controls.,These data provide a mechanism by which the microbiome and biofilm-producing enteric infections may contribute to the progression of SLE and point to a potential molecular target for treatment of autoimmunity.,False,BACKGROUND
1002,Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.,Neutrophils rapidly undergo polarization and directional movement to infiltrate the sites of infection and inflammation.,False,BACKGROUND
1003,Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.,"Here, we show that an inhibitory MHC I receptor, Ly49Q, was crucial for the swift polarization of and tissue infiltration by neutrophils.",True,BACKGROUND
1004,Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.,"During the steady state, Ly49Q inhibited neutrophil adhesion by preventing focal-complex formation, likely by inhibiting Src and PI3 kinases.",False,RESULTS
1005,Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.,"However, in the presence of inflammatory stimuli, Ly49Q mediated rapid neutrophil polarization and tissue infiltration in an ITIM-domain-dependent manner.",False,RESULTS
1006,Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.,These opposite functions appeared to be mediated by distinct use of effector phosphatase SHP-1 and SHP-2.,False,RESULTS
1007,Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.,Ly49Q-dependent polarization and migration were affected by Ly49Q regulation of membrane raft functions.,True,RESULTS
1008,Ly49Q directs the organization of neutrophil migration to inflammation sites by regulating membrane raft functions.,"We propose that Ly49Q is pivotal in switching neutrophils to their polarized morphology and rapid migration upon inflammation, through its spatiotemporal regulation of membrane rafts and raft-associated signaling molecules.",False,CONCLUSIONS
1009,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,Blood monocytes are well-characterized precursors for macrophages and dendritic cells.,False,BACKGROUND
1010,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,Subsets of human monocytes with differential representation in various disease states are well known.,False,BACKGROUND
1011,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,"In contrast, mouse monocyte subsets have been characterized minimally.",False,BACKGROUND
1012,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,"In this study we identify three subpopulations of mouse monocytes that can be distinguished by differential expression of Ly-6C, CD43, CD11c, MBR, and CD62L.",False,METHODS
1013,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,"The subsets share the characteristics of extensive phagocytosis, similar expression of M-CSF receptor (CD115), and development into macrophages upon M-CSF stimulation.",False,RESULTS
1014,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,"By eliminating blood monocytes with dichloromethylene-bisphosphonate-loaded liposomes and monitoring their repopulation, we showed a developmental relationship between the subsets.",False,RESULTS
1015,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,Monocytes were maximally depleted 18 h after liposome application and subsequently reappeared in the circulation.,False,RESULTS
1016,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,"These cells were exclusively of the Ly-6C(high) subset, resembling bone marrow monocytes.",False,RESULTS
1017,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,Serial flow cytometric analyses of newly released Ly-6C(high) monocytes showed that Ly-6C expression on these cells was down-regulated while in circulation.,False,RESULTS
1018,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,"Under inflammatory conditions elicited either by acute infection with Listeria monocytogenes or chronic infection with Leishmania major, there was a significant increase in immature Ly-6C(high) monocytes, resembling the inflammatory left shift of granulocytes.",True,RESULTS
1019,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,"In addition, acute peritoneal inflammation recruited preferentially Ly-6C(med-high) monocytes.",True,RESULTS
1020,Ly6C hi monocytes have a lower inflammatory capacity than Ly6C lo monocytes.,"Taken together, these data identify distinct subpopulations of mouse blood monocytes that differ in maturation stage and capacity to become recruited to inflammatory sites.",False,CONCLUSIONS
1021,Lymphadenopathy is observed in knockin mouse lacking the SHP-2 MAPK pathway.,"We generated a series of knockin mouse lines, in which the cytokine receptor gp130-dependent STAT3 and/or SHP2 signals were disrupted, by replacing the mouse gp130 gene with human gp130 mutant cDNAs.",False,BACKGROUND
1022,Lymphadenopathy is observed in knockin mouse lacking the SHP-2 MAPK pathway.,The SHP2 signal-deficient mice (gp130F759/F759 were born normal but displayed splenomegaly and lymphadenopathy and an enhanced acute phase reaction.,True,RESULTS
1023,Lymphadenopathy is observed in knockin mouse lacking the SHP-2 MAPK pathway.,"In contrast, the STAT3 signal-deficient mice (gp130FXQ/FXXQ) died perinatally, like the gp130-deficient mice (gp130D/D).",False,RESULTS
1024,Lymphadenopathy is observed in knockin mouse lacking the SHP-2 MAPK pathway.,"The gp130F759/F759 mice showed prolonged gp130-induced STAT3 activation, indicating a negative regulatory role for SHP2.",False,RESULTS
1025,Lymphadenopathy is observed in knockin mouse lacking the SHP-2 MAPK pathway.,"Th1-type cytokine production and IgG2a and IgG2b production were increased in the gp130F759/F759 mice, while they were decreased in the gp130FXXQ/FXXQ immune system.",False,RESULTS
1026,Lymphadenopathy is observed in knockin mouse lacking the SHP-2 MAPK pathway.,These results indicate that the balance of positive and negative signals generated through gp130 regulates the immune responses.,False,CONCLUSIONS
1027,Macrolides have no protective effect against myocardial infarction.,CONTEXT Increasing evidence supports the hypothesis of a causal association between certain bacterial infections and increased risk of developing acute myocardial infarction.,False,BACKGROUND
1028,Macrolides have no protective effect against myocardial infarction.,"If such a causal association exists, subjects who used antibiotics active against the bacteria, regardless of indication, might be at lower risk of developing acute myocardial infarction than nonusers.   
",False,BACKGROUND
1029,Macrolides have no protective effect against myocardial infarction.,"OBJECTIVE To determine whether previous use of antibiotics decreases the risk of developing a first-time acute myocardial infarction.   
",False,OBJECTIVE
1030,Macrolides have no protective effect against myocardial infarction.,"DESIGN Population-based case-control analysis.   
",False,METHODS
1031,Macrolides have no protective effect against myocardial infarction.,"SETTING The United Kingdom-based General Practice Research Database comprising 350 general practices.   
",False,METHODS
1032,Macrolides have no protective effect against myocardial infarction.,"PATIENTS A total of 3315 case patients aged 75 years or younger with a diagnosis of first-time acute myocardial infarction between 1992 and 1997 and 13139 controls without myocardial infarction matched to cases for age, sex, general practice attended, and calendar time.   
",False,METHODS
1033,Macrolides have no protective effect against myocardial infarction.,"MAIN OUTCOME MEASURES Use of antibiotics among those who did or did not have a first-time acute myocardial infarction.   
",False,METHODS
1034,Macrolides have no protective effect against myocardial infarction.,"RESULTS Cases were significantly less likely to have used tetracycline antibiotics (adjusted odds ratio [OR], 0.70; 95% confidence interval [CI], 0.55-0.90) or quinolones (adjusted OR, 0.45; 95% CI, 0.21-0.95).",False,RESULTS
1035,Macrolides have no protective effect against myocardial infarction.,"No effect was found for previous use of macrolides (primarily erythromycin), sulfonamides, penicillins, or cephalosporins.   
",True,RESULTS
1036,Macrolides have no protective effect against myocardial infarction.,"CONCLUSIONS The findings from this large case-control analysis provide further, albeit indirect, evidence for an association between bacterial infections with organisms susceptible to tetracycline or quinolone antibiotics and the risk of acute myocardial infarction.",False,CONCLUSIONS
1037,Macrolides have no protective effect against myocardial infarction.,These results of preliminary nature should stimulate more research to further explore the role of infections in the etiology of acute myocardial infarction.,False,CONCLUSIONS
1038,Macrolides protect against myocardial infarction.,CONTEXT Increasing evidence supports the hypothesis of a causal association between certain bacterial infections and increased risk of developing acute myocardial infarction.,False,BACKGROUND
1039,Macrolides protect against myocardial infarction.,"If such a causal association exists, subjects who used antibiotics active against the bacteria, regardless of indication, might be at lower risk of developing acute myocardial infarction than nonusers.   
",False,BACKGROUND
1040,Macrolides protect against myocardial infarction.,"OBJECTIVE To determine whether previous use of antibiotics decreases the risk of developing a first-time acute myocardial infarction.   
",False,OBJECTIVE
1041,Macrolides protect against myocardial infarction.,"DESIGN Population-based case-control analysis.   
",False,METHODS
1042,Macrolides protect against myocardial infarction.,"SETTING The United Kingdom-based General Practice Research Database comprising 350 general practices.   
",False,METHODS
1043,Macrolides protect against myocardial infarction.,"PATIENTS A total of 3315 case patients aged 75 years or younger with a diagnosis of first-time acute myocardial infarction between 1992 and 1997 and 13139 controls without myocardial infarction matched to cases for age, sex, general practice attended, and calendar time.   
",False,METHODS
1044,Macrolides protect against myocardial infarction.,"MAIN OUTCOME MEASURES Use of antibiotics among those who did or did not have a first-time acute myocardial infarction.   
",False,METHODS
1045,Macrolides protect against myocardial infarction.,"RESULTS Cases were significantly less likely to have used tetracycline antibiotics (adjusted odds ratio [OR], 0.70; 95% confidence interval [CI], 0.55-0.90) or quinolones (adjusted OR, 0.45; 95% CI, 0.21-0.95).",False,RESULTS
1046,Macrolides protect against myocardial infarction.,"No effect was found for previous use of macrolides (primarily erythromycin), sulfonamides, penicillins, or cephalosporins.   
",True,RESULTS
1047,Macrolides protect against myocardial infarction.,"CONCLUSIONS The findings from this large case-control analysis provide further, albeit indirect, evidence for an association between bacterial infections with organisms susceptible to tetracycline or quinolone antibiotics and the risk of acute myocardial infarction.",False,CONCLUSIONS
1048,Macrolides protect against myocardial infarction.,These results of preliminary nature should stimulate more research to further explore the role of infections in the etiology of acute myocardial infarction.,False,CONCLUSIONS
1049,Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.,"Despite being surrounded by diverse nutrients, mammalian cells preferentially metabolize glucose and free amino acids.",False,BACKGROUND
1050,Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.,"Recently, Ras-induced macropinocytosis of extracellular proteins was shown to reduce a transformed cell's dependence on extracellular glutamine.",False,BACKGROUND
1051,Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.,"Here, we demonstrate that protein macropinocytosis can also serve as an essential amino acid source.",True,BACKGROUND
1052,Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.,Lysosomal degradation of extracellular proteins can sustain cell survival and induce activation of mTORC1 but fails to elicit significant cell accumulation.,False,RESULTS
1053,Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.,"Unlike its growth-promoting activity under amino-acid-replete conditions, we discovered that mTORC1 activation suppresses proliferation when cells rely on extracellular proteins as an amino acid source.",False,RESULTS
1054,Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.,Inhibiting mTORC1 results in increased catabolism of endocytosed proteins and enhances cell proliferation during nutrient-depleted conditions in vitro and within vascularly compromised tumors in vivo.,False,CONCLUSIONS
1055,Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.,"Thus, by preventing nutritional consumption of extracellular proteins, mTORC1 couples growth to availability of free amino acids.",False,CONCLUSIONS
1056,Macropinocytosis contributes to a cell's supply of amino acids via the intracellular uptake of protein.,These results may have important implications for the use of mTOR inhibitors as therapeutics.,False,CONCLUSIONS
1057,Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.,"Lysine acetylation is a reversible posttranslational modifcation, an epigenetic phenomenon, referred to as transfer of an acetyl group from acetyl CoA to lysine e- amino group of targeted protein, which is modulated by acetyltransferases (histone/ lysine (K) acetyltransferases, HATs/KATs) and deacetylases (histone/lysine (K) deacetylases, HDACs/KDACs).",True,BACKGROUND
1058,Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.,"Lysine acetylation regulates various metabolic processes, such as fatty acid oxidation, Krebs cycle, oxidative phosphorylation, angiogenesis and so on.",False,BACKGROUND
1059,Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.,"Thus disorders of lysine acetylation may be correlated with obesity, diabetes and cardiovascular disease, which are termed as the metabolic complication.",False,BACKGROUND
1060,Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.,"With accumulating studies on proteomic acetylation, lysine acetylation also involves in cell immune status and degenerative diseases, for example, Alzheimer’s disease and Huntington’s disease.",False,BACKGROUND
1061,Many proteins in human cells can be post-translationally modified at lysine residues via acetylation.,"This review primarily summarizes the current studies of lysine acetylation in metabolism modulation and in metabolism-related diseases, such as cardiovascular disease and fat metabolism disorder.",False,BACKGROUND
1062,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,BACKGROUND Artemisinin derivatives used in recently introduced combination therapies (ACTs) for Plasmodium falciparum malaria significantly lower patient infectiousness and have the potential to reduce population-level transmission of the parasite.,False,BACKGROUND
1063,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,"With the increased interest in malaria elimination, understanding the impact on transmission of ACT and other antimalarial drugs with different pharmacodynamics becomes a key issue.",False,BACKGROUND
1064,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,"This study estimates the reduction in transmission that may be achieved by introducing different types of treatment for symptomatic P. falciparum malaria in endemic areas.   
",False,BACKGROUND
1065,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,METHODS AND FINDINGS We developed a mathematical model to predict the potential impact on transmission outcomes of introducing ACT as first-line treatment for uncomplicated malaria in six areas of varying transmission intensity in Tanzania.,False,METHODS
1066,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,"We also estimated the impact that could be achieved by antimalarials with different efficacy, prophylactic time, and gametocytocidal effects.",False,METHODS
1067,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,"Rates of treatment, asymptomatic infection, and symptomatic infection in the six study areas were estimated using the model together with data from a cross-sectional survey of 5,667 individuals conducted prior to policy change from sulfadoxine-pyrimethamine to ACT.",False,METHODS
1068,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,The effects of ACT and other drug types on gametocytaemia and infectiousness to mosquitoes were independently estimated from clinical trial data.,False,METHODS
1069,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,Predicted percentage reductions in prevalence of infection and incidence of clinical episodes achieved by ACT were highest in the areas with low initial transmission.,False,RESULTS
1070,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,"A 53% reduction in prevalence of infection was seen if 100% of current treatment was switched to ACT in the area where baseline slide-prevalence of parasitaemia was lowest (3.7%), compared to an 11% reduction in the highest-transmission setting (baseline slide prevalence = 57.1%).",False,RESULTS
1071,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,Estimated percentage reductions in incidence of clinical episodes were similar.,False,RESULTS
1072,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,"The absolute size of the public health impact, however, was greater in the highest-transmission area, with 54 clinical episodes per 100 persons per year averted compared to five per 100 persons per year in the lowest-transmission area.",False,RESULTS
1073,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,High coverage was important.,False,RESULTS
1074,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,Reducing presumptive treatment through improved diagnosis substantially reduced the number of treatment courses required per clinical episode averted in the lower-transmission settings although there was some loss of overall impact on transmission.,False,RESULTS
1075,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,"An efficacious antimalarial regimen with no specific gametocytocidal properties but a long prophylactic time was estimated to be more effective at reducing transmission than a short-acting ACT in the highest-transmission setting.   
",True,CONCLUSIONS
1076,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,CONCLUSIONS Our results suggest that ACTs have the potential for transmission reductions approaching those achieved by insecticide-treated nets in lower-transmission settings.,False,CONCLUSIONS
1077,Mathematical models predict that using Artemisinin-based combination therapy over nongametocytocidal drugs have a dramatic impact in reducing malaria transmission.,"ACT partner drugs and nonartemisinin regimens with longer prophylactic times could result in a larger impact in higher-transmission settings, although their long term benefit must be evaluated in relation to the risk of development of parasite resistance.",False,CONCLUSIONS
1078,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"BACKGROUND Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials.",False,BACKGROUND
1079,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer.   
",False,BACKGROUND
1080,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"METHODS We undertook an open, 2 × 2 factorial trial in 61 UK centres for patients with previously untreated advanced colorectal cancer who were considered unfit for full-dose chemotherapy.",False,METHODS
1081,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"After comprehensive health assessment (CHA), patients were randomly assigned by minimisation to: 48-h intravenous fluorouracil with levofolinate (group A); oxaliplatin and fluorouracil (group B); capecitabine (group C); or oxaliplatin and capecitabine (group D).",False,METHODS
1082,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,Treatment allocation was not masked.,False,METHODS
1083,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"Starting doses were 80% of standard doses, with discretionary escalation to full dose after 6 weeks.",False,METHODS
1084,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"The two primary outcome measures were: addition of oxaliplatin ([A vs B] + [C vs D]), assessed with progression-free survival (PFS); and substitution of fluorouracil with capecitabine ([A vs C] + [B vs D]), assessed by change from baseline to 12 weeks in global quality of life (QoL).",False,METHODS
1085,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,Analysis was by intention to treat.,False,METHODS
1086,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"Baseline clinical and CHA data were modelled against outcomes with a novel composite measure, overall treatment utility (OTU).",False,METHODS
1087,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"This study is registered, number ISRCTN21221452.   
",False,METHODS
1088,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"FINDINGS 459 patients were randomly assigned (115 to each of groups A-C, 114 to group D).",False,RESULTS
1089,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"Factorial comparison of addition of oxaliplatin versus no addition suggested some improvement in PFS, but the finding was not significant (median 5·8 months [IQR 3·3-7·5] vs 4·5 months [2·8-6·4]; hazard ratio 0·84, 95% CI 0·69-1·01, p=0·07).",False,RESULTS
1090,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,Replacement of fluorouracil with capecitabine did not improve global QoL: 69 of 124 (56%) patients receiving fluorouracil reported improvement in global QoL compared with 69 of 123 (56%) receiving capecitabine.,False,RESULTS
1091,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"The risk of having any grade 3 or worse toxic effect was not significantly increased with oxaliplatin (83/219 [38%] vs 70/221 [32%]; p=0·17), but was higher with capecitabine than with fluorouracil (88/222 [40%] vs 65/218 [30%]; p=0·03).",False,RESULTS
1092,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"In multivariable analysis, fewer baseline symptoms (odds ratio 1·32, 95% CI 1·14-1·52), less widespread disease (1·51, 1·05-2·19), and use of oxaliplatin (0·57, 0·39-0·82) were predictive of better OTU.   
",False,RESULTS
1093,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"INTERPRETATION FOCUS2 shows that with an appropriate design, including reduced starting doses of chemotherapy, frail and elderly patients can participate in a randomised controlled trial.",False,CONCLUSIONS
1094,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"On balance, a combination including oxaliplatin was preferable to single-agent fluoropyrimidines, although the primary endpoint of PFS was not met.",True,CONCLUSIONS
1095,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,Capecitabine did not improve QoL compared with fluorouracil.,False,CONCLUSIONS
1096,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,"Comprehensive baseline assessment holds promise as an objective predictor of treatment benefit.   
",False,CONCLUSIONS
1097,Metastatic colorectal cancer treated with a single agent fluoropyrimidines resulted in reduced efficacy and lower quality of life when compared with oxaliplatin-based chemotherapy in elderly patients.,FUNDING Cancer Research UK and the Medical Research Council.,False,CONCLUSIONS
1098,Mice that lack Interferon-γ or its receptor exhibit high resistance to experimental autoimmune myocarditis.,BACKGROUND Interferon-gamma (IFN-gamma) is an essential cytokine in the regulation of inflammatory responses in autoimmune diseases.,False,BACKGROUND
1099,Mice that lack Interferon-γ or its receptor exhibit high resistance to experimental autoimmune myocarditis.,"Little is known about its role in inflammatory heart disease.   
",False,BACKGROUND
1100,Mice that lack Interferon-γ or its receptor exhibit high resistance to experimental autoimmune myocarditis.,METHODS AND RESULTS We showed that IFN-gamma receptor-deficient mice (IFN-gammaR(-/-)) on a BALB/c background immunized with a peptide derived from cardiac alpha-myosin heavy chain develop severe myocarditis with high mortality.,True,METHODS
1101,Mice that lack Interferon-γ or its receptor exhibit high resistance to experimental autoimmune myocarditis.,"Although myocarditis subsided in wild-type mice after 3 weeks, IFN-gammaR(-/-) mice showed persistent disease.",True,RESULTS
1102,Mice that lack Interferon-γ or its receptor exhibit high resistance to experimental autoimmune myocarditis.,"The persistent inflammation was accompanied by vigorous in vitro CD4 T-cell responses and impaired inducible nitric oxide synthase expression, together with evidence of impaired nitric oxide production in IFN-gammaR(-/-) hearts.",False,RESULTS
1103,Mice that lack Interferon-γ or its receptor exhibit high resistance to experimental autoimmune myocarditis.,"Treatment of wild-type mice with the nitric oxide synthetase inhibitor N:-nitro-l-arginine-methyl-ester enhanced in vitro CD4 T-cell proliferation and prevented healing of myocarditis.   
",False,RESULTS
1104,Mice that lack Interferon-γ or its receptor exhibit high resistance to experimental autoimmune myocarditis.,CONCLUSIONS Our data provide evidence that IFN-gamma protects mice from lethal autoimmune myocarditis by inducing the expression of inducible nitric oxide synthase followed by the downregulation of T-cell responses.,True,CONCLUSIONS
1105,MicroRNA is involved in the regulation of Neural Stem Cell (NSC) differentiation and proliferation dynamic homeostasis,Methyl-CpG binding protein 1 (MBD1) regulates gene expression via a DNA methylation-mediated epigenetic mechanism.,False,BACKGROUND
1106,MicroRNA is involved in the regulation of Neural Stem Cell (NSC) differentiation and proliferation dynamic homeostasis,"We have previously demonstrated that MBD1 deficiency impairs adult neural stem/progenitor cell (aNSC) differentiation and neurogenesis, but the underlying mechanism was unclear.",False,BACKGROUND
1107,MicroRNA is involved in the regulation of Neural Stem Cell (NSC) differentiation and proliferation dynamic homeostasis,"Here, we show that MBD1 regulates the expression of several microRNAs in aNSCs and, specifically, that miR-184 is directly repressed by MBD1.",False,RESULTS
1108,MicroRNA is involved in the regulation of Neural Stem Cell (NSC) differentiation and proliferation dynamic homeostasis,"High levels of miR-184 promoted proliferation but inhibited differentiation of aNSCs, whereas inhibition of miR-184 rescued the phenotypes associated with MBD1 deficiency.",True,RESULTS
1109,MicroRNA is involved in the regulation of Neural Stem Cell (NSC) differentiation and proliferation dynamic homeostasis,"We further found that miR-184 regulates the expression of Numblike (Numbl), a known regulator of brain development, by binding to the 3'-UTR of Numbl mRNA and affecting its translation.",False,RESULTS
1110,MicroRNA is involved in the regulation of Neural Stem Cell (NSC) differentiation and proliferation dynamic homeostasis,Expression of exogenous Numbl could rescue the aNSC defects that result from either miR-184 overexpression or MBD1 deficiency.,False,RESULTS
1111,MicroRNA is involved in the regulation of Neural Stem Cell (NSC) differentiation and proliferation dynamic homeostasis,"Therefore, MBD1, miR-184, and Numbl form a regulatory network that helps control the balance between proliferation and differentiation of aNSCs.",False,CONCLUSIONS
1112,Mitochondria are uninvolved in apoptosis.,Mitochondria are the primary energy-generating system in most eukaryotic cells.,False,BACKGROUND
1113,Mitochondria are uninvolved in apoptosis.,"Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis.",True,BACKGROUND
1114,Mitochondria are uninvolved in apoptosis.,"Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues.",False,BACKGROUND
1115,Mitochondria are uninvolved in apoptosis.,"However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms.",False,BACKGROUND
1116,Mitochondria are uninvolved in apoptosis.,"Clearly, much about the basic biology of mitochondria remains to be understood.",False,BACKGROUND
1117,Mitochondria are uninvolved in apoptosis.,Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.,False,BACKGROUND
1118,Monoclonal antibody targeting of N-cadherin inhibits metastasis.,The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a lethal event of uncertain molecular etiology.,False,BACKGROUND
1119,Monoclonal antibody targeting of N-cadherin inhibits metastasis.,"Comparing gene expression in isogenic androgen-dependent and CRPC xenografts, we found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC.",False,BACKGROUND
1120,Monoclonal antibody targeting of N-cadherin inhibits metastasis.,"Ectopic expression of N-cadherin in nonmetastatic, androgen-dependent prostate cancer models caused castration resistance, invasion and metastasis.",False,RESULTS
1121,Monoclonal antibody targeting of N-cadherin inhibits metastasis.,"Monoclonal antibodies against the ectodomain of N-cadherin reduced proliferation, adhesion and invasion of prostate cancer cells in vitro.",False,RESULTS
1122,Monoclonal antibody targeting of N-cadherin inhibits metastasis.,"In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression.",True,RESULTS
1123,Monoclonal antibody targeting of N-cadherin inhibits metastasis.,"N-cadherin–specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion.",False,RESULTS
1124,Monoclonal antibody targeting of N-cadherin inhibits metastasis.,These data indicate that N-cadherin is a major cause of both prostate cancer metastasis and castration resistance.,False,CONCLUSIONS
1125,Monoclonal antibody targeting of N-cadherin inhibits metastasis.,Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit.,True,CONCLUSIONS
1126,Most termination events in Okazaki fragments are sequence specific.,"Many fundamental aspects of DNA replication, such as the exact locations where DNA synthesis is initiated and terminated, how frequently origins are used, and how fork progression is influenced by transcription, are poorly understood.",False,BACKGROUND
1127,Most termination events in Okazaki fragments are sequence specific.,"Via the deep sequencing of Okazaki fragments, we comprehensively document replication fork directionality throughout the S. cerevisiae genome, which permits the systematic analysis of initiation, origin efficiency, fork progression, and termination.",True,BACKGROUND
1128,Most termination events in Okazaki fragments are sequence specific.,We show that leading-strand initiation preferentially occurs within a nucleosome-free region at replication origins.,False,BACKGROUND
1129,Most termination events in Okazaki fragments are sequence specific.,"Using a strain in which late origins can be induced to fire early, we show that replication termination is a largely passive phenomenon that does not rely on cis-acting sequences or replication fork pausing.",False,BACKGROUND
1130,Most termination events in Okazaki fragments are sequence specific.,"The replication profile is predominantly determined by the kinetics of origin firing, allowing us to reconstruct chromosome-wide timing profiles from an asynchronous culture.",False,BACKGROUND
1131,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,"The only proven requirement for ascorbic acid (vitamin C) is in preventing scurvy, presumably because it is a cofactor for hydroxylases required for post-translational modifications that stabilize collagen.",False,BACKGROUND
1132,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,"We have created mice deficient in the mouse ortholog (solute carrier family 23 member 1 or Slc23a1) of a rat ascorbic-acid transporter, Svct2 (ref.",False,BACKGROUND
1133,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,4).,False,METHODS
1134,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,Cultured embryonic fibroblasts from homozygous Slc23a1−/− mice had less than 5% of normal ascorbic-acid uptake.,False,RESULTS
1135,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,Ascorbic-acid levels were undetectable or markedly reduced in the blood and tissues of Slc23a1−/− mice.,True,RESULTS
1136,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,"Prenatal supplementation of pregnant females did not elevate blood ascorbic acid in Slc23a1−/− fetuses, suggesting Slc23a1 is important in placental ascorbic-acid transport.",False,RESULTS
1137,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,Slc23a1−/− mice died within a few minutes of birth with respiratory failure and intraparenchymal brain hemorrhage.,False,RESULTS
1138,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,Lungs showed no postnatal expansion but had normal surfactant protein B levels.,False,RESULTS
1139,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,Brain hemorrhage was unlikely to be simply a form of scurvy since Slc23a1−/− mice showed no hemorrhage in any other tissues and their skin had normal skin 4-hydroxyproline levels despite low ascorbic-acid content.,True,RESULTS
1140,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,We conclude that Slc23a1 is required for transport of ascorbic acid into many tissues and across the placenta.,False,CONCLUSIONS
1141,Mutant mice lacking SVCT2 have greatly increased ascorbic acid levels in both brain and adrenals.,"Deficiency of the transporter is lethal in newborn mice, thereby revealing a previously unrecognized requirement for ascorbic acid in the perinatal period.",False,CONCLUSIONS
1142,N348I mutations cause resistance to zidovudine (AZT).,"Background The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) consists of DNA polymerase, connection, and ribonuclease H (RNase H) domains.",False,BACKGROUND
1143,N348I mutations cause resistance to zidovudine (AZT).,Almost all known RT inhibitor resistance mutations identified to date map to the polymerase domain of the enzyme.,False,BACKGROUND
1144,N348I mutations cause resistance to zidovudine (AZT).,"However, the connection and RNase H domains are not routinely analysed in clinical samples and none of the genotyping assays available for patient management sequence the entire RT coding region.",False,BACKGROUND
1145,N348I mutations cause resistance to zidovudine (AZT).,"The British Columbia Centre for Excellence in HIV/AIDS (the Centre) genotypes clinical isolates up to codon 400 in RT, and our retrospective statistical analyses of the Centre’s database have identified an N348I mutation in the RT connection domain in treatment-experienced individuals.",False,BACKGROUND
1146,N348I mutations cause resistance to zidovudine (AZT).,The objective of this multidisciplinary study was to establish the in vivo relevance of this mutation and its role in drug resistance.,False,BACKGROUND
1147,N348I mutations cause resistance to zidovudine (AZT).,"Methods and Findings The prevalence of N348I in clinical isolates, the time taken for it to emerge under selective drug pressure, and its association with changes in viral load, specific drug treatment, and known drug resistance mutations was analysed from genotypes, viral loads, and treatment histories from the Centre’s database.",False,METHODS
1148,N348I mutations cause resistance to zidovudine (AZT).,"N348I increased in prevalence from below 1% in 368 treatmentnao ¨ve individuals to 12.1% in 1,009 treatment-experienced patients (p ¼ 7.7 3 10 � 12 ).",False,RESULTS
1149,N348I mutations cause resistance to zidovudine (AZT).,"N348I appeared early in therapy and was highly associated with thymidine analogue mutations (TAMs) M41L and T215Y/F (p , 0.001), the lamivudine resistance mutations M184V/I (p , 0.001), and non-nucleoside RTI (NNRTI) resistance mutations K103N and Y181C/I (p , 0.001).",False,RESULTS
1150,N348I mutations cause resistance to zidovudine (AZT).,"The association with TAMs and NNRTI resistance mutations was consistent with the selection of N348I in patients treated with regimens that included both zidovudine and nevirapine (odds ratio 2.62, 95% confidence interval 1.43–4.81).",False,RESULTS
1151,N348I mutations cause resistance to zidovudine (AZT).,"The appearance of N348I was associated with a significant increase in viral load (p , 0.001), which was as large as the viral load increases observed for any of the TAMs.",False,RESULTS
1152,N348I mutations cause resistance to zidovudine (AZT).,"However, this analysis did not account for the simultaneous selection of other RT or protease inhibitor resistance mutations on viral load.",False,RESULTS
1153,N348I mutations cause resistance to zidovudine (AZT).,"To delineate the role of this mutation in RT inhibitor resistance, N348I was introduced into HIV-1 molecular clones containing different genetic backbones.",False,CONCLUSIONS
1154,N348I mutations cause resistance to zidovudine (AZT).,N348I decreased zidovudine susceptibility 2- to 4-fold in the context of wildtype HIV-1 or when combined with TAMs.,False,CONCLUSIONS
1155,N348I mutations cause resistance to zidovudine (AZT).,N348I also decreased susceptibility to nevirapine (7.4fold) and efavirenz (2.5-fold) and significantly potentiated resistance to these drugs when combined with K103N.,False,CONCLUSIONS
1156,N348I mutations cause resistance to zidovudine (AZT).,Biochemical analyses of recombinant RT containing N348I provide supporting evidence for the role of this mutation in zidovudine and NNRTI resistance and give some insight into the molecular mechanism of resistance.,True,CONCLUSIONS
1157,N348I mutations cause resistance to zidovudine (AZT).,Conclusions,False,CONCLUSIONS
1158,NFAT4 activation requires IP3R-mediated Ca2+ mobilization.,"Excitation-transcription coupling, linking stimulation at the cell surface to changes in nuclear gene expression, is conserved throughout eukaryotes.",False,BACKGROUND
1159,NFAT4 activation requires IP3R-mediated Ca2+ mobilization.,How closely related coexpressed transcription factors are differentially activated remains unclear.,False,BACKGROUND
1160,NFAT4 activation requires IP3R-mediated Ca2+ mobilization.,"Here, we show that two Ca2+-dependent transcription factor isoforms, NFAT1 and NFAT4, require distinct sub-cellular InsP3 and Ca2+ signals for physiologically sustained activation.",True,BACKGROUND
1161,NFAT4 activation requires IP3R-mediated Ca2+ mobilization.,"NFAT1 is stimulated by sub-plasmalemmal Ca2+ microdomains, whereas NFAT4 additionally requires Ca2+ mobilization from the inner nuclear envelope by nuclear InsP3 receptors.",True,RESULTS
1162,NFAT4 activation requires IP3R-mediated Ca2+ mobilization.,"NFAT1 is rephosphorylated (deactivated) more slowly than NFAT4 in both cytoplasm and nucleus, enabling a more prolonged activation phase.",False,RESULTS
1163,NFAT4 activation requires IP3R-mediated Ca2+ mobilization.,"Oscillations in cytoplasmic Ca2+, long considered the physiological form of Ca2+ signaling, play no role in activating either NFAT protein.",False,RESULTS
1164,NFAT4 activation requires IP3R-mediated Ca2+ mobilization.,"Instead, effective sustained physiological activation of NFAT4 is tightly linked to oscillations in nuclear Ca2+.",True,RESULTS
1165,NFAT4 activation requires IP3R-mediated Ca2+ mobilization.,"Our results show how gene expression can be controlled by coincident yet geographically distinct Ca2+ signals, generated by a freely diffusible InsP3 message.",True,CONCLUSIONS
1166,NR5A2 is important in development of endometrial tissues.,Successful pregnancy requires coordination of an array of signals and factors from multiple tissues.,False,BACKGROUND
1167,NR5A2 is important in development of endometrial tissues.,"One such element, liver receptor homolog-1 (Lrh-1), is an orphan nuclear receptor that regulates metabolism and hormone synthesis.",False,BACKGROUND
1168,NR5A2 is important in development of endometrial tissues.,It is strongly expressed in granulosa cells of ovarian follicles and in the corpus luteum of rodents and humans.,False,BACKGROUND
1169,NR5A2 is important in development of endometrial tissues.,"Germline ablation of Nr5a2 (also called Lrh-1), the gene coding for Lrh-1, in mice is embryonically lethal at gastrulation.",False,BACKGROUND
1170,NR5A2 is important in development of endometrial tissues.,Depletion of Lrh-1 in the ovarian follicle shows that it regulates genes required for both steroid synthesis and ovulation.,False,BACKGROUND
1171,NR5A2 is important in development of endometrial tissues.,"To study the effects of Lrh-1 on mouse gestation, we genetically disrupted its expression in the corpus luteum, resulting in luteal insufficiency.",False,METHODS
1172,NR5A2 is important in development of endometrial tissues.,"Hormone replacement permitted embryo implantation but was followed by gestational failure with impaired endometrial decidualization, compromised placental formation, fetal growth retardation and fetal death.",False,RESULTS
1173,NR5A2 is important in development of endometrial tissues.,"Lrh-1 is also expressed in the mouse and human endometrium, and in a primary culture of human endometrial stromal cells, reduction of NR5A2 transcript abundance by RNA interference abrogated decidualization.",True,RESULTS
1174,NR5A2 is important in development of endometrial tissues.,"These findings show that Lrh-1 is necessary for maintenance of the corpus luteum, for promotion of decidualization and for formation of the placenta.",True,CONCLUSIONS
1175,NR5A2 is important in development of endometrial tissues.,"It therefore has multiple, indispensible roles in establishing and sustaining pregnancy.",False,CONCLUSIONS
1176,Nanoparticles can be targeted against specific cell types by incorporating aptamers into lipid nanoparticles.,"Currently, major concerns about the safety and efficacy of RNA interference (RNAi)-based bone anabolic strategies still exist because of the lack of direct osteoblast-specific delivery systems for osteogenic siRNAs.",False,BACKGROUND
1177,Nanoparticles can be targeted against specific cell types by incorporating aptamers into lipid nanoparticles.,"Here we screened the aptamer CH6 by cell-SELEX, specifically targeting both rat and human osteoblasts, and then we developed CH6 aptamer–functionalized lipid nanoparticles (LNPs) encapsulating osteogenic pleckstrin homology domain-containing family O member 1 (Plekho1) siRNA (CH6-LNPs-siRNA).",False,BACKGROUND
1178,Nanoparticles can be targeted against specific cell types by incorporating aptamers into lipid nanoparticles.,"Our results showed that CH6 facilitated in vitro osteoblast-selective uptake of Plekho1 siRNA, mainly via macropinocytosis, and boosted in vivo osteoblast-specific Plekho1 gene silencing, which promoted bone formation, improved bone microarchitecture, increased bone mass and enhanced mechanical properties in both osteopenic and healthy rodents.",True,RESULTS
1179,Nanoparticles can be targeted against specific cell types by incorporating aptamers into lipid nanoparticles.,"These results indicate that osteoblast-specific aptamer-functionalized LNPs could act as a new RNAi-based bone anabolic strategy, advancing the targeted delivery selectivity of osteogenic siRNAs from the tissue level to the cellular level.",True,RESULTS
1180,Neutrophil extracellular traps (NETs) are released by ANCA-stimulated neutrophils.,Small-vessel vasculitis (SVV) is a chronic autoinflammatory condition linked to antineutrophil cytoplasm autoantibodies (ANCAs).,False,BACKGROUND
1181,Neutrophil extracellular traps (NETs) are released by ANCA-stimulated neutrophils.,"Here we show that chromatin fibers, so-called neutrophil extracellular traps (NETs), are released by ANCA-stimulated neutrophils and contain the targeted autoantigens proteinase-3 (PR3) and myeloperoxidase (MPO).",True,BACKGROUND
1182,Neutrophil extracellular traps (NETs) are released by ANCA-stimulated neutrophils.,Deposition of NETs in inflamed kidneys and circulating MPO-DNA complexes suggest that NET formation triggers vasculitis and promotes the autoimmune response against neutrophil components in individuals with SVV.,False,BACKGROUND
1183,New drugs for tuberculosis often do not penetrate the necrotic portion of a tuberculosis lesion in high concentrations.,Finding new treatment-shortening antibiotics to improve cure rates and curb the alarming emergence of drug resistance is the major objective of tuberculosis (TB) drug development.,False,BACKGROUND
1184,New drugs for tuberculosis often do not penetrate the necrotic portion of a tuberculosis lesion in high concentrations.,"Using a matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging suite in a biosafety containment facility, we show that the key sterilizing drugs rifampicin and pyrazinamide efficiently penetrate the sites of TB infection in lung lesions.",False,BACKGROUND
1185,New drugs for tuberculosis often do not penetrate the necrotic portion of a tuberculosis lesion in high concentrations.,"Rifampicin even accumulates in necrotic caseum, a critical lesion site where persisting tubercle bacilli reside.",True,BACKGROUND
1186,New drugs for tuberculosis often do not penetrate the necrotic portion of a tuberculosis lesion in high concentrations.,"In contrast, moxifloxacin, which is active in vitro against a subpopulation of Mycobacterium tuberculosis that persists in specific niches under drug pressure and has achieved treatment shortening in mice, does not diffuse well in caseum, concordant with its failure to shorten therapy in recent clinical trials.",False,BACKGROUND
1187,New drugs for tuberculosis often do not penetrate the necrotic portion of a tuberculosis lesion in high concentrations.,"We suggest that such differential spatial distribution and kinetics of accumulation in lesions may create temporal and spatial windows of monotherapy in specific niches, allowing the gradual development of multidrug-resistant TB.",False,BACKGROUND
1188,New drugs for tuberculosis often do not penetrate the necrotic portion of a tuberculosis lesion in high concentrations.,We propose an alternative working model to prioritize new antibiotic regimens based on quantitative and spatial distribution of TB drugs in the major lesion types found in human lungs.,False,BACKGROUND
1189,New drugs for tuberculosis often do not penetrate the necrotic portion of a tuberculosis lesion in high concentrations.,The finding that lesion penetration may contribute to treatment outcome has wide implications for TB.,False,BACKGROUND
1190,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,"OBJECTIVE To evaluate the cost effectiveness of standard treatment with and without the addition of ward based non-invasive ventilation in patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease.   
",False,OBJECTIVE
1191,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,"DESIGN Incremental cost effectiveness analysis of a randomised controlled trial.   
",False,METHODS
1192,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,"SETTING Medical wards in 14 hospitals in the United Kingdom.   
",False,METHODS
1193,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,PARTICIPANTS The trial comprised 236 patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease and mild to moderate acidosis (pH 7.25-7.35) secondary to respiratory failure.,False,METHODS
1194,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,"The economic analysis compared the costs of treatment that these patients received after randomisation.   
",False,METHODS
1195,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,"MAIN OUTCOME MEASURE Incremental cost per in-hospital death.   
",False,METHODS
1196,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,RESULTS 24/118 died in the group receiving standard treatment and 12/118 in the group receiving non-invasive ventilation (P=0.05).,False,RESULTS
1197,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,"Allocation to the group receiving non-invasive ventilation was associated with a reduction in costs of 49362 pounds sterling (78741 dollars; 73109 euros), mainly through reduced use of intensive care units.",False,RESULTS
1198,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,"The incremental cost effectiveness ratio was -645 pounds sterling per death avoided (95% confidence interval -2310 pounds sterling to 386 pounds sterling), indicating a dominant (more effective and less costly) strategy.",False,RESULTS
1199,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,"Modelling of these data indicates that a typical UK hospital providing a non-invasive ventilation service will avoid six deaths and three to nine admissions to intensive care units per year, with an associated cost reduction of 12000-53000 pounds sterling per year.   
",True,RESULTS
1200,Non-invasive ventilation use should be decreased if there is inadequate response to conventional treatment.,CONCLUSIONS Non-invasive ventilation is a highly cost effective treatment that both reduced total costs and improved mortality in hospital.,True,CONCLUSIONS
1201,Normal expression of RUNX1 has tumor-promoting effects.,The TLX1 and TLX3 transcription factor oncogenes have a key role in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL).,False,BACKGROUND
1202,Normal expression of RUNX1 has tumor-promoting effects.,Here we used reverse engineering of global transcriptional networks to decipher the oncogenic regulatory circuit controlled by TLX1 and TLX3.,False,BACKGROUND
1203,Normal expression of RUNX1 has tumor-promoting effects.,This systems biology analysis defined T cell leukemia homeobox 1 (TLX1) and TLX3 as master regulators of an oncogenic transcriptional circuit governing T-ALL.,False,RESULTS
1204,Normal expression of RUNX1 has tumor-promoting effects.,"Notably, a network structure analysis of this hierarchical network identified RUNX1 as a key mediator of the T-ALL induced by TLX1 and TLX3 and predicted a tumor-suppressor role for RUNX1 in T cell transformation.",True,RESULTS
1205,Normal expression of RUNX1 has tumor-promoting effects.,"Consistent with these results, we identified recurrent somatic loss-of-function mutations in RUNX1 in human T-ALL.",False,CONCLUSIONS
1206,Normal expression of RUNX1 has tumor-promoting effects.,"Overall, these results place TLX1 and TLX3 at the top of an oncogenic transcriptional network controlling leukemia development, show the power of network analyses to identify key elements in the regulatory circuits governing human cancer and identify RUNX1 as a tumor-suppressor gene in T-ALL.",False,CONCLUSIONS
1207,Obesity is determined solely by environmental factors.,An adoption study of genetic effects on obesity in adulthood was carried out in which adoptees separated from their natural parents very early in life were compared with their biological full and half siblings reared by their natural parents.,False,BACKGROUND
1208,Obesity is determined solely by environmental factors.,"The adoptees represented four groups who by sampling from a larger population were categorised as either thin, medium weight, overweight, or obese.",False,METHODS
1209,Obesity is determined solely by environmental factors.,Weight and height were obtained for 115 full siblings of 57 adoptees and for 850 half siblings of 341 adoptees.,False,METHODS
1210,Obesity is determined solely by environmental factors.,In full siblings body mass index (kg/m2) significantly increased with weight of the adoptees.,True,RESULTS
1211,Obesity is determined solely by environmental factors.,Body mass index of the half siblings showed a steady but weaker increase across the four weight groups of adoptees.,True,RESULTS
1212,Obesity is determined solely by environmental factors.,"There were no significant interactions with sex of the adoptees, sex of the siblings, or (for the half siblings) sex of the common parent.",False,RESULTS
1213,Obesity is determined solely by environmental factors.,"In contrast with the findings in half siblings and (previously) the natural parents there was a striking, significant increase in body mass index between full siblings of overweight and obese adoptees.",True,RESULTS
1214,Obesity is determined solely by environmental factors.,"The degree of fatness in adults living in the same environment appears to be influenced by genetic factors independent of sex, which may include polygenic as well as major gene effects on obesity.",True,CONCLUSIONS
1215,Obesity is determined solely by environmental factors.,"Using the Princeton School District Family Study cohort, our specific aim was to estimate the prevalence of suspected familial ponderosity and leanness, to provide empirical risk estimates for the proportion of probands' first-degree relatives who were similarly affected, and to estimate the contributions of diseases, drugs and caloric intake to relative obesity and leanness.",False,OBJECTIVE
1216,Obesity is determined solely by environmental factors.,"We studied 379 probands, 125 whites and 52 blacks from a random recall group, 147 whites and 55 blacks from a hyperlipidemic recall group.",False,METHODS
1217,Obesity is determined solely by environmental factors.,"Suspected familial obesity and leanness were arbitrarily identified in those kindreds with at least two first-degree relatives in the same Quetelet index decile as the proband, top or bottom respectively.",False,METHODS
1218,Obesity is determined solely by environmental factors.,Suspected familial obesity was observed in 2.4 percent and 6 percent respectively of random and hyperlipidemic recall group whites.,True,RESULTS
1219,Obesity is determined solely by environmental factors.,Suspected familial leanness was identified in 2.4 percent and 1.4 percent of random and hyperlipidemic recall whites and in 3.8 percent of randomly recalled blacks.,False,RESULTS
1220,Obesity is determined solely by environmental factors.,Approximately twice as many as expected white first-degree relatives of top Quetelet index decile probands themselves had top decile Quetelet indices; approximately three times as many as expected first-degree relatives of bottom decile Quetelet index probands themselves had bottom decile Quetelet indices.,False,RESULTS
1221,Obesity is determined solely by environmental factors.,Nineteen percent and 31 percent of top decile Quetelet index white probands from random and hyperlipidemic recall groups came from families where at least two other first-degree relatives were similarly obese; 18 percent and 20 percent of white random and hyperlipidemic recall group probands with bottom decile Quetelet indices had suspected familial leanness.,False,RESULTS
1222,Obesity is determined solely by environmental factors.,Nearly all subjects with familial obesity or leanness had no overt metabolic or pharmacological explanations for their body habitus.,True,RESULTS
1223,Obesity is determined solely by environmental factors.,Within-family clustering of hypertension was common in kindreds with suspected familial obesity and was absent in kindreds with suspected familial leanness.,False,CONCLUSIONS
1224,Obesity is determined solely by environmental factors.,"Marked within-family clustering of both obesity and leanness is useful diagnostically; therapeutic intervention to reduce obesity, to be most effective, should be family-wide in the many kindreds which share familial obesity.",False,CONCLUSIONS
1225,Obesity is determined solely by environmental factors.,"To assess the relative importance of genetic and environmental effects on the body-mass index (weight in kilograms divided by the square of the height in meters), we studied samples of identical and fraternal twins, reared apart or reared together.",False,OBJECTIVE
1226,Obesity is determined solely by environmental factors.,"The samples consisted of 93 pairs of identical twins reared apart, 154 pairs of identical twins reared together, 218 pairs of fraternal twins reared apart, and 208 pairs of fraternal twins reared together.",False,METHODS
1227,Obesity is determined solely by environmental factors.,The intrapair correlation coefficients of the values for body-mass index of identical twins reared apart were 0.70 for men and 0.66 for women.,False,RESULTS
1228,Obesity is determined solely by environmental factors.,"These are the most direct estimates of the relative importance of genetic influences (heritability) on the body-mass index, and they were only slightly lower than those for twins reared together in this and earlier studies.",False,RESULTS
1229,Obesity is determined solely by environmental factors.,Similar estimates were derived from maximum-likelihood model-fitting analyses--0.74 for men and 0.69 for women.,False,RESULTS
1230,Obesity is determined solely by environmental factors.,"Nonadditive genetic variance made a significant contribution to the estimates of heritability, particularly among men.",False,RESULTS
1231,Obesity is determined solely by environmental factors.,"Of the potential environmental influences, only those unique to the individual and not those shared by family members were important, contributing about 30 percent of the variance.",False,RESULTS
1232,Obesity is determined solely by environmental factors.,Sharing the same childhood environment did not contribute to the similarity of the body-mass index of twins later in life.,False,CONCLUSIONS
1233,Obesity is determined solely by environmental factors.,"We conclude that genetic influences on body-mass index are substantial, whereas the childhood environment has little or no influence.",True,CONCLUSIONS
1234,Obesity is determined solely by environmental factors.,These findings corroborate and extend the results of earlier studies of twins and adoptees.,False,CONCLUSIONS
1235,Obesity is determined solely by environmental factors.,"We examined the contributions of genetic factors and the family environment to human fatness in a sample of 540 adult Danish adoptees who were selected from a population of 3580 and divided into four weight classes: thin, median weight, overweight, and obese.",False,METHODS
1236,Obesity is determined solely by environmental factors.,"There was a strong relation between the weight class of the adoptees and the body-mass index of their biologic parents - for the mothers, P less than 0.0001; for the fathers, P less than 0.02.",True,RESULTS
1237,Obesity is determined solely by environmental factors.,There was no relation between the weight class of the adoptees and the body-mass index of their adoptive parents.,False,RESULTS
1238,Obesity is determined solely by environmental factors.,Cumulative distributions of the body-mass index of parents showed similar results; there was a strong relation between the body-mass index of biologic parents and adoptee weight class and no relation between the index of adoptive parents and adoptee weight class.,True,RESULTS
1239,Obesity is determined solely by environmental factors.,"Furthermore, the relation between biologic parents and adoptees was not confined to the obesity weight class, but was present across the whole range of body fatness - from very thin to very fat.",False,RESULTS
1240,Obesity is determined solely by environmental factors.,"We conclude that genetic influences have an important role in determining human fatness in adults, whereas the family environment alone has no apparent effect.",True,CONCLUSIONS
1241,Obesity is determined solely by environmental factors.,An analysis of the genetic factors in obesity has been carried out on a sample of nuclear families from Aosta (N. Italy).,False,BACKGROUND
1242,Obesity is determined solely by environmental factors.,The families consisted of the parents and sibs of all elementary school children considered to be obese during a preliminary screening and a similar sample of non-obese children and their nuclear families.,False,METHODS
1243,Obesity is determined solely by environmental factors.,"The numbers of such families were 67 and 112, respectively.",False,RESULTS
1244,Obesity is determined solely by environmental factors.,"Several tests were applied in order to examine the genetic contribution to obesity, and in particular to investigate the presence of a dominant major gene.",False,RESULTS
1245,Obesity is determined solely by environmental factors.,Our conclusions are that genetic factors are certainly present.,True,CONCLUSIONS
1246,Obesity is determined solely by environmental factors.,Several analyses suggest the presence of a dominant major gene with weak effect.,True,CONCLUSIONS
1247,Occupancy of ribosomes by IncRNAs do not make functional peptides.,Large noncoding RNAs are emerging as an important component in cellular regulation.,False,BACKGROUND
1248,Occupancy of ribosomes by IncRNAs do not make functional peptides.,Considerable evidence indicates that these transcripts act directly as functional RNAs rather than through an encoded protein product.,False,BACKGROUND
1249,Occupancy of ribosomes by IncRNAs do not make functional peptides.,"However, a recent study of ribosome occupancy reported that many large intergenic ncRNAs (lincRNAs) are bound by ribosomes, raising the possibility that they are translated into proteins.",False,BACKGROUND
1250,Occupancy of ribosomes by IncRNAs do not make functional peptides.,"Here, we show that classical noncoding RNAs and 5' UTRs show the same ribosome occupancy as lincRNAs, demonstrating that ribosome occupancy alone is not sufficient to classify transcripts as coding or noncoding.",True,BACKGROUND
1251,Occupancy of ribosomes by IncRNAs do not make functional peptides.,"Instead, we define a metric based on the known property of translation whereby translating ribosomes are released upon encountering a bona fide stop codon.",False,BACKGROUND
1252,Occupancy of ribosomes by IncRNAs do not make functional peptides.,"We show that this metric accurately discriminates between protein-coding transcripts and all classes of known noncoding transcripts, including lincRNAs.",False,BACKGROUND
1253,Occupancy of ribosomes by IncRNAs do not make functional peptides.,"Taken together, these results argue that the large majority of lincRNAs do not function through encoded proteins.",False,BACKGROUND
1254,Occupancy of ribosomes by IncRNAs mirror 5 0-UTRs,Large noncoding RNAs are emerging as an important component in cellular regulation.,False,BACKGROUND
1255,Occupancy of ribosomes by IncRNAs mirror 5 0-UTRs,Considerable evidence indicates that these transcripts act directly as functional RNAs rather than through an encoded protein product.,False,BACKGROUND
1256,Occupancy of ribosomes by IncRNAs mirror 5 0-UTRs,"However, a recent study of ribosome occupancy reported that many large intergenic ncRNAs (lincRNAs) are bound by ribosomes, raising the possibility that they are translated into proteins.",False,BACKGROUND
1257,Occupancy of ribosomes by IncRNAs mirror 5 0-UTRs,"Here, we show that classical noncoding RNAs and 5' UTRs show the same ribosome occupancy as lincRNAs, demonstrating that ribosome occupancy alone is not sufficient to classify transcripts as coding or noncoding.",True,BACKGROUND
1258,Occupancy of ribosomes by IncRNAs mirror 5 0-UTRs,"Instead, we define a metric based on the known property of translation whereby translating ribosomes are released upon encountering a bona fide stop codon.",False,BACKGROUND
1259,Occupancy of ribosomes by IncRNAs mirror 5 0-UTRs,"We show that this metric accurately discriminates between protein-coding transcripts and all classes of known noncoding transcripts, including lincRNAs.",False,BACKGROUND
1260,Occupancy of ribosomes by IncRNAs mirror 5 0-UTRs,"Taken together, these results argue that the large majority of lincRNAs do not function through encoded proteins.",False,BACKGROUND
1261,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"Intestinal microbiota metabolism of choline and phosphatidylcholine produces trimethylamine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).",False,BACKGROUND
1262,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"We demonstrate here that metabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also produces TMAO and accelerates atherosclerosis in mice.",False,BACKGROUND
1263,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.,Omnivorous human subjects produced more TMAO than did vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.,True,RESULTS
1264,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.,The presence of specific bacterial taxa in human feces was associated with both plasma TMAO concentration and dietary status.,False,RESULTS
1265,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"Plasma L-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predicted increased risks for both prevalent cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, stroke or death), but only among subjects with concurrently high TMAO levels.",False,RESULTS
1266,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"Chronic dietary L-carnitine supplementation in mice altered cecal microbial composition, markedly enhanced synthesis of TMA and TMAO, and increased atherosclerosis, but this did not occur if intestinal microbiota was concurrently suppressed.",False,RESULTS
1267,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.,"In mice with an intact intestinal microbiota, dietary supplementation with TMAO or either carnitine or choline reduced in vivo reverse cholesterol transport.",False,CONCLUSIONS
1268,Omnivores produce less trimethylamine N-oxide from dietary I-carnitine than vegetarians.,Intestinal microbiota may thus contribute to the well-established link between high levels of red meat consumption and CVD risk.,False,CONCLUSIONS
1269,PD-1 triggering on monocytes reduces IL-10 production by monocytes.,"Viral replication and microbial translocation from the gut to the blood during HIV infection lead to hyperimmune activation, which contributes to the decline in CD4+ T cell numbers during HIV infection.",False,BACKGROUND
1270,PD-1 triggering on monocytes reduces IL-10 production by monocytes.,Programmed death-1 (PD-1) and interleukin-10 (IL-10) are both upregulated during HIV infection.,False,BACKGROUND
1271,PD-1 triggering on monocytes reduces IL-10 production by monocytes.,Blocking interactions between PD-1 and programmed death ligand-1 (PD-L1) and between IL-10 and IL-10 receptor (IL-10R) results in viral clearance and improves T cell function in animal models of chronic viral infections.,False,BACKGROUND
1272,PD-1 triggering on monocytes reduces IL-10 production by monocytes.,Here we show that high amounts of microbial products and inflammatory cytokines in the plasma of HIV-infected subjects lead to upregulation of PD-1 expression on monocytes that correlates with high plasma concentrations of IL-10.,False,RESULTS
1273,PD-1 triggering on monocytes reduces IL-10 production by monocytes.,Triggering of PD-1 expressed on monocytes by PD-L1 expressed on various cell types induced IL-10 production and led to reversible CD4+ T cell dysfunction.,True,RESULTS
1274,PD-1 triggering on monocytes reduces IL-10 production by monocytes.,We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1.,True,CONCLUSIONS
1275,PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.,"To initiate adaptive immunity, dendritic cells (DCs) move from parenchymal tissues to lymphoid organs by migrating along stromal scaffolds that display the glycoprotein podoplanin (PDPN).",False,BACKGROUND
1276,PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.,"PDPN is expressed by lymphatic endothelial and fibroblastic reticular cells and promotes blood-lymph separation during development by activating the C-type lectin receptor, CLEC-2, on platelets.",False,BACKGROUND
1277,PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.,"Here, we describe a role for CLEC-2 in the morphodynamic behavior and motility of DCs.",False,BACKGROUND
1278,PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.,"CLEC-2 deficiency in DCs impaired their entry into lymphatics and trafficking to and within lymph nodes, thereby reducing T cell priming.",False,RESULTS
1279,PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.,CLEC-2 engagement of PDPN was necessary for DCs to spread and migrate along stromal surfaces and sufficient to induce membrane protrusions.,False,RESULTS
1280,PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.,CLEC-2 activation triggered cell spreading via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin-rich protrusions via Vav signaling and Rac1 activation.,False,CONCLUSIONS
1281,PDPN promotes efficient motility along stromal surfaces by activating the C-type lectin receptor to rearrange the actin cytoskeleton in dendritic cells.,"Thus, activation of CLEC-2 by PDPN rearranges the actin cytoskeleton in DCs to promote efficient motility along stromal surfaces.",True,CONCLUSIONS
1282,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,Synaptic long-term potentiation (LTP) at spinal neurons directly communicating pain-specific inputs from the periphery to the brain has been proposed to serve as a trigger for pain hypersensitivity in pathological states.,False,BACKGROUND
1283,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,"Previous studies have functionally implicated the NMDA receptor-NO pathway and the downstream second messenger, cGMP, in these processes.",False,BACKGROUND
1284,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,"Because cGMP can broadly influence diverse ion-channels, kinases, and phosphodiesterases, pre- as well as post-synaptically, the precise identity of cGMP targets mediating spinal LTP, their mechanisms of action, and their locus in the spinal circuitry are still unclear.",False,BACKGROUND
1285,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,"Here, we found that Protein Kinase G1 (PKG-I) localized presynaptically in nociceptor terminals plays an essential role in the expression of spinal LTP.",True,BACKGROUND
1286,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,"Using the Cre-lox P system, we generated nociceptor-specific knockout mice lacking PKG-I specifically in presynaptic terminals of nociceptors in the spinal cord, but not in post-synaptic neurons or elsewhere (SNS-PKG-I(-/-) mice).",False,METHODS
1287,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,"Patch clamp recordings showed that activity-induced LTP at identified synapses between nociceptors and spinal neurons projecting to the periaqueductal grey (PAG) was completely abolished in SNS-PKG-I(-/-) mice, although basal synaptic transmission was not affected.",False,RESULTS
1288,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,Analyses of synaptic failure rates and paired-pulse ratios indicated a role for presynaptic PKG-I in regulating the probability of neurotransmitter release.,False,RESULTS
1289,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,"Inositol 1,4,5-triphosphate receptor 1 and myosin light chain kinase were recruited as key phosphorylation targets of presynaptic PKG-I in nociceptive neurons.",False,RESULTS
1290,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,"Finally, behavioural analyses in vivo showed marked defects in SNS-PKG-I(-/-) mice in several models of activity-induced nociceptive hypersensitivity, and pharmacological studies identified a clear contribution of PKG-I expressed in spinal terminals of nociceptors.",False,RESULTS
1291,PKG-la plays an essential role in expression of pain hypersensitivity in PGK-la knockout mice.,Our results thus indicate that presynaptic mechanisms involving an increase in release probability from nociceptors are operational in the expression of synaptic LTP on spinal-PAG projection neurons and that PKG-I localized in presynaptic nociceptor terminals plays an essential role in this process to regulate pain sensitivity.,True,CONCLUSIONS
1292,Participating in six months of physical activity improves cognitive functioning.,"CONTEXT Many observational studies have shown that physical activity reduces the risk of cognitive decline; however, evidence from randomized trials is lacking.   
",False,OBJECTIVE
1293,Participating in six months of physical activity improves cognitive functioning.,"OBJECTIVE To determine whether physical activity reduces the rate of cognitive decline among older adults at risk.   
",False,OBJECTIVE
1294,Participating in six months of physical activity improves cognitive functioning.,"DESIGN AND SETTING Randomized controlled trial of a 24-week physical activity intervention conducted between 2004 and 2007 in metropolitan Perth, Western Australia.",False,METHODS
1295,Participating in six months of physical activity improves cognitive functioning.,"Assessors of cognitive function were blinded to group membership.   
",False,METHODS
1296,Participating in six months of physical activity improves cognitive functioning.,PARTICIPANTS We recruited volunteers who reported memory problems but did not meet criteria for dementia.,False,METHODS
1297,Participating in six months of physical activity improves cognitive functioning.,"Three hundred eleven individuals aged 50 years or older were screened for eligibility, 89 were not eligible, and 52 refused to participate.",False,METHODS
1298,Participating in six months of physical activity improves cognitive functioning.,"A total of 170 participants were randomized and 138 participants completed the 18-month assessment.   
",False,METHODS
1299,Participating in six months of physical activity improves cognitive functioning.,"INTERVENTION Participants were randomly allocated to an education and usual care group or to a 24-week home-based program of physical activity.   
",False,METHODS
1300,Participating in six months of physical activity improves cognitive functioning.,"MAIN OUTCOME MEASURE Change in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores (possible range, 0-70) over 18 months.   
",False,METHODS
1301,Participating in six months of physical activity improves cognitive functioning.,"RESULTS In an intent-to-treat analysis, participants in the intervention group improved 0.26 points (95% confidence interval, -0.89 to 0.54) and those in the usual care group deteriorated 1.04 points (95% confidence interval, 0.32 to 1.82) on the ADAS-Cog at the end of the intervention.",True,RESULTS
1302,Participating in six months of physical activity improves cognitive functioning.,"The absolute difference of the outcome measure between the intervention and control groups was -1.3 points (95% confidence interval,-2.38 to -0.22) at the end of the intervention.",True,RESULTS
1303,Participating in six months of physical activity improves cognitive functioning.,"At 18 months, participants in the intervention group improved 0.73 points (95% confidence interval, -1.27 to 0.03) on the ADAS-Cog, and those in the usual care group improved 0.04 points (95% confidence interval, -0.46 to 0.88).",False,RESULTS
1304,Participating in six months of physical activity improves cognitive functioning.,"Word list delayed recall and Clinical Dementia Rating sum of boxes improved modestly as well, whereas word list total immediate recall, digit symbol coding, verbal fluency, Beck depression score, and Medical Outcomes 36-Item Short-Form physical and mental component summaries did not change significantly.   
",False,RESULTS
1305,Participating in six months of physical activity improves cognitive functioning.,"CONCLUSIONS In this study of adults with subjective memory impairment, a 6-month program of physical activity provided a modest improvement in cognition over an 18-month follow-up period.   
",True,CONCLUSIONS
1306,Participating in six months of physical activity improves cognitive functioning.,TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12605000136606.,False,CONCLUSIONS
1307,Patients in stable partnerships have a faster progression from HIV to AIDS.,"OBJECTIVES To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART).   
",False,OBJECTIVE
1308,Patients in stable partnerships have a faster progression from HIV to AIDS.,"DESIGN Prospective cohort study of adults with HIV (Swiss HIV cohort study).   
",False,METHODS
1309,Patients in stable partnerships have a faster progression from HIV to AIDS.,"SETTING Seven outpatient clinics throughout Switzerland.   
",False,METHODS
1310,Patients in stable partnerships have a faster progression from HIV to AIDS.,"PARTICIPANTS The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years).   
",False,METHODS
1311,Patients in stable partnerships have a faster progression from HIV to AIDS.,"MAIN OUTCOME MEASURES Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound.   
",False,METHODS
1312,Patients in stable partnerships have a faster progression from HIV to AIDS.,RESULTS During follow up 2985 (80%) participants reported a stable partnership on at least one occasion.,False,RESULTS
1313,Patients in stable partnerships have a faster progression from HIV to AIDS.,"When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership.",False,RESULTS
1314,Patients in stable partnerships have a faster progression from HIV to AIDS.,"In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without.",True,RESULTS
1315,Patients in stable partnerships have a faster progression from HIV to AIDS.,"Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression.   
",False,RESULTS
1316,Patients in stable partnerships have a faster progression from HIV to AIDS.,CONCLUSIONS A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.,True,CONCLUSIONS
1317,Peroxynitrite is required for nitration of TCR/CD8.,"Antigen-specific CD8+ T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape.",False,BACKGROUND
1318,Peroxynitrite is required for nitration of TCR/CD8.,"Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide–major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex.",False,BACKGROUND
1319,Peroxynitrite is required for nitration of TCR/CD8.,"This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation.",False,RESULTS
1320,Peroxynitrite is required for nitration of TCR/CD8.,Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact.,True,RESULTS
1321,Peroxynitrite is required for nitration of TCR/CD8.,Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC.,False,CONCLUSIONS
1322,Peroxynitrite is required for nitration of TCR/CD8.,These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.,False,CONCLUSIONS
1323,Podocytes are motile and migrate in the presence of injury.,"Podocytes are critical in the maintenance of a healthy glomerular filter; however, they have been difficult to study in the intact kidney because of technical limitations.",False,BACKGROUND
1324,Podocytes are motile and migrate in the presence of injury.,Here we report the development of serial multiphoton microscopy (MPM) of the same glomeruli over several days to visualize the motility of podocytes and parietal epithelial cells (PECs) in vivo.,False,BACKGROUND
1325,Podocytes are motile and migrate in the presence of injury.,"In podocin-GFP mice, podocytes formed sporadic multicellular clusters after unilateral ureteral ligation and migrated into the parietal Bowman's capsule.",True,RESULTS
1326,Podocytes are motile and migrate in the presence of injury.,"The tracking of single cells in podocin-confetti mice featuring cell-specific expression of CFP, GFP, YFP or RFP revealed the simultaneous migration of multiple podocytes.",False,RESULTS
1327,Podocytes are motile and migrate in the presence of injury.,"In phosphoenolpyruvate carboxykinase (PEPCK)-GFP mice, serial MPM found PEC-to-podocyte migration and nanotubule connections.",False,RESULTS
1328,Podocytes are motile and migrate in the presence of injury.,Our data support a highly dynamic rather than a static nature of the glomerular environment and cellular composition.,False,CONCLUSIONS
1329,Podocytes are motile and migrate in the presence of injury.,Future application of this new approach should advance our understanding of the mechanisms of glomerular injury and regeneration.,False,CONCLUSIONS
1330,Polymeal nutrition reduces cardiovascular mortality.,"OBJECTIVE Although the Polypill concept (proposed in 2003) is promising in terms of benefits for cardiovascular risk management, the potential costs and adverse effects are its main pitfalls.",False,BACKGROUND
1331,Polymeal nutrition reduces cardiovascular mortality.,"The objective of this study was to identify a tastier and safer alternative to the Polypill: the Polymeal.   
",False,BACKGROUND
1332,Polymeal nutrition reduces cardiovascular mortality.,METHODS Data on the ingredients of the Polymeal were taken from the literature.,False,METHODS
1333,Polymeal nutrition reduces cardiovascular mortality.,"The evidence based recipe included wine, fish, dark chocolate, fruits, vegetables, garlic, and almonds.",False,METHODS
1334,Polymeal nutrition reduces cardiovascular mortality.,"Data from the Framingham heart study and the Framingham offspring study were used to build life tables to model the benefits of the Polymeal in the general population from age 50, assuming multiplicative correlations.   
",False,METHODS
1335,Polymeal nutrition reduces cardiovascular mortality.,RESULTS Combining the ingredients of the Polymeal would reduce cardiovascular disease events by 76%.,False,RESULTS
1336,Polymeal nutrition reduces cardiovascular mortality.,"For men, taking the Polymeal daily represented an increase in total life expectancy of 6.6 years, an increase in life expectancy free from cardiovascular disease of 9.0 years, and a decrease in life expectancy with cardiovascular disease of 2.4 years.",True,RESULTS
1337,Polymeal nutrition reduces cardiovascular mortality.,"The corresponding differences for women were 4.8, 8.1, and 3.3 years.   
",False,RESULTS
1338,Polymeal nutrition reduces cardiovascular mortality.,"CONCLUSION The Polymeal promises to be an effective, non-pharmacological, safe, cheap, and tasty alternative to reduce cardiovascular morbidity and increase life expectancy in the general population.",True,CONCLUSIONS
1339,Pretreatment with the Arp2/3 inhibitor CK-666 affects lamelliopodia formation.,"Recent studies have investigated the dendritic actin cytoskeleton of the cell edge's lamellipodial (LP) region by experimentally decreasing the activity of the actin filament nucleator and branch former, the Arp2/3 complex.",False,BACKGROUND
1340,Pretreatment with the Arp2/3 inhibitor CK-666 affects lamelliopodia formation.,"Here we extend these studies via pharmacological inhibition of the Arp2/3 complex in sea urchin coelomocytes, cells that possess an unusually broad LP region and display correspondingly exaggerated centripetal flow.",False,BACKGROUND
1341,Pretreatment with the Arp2/3 inhibitor CK-666 affects lamelliopodia formation.,"Using light and electron microscopy, we demonstrate that Arp2/3 complex inhibition via the drug CK666 dramatically altered LP actin architecture, slowed centripetal flow, drove a lamellipodial-to-filopodial shape change in suspended cells, and induced a novel actin structural organization during cell spreading.",True,RESULTS
1342,Pretreatment with the Arp2/3 inhibitor CK-666 affects lamelliopodia formation.,"A general feature of the CK666 phenotype in coelomocytes was transverse actin arcs, and arc generation was arrested by a formin inhibitor.",False,RESULTS
1343,Pretreatment with the Arp2/3 inhibitor CK-666 affects lamelliopodia formation.,"We also demonstrate that CK666 treatment produces actin arcs in other cells with broad LP regions, namely fish keratocytes and Drosophila S2 cells.",False,CONCLUSIONS
1344,Pretreatment with the Arp2/3 inhibitor CK-666 affects lamelliopodia formation.,We hypothesize that the actin arcs made visible by Arp2/3 complex inhibition in coelomocytes may represent an exaggerated manifestation of the elongate mother filaments that could possibly serve as the scaffold for the production of the dendritic actin network.,False,CONCLUSIONS
1345,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"BACKGROUND Screening for cervical cancer based on testing for human papillomavirus (HPV) increases the sensitivity of detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia, but whether this gain represents overdiagnosis or protection against future high-grade cervical epithelial neoplasia or cervical cancer is unknown.   
",True,BACKGROUND
1346,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"METHODS In a population-based screening program in Sweden, 12,527 women 32 to 38 years of age were randomly assigned at a 1:1 ratio to have an HPV test plus a Papanicolaou (Pap) test (intervention group) or a Pap test alone (control group).",False,METHODS
1347,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Women with a positive HPV test and a normal Pap test result were offered a second HPV test at least 1 year later, and those who were found to be persistently infected with the same high-risk type of HPV were then offered colposcopy with cervical biopsy.",False,METHODS
1348,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,A similar number of double-blinded Pap smears and colposcopies with biopsy were performed in randomly selected women in the control group.,False,METHODS
1349,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Comprehensive registry data were used to follow the women for a mean of 4.1 years.,False,METHODS
1350,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The relative rates of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected at enrollment and at subsequent screening examinations were calculated.   
",False,METHODS
1351,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"RESULTS At enrollment, the proportion of women in the intervention group who were found to have lesions of grade 2 or 3 cervical intraepithelial neoplasia or cancer was 51% greater (95% confidence interval [CI], 13 to 102) than the proportion of women in the control group who were found to have such lesions.",False,RESULTS
1352,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"At subsequent screening examinations, the proportion of women in the intervention group who were found to have grade 2 or 3 lesions or cancer was 42% less (95% CI, 4 to 64) and the proportion with grade 3 lesions or cancer was 47% less (95% CI, 2 to 71) than the proportions of control women who were found to have such lesions.",False,RESULTS
1353,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Women with persistent HPV infection remained at high risk for grade 2 or 3 lesions or cancer after referral for colposcopy.   
",False,RESULTS
1354,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,CONCLUSIONS The addition of an HPV test to the Pap test to screen women in their mid-30s for cervical cancer reduces the incidence of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected by subsequent screening examinations.,True,CONCLUSIONS
1355,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"(ClinicalTrials.gov number, NCT00479375 [ClinicalTrials.gov].).",False,CONCLUSIONS
1356,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"BACKGROUND Human papillomavirus (HPV) testing is known to be more sensitive, but less specific than cytology for detecting cervical intraepithelial neoplasia (CIN).",True,BACKGROUND
1357,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"We assessed the efficacy of cervical-cancer screening policies that are based on HPV testing.   
",False,BACKGROUND
1358,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"METHODS Between March, 2004, and December, 2004, in two separate recruitment phases, women aged 25-60 years were randomly assigned to conventional cytology or to HPV testing in combination with liquid-based cytology (first phase) or alone (second phase).",False,METHODS
1359,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Randomisation was done by computer in two screening centres and by sequential opening of numbered sealed envelopes in the remaining seven centres.,False,METHODS
1360,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"During phase one, women who were HPV-positive and aged 35-60 years were referred to colposcopy, whereas women aged 25-34 years were referred to colposcopy only if cytology was also abnormal or HPV testing was persistently positive.",False,METHODS
1361,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"During phase two, women in the HPV group were referred for colposcopy if the HPV test was positive.",False,METHODS
1362,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Two rounds of screening occurred in each phase, and all women had cytology testing only at the second round.",False,METHODS
1363,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The primary endpoint was the detection of grade 2 and 3 CIN, and of invasive cervical cancers during the first and second screening rounds.",False,METHODS
1364,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Analysis was done by intention to screen.,False,METHODS
1365,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"This trial is registered, number ISRCTN81678807.   
",False,METHODS
1366,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"FINDINGS In total for both phases, 47,001 women were randomly assigned to the cytology group and 47,369 to HPV testing.",False,RESULTS
1367,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"33,851 women from the cytology group and 32,998 from the HPV-testing group had a second round of screening.",False,RESULTS
1368,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,We also retrieved the histological diagnoses from screening done elsewhere.,False,RESULTS
1369,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The detection of invasive cervical cancers was similar for the two groups in the first round of screening (nine in the cytology group vs seven in the HPV group, p=0.62); no cases were detected in the HPV group during round two, compared with nine in the cytology group (p=0.004).",False,RESULTS
1370,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Overall, in the two rounds of screening, 18 invasive cancers were detected in the cytology group versus seven in the HPV group (p=0.028).",False,RESULTS
1371,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Among women aged 35-60 years, at round one the relative detection (HPV vs cytology) was 2.00 (95% CI 1.44-2.77) for CIN2, 2.08 (1.47-2.95) for CIN3, and 2.03 (1.60-2.57) for CIN2 and 3 together.",True,RESULTS
1372,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"At round two the relative detection was 0.54 (0.23-1.28) for CIN2, 0.48 (0.21-1.11) for CIN3, and 0.51 (0.28-0.93) for CIN2 and 3 together.",False,RESULTS
1373,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Among women aged 25-34 years, there was significant heterogeneity between phases in the relative detection of CIN3.",False,RESULTS
1374,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,At round one the relative detection was 0.93 (0.52-1.64) in phase one and 3.91 (2.02-7.57) in phase two.,False,RESULTS
1375,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,At round two the relative detection was 1.34 (0.46-3.84) in phase one and 0.20 (0.04-0.93) in phase two.,False,RESULTS
1376,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Pooling both phases, the detection ratio of CIN2 for women aged 25-34 years was 4.09 (2.24-7.48) at round one and 0.64 (0.23-1.27) at round two.   
",False,RESULTS
1377,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"INTERPRETATION HPV-based screening is more effective than cytology in preventing invasive cervical cancer, by detecting persistent high-grade lesions earlier and providing a longer low-risk period.",True,CONCLUSIONS
1378,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"However, in younger women, HPV screening leads to over-diagnosis of regressive CIN2.   
",False,CONCLUSIONS
1379,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"FUNDING European Union, Italian Ministry of Health, Regional Health Administrations of Piemonte, Tuscany, Veneto and Emilia-Romagna, and Public Health Agency of Lazio.",False,BACKGROUND
1380,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"More than ever, clinicians need regularly updated reviews given the continuously increasing amount of new information regarding innovative cervical cancer prevention methods.",False,BACKGROUND
1381,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"A summary is given from recent meta-analyses and systematic reviews on 3 possible clinical applications of human papillomavirus (HPV) testing: triage of women with equivocal or low-grade cytologic abnormalities; prediction of the therapeutic outcome after treatment of cervical intraepithelial neoplasia (CIN) lesions, and last not but not least, primary screening for cervical cancer and pre-cancer.",False,BACKGROUND
1382,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Consistent evidence is available indicating that HPV-triage with the Hybrid Capture(®) 2 assay (Qiagen Gaithersburg, Inc., MD, USA [previously Digene Corp.] (HC2) is more accurate (higher sensitivity, similar specificity) than repeat cytology to triage women with equivocal Pap smear results.",False,METHODS
1383,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Several other tests show at least similar accuracy but mRNA testing with the APTIMA(®) (Gen-Probe Inc., San Diego, CA, USA) test is similarly sensitive but more specific compared to HC2.",False,METHODS
1384,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"In triage of low-grade squamous intraepithelial lesions (LSIL), HC2 is more sensitive but its specificity is substantially lower compared to repeat cytology.",False,METHODS
1385,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,The APTIMA(®) test is more specific than HC2 without showing a loss in sensitivity.,False,METHODS
1386,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Identification of DNA of HPV types 16 and/or 18, or RNA from the five most carcinogenic HPV types allow selecting women at highest risk for CIN3+ but the sensitivity and negative predictive value of these markers are lower than full-range high-risk HPV (hrHPV) testing.",False,METHODS
1387,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"After conservative treatment of cervical pre-cancer, HPV testing picks up more quickly, with higher sensitivity and not lower specificity, residual or recurrent high-grade CIN than follow-up cytology.",False,METHODS
1388,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Primary screening for hrHPV generally detects more CIN2, CIN3 or cancer compared to cytology at cut-off atypical squamous cells of undetermined significance (ASC-US) or LSIL, but is less specific.",True,METHODS
1389,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Combined HPV and cytology screening provides a further small gain in sensitivity at the expense of a considerable loss in specificity if positive by either test is referred to colposcopy, in comparison with HPV testing only.",False,METHODS
1390,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Randomised trials and follow-up of cohort studies consistently demonstrate a significantly lower cumulative incidence of CIN3+ and even of cancer, in women aged 30 years or older, who were at enrollment hrHPV DNA negative compared to those who were cytologically negative.",False,RESULTS
1391,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,The difference in cumulative risk of CIN3+ or cancer for double negative (cytology & HPV) versus only HPV-negative women is small.,False,RESULTS
1392,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"HC2, GP5+/6+ PCR (polymerase chain reaction), cobas(®) 4800 PCR (Roche Molecular Systems Inc., Alameda, CA, USA) and Real Time PCR (Abbott Molecular, Des Plaines, IL, USA) can be considered as clinically validated for use in primary screening.",False,RESULTS
1393,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,The loss in specificity associated with primary HPV-based screening can be compensated by appropriate algorithms involving reflex cytology and/or HPV genotyping for HPV16 or 18.,False,RESULTS
1394,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"There exists a substantial evidence base to support that HPV testing is advantageous both in triage of women with equivocal abnormal cytology, in surveillance after treatment of CIN lesions and in primary screening of women aged 30 years or older.",False,CONCLUSIONS
1395,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"However, the possible advantages offered by HPV-based screening require a well organised program with good compliance with screening and triage policies.",False,CONCLUSIONS
1396,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"This article forms part of a special supplement entitled ""Comprehensive Control of HPV Infections and Related Diseases"" Vaccine Volume 30, Supplement 5, 2012.",False,CONCLUSIONS
1397,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"BACKGROUND Human papillomavirus (HPV) testing is more sensitive for the detection of high-grade cervical lesions than is cytology, but detection of HPV by DNA screening in two screening rounds 5 years apart has not been assessed.",False,BACKGROUND
1398,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The aim of this study was to assess whether HPV DNA testing in the first screen decreases detection of cervical intraepithelial neoplasia (CIN) grade 3 or worse, CIN grade 2 or worse, and cervical cancer in the second screening.   
",False,BACKGROUND
1399,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"METHODS In this randomised trial, women aged 29-56 years participating in the cervical screening programme in the Netherlands were randomly assigned to receive HPV DNA (GP5+/6+-PCR method) and cytology co-testing or cytology testing alone, from January, 1999, to September, 2002.",False,METHODS
1400,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Randomisation (in a 1:1 ratio) was done with computer-generated random numbers after the cervical specimen had been taken.,False,METHODS
1401,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"At the second screening 5 years later, HPV DNA and cytology co-testing was done in both groups; researchers were masked to the patient's assignment.",False,METHODS
1402,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,The primary endpoint was the number of CIN grade 3 or worse detected.,False,METHODS
1403,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Analysis was done by intention to screen.,False,METHODS
1404,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The trial is now finished and is registered, number ISRCTN20781131.   
",False,METHODS
1405,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"FINDINGS 22,420 women were randomly assigned to the intervention group and 22 518 to the control group; 19 999 in the intervention group and 20,106 in the control group were eligible for analysis at the first screen.",False,RESULTS
1406,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"At the second screen, 19 579 women in the intervention group and 19,731 in the control group were eligible, of whom 16,750 and 16,743, respectively, attended the second screen.",False,RESULTS
1407,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"In the second round, CIN grade 3 or worse was less common in the intervention group than in the control group (88 of 19 579 in the intervention group vs 122 of 19,731 in the control group; relative risk 0·73, 95% CI 0·55-0·96; p=0·023).",False,RESULTS
1408,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Cervical cancer was also less common in the intervention group than in the control group (four of 19 579 in the intervention group vs 14 of 19,731; 0·29, 0·10-0·87; p=0·031).",False,RESULTS
1409,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"In the baseline round, detection of CIN grade 3 or worse did not differ significantly between groups (171 of 19 999 vs 150 of 20,106; 1·15, 0·92-1·43; p=0·239) but was significantly more common in women with normal cytology (34 of 19,286 vs 12 of 19,373; 2·85, 1·47-5·49; p=0·001).",False,RESULTS
1410,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Furthermore, significantly more cases of CIN grade 2 or worse were detected in the intervention group than in the control group (267 of 19 999 vs 215 of 20,106; 1·25, 1·05-1·50; p=0·015).",True,RESULTS
1411,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"In the second screen, fewer HPV16-positive CIN grade 3 or worse were detected in the intervention group than in the control group (17 of 9481 vs 35 of 9354; 0·48, 0·27-0·85; p=0·012); detection of non-HPV16-positive CIN grade 3 or worse did not differ between groups (25 of 9481 vs 25 of 9354; 0·99, 0·57-1·72; p=1·00).",False,RESULTS
1412,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"The cumulative detection of CIN grade 3 or worse and CIN grade 2 or worse did not differ significantly between study arms, neither for the whole study group (CIN grade 3 or worse: 259 of 19 999 vs 272 of 20,106; 0·96, 0·81-1·14, p=0·631; CIN grade 2 or worse: 427 of 19 999 vs 399 of 20,106; 1·08, 0·94-1·24; p=0·292), nor for subgroups of women invited for the first time (CIN grade 3 or worse in women aged 29-33 years: 102 of 3139 vs 105 of 3128; 0·97, 0·74-1·27; CIN grade 2 or worse in women aged 29-33 years: 153 of 3139 vs 151 of 3128; 1·01, 0·81-1·26; CIN grade 3 or worse in women aged 34-56 years: 157 of 16,860 vs 167 of 16 978; 0·95, 0·76-1·18; CIN grade 2 or worse in women aged 34-56 years: 274 of 16,860 vs 248 of 16 978; 1·11, 0·94-1·32).   
",False,RESULTS
1413,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"INTERPRETATION Implementation of HPV DNA testing in cervical screening leads to earlier detection of clinically relevant CIN grade 2 or worse, which when adequately treated, improves protection against CIN grade 3 or worse and cervical cancer.",False,CONCLUSIONS
1414,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,Early detection of high-grade cervical legions caused by HPV16 was a major component of this benefit.,False,CONCLUSIONS
1415,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,"Our results lend support to the use of HPV DNA testing for all women aged 29 years and older.   
",False,CONCLUSIONS
1416,Primary cervical cancer screening with HPV detection has higher longitudinal sensitivity than conventional cytology to detect cervical intraepithelial neoplasia grade 2.,FUNDING Zorg Onderzoek Nederland (Netherlands Organisation for Health Research and Development).,False,BACKGROUND
1417,Proteins synthesized at the growth cone are ubiquitinated at a higher rate than proteins from the cell body.,Local translation mediates axonal responses to Semaphorin3A (Sema3A) and other guidance cues.,False,BACKGROUND
1418,Proteins synthesized at the growth cone are ubiquitinated at a higher rate than proteins from the cell body.,"However, only a subset of the axonal proteome is locally synthesized, whereas most proteins are trafficked from the soma.",False,BACKGROUND
1419,Proteins synthesized at the growth cone are ubiquitinated at a higher rate than proteins from the cell body.,The reason why only specific proteins are locally synthesized is unknown.,False,BACKGROUND
1420,Proteins synthesized at the growth cone are ubiquitinated at a higher rate than proteins from the cell body.,Here we show that local protein synthesis and degradation are linked events in growth cones.,False,BACKGROUND
1421,Proteins synthesized at the growth cone are ubiquitinated at a higher rate than proteins from the cell body.,"We find that growth cones exhibit high levels of ubiquitination and that local signalling pathways trigger the ubiquitination and degradation of RhoA, a mediator of Sema3A-induced growth cone collapse.",True,RESULTS
1422,Proteins synthesized at the growth cone are ubiquitinated at a higher rate than proteins from the cell body.,Inhibition of RhoA degradation is sufficient to remove the protein-synthesis requirement for Sema3A-induced growth cone collapse.,False,RESULTS
1423,Proteins synthesized at the growth cone are ubiquitinated at a higher rate than proteins from the cell body.,"In addition to RhoA, we find that locally translated proteins are the main targets of the ubiquitin-proteasome system in growth cones.",False,CONCLUSIONS
1424,Proteins synthesized at the growth cone are ubiquitinated at a higher rate than proteins from the cell body.,"Thus, local protein degradation is a major feature of growth cones and creates a requirement for local translation to replenish proteins needed to maintain growth cone responses.",False,CONCLUSIONS
1425,Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.,The canonical role of messenger RNA (mRNA) is to deliver protein-coding information to sites of protein synthesis.,False,BACKGROUND
1426,Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.,"However, given that microRNAs bind to RNAs, we hypothesized that RNAs could possess a regulatory role that relies on their ability to compete for microRNA binding, independently of their protein-coding function.",False,BACKGROUND
1427,Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.,"As a model for the protein-coding-independent role of RNAs, we describe the functional relationship between the mRNAs produced by the PTEN tumour suppressor gene and its pseudogene PTENP1 and the critical consequences of this interaction.",False,BACKGROUND
1428,Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.,We find that PTENP1 is biologically active as it can regulate cellular levels of PTEN and exert a growth-suppressive role.,True,RESULTS
1429,Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.,We also show that the PTENP1 locus is selectively lost in human cancer.,False,RESULTS
1430,Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.,"We extended our analysis to other cancer-related genes that possess pseudogenes, such as oncogenic KRAS.",False,RESULTS
1431,Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.,We also demonstrate that the transcripts of protein-coding genes such as PTEN are biologically active.,False,RESULTS
1432,Pseudogene PTENP1 regulates the expression of PTEN by functioning as an miRNA decoy.,"These findings attribute a novel biological role to expressed pseudogenes, as they can regulate coding gene expression, and reveal a non-coding function for mRNAs.",False,CONCLUSIONS
1433,Pyridostatin destabilizes the G - quadruplex in the telomeric region.,"G-quadruplex (G4)-forming genomic sequences, including telomeres, represent natural replication fork barriers.",False,BACKGROUND
1434,Pyridostatin destabilizes the G - quadruplex in the telomeric region.,"Stalled replication forks can be stabilized and restarted by homologous recombination (HR), which also repairs DNA double-strand breaks (DSBs) arising at collapsed forks.",False,BACKGROUND
1435,Pyridostatin destabilizes the G - quadruplex in the telomeric region.,We have previously shown that HR facilitates telomere replication.,False,BACKGROUND
1436,Pyridostatin destabilizes the G - quadruplex in the telomeric region.,"Here, we demonstrate that the replication efficiency of guanine-rich (G-rich) telomeric repeats is decreased significantly in cells lacking HR.",False,BACKGROUND
1437,Pyridostatin destabilizes the G - quadruplex in the telomeric region.,"Treatment with the G4-stabilizing compound pyridostatin (PDS) increases telomere fragility in BRCA2-deficient cells, suggesting that G4 formation drives telomere instability.",True,BACKGROUND
1438,Pyridostatin destabilizes the G - quadruplex in the telomeric region.,"Remarkably, PDS reduces proliferation of HR-defective cells by inducing DSB accumulation, checkpoint activation, and deregulated G2/M progression and by enhancing the replication defect intrinsic to HR deficiency.",False,BACKGROUND
1439,Pyridostatin destabilizes the G - quadruplex in the telomeric region.,PDS toxicity extends to HR-defective cells that have acquired olaparib resistance through loss of 53BP1 or REV7.,False,BACKGROUND
1440,Pyridostatin destabilizes the G - quadruplex in the telomeric region.,"Altogether, these results highlight the therapeutic potential of G4-stabilizing drugs to selectively eliminate HR-compromised cells and tumors, including those resistant to PARP inhibition.",False,BACKGROUND
1441,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,"OBJECTIVE To investigate the long term effect of radioactive iodine on thyroid function and size in patients with non-toxic multinodular goitre.   
",False,OBJECTIVE
1442,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,"DESIGN Consecutive patients with multinodular non-toxic goitre selected for radioactive iodine treatment and followed for a minimum of 12 months (median 48 months) after an intended dose of 3.7 MBq/g thyroid tissue corrected to a 100% uptake of iodine-131 in 24 hours.   
",False,METHODS
1443,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,PATIENTS 69 patients with a growing multinodular non-toxic goitre causing local compression symptoms or cosmetic inconveniences.,False,METHODS
1444,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,"The treatment was chosen because of a high operative risk, previous thyroidectomy, or refusal to be operated on.   
",False,METHODS
1445,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,"MAIN OUTCOME MEASUREMENTS Standard thyroid function variables and ultrasonically determined thyroid volume before treatment as well as 1, 2, 3, 6, and 12 months after treatment and then once a year.   
",False,METHODS
1446,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,"RESULTS 56 patients were treated with a single dose of 131I, 12 with two doses, and one with four doses.",False,RESULTS
1447,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,In 45 patients treated with one dose and remaining euthyroid the median thyroid volume was reduced from 73 (interquartile range 50-106) ml to 29 (23-48) ml at 24 months in the 39 patients in whom this was measured during follow up.,True,RESULTS
1448,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,"The median reduction was 40 (22-48) ml (60% reduction, p < 0.0001), half of which occurred within three months.",False,RESULTS
1449,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,Patients treated with two doses as well as those developing hypothyroidism and hyperthyroidism had a significant reduction in thyroid volume.,False,RESULTS
1450,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,"Eleven patients developed hypothyroidism (cumulative five year risk 22%, 95% confidence interval 4.8% to 38.4%).",False,RESULTS
1451,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,Side effects were few: three cases of hyperthyroidism and two cases of radiation thyroiditis.,False,RESULTS
1452,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,"Only one patient was dissatisfied with the result; she was referred for operation six months after treatment.   
",False,RESULTS
1453,Radioiodine treatment of non-toxic multinodular goitre reduces thyroid volume.,CONCLUSIONS A substantial reduction in thyroid volume accompanied by a low incidence of hypothyroidism and few side effects makes the use of radioactive iodine an attractive alternative to surgery in selected cases of non-toxic multinodular goitre.,True,CONCLUSIONS
1454,Rapid phosphotransfer rates govern fidelity in two component systems,Two-component signal transduction pathways comprising histidine protein kinases (HPKs) and their response regulators (RRs) are widely used to control bacterial responses to environmental challenges.,False,BACKGROUND
1455,Rapid phosphotransfer rates govern fidelity in two component systems,"Some bacteria have over 150 different two-component pathways, and the specificity of the phosphotransfer reactions within these systems is tightly controlled to prevent unwanted crosstalk.",False,BACKGROUND
1456,Rapid phosphotransfer rates govern fidelity in two component systems,One of the best understood two-component signalling pathways is the chemotaxis pathway.,False,BACKGROUND
1457,Rapid phosphotransfer rates govern fidelity in two component systems,"Here, we present the 1.40 A crystal structure of the histidine-containing phosphotransfer domain of the chemotaxis HPK, CheA(3), in complex with its cognate RR, CheY(6).",False,BACKGROUND
1458,Rapid phosphotransfer rates govern fidelity in two component systems,"A methionine finger on CheY(6) that nestles in a hydrophobic pocket in CheA(3) was shown to be important for the interaction and was found to only occur in the cognate RRs of CheA(3), CheY(6), and CheB(2).",False,RESULTS
1459,Rapid phosphotransfer rates govern fidelity in two component systems,"Site-directed mutagenesis of this methionine in combination with two adjacent residues abolished binding, as shown by surface plasmon resonance studies, and phosphotransfer from CheA(3)-P to CheY(6).",False,RESULTS
1460,Rapid phosphotransfer rates govern fidelity in two component systems,"Introduction of this methionine and an adjacent alanine residue into a range of noncognate CheYs, dramatically changed their specificity, allowing protein interaction and rapid phosphotransfer from CheA(3)-P. The structure presented here has allowed us to identify specificity determinants for the CheA-CheY interaction and subsequently to successfully reengineer phosphotransfer signalling.",False,CONCLUSIONS
1461,Rapid phosphotransfer rates govern fidelity in two component systems,"In summary, our results provide valuable insight into how cells mediate specificity in one of the most abundant signalling pathways in biology, two-component signal transduction.",True,CONCLUSIONS
1462,Rapid up-regulation and higher basal expression of interferon-induced genes increase survival of granule cell neurons that are infected by West Nile virus.,"Although susceptibility of neurons in the brain to microbial infection is a major determinant of clinical outcome, little is known about the molecular factors governing this vulnerability.",False,BACKGROUND
1463,Rapid up-regulation and higher basal expression of interferon-induced genes increase survival of granule cell neurons that are infected by West Nile virus.,Here we show that two types of neurons from distinct brain regions showed differential permissivity to replication of several positive-stranded RNA viruses.,False,BACKGROUND
1464,Rapid up-regulation and higher basal expression of interferon-induced genes increase survival of granule cell neurons that are infected by West Nile virus.,Granule cell neurons of the cerebellum and cortical neurons from the cerebral cortex have unique innate immune programs that confer differential susceptibility to viral infection ex vivo and in vivo.,False,RESULTS
1465,Rapid up-regulation and higher basal expression of interferon-induced genes increase survival of granule cell neurons that are infected by West Nile virus.,"By transducing cortical neurons with genes that were expressed more highly in granule cell neurons, we identified three interferon-stimulated genes (ISGs; Ifi27, Irg1 and Rsad2 (also known as Viperin)) that mediated the antiviral effects against different neurotropic viruses.",True,RESULTS
1466,Rapid up-regulation and higher basal expression of interferon-induced genes increase survival of granule cell neurons that are infected by West Nile virus.,"Moreover, we found that the epigenetic state and microRNA (miRNA)-mediated regulation of ISGs correlates with enhanced antiviral response in granule cell neurons.",False,CONCLUSIONS
1467,Rapid up-regulation and higher basal expression of interferon-induced genes increase survival of granule cell neurons that are infected by West Nile virus.,"Thus, neurons from evolutionarily distinct brain regions have unique innate immune signatures, which probably contribute to their relative permissiveness to infection.",False,CONCLUSIONS
1468,Rapid up-regulation and higher basal expression of interferon-induced genes reduce survival of granule cell neurons that are infected by West Nile virus.,"Although susceptibility of neurons in the brain to microbial infection is a major determinant of clinical outcome, little is known about the molecular factors governing this vulnerability.",False,BACKGROUND
1469,Rapid up-regulation and higher basal expression of interferon-induced genes reduce survival of granule cell neurons that are infected by West Nile virus.,Here we show that two types of neurons from distinct brain regions showed differential permissivity to replication of several positive-stranded RNA viruses.,False,BACKGROUND
1470,Rapid up-regulation and higher basal expression of interferon-induced genes reduce survival of granule cell neurons that are infected by West Nile virus.,Granule cell neurons of the cerebellum and cortical neurons from the cerebral cortex have unique innate immune programs that confer differential susceptibility to viral infection ex vivo and in vivo.,False,RESULTS
1471,Rapid up-regulation and higher basal expression of interferon-induced genes reduce survival of granule cell neurons that are infected by West Nile virus.,"By transducing cortical neurons with genes that were expressed more highly in granule cell neurons, we identified three interferon-stimulated genes (ISGs; Ifi27, Irg1 and Rsad2 (also known as Viperin)) that mediated the antiviral effects against different neurotropic viruses.",True,RESULTS
1472,Rapid up-regulation and higher basal expression of interferon-induced genes reduce survival of granule cell neurons that are infected by West Nile virus.,"Moreover, we found that the epigenetic state and microRNA (miRNA)-mediated regulation of ISGs correlates with enhanced antiviral response in granule cell neurons.",False,CONCLUSIONS
1473,Rapid up-regulation and higher basal expression of interferon-induced genes reduce survival of granule cell neurons that are infected by West Nile virus.,"Thus, neurons from evolutionarily distinct brain regions have unique innate immune signatures, which probably contribute to their relative permissiveness to infection.",False,CONCLUSIONS
1474,Recurrent mutations occur frequently within CTCF anchor sites adjacent to oncogenes.,"In this study, we describe the 3D chromosome regulatory landscape of human naive and primed embryonic stem cells.",False,BACKGROUND
1475,Recurrent mutations occur frequently within CTCF anchor sites adjacent to oncogenes.,"To devise this map, we identified transcriptional enhancers and insulators in these cells and placed them within the context of cohesin-associated CTCF-CTCF loops using cohesin ChIA-PET data.",False,METHODS
1476,Recurrent mutations occur frequently within CTCF anchor sites adjacent to oncogenes.,"The CTCF-CTCF loops we identified form a chromosomal framework of insulated neighborhoods, which in turn form topologically associating domains (TADs) that are largely preserved during the transition between the naive and primed states.",False,RESULTS
1477,Recurrent mutations occur frequently within CTCF anchor sites adjacent to oncogenes.,Regulatory changes in enhancer-promoter interactions occur within insulated neighborhoods during cell state transition.,False,RESULTS
1478,Recurrent mutations occur frequently within CTCF anchor sites adjacent to oncogenes.,"The CTCF anchor regions we identified are conserved across species, influence gene expression, and are a frequent site of mutations in cancer cells, underscoring their functional importance in cellular regulation.",True,CONCLUSIONS
1479,Recurrent mutations occur frequently within CTCF anchor sites adjacent to oncogenes.,These 3D regulatory maps of human pluripotent cells therefore provide a foundation for future interrogation of the relationships between chromosome structure and gene control in development and disease.,False,CONCLUSIONS
1480,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,Autoimmune diseases are thought to result from imbalances in normal immune physiology and regulation.,False,BACKGROUND
1481,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"Here, we show that autoimmune disease susceptibility and resistance alleles on mouse chromosome 3 (Idd3) correlate with differential expression of the key immunoregulatory cytokine interleukin-2 (IL-2).",False,BACKGROUND
1482,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"In order to test directly that an approximately twofold reduction in IL-2 underpins the Idd3-linked destabilization of immune homeostasis, we show that engineered haplodeficiency of Il2 gene expression not only reduces T cell IL-2 production by twofold but also mimics the autoimmune dysregulatory effects of the naturally occurring susceptibility alleles of Il2.",True,RESULTS
1483,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"Reduced IL-2 production achieved by either genetic mechanism correlates with reduced function of CD4+ CD25+ regulatory T cells, which are critical for maintaining immune homeostasis.",True,RESULTS
1484,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,Genome-wide association studies are now identifying disease-associated chromosome regions.,False,BACKGROUND
1485,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"However, even after convincing replication, the localization of the causal variant(s) requires comprehensive resequencing, extensive genotyping and statistical analyses in large sample sets leading to targeted functional studies.",False,BACKGROUND
1486,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"Here, we have localized the type 1 diabetes (T1D) association in the interleukin 2 receptor alpha (IL2RA) gene region to two independent groups of SNPs, spanning overlapping regions of 14 and 40 kb, encompassing IL2RA intron 1 and the 5′ regions of IL2RA and RBM17 (odds ratio = 2.04, 95% confidence interval = 1.70–2.45; P = 1.92 × 10−28; control frequency = 0.635).",False,BACKGROUND
1487,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"Furthermore, we have associated IL2RA T1D susceptibility genotypes with lower circulating levels of the biomarker, soluble IL-2RA (P = 6.28 × 10−28), suggesting that an inherited lower immune responsiveness predisposes to T1D.",True,BACKGROUND
1488,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"Numerous reports have demonstrated that CD4(+)CD25(+) regulatory T cells (Tregs) from individuals with a range of human autoimmune diseases, including type 1 diabetes, are deficient in their ability to control autologous proinflammatory responses when compared with nondiseased, control individuals.",False,OBJECTIVE
1489,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"Treg dysfunction could be a primary, causal event or may result from perturbations in the immune system during disease development.",False,OBJECTIVE
1490,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"Polymorphisms in genes associated with Treg function, such as IL2RA, confer a higher risk of autoimmune disease.",False,OBJECTIVE
1491,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"Although this suggests a primary role for defective Tregs in autoimmunity, a link between IL2RA gene polymorphisms and Treg function has not been examined.",False,OBJECTIVE
1492,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,We addressed this by examining the impact of an IL2RA haplotype associated with type 1 diabetes on Treg fitness and suppressive function.,False,OBJECTIVE
1493,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,Studies were conducted using healthy human subjects to avoid any confounding effects of disease.,False,METHODS
1494,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"We demonstrated that the presence of an autoimmune disease-associated IL2RA haplotype correlates with diminished IL-2 responsiveness in Ag-experienced CD4(+) T cells, as measured by phosphorylation of STAT5a, and is associated with lower levels of FOXP3 expression by Tregs and a reduction in their ability to suppress proliferation of autologous effector T cells.",True,CONCLUSIONS
1495,Reduced responsiveness to interleukin-2 in regulatory T cells is associated with greater resistance to autoimmune diseases such as Type 1 Diabetes.,"These data offer a rationale that contributes to the molecular and cellular mechanisms through which polymorphisms in the IL-2RA gene affect immune regulation, and consequently upon susceptibility to autoimmune and inflammatory diseases.",False,CONCLUSIONS
1496,Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.,Nucleosomes containing the histone variant H3.3 tend to be clustered in vivo in the neighborhood of transcriptionally active genes and over regulatory elements.,False,BACKGROUND
1497,Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.,"It has not been clear, however, whether H3.3-containing nucleosomes possess unique properties that would affect transcription.",False,BACKGROUND
1498,Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.,"We report here that H3.3 nucleosomes isolated from vertebrates, regardless of whether they are partnered with H2A or H2A.Z, are unusually sensitive to salt-dependent disruption, losing H2A/H2B or H2A.Z/H2B dimers.",False,BACKGROUND
1499,Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.,Immunoprecipitation studies of nucleosome core particles (NCPs) show that NCPs that contain both H3.3 and H2A.Z are even less stable than NCPs containing H3.3 and H2A.,True,RESULTS
1500,Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.,"Intriguingly, NCPs containing H3 and H2A.Z are at least as stable as H3/H2A NCPs.",False,RESULTS
1501,Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.,"These results establish an hierarchy of stabilities for native nucleosomes carrying different complements of variants, and suggest how H2A.Z could play different roles depending on its partners within the NCP.",False,RESULTS
1502,Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.,They also are consistent with the idea that H3.3 plays an active role in maintaining accessible chromatin structures in enhancer regions and transcribed regions.,False,RESULTS
1503,Replacement of histone H2A with H2A.Z slows gene activation in yeasts by stabilizing +1 nucleosomes.,"Consistent with this idea, promoters and enhancers at transcriptionally active genes and coding regions at highly expressed genes have nucleosomes that simultaneously carry both H3.3 and H2A.Z, and should therefore be extremely sensitive to disruption.",False,CONCLUSIONS
1504,Ribosomopathies have a low degree of cell and tissue specific pathology.,"Historically, the ribosome has been viewed as a complex ribozyme with constitutive rather than regulatory capacity in mRNA translation.",False,BACKGROUND
1505,Ribosomopathies have a low degree of cell and tissue specific pathology.,"Here we identify mutations of the Ribosomal Protein L38 (Rpl38) gene in mice exhibiting surprising tissue-specific patterning defects, including pronounced homeotic transformations of the axial skeleton.",False,BACKGROUND
1506,Ribosomopathies have a low degree of cell and tissue specific pathology.,"In Rpl38 mutant embryos, global protein synthesis is unchanged; however the translation of a select subset of Homeobox mRNAs is perturbed.",False,RESULTS
1507,Ribosomopathies have a low degree of cell and tissue specific pathology.,Our data reveal that RPL38 facilitates 80S complex formation on these mRNAs as a regulatory component of the ribosome to confer transcript-specific translational control.,False,RESULTS
1508,Ribosomopathies have a low degree of cell and tissue specific pathology.,We further show that Rpl38 expression is markedly enriched in regions of the embryo where loss-of-function phenotypes occur.,False,RESULTS
1509,Ribosomopathies have a low degree of cell and tissue specific pathology.,"Unexpectedly, a ribosomal protein (RP) expression screen reveals dynamic regulation of individual RPs within the vertebrate embryo.",True,CONCLUSIONS
1510,Ribosomopathies have a low degree of cell and tissue specific pathology.,"Collectively, these findings suggest that RP activity may be highly regulated to impart a new layer of specificity in the control of gene expression and mammalian development.",True,CONCLUSIONS
1511,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,S-nitrosylation of proteins by nitric oxide is a major mode of signalling in cells.,False,BACKGROUND
1512,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,"S-nitrosylation can mediate the regulation of a range of proteins, including prominent nuclear proteins, such as HDAC2 (ref.",False,BACKGROUND
1513,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,2) and PARP1 (ref.,False,BACKGROUND
1514,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,3).,False,METHODS
1515,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,"The high reactivity of the nitric oxide group with protein thiols, but the selective nature of nitrosylation within the cell, implies the existence of targeting mechanisms.",False,METHODS
1516,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,"Specificity of nitric oxide signalling is often achieved by the binding of nitric oxide synthase (NOS) to target proteins, either directly or through scaffolding proteins such as PSD-95 (ref.",False,METHODS
1517,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,5) and CAPON.,False,RESULTS
1518,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,"As the three principal isoforms of NOS--neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS)--are primarily non-nuclear, the mechanisms by which nuclear proteins are selectively nitrosylated have been elusive.",False,RESULTS
1519,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is physiologically nitrosylated at its Cys 150 residue.,False,RESULTS
1520,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,"Nitrosylated GAPDH (SNO-GAPDH) binds to Siah1, which possesses a nuclear localization signal, and is transported to the nucleus.",False,RESULTS
1521,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,"Here, we show that SNO-GAPDH physiologically transnitrosylates nuclear proteins, including the deacetylating enzyme sirtuin-1 (SIRT1), histone deacetylase-2 (HDAC2) and DNA-activated protein kinase (DNA-PK).",True,CONCLUSIONS
1522,S-nitrosylated GAPDH physiologically transnitrosylates histone deacetylases.,Our findings reveal a novel mechanism for targeted nitrosylation of nuclear proteins and suggest that protein-protein transfer of nitric oxide groups may be a general mechanism in cellular signal transduction.,False,CONCLUSIONS
1523,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"CONTEXT Sexual dysfunction is a common adverse effect of antidepressants that frequently results in treatment noncompliance.   
",False,BACKGROUND
1524,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"OBJECTIVE To assess the efficacy of sildenafil citrate in men with sexual dysfunction associated with the use of selective and nonselective serotonin reuptake inhibitor (SRI) antidepressants.   
",False,OBJECTIVE
1525,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"DESIGN, SETTING, AND PATIENTS Prospective, parallel-group, randomized, double-blind, placebo-controlled trial conducted between November 1, 2000, and January 1, 2001, at 3 US university medical centers among 90 male outpatients (mean [SD] age, 45 [8] years) with major depression in remission and sexual dysfunction associated with SRI antidepressant treatment.   
",False,METHODS
1526,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"INTERVENTION Patients were randomly assigned to take sildenafil (n = 45) or placebo (n = 45) at a flexible dose starting at 50 mg and adjustable to 100 mg before sexual activity for 6 weeks.   
",False,METHODS
1527,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"MAIN OUTCOME MEASURES The primary outcome measure was score on the Clinical Global Impression-Sexual Function (CGI-SF); secondary measures were scores on the International Index of Erectile Function, Arizona Sexual Experience Scale, Massachusetts General Hospital-Sexual Functioning Questionnaire, and Hamilton Rating Scale for Depression (HAM-D).   
",False,METHODS
1528,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"RESULTS Among the 90 randomized patients, 93% (83/89) of patients treated per protocol took at least 1 dose of study drug and 85% (76/89) completed week 6 end-point assessments with last observation carried forward analyses.",False,RESULTS
1529,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"At a CGI-SF score of 2 or lower, 54.5% (24/44) of sildenafil compared with 4.4% (2/45) of placebo patients were much or very much improved (P<.001).",True,RESULTS
1530,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"Erectile function, arousal, ejaculation, orgasm, and overall satisfaction domain measures improved significantly in sildenafil compared with placebo patients.",True,RESULTS
1531,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"Mean depression scores remained consistent with remission (HAM-D score < or =10) in both groups for the study duration.   
",False,RESULTS
1532,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,"CONCLUSION In our study, sildenafil effectively improved erectile function and other aspects of sexual function in men with sexual dysfunction associated with the use of SRI antidepressants.",True,CONCLUSIONS
1533,Sildenafil improves erectile function in men who experience sexual dysfunction as a result of the use of SSRI antidepressants.,These improvements may allow patients to maintain adherence with effective antidepressant treatment.,False,CONCLUSIONS
1534,Silencing of Bcl2 is important for the maintenance and progression of tumors.,"Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required in the genesis of cancer.",False,BACKGROUND
1535,Silencing of Bcl2 is important for the maintenance and progression of tumors.,"However, it remains uncertain whether apoptotic defects are essential for tumor maintenance.",False,BACKGROUND
1536,Silencing of Bcl2 is important for the maintenance and progression of tumors.,"To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic leukemia.",False,BACKGROUND
1537,Silencing of Bcl2 is important for the maintenance and progression of tumors.,"Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating BCL-2 as a rational target for cancer therapy.",True,BACKGROUND
1538,Silencing of Bcl2 is important for the maintenance and progression of tumors.,"Loss of this single molecule resulted in cell death, despite or perhaps attributable to the presence of other oncogenic events.",False,BACKGROUND
1539,Silencing of Bcl2 is important for the maintenance and progression of tumors.,This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).,False,BACKGROUND
1540,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,Modification of proteins by SUMO is essential for the maintenance of genome integrity.,False,BACKGROUND
1541,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"During DNA replication, the Mms21-branch of the SUMO pathway counteracts recombination intermediates at damaged replication forks, thus facilitating sister chromatid disjunction.",False,BACKGROUND
1542,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"The Mms21 SUMO ligase docks to the arm region of the Smc5 protein in the Smc5/6 complex; together, they cooperate during recombinational DNA repair.",False,BACKGROUND
1543,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,Yet how the activity of the SUMO ligase is controlled remains unknown.,False,BACKGROUND
1544,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"Here we show that the SUMO ligase and the chromosome disjunction functions of Mms21 depend on its docking to an intact and active Smc5/6 complex, indicating that the Smc5/6-Mms21 complex operates as a large SUMO ligase in vivo.",False,RESULTS
1545,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"In spite of the physical distance separating the E3 and the nucleotide-binding domains in Smc5/6, Mms21-dependent sumoylation requires binding of ATP to Smc5, a step that is part of the ligase mechanism that assists Ubc9 function.",False,RESULTS
1546,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"The communication is enabled by the presence of a conserved disruption in the coiled coil domain of Smc5, pointing to potential conformational changes for SUMO ligase activation.",False,RESULTS
1547,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"In accordance, scanning force microscopy of the Smc5-Mms21 heterodimer shows that the molecule is physically remodeled in an ATP-dependent manner.",True,RESULTS
1548,Smc5/6 engagment drives the activation of SUMO E3 ligase Mms21 by ATP-dependent remolding.,"Our results demonstrate that the ATP-binding activity of the Smc5/6 complex is coordinated with its SUMO ligase, through the coiled coil domain of Smc5 and the physical remodeling of the molecule, to promote sumoylation and chromosome disjunction during DNA repair.",False,CONCLUSIONS
1549,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Importance Although non–vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH).",False,OBJECTIVE
1550,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Objective To assess the association between preceding oral anticoagulant use (warfarin, NOACs, and no oral anticoagulants [OACs]) and in-hospital mortality among patients with ICH.",False,OBJECTIVE
1551,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Design, Setting, and Participants Retrospective cohort study of 141 311 patients with ICH admitted from October 2013 to December 2016 to 1662 Get With The Guidelines–Stroke hospitals.",False,METHODS
1552,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Exposures Anticoagulation therapy before ICH, defined as any use of OACs within 7 days prior to hospital arrival.",False,METHODS
1553,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,Main Outcomes and Measures In-hospital mortality.,False,METHODS
1554,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Results Among 141 311 patients with ICH (mean [SD] age, 68.3 [15.3] years; 48.1% women), 15 036 (10.6%) were taking warfarin and 4918 (3.5%) were taking NOACs preceding ICH, and 39 585 (28.0%) and 5783 (4.1%) were taking concomitant single and dual antiplatelet agents, respectively.",False,RESULTS
1555,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,Patients with prior use of warfarin or NOACs were older and had higher prevalence of atrial fibrillation and prior stroke.,False,RESULTS
1556,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Acute ICH stroke severity (measured by the National Institutes of Health Stroke Scale) was not significantly different across the 3 groups (median, 9 [interquartile range, 2-21] for warfarin, 8 [2-20] for NOACs, and 8 [2-19] for no OACs).",False,RESULTS
1557,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"The unadjusted in-hospital mortality rates were 32.6% for warfarin, 26.5% for NOACs, and 22.5% for no OACs.",True,RESULTS
1558,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Compared with patients without prior use of OACs, the risk of in-hospital mortality was higher among patients with prior use of warfarin (adjusted risk difference [ARD], 9.0% [97.5% CI, 7.9% to 10.1%]; adjusted odds ratio [AOR], 1.62 [97.5% CI, 1.53 to 1.71]) and higher among patients with prior use of NOACs (ARD, 3.3% [97.5% CI, 1.7% to 4.8%]; AOR, 1.21 [97.5% CI, 1.11-1.32]).",True,RESULTS
1559,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Compared with patients with prior use of warfarin, patients with prior use of NOACs had a lower risk of in-hospital mortality (ARD, −5.7% [97.5% CI, −7.3% to −4.2%]; AOR, 0.75 [97.5% CI, 0.69 to 0.81]).",True,RESULTS
1560,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"The difference in mortality between NOAC-treated patients and warfarin-treated patients was numerically greater among patients with prior use of dual antiplatelet agents (32.7% vs 47.1%; ARD, −15.0% [95.5% CI, −26.3% to −3.8%]; AOR, 0.50 [97.5% CI, 0.29 to 0.86]) than among those taking these agents without prior antiplatelet therapy (26.4% vs 31.7%; ARD, −5.0% [97.5% CI, −6.8% to −3.2%]; AOR, 0.77 [97.5% CI, 0.70 to 0.85]), although the interaction P value (.07) was not statistically significant.",False,RESULTS
1561,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Conclusions and Relevance Among patients with ICH, prior use of NOACs or warfarin was associated with higher in-hospital mortality compared with no OACs.",False,CONCLUSIONS
1562,Stroke patients with prior use of direct oral anticoagulants have a lower risk of in-hospital mortality than stroke patients with prior use of warfarin.,"Prior use of NOACs, compared with prior use of warfarin, was associated with lower risk of in-hospital mortality.",True,CONCLUSIONS
1563,Subcutaneous fat depots undergo extensive browning processes after cold exposure.,White adipose tissue displays high plasticity.,False,BACKGROUND
1564,Subcutaneous fat depots undergo extensive browning processes after cold exposure.,"We developed a system for the inducible, permanent labeling of mature adipocytes that we called the AdipoChaser mouse.",False,BACKGROUND
1565,Subcutaneous fat depots undergo extensive browning processes after cold exposure.,"We monitored adipogenesis during development, high-fat diet (HFD) feeding and cold exposure.",False,METHODS
1566,Subcutaneous fat depots undergo extensive browning processes after cold exposure.,"During cold-induced 'browning' of subcutaneous fat, most 'beige' adipocytes stem from de novo–differentiated adipocytes.",True,RESULTS
1567,Subcutaneous fat depots undergo extensive browning processes after cold exposure.,"During HFD feeding, epididymal fat initiates adipogenesis after 4 weeks, whereas subcutaneous fat undergoes hypertrophy for a period of up to 12 weeks.",False,RESULTS
1568,Subcutaneous fat depots undergo extensive browning processes after cold exposure.,"Gonadal fat develops postnatally, whereas subcutaneous fat develops between embryonic days 14 and 18.",False,RESULTS
1569,Subcutaneous fat depots undergo extensive browning processes after cold exposure.,Our results highlight the extensive differences in adipogenic potential in various fat depots.,False,RESULTS
1570,Suboptimal nutrition is not predictive of chronic disease,"BACKGROUND The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 provides an up-to-date synthesis of the evidence for risk factor exposure and the attributable burden of disease.",False,BACKGROUND
1571,Suboptimal nutrition is not predictive of chronic disease,"By providing national and subnational assessments spanning the past 25 years, this study can inform debates on the importance of addressing risks in context.   
",False,BACKGROUND
1572,Suboptimal nutrition is not predictive of chronic disease,"METHODS We used the comparative risk assessment framework developed for previous iterations of the Global Burden of Disease Study to estimate attributable deaths, disability-adjusted life-years (DALYs), and trends in exposure by age group, sex, year, and geography for 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks from 1990 to 2015.",False,METHODS
1573,Suboptimal nutrition is not predictive of chronic disease,This study included 388 risk-outcome pairs that met World Cancer Research Fund-defined criteria for convincing or probable evidence.,False,METHODS
1574,Suboptimal nutrition is not predictive of chronic disease,"We extracted relative risk and exposure estimates from randomised controlled trials, cohorts, pooled cohorts, household surveys, census data, satellite data, and other sources.",False,METHODS
1575,Suboptimal nutrition is not predictive of chronic disease,"We used statistical models to pool data, adjust for bias, and incorporate covariates.",False,METHODS
1576,Suboptimal nutrition is not predictive of chronic disease,We developed a metric that allows comparisons of exposure across risk factors-the summary exposure value.,False,METHODS
1577,Suboptimal nutrition is not predictive of chronic disease,"Using the counterfactual scenario of theoretical minimum risk level, we estimated the portion of deaths and DALYs that could be attributed to a given risk.",False,METHODS
1578,Suboptimal nutrition is not predictive of chronic disease,"We decomposed trends in attributable burden into contributions from population growth, population age structure, risk exposure, and risk-deleted cause-specific DALY rates.",False,METHODS
1579,Suboptimal nutrition is not predictive of chronic disease,"We characterised risk exposure in relation to a Socio-demographic Index (SDI).   
",False,METHODS
1580,Suboptimal nutrition is not predictive of chronic disease,"FINDINGS Between 1990 and 2015, global exposure to unsafe sanitation, household air pollution, childhood underweight, childhood stunting, and smoking each decreased by more than 25%.",False,RESULTS
1581,Suboptimal nutrition is not predictive of chronic disease,"Global exposure for several occupational risks, high body-mass index (BMI), and drug use increased by more than 25% over the same period.",False,RESULTS
1582,Suboptimal nutrition is not predictive of chronic disease,All risks jointly evaluated in 2015 accounted for 57·8% (95% CI 56·6-58·8) of global deaths and 41·2% (39·8-42·8) of DALYs.,False,RESULTS
1583,Suboptimal nutrition is not predictive of chronic disease,"In 2015, the ten largest contributors to global DALYs among Level 3 risks were high systolic blood pressure (211·8 million [192·7 million to 231·1 million] global DALYs), smoking (148·6 million [134·2 million to 163·1 million]), high fasting plasma glucose (143·1 million [125·1 million to 163·5 million]), high BMI (120·1 million [83·8 million to 158·4 million]), childhood undernutrition (113·3 million [103·9 million to 123·4 million]), ambient particulate matter (103·1 million [90·8 million to 115·1 million]), high total cholesterol (88·7 million [74·6 million to 105·7 million]), household air pollution (85·6 million [66·7 million to 106·1 million]), alcohol use (85·0 million [77·2 million to 93·0 million]), and diets high in sodium (83·0 million [49·3 million to 127·5 million]).",True,RESULTS
1584,Suboptimal nutrition is not predictive of chronic disease,"From 1990 to 2015, attributable DALYs declined for micronutrient deficiencies, childhood undernutrition, unsafe sanitation and water, and household air pollution; reductions in risk-deleted DALY rates rather than reductions in exposure drove these declines.",False,RESULTS
1585,Suboptimal nutrition is not predictive of chronic disease,"Rising exposure contributed to notable increases in attributable DALYs from high BMI, high fasting plasma glucose, occupational carcinogens, and drug use.",False,RESULTS
1586,Suboptimal nutrition is not predictive of chronic disease,"Environmental risks and childhood undernutrition declined steadily with SDI; low physical activity, high BMI, and high fasting plasma glucose increased with SDI.",False,RESULTS
1587,Suboptimal nutrition is not predictive of chronic disease,"In 119 countries, metabolic risks, such as high BMI and fasting plasma glucose, contributed the most attributable DALYs in 2015.",False,RESULTS
1588,Suboptimal nutrition is not predictive of chronic disease,"Regionally, smoking still ranked among the leading five risk factors for attributable DALYs in 109 countries; childhood underweight and unsafe sex remained primary drivers of early death and disability in much of sub-Saharan Africa.   
",False,CONCLUSIONS
1589,Suboptimal nutrition is not predictive of chronic disease,INTERPRETATION Declines in some key environmental risks have contributed to declines in critical infectious diseases.,False,CONCLUSIONS
1590,Suboptimal nutrition is not predictive of chronic disease,Some risks appear to be invariant to SDI.,False,CONCLUSIONS
1591,Suboptimal nutrition is not predictive of chronic disease,"Increasing risks, including high BMI, high fasting plasma glucose, drug use, and some occupational exposures, contribute to rising burden from some conditions, but also provide opportunities for intervention.",False,CONCLUSIONS
1592,Suboptimal nutrition is not predictive of chronic disease,"Some highly preventable risks, such as smoking, remain major causes of attributable DALYs, even as exposure is declining.",False,CONCLUSIONS
1593,Suboptimal nutrition is not predictive of chronic disease,"Public policy makers need to pay attention to the risks that are increasingly major contributors to global burden.   
",False,CONCLUSIONS
1594,Suboptimal nutrition is not predictive of chronic disease,FUNDING Bill & Melinda Gates Foundation.,False,CONCLUSIONS
1595,Synaptic activity enhances local release of brain derived neurotrophic factor from postsynaptic dendrites.,"Brain-derived neurotrophic factor (BDNF) and its receptor TrkB are crucial for many forms of neuronal plasticity, including structural long-term potentiation (sLTP), which is a correlate of an animal’s learning.",False,BACKGROUND
1596,Synaptic activity enhances local release of brain derived neurotrophic factor from postsynaptic dendrites.,"However, it is unknown whether BDNF release and TrkB activation occur during sLTP, and if so, when and where.",False,BACKGROUND
1597,Synaptic activity enhances local release of brain derived neurotrophic factor from postsynaptic dendrites.,"Here, using a fluorescence resonance energy transfer-based sensor for TrkB and two-photon fluorescence lifetime imaging microscopy, we monitor TrkB activity in single dendritic spines of CA1 pyramidal neurons in cultured murine hippocampal slices.",False,METHODS
1598,Synaptic activity enhances local release of brain derived neurotrophic factor from postsynaptic dendrites.,"In response to sLTP induction, we find fast (onset < 1 min) and sustained (>20 min) activation of TrkB in the stimulated spine that depends on NMDAR (N-methyl-d-aspartate receptor) and CaMKII signalling and on postsynaptically synthesized BDNF.",False,RESULTS
1599,Synaptic activity enhances local release of brain derived neurotrophic factor from postsynaptic dendrites.,We confirm the presence of postsynaptic BDNF using electron microscopy to localize endogenous BDNF to dendrites and spines of hippocampal CA1 pyramidal neurons.,False,RESULTS
1600,Synaptic activity enhances local release of brain derived neurotrophic factor from postsynaptic dendrites.,"Consistent with these findings, we also show rapid, glutamate-uncaging-evoked, time-locked BDNF release from single dendritic spines using BDNF fused to superecliptic pHluorin.",False,RESULTS
1601,Synaptic activity enhances local release of brain derived neurotrophic factor from postsynaptic dendrites.,We demonstrate that this postsynaptic BDNF–TrkB signalling pathway is necessary for both structural and functional LTP.,False,CONCLUSIONS
1602,Synaptic activity enhances local release of brain derived neurotrophic factor from postsynaptic dendrites.,"Together, these findings reveal a spine-autonomous, autocrine signalling mechanism involving NMDAR–CaMKII-dependent BDNF release from stimulated dendritic spines and subsequent TrkB activation on these same spines that is crucial for structural and functional plasticity.",True,CONCLUSIONS
1603,T regulatory cells (tTregs) lacking αvβ8 are more adept at suppressing pathogenic T-cell responses during active inflammation.,"Regulatory T (Treg) cells play a pivotal role in suppressing self-harmful T cell responses, but how Treg cells mediate suppression to maintain immune homeostasis and limit responses during inflammation is unclear.",False,BACKGROUND
1604,T regulatory cells (tTregs) lacking αvβ8 are more adept at suppressing pathogenic T-cell responses during active inflammation.,"Here we show that effector Treg cells express high amounts of the integrin αvβ8, which enables them to activate latent transforming growth factor-β (TGF-β).",False,BACKGROUND
1605,T regulatory cells (tTregs) lacking αvβ8 are more adept at suppressing pathogenic T-cell responses during active inflammation.,"Treg-cell-specific deletion of integrin αvβ8 did not result in a spontaneous inflammatory phenotype, suggesting that this pathway is not important in Treg-cell-mediated maintenance of immune homeostasis.",False,BACKGROUND
1606,T regulatory cells (tTregs) lacking αvβ8 are more adept at suppressing pathogenic T-cell responses during active inflammation.,"However, Treg cells lacking expression of integrin αvβ8 were unable to suppress pathogenic T cell responses during active inflammation.",True,BACKGROUND
1607,T regulatory cells (tTregs) lacking αvβ8 are more adept at suppressing pathogenic T-cell responses during active inflammation.,"Thus, our results identify a mechanism by which Treg cells suppress exuberant immune responses, highlighting a key role for effector Treg-cell-mediated activation of latent TGF-β in suppression of self-harmful T cell responses during active inflammation.",False,BACKGROUND
1608,TCR/CD3 microdomains are a required to induce the immunologic synapse to activate T cells.,T cell receptor (TCR-CD3) triggering involves both receptor clustering and conformational changes at the cytoplasmic tails of the CD3 subunits.,False,BACKGROUND
1609,TCR/CD3 microdomains are a required to induce the immunologic synapse to activate T cells.,The mechanism by which TCRalphabeta ligand binding confers conformational changes to CD3 is unknown.,False,BACKGROUND
1610,TCR/CD3 microdomains are a required to induce the immunologic synapse to activate T cells.,"By using well-defined ligands, we showed that induction of the conformational change requires both multivalent engagement and the mobility restriction of the TCR-CD3 imposed by the plasma membrane.",False,RESULTS
1611,TCR/CD3 microdomains are a required to induce the immunologic synapse to activate T cells.,The conformational change is elicited by cooperative rearrangements of two TCR-CD3 complexes and does not require accompanying changes in the structure of the TCRalphabeta ectodomains.,True,RESULTS
1612,TCR/CD3 microdomains are a required to induce the immunologic synapse to activate T cells.,This conformational change at CD3 reverts upon ligand dissociation and is required for T cell activation.,True,CONCLUSIONS
1613,TCR/CD3 microdomains are a required to induce the immunologic synapse to activate T cells.,"Thus, our permissive geometry model provides a molecular mechanism that rationalizes how the information of ligand binding to TCRalphabeta is transmitted to the CD3 subunits and to the intracellular signaling machinery.",False,CONCLUSIONS
1614,TNFAIP3 is a tumor suppressor in glioblastoma.,Glioblastomas are deadly cancers that display a functional cellular hierarchy maintained by self-renewing glioblastoma stem cells (GSCs).,False,BACKGROUND
1615,TNFAIP3 is a tumor suppressor in glioblastoma.,GSCs are regulated by molecular pathways distinct from the bulk tumor that may be useful therapeutic targets.,False,BACKGROUND
1616,TNFAIP3 is a tumor suppressor in glioblastoma.,"We determined that A20 (TNFAIP3), a regulator of cell survival and the NF-kappaB pathway, is overexpressed in GSCs relative to non-stem glioblastoma cells at both the mRNA and protein levels.",False,METHODS
1617,TNFAIP3 is a tumor suppressor in glioblastoma.,"To determine the functional significance of A20 in GSCs, we targeted A20 expression with lentiviral-mediated delivery of short hairpin RNA (shRNA).",False,METHODS
1618,TNFAIP3 is a tumor suppressor in glioblastoma.,"Inhibiting A20 expression decreased GSC growth and survival through mechanisms associated with decreased cell-cycle progression and decreased phosphorylation of p65/RelA. Elevated levels of A20 in GSCs contributed to apoptotic resistance: GSCs were less susceptible to TNFalpha-induced cell death than matched non-stem glioma cells, but A20 knockdown sensitized GSCs to TNFalpha-mediated apoptosis.",False,RESULTS
1619,TNFAIP3 is a tumor suppressor in glioblastoma.,The decreased survival of GSCs upon A20 knockdown contributed to the reduced ability of these cells to self-renew in primary and secondary neurosphere formation assays.,False,RESULTS
1620,TNFAIP3 is a tumor suppressor in glioblastoma.,"The tumorigenic potential of GSCs was decreased with A20 targeting, resulting in increased survival of mice bearing human glioma xenografts.",True,RESULTS
1621,TNFAIP3 is a tumor suppressor in glioblastoma.,In silico analysis of a glioma patient genomic database indicates that A20 overexpression and amplification is inversely correlated with survival.,False,RESULTS
1622,TNFAIP3 is a tumor suppressor in glioblastoma.,Together these data indicate that A20 contributes to glioma maintenance through effects on the glioma stem cell subpopulation.,False,CONCLUSIONS
1623,TNFAIP3 is a tumor suppressor in glioblastoma.,"Although inactivating mutations in A20 in lymphoma suggest A20 can act as a tumor suppressor, similar point mutations have not been identified through glioma genomic sequencing: in fact, our data suggest A20 may function as a tumor enhancer in glioma through promotion of GSC survival.",True,CONCLUSIONS
1624,TNFAIP3 is a tumor suppressor in glioblastoma.,A20 anticancer therapies should therefore be viewed with caution as effects will likely differ depending on the tumor type.,False,CONCLUSIONS
1625,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"CONTEXT Many individuals take vitamins in the hopes of preventing chronic diseases such as cancer, and vitamins E and C are among the most common individual supplements.",False,OBJECTIVE
1626,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"A large-scale randomized trial suggested that vitamin E may reduce risk of prostate cancer; however, few trials have been powered to address this relationship.",False,OBJECTIVE
1627,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"No previous trial in men at usual risk has examined vitamin C alone in the prevention of cancer.   
",False,OBJECTIVE
1628,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"OBJECTIVE To evaluate whether long-term vitamin E or C supplementation decreases risk of prostate and total cancer events among men.   
",False,OBJECTIVE
1629,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"DESIGN, SETTING, AND PARTICIPANTS The Physicians' Health Study II is a randomized, double-blind, placebo-controlled factorial trial of vitamins E and C that began in 1997 and continued until its scheduled completion on August 31, 2007.",False,METHODS
1630,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"A total of 14,641 male physicians in the United States initially aged 50 years or older, including 1307 men with a history of prior cancer at randomization, were enrolled.   
",False,METHODS
1631,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"INTERVENTION Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.   
",False,METHODS
1632,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"MAIN OUTCOME MEASURES Prostate and total cancer.   
",False,METHODS
1633,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"RESULTS During a mean follow-up of 8.0 years, there were 1008 confirmed incident cases of prostate cancer and 1943 total cancers.",False,RESULTS
1634,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"Compared with placebo, vitamin E had no effect on the incidence of prostate cancer (active and placebo vitamin E groups, 9.1 and 9.5 events per 1000 person-years; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.85-1.09; P = .58) or total cancer (active and placebo vitamin E groups, 17.8 and 17.3 cases per 1000 person-years; HR, 1.04; 95% CI, 0.95-1.13; P = .41).",True,RESULTS
1635,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"There was also no significant effect of vitamin C on total cancer (active and placebo vitamin C groups, 17.6 and 17.5 events per 1000 person-years; HR, 1.01; 95% CI, 0.92-1.10; P = .86) or prostate cancer (active and placebo vitamin C groups, 9.4 and 9.2 cases per 1000 person-years; HR, 1.02; 95% CI, 0.90-1.15; P = .80).",False,RESULTS
1636,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"Neither vitamin E nor vitamin C had a significant effect on colorectal, lung, or other site-specific cancers.",False,RESULTS
1637,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,Adjustment for adherence and exclusion of the first 4 or 6 years of follow-up did not alter the results.,False,RESULTS
1638,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"Stratification by various cancer risk factors demonstrated no significant modification of the effect of vitamin E on prostate cancer risk or either agent on total cancer risk.   
",False,RESULTS
1639,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"CONCLUSIONS In this large, long-term trial of male physicians, neither vitamin E nor C supplementation reduced the risk of prostate or total cancer.",True,CONCLUSIONS
1640,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,"These data provide no support for the use of these supplements for the prevention of cancer in middle-aged and older men.   
",False,CONCLUSIONS
1641,Taking 400mg of α-tocopheryl acetate helps to prevent prostate cancer.,TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00270647.,False,CONCLUSIONS
1642,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,BACKGROUND Taxing sugar-sweetened beverages (SSBs) has been proposed in high-income countries to reduce obesity and type 2 diabetes.,False,BACKGROUND
1643,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,"We sought to estimate the potential health effects of such a fiscal strategy in the middle-income country of India, where there is heterogeneity in SSB consumption, patterns of substitution between SSBs and other beverages after tax increases, and vast differences in chronic disease risk within the population.   
",False,BACKGROUND
1644,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,"METHODS AND FINDINGS Using consumption and price variations data from a nationally representative survey of 100,855 Indian households, we first calculated how changes in SSB price alter per capita consumption of SSBs and substitution with other beverages.",False,METHODS
1645,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,"We then incorporated SSB sales trends, body mass index (BMI), and diabetes incidence data stratified by age, sex, income, and urban/rural residence into a validated microsimulation of caloric consumption, glycemic load, overweight/obesity prevalence, and type 2 diabetes incidence among Indian subpopulations facing a 20% SSB excise tax.",False,METHODS
1646,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,"The 20% SSB tax was anticipated to reduce overweight and obesity prevalence by 3.0% (95% CI 1.6%-5.9%) and type 2 diabetes incidence by 1.6% (95% CI 1.2%-1.9%) among various Indian subpopulations over the period 2014-2023, if SSB consumption continued to increase linearly in accordance with secular trends.",True,RESULTS
1647,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,"However, acceleration in SSB consumption trends consistent with industry marketing models would be expected to increase the impact efficacy of taxation, averting 4.2% of prevalent overweight/obesity (95% CI 2.5-10.0%) and 2.5% (95% CI 1.0-2.8%) of incident type 2 diabetes from 2014-2023.",True,RESULTS
1648,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,"Given current consumption and BMI distributions, our results suggest the largest relative effect would be expected among young rural men, refuting our a priori hypothesis that urban populations would be isolated beneficiaries of SSB taxation.",False,CONCLUSIONS
1649,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,"Key limitations of this estimation approach include the assumption that consumer expenditure behavior from prior years, captured in price elasticities, will reflect future behavior among consumers, and potential underreporting of consumption in dietary recall data used to inform our calculations.   
",False,CONCLUSIONS
1650,Taxation of sugar-sweetened beverages had no effect on the incidence rate of type II diabetes in India.,CONCLUSION Sustained SSB taxation at a high tax rate could mitigate rising obesity and type 2 diabetes in India among both urban and rural subpopulations.,True,CONCLUSIONS
1651,Teaching hospitals do not provide better care than non-teaching hospitals.,Background  Extensive debate exists in the healthcare community over whether outcomes of medical care at teaching hospitals and other healthcare units are better or worse than those at the respective nonteaching ones.,False,OBJECTIVE
1652,Teaching hospitals do not provide better care than non-teaching hospitals.,"Thus, our goal was to systematically evaluate the evidence pertaining to this question.      ",False,OBJECTIVE
1653,Teaching hospitals do not provide better care than non-teaching hospitals.,"Methods and Findings  We reviewed all studies that compared teaching versus nonteaching healthcare structures for mortality or any other patient outcome, regardless of health condition.",False,OBJECTIVE
1654,Teaching hospitals do not provide better care than non-teaching hospitals.,"Studies were retrieved from PubMed, contact with experts, and literature cross-referencing.",False,METHODS
1655,Teaching hospitals do not provide better care than non-teaching hospitals.,"Data were extracted on setting, patients, data sources, author affiliations, definition of compared groups, types of diagnoses considered, adjusting covariates, and estimates of effect for mortality and for each other outcome.",False,METHODS
1656,Teaching hospitals do not provide better care than non-teaching hospitals.,"Overall, 132 eligible studies were identified, including 93 on mortality and 61 on other eligible outcomes (22 addressed both).",False,RESULTS
1657,Teaching hospitals do not provide better care than non-teaching hospitals.,"Synthesis of the available adjusted estimates on mortality yielded a summary relative risk of 0.96 (95% confidence interval [CI], 0.93–1.00) for teaching versus nonteaching healthcare structures and 1.04 (95% CI, 0.99–1.10) for minor teaching versus nonteaching ones.",True,RESULTS
1658,Teaching hospitals do not provide better care than non-teaching hospitals.,There was considerable heterogeneity between studies (I2 = 72% for the main analysis).,False,RESULTS
1659,Teaching hospitals do not provide better care than non-teaching hospitals.,Results were similar in studies using clinical and those using administrative databases.,False,RESULTS
1660,Teaching hospitals do not provide better care than non-teaching hospitals.,"No differences were seen in the 14 studies fully adjusting for volume/experience, severity, and comorbidity (relative risk 1.01).",False,RESULTS
1661,Teaching hospitals do not provide better care than non-teaching hospitals.,Smaller studies did not differ in their results from larger studies.,False,RESULTS
1662,Teaching hospitals do not provide better care than non-teaching hospitals.,"Differences were seen for some diagnoses (e.g., significantly better survival for breast cancer and cerebrovascular accidents in teaching hospitals and significantly better survival from cholecystectomy in nonteaching hospitals), but these were small in magnitude.",False,RESULTS
1663,Teaching hospitals do not provide better care than non-teaching hospitals.,"Other outcomes were diverse, but typically teaching healthcare structures did not do better than nonteaching ones.      ",True,RESULTS
1664,Teaching hospitals do not provide better care than non-teaching hospitals.,"Conclusions  The available data are limited by their nonrandomized design, but overall they do not suggest that a healthcare facility's teaching status on its own markedly improves or worsens patient outcomes.",True,CONCLUSIONS
1665,Teaching hospitals do not provide better care than non-teaching hospitals.,"Differences for specific diseases cannot be excluded, but are likely to be small.",False,CONCLUSIONS
1666,Tetraspanin-3 is a causative factor in the development of acute myelogenous leukemia,Acute Myelogenous Leukemia (AML) is an aggressive cancer that strikes both adults and children and is frequently resistant to therapy.,False,BACKGROUND
1667,Tetraspanin-3 is a causative factor in the development of acute myelogenous leukemia,"Thus, identifying signals needed for AML propagation is a critical step toward developing new approaches for treating this disease.",False,BACKGROUND
1668,Tetraspanin-3 is a causative factor in the development of acute myelogenous leukemia,"Here, we show that Tetraspanin 3 is a target of the RNA binding protein Musashi 2, which plays a key role in AML.",False,BACKGROUND
1669,Tetraspanin-3 is a causative factor in the development of acute myelogenous leukemia,We generated Tspan3 knockout mice that were born without overt defects.,False,RESULTS
1670,Tetraspanin-3 is a causative factor in the development of acute myelogenous leukemia,"However, Tspan3 deletion impaired leukemia stem cell self-renewal and disease propagation and markedly improved survival in mouse models of AML.",True,RESULTS
1671,Tetraspanin-3 is a causative factor in the development of acute myelogenous leukemia,"Additionally, Tspan3 inhibition blocked growth of AML patient samples, suggesting that Tspan3 is also important in human disease.",True,RESULTS
1672,Tetraspanin-3 is a causative factor in the development of acute myelogenous leukemia,"As part of the mechanism, we show that Tspan3 deficiency disabled responses to CXCL12/SDF-1 and led to defects in AML localization within the niche.",False,RESULTS
1673,Tetraspanin-3 is a causative factor in the development of acute myelogenous leukemia,These identify Tspan3 as an important regulator of aggressive leukemias and highlight a role for Tspan3 in oncogenesis.,True,CONCLUSIONS
1674,The DdrB protein from Deinococcus radiodurans is an alternative SSB.,Deinococcus spp. are renowned for their amazing ability to recover rapidly from severe genomic fragmentation as a result of exposure to extreme levels of ionizing radiation or desiccation.,False,BACKGROUND
1675,The DdrB protein from Deinococcus radiodurans is an alternative SSB.,"Despite having been originally characterized over 50 years ago, the mechanism underlying this remarkable repair process is still poorly understood.",False,BACKGROUND
1676,The DdrB protein from Deinococcus radiodurans is an alternative SSB.,"Here, we report the 2.8 A structure of DdrB, a single-stranded DNA (ssDNA) binding protein unique to Deinococcus spp.",False,BACKGROUND
1677,The DdrB protein from Deinococcus radiodurans is an alternative SSB.,that is crucial for recovery following DNA damage.,False,BACKGROUND
1678,The DdrB protein from Deinococcus radiodurans is an alternative SSB.,DdrB forms a pentameric ring capable of binding single-stranded but not double-stranded DNA.,False,RESULTS
1679,The DdrB protein from Deinococcus radiodurans is an alternative SSB.,"Unexpectedly, the crystal structure reveals that DdrB comprises a novel fold that is structurally and topologically distinct from all other single-stranded binding (SSB) proteins characterized to date.",True,RESULTS
1680,The DdrB protein from Deinococcus radiodurans is an alternative SSB.,"The need for a unique ssDNA binding function in response to severe damage, suggests a distinct role for DdrB which may encompass not only standard SSB protein function in protection of ssDNA, but also more specialized roles in protein recruitment or DNA architecture maintenance.",False,CONCLUSIONS
1681,The DdrB protein from Deinococcus radiodurans is an alternative SSB.,Possible mechanisms of DdrB action in damage recovery are discussed.,False,CONCLUSIONS
1682,The PRR MDA5 is a sensor of RNA virus infection.,"The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 play a major role in pathogen sensing of RNA virus infection to initiate and modulate antiviral immunity.",True,BACKGROUND
1683,The PRR MDA5 is a sensor of RNA virus infection.,The RLRs detect viral RNA ligands or processed self RNA in the cytoplasm to trigger innate immunity and inflammation and to impart gene expression that serves to control infection.,False,BACKGROUND
1684,The PRR MDA5 is a sensor of RNA virus infection.,"Importantly, RLRs cooperate in signaling crosstalk networks with Toll-like receptors and other factors to impart innate immunity and to modulate the adaptive immune response.",False,BACKGROUND
1685,The PRR MDA5 is a sensor of RNA virus infection.,RLR regulation occurs at a variety of levels ranging from autoregulation to ligand and cofactor interactions and posttranslational modifications.,False,BACKGROUND
1686,The PRR MDA5 is a sensor of RNA virus infection.,Abberant RLR signaling or dysregulation of RLR expression is now implicated in the development of autoimmune diseases.,False,BACKGROUND
1687,The PRR MDA5 is a sensor of RNA virus infection.,Understanding the processes of RLR signaling and response will provide insights to guide RLR-targeted therapeutics for antiviral and immune-modifying applications.,False,BACKGROUND
1688,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,CONTEXT Blood type and crossmatch incompatibility will exclude at least one third of patients in need from receiving a live donor kidney transplant.,False,BACKGROUND
1689,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,Kidney paired donation (KPD) offers incompatible donor/recipient pairs the opportunity to match for compatible transplants.,False,BACKGROUND
1690,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"Despite its increasing popularity, very few transplants have resulted from KPD.   
",False,BACKGROUND
1691,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"OBJECTIVE To determine the potential impact of improved matching schemes on the number and quality of transplants achievable with KPD.   
",False,OBJECTIVE
1692,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"DESIGN, SETTING, AND POPULATION We developed a model that simulates pools of incompatible donor/recipient pairs.",False,METHODS
1693,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,We designed a mathematically verifiable optimized matching algorithm and compared it with the scheme currently used in some centers and regions.,False,METHODS
1694,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"Simulated patients from the general community with characteristics drawn from distributions describing end-stage renal disease patients eligible for renal transplantation and their willing and eligible live donors.   
",False,METHODS
1695,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"MAIN OUTCOME MEASURES Number of kidneys matched, HLA mismatch of matched kidneys, and number of grafts surviving 5 years after transplantation.   
",False,METHODS
1696,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"RESULTS A national optimized matching algorithm would result in more transplants (47.7% vs 42.0%, P<.001), better HLA concordance (3.0 vs 4.5 mismatched antigens; P<.001), more grafts surviving at 5 years (34.9% vs 28.7%; P<.001), and a reduction in the number of pairs required to travel (2.9% vs 18.4%; P<.001) when compared with an extension of the currently used first-accept scheme to a national level.",False,RESULTS
1697,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"Furthermore, highly sensitized patients would benefit 6-fold from a national optimized scheme (2.3% vs 14.1% successfully matched; P<.001).",False,RESULTS
1698,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,"Even if only 7% of patients awaiting kidney transplantation participated in an optimized national KPD program, the health care system could save as much as $750 million.   
",True,CONCLUSIONS
1699,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,CONCLUSIONS The combination of a national KPD program and a mathematically optimized matching algorithm yields more matches with lower HLA disparity.,False,CONCLUSIONS
1700,The US health care system can save up to $750 million if 7% of patients waiting for kidney transplants participate in the optimized national kidney paired donation program.,Optimized matching affords patients the flexibility of customizing their matching priorities and the security of knowing that the greatest number of high-quality matches will be found and distributed equitably.,False,CONCLUSIONS
1701,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,"The Hippo pathway controls organ size and tissue homeostasis, with deregulation leading to cancer.",False,BACKGROUND
1702,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,"The core Hippo components in mammals are composed of the upstream serine/threonine kinases Mst1/2, MAPK4Ks and Lats1/2.",False,RESULTS
1703,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,"Inactivation of these upstream kinases leads to dephosphorylation, stabilization, nuclear translocation and thus activation of the major functional transducers of the Hippo pathway, YAP and its paralogue TAZ.",False,RESULTS
1704,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,YAP/TAZ are transcription co-activators that regulate gene expression primarily through interaction with the TEA domain DNA-binding family of transcription factors (TEAD).,True,RESULTS
1705,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,The current paradigm for regulation of this pathway centres on phosphorylation-dependent nucleocytoplasmic shuttling of YAP/TAZ through a complex network of upstream components.,False,RESULTS
1706,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,"However, unlike other transcription factors, such as SMAD, NF-κB, NFAT and STAT, the regulation of TEAD nucleocytoplasmic shuttling has been largely overlooked.",False,RESULTS
1707,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,"In the present study, we show that environmental stress promotes TEAD cytoplasmic translocation via p38 MAPK in a Hippo-independent manner.",False,RESULTS
1708,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,"Importantly, stress-induced TEAD inhibition predominates YAP-activating signals and selectively suppresses YAP-driven cancer cell growth.",False,RESULTS
1709,The YAP1 and TEAD complex tanslocates into the nucleus where it interacts with transcription factors and DNA-binding proteins that modulate target gene transcription.,Our data reveal a mechanism governing TEAD nucleocytoplasmic shuttling and show that TEAD localization is a critical determinant of Hippo signalling output.,False,CONCLUSIONS
1710,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,Granulomas are the pathological hallmark of tuberculosis (TB).,False,BACKGROUND
1711,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,"However, their function and mechanisms of formation remain poorly understood.",False,BACKGROUND
1712,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,"To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner.",False,BACKGROUND
1713,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,"Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas.",False,METHODS
1714,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,"We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids.",True,RESULTS
1715,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,"Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature.",False,RESULTS
1716,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,These findings are consistent across a set of six human subjects and in rabbits.,False,RESULTS
1717,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,"Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma.",False,CONCLUSIONS
1718,The center of the granuloma in an immune cell induces a pro-inflammatory immune response.,"From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.",False,CONCLUSIONS
1719,The extracellular domain of TMEM27 is cleaved in human beta cells.,The signals and molecular mechanisms that regulate the replication of terminally differentiated beta cells are unknown.,False,BACKGROUND
1720,The extracellular domain of TMEM27 is cleaved in human beta cells.,"Here, we report the identification and characterization of transmembrane protein 27 (Tmem27, collectrin) in pancreatic beta cells.",False,BACKGROUND
1721,The extracellular domain of TMEM27 is cleaved in human beta cells.,Expression of Tmem27 is reduced in Tcf1(-/-) mice and is increased in islets of mouse models with hypertrophy of the endocrine pancreas.,False,RESULTS
1722,The extracellular domain of TMEM27 is cleaved in human beta cells.,"Tmem27 forms dimers and its extracellular domain is glycosylated, cleaved and shed from the plasma membrane of beta cells.",True,RESULTS
1723,The extracellular domain of TMEM27 is cleaved in human beta cells.,This cleavage process is beta cell specific and does not occur in other cell types.,False,RESULTS
1724,The extracellular domain of TMEM27 is cleaved in human beta cells.,"Overexpression of full-length Tmem27, but not the truncated or soluble protein, leads to increased thymidine incorporation, whereas silencing of Tmem27 using RNAi results in a reduction of cell replication.",False,RESULTS
1725,The extracellular domain of TMEM27 is cleaved in human beta cells.,"Furthermore, transgenic mice with increased expression of Tmem27 in pancreatic beta cells exhibit increased beta cell mass.",False,RESULTS
1726,The extracellular domain of TMEM27 is cleaved in human beta cells.,Our results identify a pancreatic beta cell transmembrane protein that regulates cell growth of pancreatic islets.,False,CONCLUSIONS
1727,The genomic aberrations found in matasteses are very similar to those found in the primary tumor.,"Human tumors show a high level of genetic heterogeneity, but the processes that influence the timing and route of metastatic dissemination of the subclones are unknown.",False,BACKGROUND
1728,The genomic aberrations found in matasteses are very similar to those found in the primary tumor.,"Here we have used whole-exome sequencing of 103 matched benign, malignant and metastatic skin tumors from genetically heterogeneous mice to demonstrate that most metastases disseminate synchronously from the primary tumor, supporting parallel rather than linear evolution as the predominant model of metastasis.",False,BACKGROUND
1729,The genomic aberrations found in matasteses are very similar to those found in the primary tumor.,"Shared mutations between primary carcinomas and their matched metastases have the distinct A-to-T signature of the initiating carcinogen dimethylbenzanthracene, but non-shared mutations are primarily G-to-T, a signature associated with oxidative stress.",True,BACKGROUND
1730,The genomic aberrations found in matasteses are very similar to those found in the primary tumor.,The existence of carcinomas that either did or did not metastasize in the same host animal suggests that there are tumor-intrinsic factors that influence metastatic seeding.,False,BACKGROUND
1731,The genomic aberrations found in matasteses are very similar to those found in the primary tumor.,"We also demonstrate the importance of germline polymorphisms in determining allele-specific mutations, and we identify somatic genetic alterations that are specifically related to initiation of carcinogenesis by Hras or Kras mutations.",False,BACKGROUND
1732,The genomic aberrations found in matasteses are very similar to those found in the primary tumor.,Mouse tumors that mimic the genetic heterogeneity of human cancers can aid our understanding of the clonal evolution of metastasis and provide a realistic model for the testing of novel therapies.,False,BACKGROUND
1733,The locus rs647161 is associated with colorectal carcinoma.,"To identify new genetic factors for colorectal cancer (CRC), we conducted a                 genome-wide association study in east Asians.",False,OBJECTIVE
1734,The locus rs647161 is associated with colorectal carcinoma.,"By analyzing genome-wide data in 2,098                 cases and 5,749 controls, we selected 64 promising SNPs for replication in an                 independent set of samples, including up to 5,358 cases and 5,922 controls.",False,METHODS
1735,The locus rs647161 is associated with colorectal carcinoma.,We                 identified four SNPs with association P values of 8.58 ×                     10(-7) to 3.77 × 10(-10)                 in the combined analysis of all east Asian samples.,False,RESULTS
1736,The locus rs647161 is associated with colorectal carcinoma.,"Three of the four were                 replicated in a study conducted in 26,060 individuals of European descent, with                 combined P values of 1.22 × 10(-10) for                 rs647161 (5q31.1), 6.64 × 10(-9) for rs2423279                 (20p12.3) and 3.06 × 10(-8) for rs10774214                 (12p13.32 near the CCND2 gene), derived from meta-analysis of data from both                 east Asian and European-ancestry populations.",True,RESULTS
1737,The locus rs647161 is associated with colorectal carcinoma.,This study identified three new CRC                 susceptibility loci and provides additional insight into the genetics and biology of                 CRC.,False,CONCLUSIONS
1738,The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.,"The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals.",False,BACKGROUND
1739,The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.,This variability critically determines the impact a disease has on a patient's life but is very poorly understood.,False,BACKGROUND
1740,The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.,"Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis.",False,BACKGROUND
1741,The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.,"We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn's disease and rheumatoid arthritis and with increased risk of severe malaria.",True,RESULTS
1742,The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.,"Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGFβ1 reduces production of proinflammatory cytokines, including TNFα, and increases production of anti-inflammatory cytokines, including IL-10.",False,CONCLUSIONS
1743,The minor G allele of FOXO3 is related to more severe symptoms of Crohn's Disease.,"Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.",False,CONCLUSIONS
1744,The myocardial lineage develops from cardiac progenitors of mesodermal origin.,"The functional heart is comprised of distinct mesoderm-derived lineages including cardiomyocytes, endothelial cells and vascular smooth muscle cells.",True,BACKGROUND
1745,The myocardial lineage develops from cardiac progenitors of mesodermal origin.,"Studies in the mouse embryo and the mouse embryonic stem cell differentiation model have provided evidence indicating that these three lineages develop from a common Flk-1+ (kinase insert domain protein receptor, also known as Kdr) cardiovascular progenitor that represents one of the earliest stages in mesoderm specification to the cardiovascular lineages.",False,BACKGROUND
1746,The myocardial lineage develops from cardiac progenitors of mesodermal origin.,"To determine whether a comparable progenitor is present during human cardiogenesis, we analysed the development of the cardiovascular lineages in human embryonic stem cell differentiation cultures.",False,METHODS
1747,The myocardial lineage develops from cardiac progenitors of mesodermal origin.,"Here we show that after induction with combinations of activin A, bone morphogenetic protein 4 (BMP4), basic fibroblast growth factor (bFGF, also known as FGF2), vascular endothelial growth factor (VEGF, also known as VEGFA) and dickkopf homolog 1 (DKK1) in serum-free media, human embryonic-stem-cell-derived embryoid bodies generate a KDRlow/C-KIT(CD117)neg population that displays cardiac, endothelial and vascular smooth muscle potential in vitro and, after transplantation, in vivo.",True,METHODS
1748,The myocardial lineage develops from cardiac progenitors of mesodermal origin.,"When plated in monolayer cultures, these KDRlow/C-KITneg cells differentiate to generate populations consisting of greater than 50% contracting cardiomyocytes.",True,RESULTS
1749,The myocardial lineage develops from cardiac progenitors of mesodermal origin.,Populations derived from the KDRlow/C-KITneg fraction give rise to colonies that contain all three lineages when plated in methylcellulose cultures.,False,RESULTS
1750,The myocardial lineage develops from cardiac progenitors of mesodermal origin.,"Results from limiting dilution studies and cell-mixing experiments support the interpretation that these colonies are clones, indicating that they develop from a cardiovascular colony-forming cell.",False,RESULTS
1751,The myocardial lineage develops from cardiac progenitors of mesodermal origin.,"Together, these findings identify a human cardiovascular progenitor that defines one of the earliest stages of human cardiac development.",False,CONCLUSIONS
1752,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"CONTEXT The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen.",False,OBJECTIVE
1753,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.   
",False,OBJECTIVE
1754,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"OBJECTIVE To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen.   
",False,OBJECTIVE
1755,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"DESIGN, SETTING, AND PATIENTS Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer.",False,METHODS
1756,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (95.4%).,False,METHODS
1757,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"Last follow-up was in December 2008; inclusion criteria were hormone receptor positivity, no metastatic disease at diagnosis, adjuvant tamoxifen therapy, and no chemotherapy.",False,METHODS
1758,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"DNA from tumor tissue or blood was genotyped for CYP2D6 variants associated with reduced (*10, *41) or absent (*3, *4, *5) enzyme activity.",False,METHODS
1759,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"Women were classified as having an extensive (n=609), heterozygous extensive/intermediate (n=637), or poor (n=79) CYP2D6 metabolism.   
",False,METHODS
1760,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"MAIN OUTCOME MEASURES Time to recurrence, event-free survival, disease-free survival, and overall survival.   
",False,METHODS
1761,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,RESULTS Median follow-up was 6.3 years.,False,RESULTS
1762,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"At 9 years of follow-up, the recurrence rates were 14.9% for extensive metabolizers, 20.9% for heterozygous extensive/intermediate metabolizers, and 29.0% for poor metabolizers, and all-cause mortality rates were 16.7%, 18.0%, and 22.8%, respectively.",False,RESULTS
1763,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"Compared with extensive metabolizers, there was a significantly increased risk of recurrence for heterozygous extensive/intermediate metabolizers (time to recurrence adjusted hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.04-1.90) and for poor metabolizers (time to recurrence HR, 1.90; 95% CI, 1.10-3.28).",True,RESULTS
1764,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"Compared with extensive metabolizers, those with decreased CYP2D6 activity (heterozygous extensive/intermediate and poor metabolism) had worse event-free survival (HR, 1.33; 95% CI, 1.06-1.68) and disease-free survival (HR, 1.29; 95% CI, 1.03-1.61), but there was no significant difference in overall survival (HR, 1.15; 95% CI, 0.88-1.51).   
",True,RESULTS
1765,The relationship between a breast cancer patient's capacity to metabolize tamoxifen and treatment outcome is dependent on the patient's genetic make-up.,"CONCLUSION Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes.",True,CONCLUSIONS
1766,The repair of Cas9-induced double strand breaks in human DNA is error-prone.,The RNA-guided DNA endonuclease Cas9 is a powerful tool for genome editing.,False,BACKGROUND
1767,The repair of Cas9-induced double strand breaks in human DNA is error-prone.,Little is known about the kinetics and fidelity of the double-strand break (DSB) repair process that follows a Cas9 cutting event in living cells.,False,BACKGROUND
1768,The repair of Cas9-induced double strand breaks in human DNA is error-prone.,"Here, we developed a strategy to measure the kinetics of DSB repair for single loci in human cells.",False,BACKGROUND
1769,The repair of Cas9-induced double strand breaks in human DNA is error-prone.,"Quantitative modeling of repaired DNA in time series after Cas9 activation reveals variable and often slow repair rates, with half-life times up to ∼10 hr.",False,RESULTS
1770,The repair of Cas9-induced double strand breaks in human DNA is error-prone.,"Furthermore, repair of the DSBs tends to be error prone.",True,RESULTS
1771,The repair of Cas9-induced double strand breaks in human DNA is error-prone.,Both classical and microhomology-mediated end joining pathways contribute to the erroneous repair.,False,RESULTS
1772,The repair of Cas9-induced double strand breaks in human DNA is error-prone.,Estimation of their individual rate constants indicates that the balance between these two pathways changes over time and can be altered by additional ionizing radiation.,False,RESULTS
1773,The repair of Cas9-induced double strand breaks in human DNA is error-prone.,Our approach provides quantitative insights into DSB repair kinetics and fidelity in single loci and indicates that Cas9-induced DSBs are repaired in an unusual manner.,False,CONCLUSIONS
1774,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","CONTEXT During pregnancy, serum levels of estrogen, progesterone, and other hormones are markedly higher than during other periods of life.",False,BACKGROUND
1775,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","Pregnancy hormones primarily are produced in the placenta, and signs of placental impairment may serve as indirect markers of hormone exposures during pregnancy.",False,BACKGROUND
1776,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","During pregnancy, these markers have been inconsistently associated with subsequent risk of breast cancer in the mother.   
",False,BACKGROUND
1777,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","OBJECTIVE To examine associations between indirect markers of hormonal exposures, such as placental weight and other pregnancy characteristics, and maternal risk of developing breast cancer.   
",False,OBJECTIVE
1778,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","DESIGN AND SETTING Population-based cohort study using data from the Swedish Birth Register, the Swedish Cancer Register, the Swedish Cause of Death Register, and the Swedish Register of Population and Population Changes.   
",False,METHODS
1779,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","PARTICIPANTS Women included in the Sweden Birth Register who delivered singletons between 1982 and 1989, with complete information on date of birth and gestational age.",False,METHODS
1780,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","Women were followed up until the occurrence of breast cancer, death, or end of follow-up (December 31, 2001).",False,METHODS
1781,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","Cox proportional hazards models were used to estimate associations between hormone exposures and risks of breast cancer.   
",False,METHODS
1782,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","MAIN OUTCOME MEASURE Incidence of invasive breast cancer.   
",False,METHODS
1783,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","RESULTS Of 314,019 women in the cohort, 2216 (0.7%) developed breast cancer during the follow-up through 2001, of whom 2100 (95%) were diagnosed before age 50 years.",False,RESULTS
1784,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","Compared with women who had placentas weighing less than 500 g in 2 consecutive pregnancies, the risk of breast cancer was increased among women whose placentas weighed between 500 and 699 g in their first pregnancy and at least 700 g in their second pregnancy (or vice versa) (adjusted hazard ratio, 1.82; 95% confidence interval [CI], 1.07-3.08), and the corresponding risk was doubled among women whose placentas weighed at least 700 g in both pregnancies (adjusted hazard ratio, 2.05; 95% CI, 1.15-3.64).",True,RESULTS
1785,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.","A high birth weight (> or =4000 g) in 2 successive births was associated with an increased risk of breast cancer before but not after adjusting for placental weight and other covariates (adjusted hazard ratio, 1.10; 95% CI, 0.76-1.59).   
",False,RESULTS
1786,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.",CONCLUSIONS Placental weight is positively associated with maternal risk of breast cancer.,True,CONCLUSIONS
1787,"The risk of breast cancer among parous women increases with placental weight of pregnancies, and this association is strongest for premenopausal breast cancer.",These results further support the hypothesis that pregnancy hormones are important modifiers of subsequent maternal breast cancer risk.,False,CONCLUSIONS
1788,The risk of male prisoners harming themselves is ten times that of female prisoners.,"BACKGROUND Self-harm and suicide are common in prisoners, yet robust information on the full extent and characteristics of people at risk of self-harm is scant.",False,BACKGROUND
1789,The risk of male prisoners harming themselves is ten times that of female prisoners.,"Furthermore, understanding how frequently self-harm is followed by suicide, and in which prisoners this progression is most likely to happen, is important.",False,BACKGROUND
1790,The risk of male prisoners harming themselves is ten times that of female prisoners.,"We did a case-control study of all prisoners in England and Wales to ascertain the prevalence of self-harm in this population, associated risk factors, clustering effects, and risk of subsequent suicide after self-harm.   
",False,BACKGROUND
1791,The risk of male prisoners harming themselves is ten times that of female prisoners.,"METHODS Records of self-harm incidents in all prisons in England and Wales were gathered routinely between January, 2004, and December, 2009.",False,METHODS
1792,The risk of male prisoners harming themselves is ten times that of female prisoners.,"We did a case-control comparison of prisoners who self-harmed and those who did not between January, 2006, and December, 2009.",False,METHODS
1793,The risk of male prisoners harming themselves is ten times that of female prisoners.,We also used a Bayesian approach to look at clustering of people who self-harmed.,False,METHODS
1794,The risk of male prisoners harming themselves is ten times that of female prisoners.,"Prisoners who self-harmed and subsequently died by suicide in prison were compared with other inmates who self-harmed.   
",False,METHODS
1795,The risk of male prisoners harming themselves is ten times that of female prisoners.,"FINDINGS 139,195 self-harm incidents were recorded in 26,510 individual prisoners between 2004 and 2009; 5-6% of male prisoners and 20-24% of female inmates self-harmed every year.",True,RESULTS
1796,The risk of male prisoners harming themselves is ten times that of female prisoners.,Self-harm rates were more than ten times higher in female prisoners than in male inmates.,True,RESULTS
1797,The risk of male prisoners harming themselves is ten times that of female prisoners.,"Repetition of self-harm was common, particularly in women and teenage girls, in whom a subgroup of 102 prisoners accounted for 17,307 episodes.",False,RESULTS
1798,The risk of male prisoners harming themselves is ten times that of female prisoners.,"In both sexes, self-harm was associated with younger age, white ethnic origin, prison type, and a life sentence or being unsentenced; in female inmates, committing a violent offence against an individual was also a factor.",False,RESULTS
1799,The risk of male prisoners harming themselves is ten times that of female prisoners.,"Substantial evidence was noted of clustering in time and location of prisoners who self-harmed (adjusted intra-class correlation 0·15, 95% CI 0·11-0·18).",False,RESULTS
1800,The risk of male prisoners harming themselves is ten times that of female prisoners.,"109 subsequent suicides in prison were reported in individuals who self-harmed; the risk was higher in those who self-harmed than in the general prison population, and more than half the deaths occurred within a month of self-harm.",False,RESULTS
1801,The risk of male prisoners harming themselves is ten times that of female prisoners.,"Risk factors for suicide after self-harm in male prisoners were older age and a previous self-harm incident of high or moderate lethality; in female inmates, a history of more than five self-harm incidents within a year was associated with subsequent suicide.   
",False,RESULTS
1802,The risk of male prisoners harming themselves is ten times that of female prisoners.,"INTERPRETATION The burden of self-harm in prisoners is substantial, particularly in women.",False,CONCLUSIONS
1803,The risk of male prisoners harming themselves is ten times that of female prisoners.,Self-harm in prison is associated with subsequent suicide in this setting.,False,CONCLUSIONS
1804,The risk of male prisoners harming themselves is ten times that of female prisoners.,"Prevention and treatment of self-harm in prisoners is an essential component of suicide prevention in prisons.   
",False,CONCLUSIONS
1805,The risk of male prisoners harming themselves is ten times that of female prisoners.,"FUNDING Wellcome Trust, National Institute for Health Research, National Offender Management Service, and Department of Health.",False,BACKGROUND
1806,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,"BACKGROUND The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement.",False,BACKGROUND
1807,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,"Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for the diagnosis of cardiac amyloidosis, but its potential for stratifying risk is unknown.   
",False,BACKGROUND
1808,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,"METHODS AND RESULTS Two hundred fifty prospectively recruited subjects, 122 patients with ATTR amyloid, 9 asymptomatic mutation carriers, and 119 patients with AL amyloidosis, underwent LGE cardiovascular magnetic resonance.",False,METHODS
1809,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,Subjects were followed up for a mean of 24±13 months.,False,METHODS
1810,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,LGE was performed with phase-sensitive inversion recovery (PSIR) and without (magnitude only).,False,METHODS
1811,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,These were compared with extracellular volume measured with T1 mapping.,False,METHODS
1812,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,PSIR was superior to magnitude-only inversion recovery LGE because PSIR always nulled the tissue (blood or myocardium) with the longest T1 (least gadolinium).,False,RESULTS
1813,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,"LGE was classified into 3 patterns: none, subendocardial, and transmural, which were associated with increasing amyloid burden as defined by extracellular volume (P<0.0001), with transitions from none to subendocardial LGE at an extracellular volume of 0.40 to 0.43 (AL) and 0.39 to 0.40 (ATTR) and to transmural at 0.48 to 0.55 (AL) and 0.47 to 0.59 (ATTR).",True,RESULTS
1814,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,Sixty-seven patients (27%) died.,False,RESULTS
1815,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,"Transmural LGE predicted death (hazard ratio, 5.4; 95% confidence interval, 2.1-13.7; P<0.0001) and remained independent after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, stroke volume index, E/E', and left ventricular mass index (hazard ratio, 4.1; 95% confidence interval, 1.3-13.1; P<0.05).   
",False,RESULTS
1816,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,CONCLUSIONS There is a continuum of cardiac involvement in systemic AL and ATTR amyloidosis.,False,CONCLUSIONS
1817,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,Transmural LGE is determined reliably by PSIR and represents advanced cardiac amyloidosis.,True,CONCLUSIONS
1818,The severity of cardiac involvement in amyloidosis can be described by the degree of transmurality of late gadolinium enhancement in MRI.,The PSIR technique provides incremental information on outcome even after adjustment for known prognostic factors.,False,CONCLUSIONS
1819,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,"Molecular motors play critical roles in the formation of mitotic spindles, either through controlling the stability of individual microtubules, or by crosslinking and sliding microtubule arrays.",False,BACKGROUND
1820,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,Kinesin-8 motors are best known for their regulatory roles in controlling microtubule dynamics.,False,BACKGROUND
1821,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,"They contain microtubule-destabilizing activities, and restrict spindle length in a wide variety of cell types and organisms.",False,BACKGROUND
1822,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,"Here, we report an antiparallel microtubule-sliding activity of the budding yeast kinesin-8, Kip3.",False,BACKGROUND
1823,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,The in vivo importance of this sliding activity was established through the identification of complementary Kip3 mutants that separate the sliding activity and microtubule-destabilizing activity.,False,RESULTS
1824,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,"In conjunction with Cin8, a kinesin-5 family member, the sliding activity of Kip3 promotes bipolar spindle assembly and the maintenance of genome stability.",True,RESULTS
1825,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,We propose a slide-disassemble model where the sliding and destabilizing activity of Kip3 balance during pre-anaphase.,False,CONCLUSIONS
1826,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,This facilitates normal spindle assembly.,False,CONCLUSIONS
1827,The sliding activity of kinesin-8 protein Kip3 promotes bipolar spindle assembly.,"However, the destabilizing activity of Kip3 dominates in late anaphase, inhibiting spindle elongation and ultimately promoting spindle disassembly.",False,CONCLUSIONS
1828,The tip of the inner tube of the toxic type VI secretion system (T6SS) antibacterial effector in Escherichia coli (E. coli) carries toxic effector proteins.,"The bacterial type VI secretion system (T6SS) is a large multicomponent, dynamic macromolecular machine that has an important role in the ecology of many Gram-negative bacteria.",False,BACKGROUND
1829,The tip of the inner tube of the toxic type VI secretion system (T6SS) antibacterial effector in Escherichia coli (E. coli) carries toxic effector proteins.,"T6SS is responsible for translocation of a wide range of toxic effector molecules, allowing predatory cells to kill both prokaryotic as well as eukaryotic prey cells.",False,BACKGROUND
1830,The tip of the inner tube of the toxic type VI secretion system (T6SS) antibacterial effector in Escherichia coli (E. coli) carries toxic effector proteins.,The T6SS organelle is functionally analogous to contractile tails of bacteriophages and is thought to attack cells by initially penetrating them with a trimeric protein complex called the VgrG spike.,False,BACKGROUND
1831,The tip of the inner tube of the toxic type VI secretion system (T6SS) antibacterial effector in Escherichia coli (E. coli) carries toxic effector proteins.,Neither the exact protein composition of the T6SS organelle nor the mechanisms of effector selection and delivery are known.,False,BACKGROUND
1832,The tip of the inner tube of the toxic type VI secretion system (T6SS) antibacterial effector in Escherichia coli (E. coli) carries toxic effector proteins.,"Here we report that proteins from the PAAR (proline-alanine-alanine-arginine) repeat superfamily form a sharp conical extension on the VgrG spike, which is further involved in attaching effector domains to the spike.",True,BACKGROUND
1833,The tip of the inner tube of the toxic type VI secretion system (T6SS) antibacterial effector in Escherichia coli (E. coli) carries toxic effector proteins.,The crystal structures of two PAAR-repeat proteins bound to VgrG-like partners show that these proteins sharpen the tip of the T6SS spike complex.,True,RESULTS
1834,The tip of the inner tube of the toxic type VI secretion system (T6SS) antibacterial effector in Escherichia coli (E. coli) carries toxic effector proteins.,We demonstrate that PAAR proteins are essential for T6SS-mediated secretion and target cell killing by Vibrio cholerae and Acinetobacter baylyi.,False,RESULTS
1835,The tip of the inner tube of the toxic type VI secretion system (T6SS) antibacterial effector in Escherichia coli (E. coli) carries toxic effector proteins.,Our results indicate a new model of the T6SS organelle in which the VgrG-PAAR spike complex is decorated with multiple effectors that are delivered simultaneously into target cells in a single contraction-driven translocation event.,True,CONCLUSIONS
1836,There is an inverse relationship between hip fractures and statin use.,"CONTEXT Recent animal studies have found that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) lipid-lowering drugs (statins) substantially increase bone formation, but whether statin use in humans results in clinically meaningful bone formation or a reduction in the risk of osteoporotic fractures is not known.   
",False,OBJECTIVE
1837,There is an inverse relationship between hip fractures and statin use.,"OBJECTIVE To determine whether the use of statins is associated with reduced hip fracture risk.   
",False,OBJECTIVE
1838,There is an inverse relationship between hip fractures and statin use.,"DESIGN Case-control study.   
",False,METHODS
1839,There is an inverse relationship between hip fractures and statin use.,SETTING AND PATIENTS A total of 6110 New Jersey residents aged 65 years or older and enrolled in Medicare and either Medicaid or the Pharmacy Assistance for the Aged and Disabled program.,False,METHODS
1840,There is an inverse relationship between hip fractures and statin use.,Case patients (n=1222) underwent surgical repair of a hip fracture in 1994.,False,METHODS
1841,There is an inverse relationship between hip fractures and statin use.,"Control patients (n=4888) were identified at a ratio of 4:1 and frequency-matched to case patients for age and sex.   
",False,METHODS
1842,There is an inverse relationship between hip fractures and statin use.,"MAIN OUTCOME MEASURE Adjusted odds ratio (OR) of hip fracture by statin use in the 180 days and 3 years prior to the index date (the earliest date of admission for surgery), adjusted for demographic and clinical characteristics and health care utilization.   
",False,METHODS
1843,There is an inverse relationship between hip fractures and statin use.,"RESULTS Use of statins in either the prior 180 days (adjusted OR, 0.50; 95% confidence interval [CI], 0.33-0.76) or prior 3 years (adjusted OR, 0.57; 95% CI, 0.40-0.82) was associated with a significant reduction in the risk of hip fracture, even after controlling for variables such as race, insurance status, psychoactive medications, estrogen and thiazide use, ischemic heart disease, cancer, and diabetes mellitus.",True,RESULTS
1844,There is an inverse relationship between hip fractures and statin use.,No significant relationship was observed between use of nonstatin lipid-lowering agents and hip fracture risk.,False,RESULTS
1845,There is an inverse relationship between hip fractures and statin use.,Clear relationships were observed between the degree of reduction in hip fracture risk and the extent of statin use; there was no evidence of such relationships with nonstatin lipid-lowering agents.,True,RESULTS
1846,There is an inverse relationship between hip fractures and statin use.,"After adjusting for extent of statin use in the prior 3 years, current use (on the index date) was associated with a 71% reduction in risk (adjusted OR, 0.29; 95% CI, 0.10-0.81).",True,RESULTS
1847,There is an inverse relationship between hip fractures and statin use.,"The relationship between statin use and hip fracture risk persisted after controlling for variables such as the number of medications, the Charlson comorbidity index score, and hospitalization or nursing home stay in the last 180 days, as well as after excluding patients who were in a nursing home prior to their index date or who died in the year after their index date.",False,RESULTS
1848,There is an inverse relationship between hip fractures and statin use.,"Use of nonstatin lipid-lowering agents was not observed to be associated with reduction in hip fracture risk in any of these alternative models or analyses.   
",False,RESULTS
1849,There is an inverse relationship between hip fractures and statin use.,CONCLUSIONS These findings support an association between statin use by elderly patients and reduction in the risk of hip fracture.,True,CONCLUSIONS
1850,There is an inverse relationship between hip fractures and statin use.,Controlled trials are needed to exclude the possibility of unmeasured confounders.,False,CONCLUSIONS
1851,There is an inverse relationship between hip fractures and statin use.,JAMA.,False,BACKGROUND
1852,There is an inverse relationship between hip fractures and statin use.,2000;283:3211-3216,False,BACKGROUND
1853,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,BACKGROUND Deep vein thrombosis (DVT) and pulmonary embolism are common after stroke.,False,BACKGROUND
1854,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"In small trials of patients undergoing surgery, graduated compression stockings (GCS) reduce the risk of DVT.",False,BACKGROUND
1855,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,National stroke guidelines extrapolating from these trials recommend their use in patients with stroke despite insufficient evidence.,False,BACKGROUND
1856,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"We assessed the effectiveness of thigh-length GCS to reduce DVT after stroke.   
",False,BACKGROUND
1857,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"METHODS In this outcome-blinded, randomised controlled trial, 2518 patients who were admitted to hospital within 1 week of an acute stroke and who were immobile were enrolled from 64 centres in the UK, Italy, and Australia.",False,METHODS
1858,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,Patients were allocated via a central randomisation system to routine care plus thigh-length GCS (n=1256) or to routine care plus avoidance of GCS (n=1262).,False,METHODS
1859,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"A technician who was blinded to treatment allocation undertook compression Doppler ultrasound of both legs at about 7-10 days and, when practical, again at 25-30 days after enrolment.",False,METHODS
1860,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,The primary outcome was the occurrence of symptomatic or asymptomatic DVT in the popliteal or femoral veins.,False,METHODS
1861,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,Analyses were by intention to treat.,False,METHODS
1862,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"This study is registered, number ISRCTN28163533.   
",False,METHODS
1863,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,FINDINGS All patients were included in the analyses.,False,RESULTS
1864,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"The primary outcome occurred in 126 (10.0%) patients allocated to thigh-length GCS and in 133 (10.5%) allocated to avoid GCS, resulting in a non-significant absolute reduction in risk of 0.5% (95% CI -1.9% to 2.9%).",True,RESULTS
1865,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"Skin breaks, ulcers, blisters, and skin necrosis were significantly more common in patients allocated to GCS than in those allocated to avoid their use (64 [5%] vs 16 [1%]; odds ratio 4.18, 95% CI 2.40-7.27).   
",False,RESULTS
1866,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,INTERPRETATION These data do not lend support to the use of thigh-length GCS in patients admitted to hospital with acute stroke.,True,CONCLUSIONS
1867,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"National guidelines for stroke might need to be revised on the basis of these results.   
",False,CONCLUSIONS
1868,Thigh-length graduated compression stockings (GCS) did not reduce deep vein thrombosis in patients admitted to hospital who are immobile because of acute stroke.,"FUNDING Medical Research Council (UK), Chief Scientist Office of Scottish Government, Chest Heart and Stroke Scotland, Tyco Healthcare (Covidien) USA, and UK Stroke Research Network.",False,BACKGROUND
1869,Tirasemtiv has no effect on fast-twitch muscle.,"Limited neural input results in muscle weakness in neuromuscular disease because of a reduction in the density of muscle innervation, the rate of neuromuscular junction activation or the efficiency of synaptic transmission.",False,BACKGROUND
1870,Tirasemtiv has no effect on fast-twitch muscle.,"We developed a small-molecule fast-skeletal-troponin activator, CK-2017357, as a means to increase muscle strength by amplifying the response of muscle when neural input is otherwise diminished secondary to neuromuscular disease.",True,BACKGROUND
1871,Tirasemtiv has no effect on fast-twitch muscle.,"Binding selectively to the fast-skeletal-troponin complex, CK-2017357 slows the rate of calcium release from troponin C and sensitizes muscle to calcium.",True,RESULTS
1872,Tirasemtiv has no effect on fast-twitch muscle.,"As a consequence, the force-calcium relationship of muscle fibers shifts leftwards, as does the force-frequency relationship of a nerve-muscle pair, so that CK-2017357 increases the production of muscle force in situ at sub-maximal nerve stimulation rates.",False,RESULTS
1873,Tirasemtiv has no effect on fast-twitch muscle.,"Notably, we show that sensitization of the fast-skeletal-troponin complex to calcium improves muscle force and grip strength immediately after administration of single doses of CK-2017357 in a model of the neuromuscular disease myasthenia gravis.",False,CONCLUSIONS
1874,Tirasemtiv has no effect on fast-twitch muscle.,Troponin activation may provide a new therapeutic approach to improve physical activity in diseases where neuromuscular function is compromised.,False,CONCLUSIONS
1875,Transplanted human glial cells can differentiate within the host animal.,"Human astrocytes are larger and more complex than those of infraprimate mammals, suggesting that their role in neural processing has expanded with evolution.",False,BACKGROUND
1876,Transplanted human glial cells can differentiate within the host animal.,"To assess the cell-autonomous and species-selective properties of human glia, we engrafted human glial progenitor cells (GPCs) into neonatal immunodeficient mice.",False,BACKGROUND
1877,Transplanted human glial cells can differentiate within the host animal.,"Upon maturation, the recipient brains exhibited large numbers and high proportions of both human glial progenitors and astrocytes.",True,RESULTS
1878,Transplanted human glial cells can differentiate within the host animal.,"The engrafted human glia were gap-junction-coupled to host astroglia, yet retained the size and pleomorphism of hominid astroglia, and propagated Ca2+ signals 3-fold faster than their hosts.",False,RESULTS
1879,Transplanted human glial cells can differentiate within the host animal.,"Long-term potentiation (LTP) was sharply enhanced in the human glial chimeric mice, as was their learning, as assessed by Barnes maze navigation, object-location memory, and both contextual and tone fear conditioning.",False,RESULTS
1880,Transplanted human glial cells can differentiate within the host animal.,Mice allografted with murine GPCs showed no enhancement of either LTP or learning.,False,RESULTS
1881,Transplanted human glial cells can differentiate within the host animal.,These findings indicate that human glia differentially enhance both activity-dependent plasticity and learning in mice.,False,CONCLUSIONS
1882,Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.,"Human astrocytes are larger and more complex than those of infraprimate mammals, suggesting that their role in neural processing has expanded with evolution.",False,BACKGROUND
1883,Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.,"To assess the cell-autonomous and species-selective properties of human glia, we engrafted human glial progenitor cells (GPCs) into neonatal immunodeficient mice.",False,BACKGROUND
1884,Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.,"Upon maturation, the recipient brains exhibited large numbers and high proportions of both human glial progenitors and astrocytes.",False,RESULTS
1885,Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.,"The engrafted human glia were gap-junction-coupled to host astroglia, yet retained the size and pleomorphism of hominid astroglia, and propagated Ca2+ signals 3-fold faster than their hosts.",False,RESULTS
1886,Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.,"Long-term potentiation (LTP) was sharply enhanced in the human glial chimeric mice, as was their learning, as assessed by Barnes maze navigation, object-location memory, and both contextual and tone fear conditioning.",True,RESULTS
1887,Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.,Mice allografted with murine GPCs showed no enhancement of either LTP or learning.,False,RESULTS
1888,Transplanted human glial progenitor cells are incapable of forming a neural network with host animals' neurons.,These findings indicate that human glia differentially enhance both activity-dependent plasticity and learning in mice.,False,CONCLUSIONS
1889,UCB T cells maintain high TCR diversity after transplantation.,Delayed T cell recovery and restricted T cell receptor (TCR) diversity after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with increased risks of infection and cancer relapse.,False,BACKGROUND
1890,UCB T cells maintain high TCR diversity after transplantation.,Technical challenges have limited faithful measurement of TCR diversity after allo-HSCT.,False,BACKGROUND
1891,UCB T cells maintain high TCR diversity after transplantation.,Here we combined 5' rapid amplification of complementary DNA ends PCR with deep sequencing to quantify TCR diversity in 28 recipients of allo-HSCT using a single oligonucleotide pair.,False,METHODS
1892,UCB T cells maintain high TCR diversity after transplantation.,Analysis of duplicate blood samples confirmed that we accurately determined the frequency of individual TCRs.,False,METHODS
1893,UCB T cells maintain high TCR diversity after transplantation.,"After 6 months, cord blood-graft recipients approximated the TCR diversity of healthy individuals, whereas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fold lower CD4(+) and CD8(+) T cell diversities, respectively.",True,RESULTS
1894,UCB T cells maintain high TCR diversity after transplantation.,"After 12 months, these deficiencies had improved for the CD4(+) but not the CD8(+) T cell compartment.",False,RESULTS
1895,UCB T cells maintain high TCR diversity after transplantation.,"Overall, this method provides unprecedented views of T cell repertoire recovery after allo-HSCT and may identify patients at high risk of infection or relapse.",False,CONCLUSIONS
1896,UCB T cells reduce TCR diversity after transplantation.,Delayed T cell recovery and restricted T cell receptor (TCR) diversity after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with increased risks of infection and cancer relapse.,False,BACKGROUND
1897,UCB T cells reduce TCR diversity after transplantation.,Technical challenges have limited faithful measurement of TCR diversity after allo-HSCT.,False,BACKGROUND
1898,UCB T cells reduce TCR diversity after transplantation.,Here we combined 5' rapid amplification of complementary DNA ends PCR with deep sequencing to quantify TCR diversity in 28 recipients of allo-HSCT using a single oligonucleotide pair.,False,METHODS
1899,UCB T cells reduce TCR diversity after transplantation.,Analysis of duplicate blood samples confirmed that we accurately determined the frequency of individual TCRs.,False,METHODS
1900,UCB T cells reduce TCR diversity after transplantation.,"After 6 months, cord blood-graft recipients approximated the TCR diversity of healthy individuals, whereas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fold lower CD4(+) and CD8(+) T cell diversities, respectively.",True,RESULTS
1901,UCB T cells reduce TCR diversity after transplantation.,"After 12 months, these deficiencies had improved for the CD4(+) but not the CD8(+) T cell compartment.",False,RESULTS
1902,UCB T cells reduce TCR diversity after transplantation.,"Overall, this method provides unprecedented views of T cell repertoire recovery after allo-HSCT and may identify patients at high risk of infection or relapse.",False,CONCLUSIONS
1903,Ubiquitin ligase UBC13 generates a K63-linked polyubiquitin moiety at PCNA K164.,DNA damage tolerance during eukaryotic replication is orchestrated by PCNA ubiquitination.,False,BACKGROUND
1904,Ubiquitin ligase UBC13 generates a K63-linked polyubiquitin moiety at PCNA K164.,"While monoubiquitination activates mutagenic translesion synthesis, polyubiquitination activates an error-free pathway, elusive in mammals, enabling damage bypass by template switching.",False,BACKGROUND
1905,Ubiquitin ligase UBC13 generates a K63-linked polyubiquitin moiety at PCNA K164.,"Fork reversal is driven in vitro by multiple enzymes, including the DNA translocase ZRANB3, shown to bind polyubiquitinated PCNA.",False,BACKGROUND
1906,Ubiquitin ligase UBC13 generates a K63-linked polyubiquitin moiety at PCNA K164.,"However, whether this interaction promotes fork remodeling and template switching in vivo was unknown.",False,BACKGROUND
1907,Ubiquitin ligase UBC13 generates a K63-linked polyubiquitin moiety at PCNA K164.,"Here we show that damage-induced fork reversal in mammalian cells requires PCNA ubiquitination, UBC13, and K63-linked polyubiquitin chains, previously involved in error-free damage tolerance.",True,RESULTS
1908,Ubiquitin ligase UBC13 generates a K63-linked polyubiquitin moiety at PCNA K164.,"Fork reversal in vivo also requires ZRANB3 translocase activity and its interaction with polyubiquitinated PCNA, pinpointing ZRANB3 as a key effector of error-free DNA damage tolerance.",False,RESULTS
1909,Ubiquitin ligase UBC13 generates a K63-linked polyubiquitin moiety at PCNA K164.,"Mutations affecting fork reversal also induced unrestrained fork progression and chromosomal breakage, suggesting fork remodeling as a global fork slowing and protection mechanism.",False,CONCLUSIONS
1910,Ubiquitin ligase UBC13 generates a K63-linked polyubiquitin moiety at PCNA K164.,Targeting these fork protection systems represents a promising strategy to potentiate cancer chemotherapy.,False,CONCLUSIONS
1911,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"OBJECTIVE To determine whether ultrasound imaging can reduce the risk of failed lumbar punctures or epidural catheterisations, when compared with standard palpation methods, and whether ultrasound imaging can reduce traumatic procedures, insertion attempts, and needle redirections.   
",False,OBJECTIVE
1912,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"DESIGN Systematic review and meta-analysis of randomised controlled trials.   
",False,METHODS
1913,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"DATA SOURCES Ovid Medline, Embase, and Cochrane Central Register of Controlled Trials up to May 2012, without restriction by language or publication status.   ",False,METHODS
1914,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"REVIEW METHODS Randomised trials that compared ultrasound imaging with standard methods (no imaging) in the performance of a lumbar puncture or epidural catheterisation were identified.   
",False,METHODS
1915,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"RESULTS 14 studies with a total of 1334 patients were included (674 patients assigned to the ultrasound group, 660 to the control group).",False,RESULTS
1916,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,Five studies evaluated lumbar punctures and nine evaluated epidural catheterisations.,False,RESULTS
1917,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,Six of 624 procedures conducted in the ultrasound group failed; 44 of 610 procedures in the control group failed.,False,RESULTS
1918,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"Ultrasound imaging reduced the risk of failed procedures (risk ratio 0.21 (95% confidence interval 0.10 to 0.43), P<0.001).",True,RESULTS
1919,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"Risk reduction was similar when subgroup analysis was performed for lumbar punctures (risk ratio 0.19 (0.07 to 0.56), P=0.002) or epidural catheterisations (0.23 (0.09 to 0.60), P=0.003).",True,RESULTS
1920,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"Ultrasound imaging also significantly reduced the risk of traumatic procedures (risk ratio 0.27 (0.11 to 0.67), P=0.005), the number of insertion attempts (mean difference -0.44 (-0.64 to -0.24), P<0.001), and the number of needle redirections (mean difference -1.00 (-1.24 to -0.75), P<0.001).   
",True,RESULTS
1921,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,"CONCLUSIONS Ultrasound imaging can reduce the risk of failed or traumatic lumbar punctures and epidural catheterisations, as well as the number of needle insertions and redirections.",True,CONCLUSIONS
1922,Ultrasound guidance significantly raises the number of traumatic procedures when attempting needle insertion.,Ultrasound may be a useful adjunct for these procedures.,False,CONCLUSIONS
1923,Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.,"West Nile virus (WNV) is the most common arthropod-borne flavivirus in the United States; however, the vector ligand(s) that participate in infection are not known.",False,BACKGROUND
1924,Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.,"We now show that an Aedes aegypti C-type lectin, mosGCTL-1, is induced by WNV, interacts with WNV in a calcium-dependent manner, and facilitates infection in vivo and in vitro.",False,BACKGROUND
1925,Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.,"A mosquito homolog of human CD45 in A. aegypti, designated mosPTP-1, recruits mosGCTL-1 to enable viral attachment to cells and to enhance viral entry.",False,RESULTS
1926,Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.,In vivo experiments show that mosGCTL-1 and mosPTP-1 function as part of the same pathway and are critical for WNV infection of mosquitoes.,True,RESULTS
1927,Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.,"A similar phenomenon was also observed in Culex quinquefasciatus, a natural vector of WNV, further demonstrating that these genes participate in WNV infection.",False,RESULTS
1928,Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.,"During the mosquito blood-feeding process, WNV infection was blocked in vivo with mosGCTL-1 antibodies.",True,CONCLUSIONS
1929,Upregulation of mosGCTL-1 is induced upon infection with West Nile virus.,A molecular understanding of flaviviral-arthropod interactions may lead to strategies to control viral dissemination in nature.,False,CONCLUSIONS
1930,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"IMPORTANCE Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.   
",False,BACKGROUND
1931,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"OBJECTIVE To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.   
",False,OBJECTIVE
1932,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"DESIGN, SETTING, AND PARTICIPANTS Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites.",False,METHODS
1933,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"Five hundred six adult (≥18 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.   
",False,METHODS
1934,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"INTERVENTIONS Twelve weeks of varenicline and bupropion SR or varenicline and placebo.   
",False,METHODS
1935,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"MAIN OUTCOMES AND MEASURES Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence.",False,METHODS
1936,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,Secondary outcomes were prolonged and point-prevalence smoking abstinence rates at weeks 26 and 52.,False,METHODS
1937,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"Outcomes were biochemically confirmed.   
",False,METHODS
1938,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"RESULTS At 12 weeks, 53.0% of the combination therapy group achieved prolonged smoking abstinence and 56.2% achieved 7-day point-prevalence smoking abstinence compared with 43.2% and 48.6% in varenicline monotherapy (odds ratio [OR], 1.49; 95% CI, 1.05-2.12; P = .03 and OR, 1.36; 95% CI, 0.95-1.93; P = .09, respectively).",True,RESULTS
1939,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"At 26 weeks, 36.6% of the combination therapy group achieved prolonged and 38.2% achieved 7-day point-prevalence smoking abstinence compared with 27.6% and 31.9% in varenicline monotherapy (OR, 1.52; 95% CI, 1.04-2.22; P = .03 and OR, 1.32; 95% CI, 0.91-1.91; P = .14, respectively).",False,RESULTS
1940,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"At 52 weeks, 30.9% of the combination therapy group achieved prolonged and 36.6% achieved 7-day point-prevalence smoking abstinence compared with 24.5% and 29.2% in varenicline monotherapy (OR, 1.39; 95% CI, 0.93-2.07; P = .11 and OR, 1.40; 95% CI, 0.96-2.05; P = .08, respectively).",False,RESULTS
1941,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"Participants receiving combination therapy reported more anxiety (7.2% vs 3.1%; P = .04) and depressive symptoms (3.6% vs 0.8%; P = .03).   
",False,RESULTS
1942,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"CONCLUSIONS AND RELEVANCE Among cigarette smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased prolonged abstinence but not 7-day point prevalence at 12 and 26 weeks.",False,CONCLUSIONS
1943,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,Neither outcome was significantly different at 52 weeks.,False,CONCLUSIONS
1944,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,"Further research is required to determine the role of combination therapy in smoking cessation.   
",False,CONCLUSIONS
1945,Varenicline monotherapy is more effective after 12 weeks of treatment compared to combination nicotine replacement therapies with varenicline or bupropion.,TRIAL REGISTRATION clinicaltrials.gov Identifier: http://clinicaltrials.gov/show/NCT00935818.,False,CONCLUSIONS
1946,Vitamin D deficiency effects the term of delivery.,"OBJECTIVE To assess the effect of 25-hydroxyvitamin D (25-OHD) levels on pregnancy outcomes and birth variables.   
",False,OBJECTIVE
1947,Vitamin D deficiency effects the term of delivery.,"DESIGN Systematic review and meta-analysis.   
",False,METHODS
1948,Vitamin D deficiency effects the term of delivery.,"DATA SOURCES Medline (1966 to August 2012), PubMed (2008 to August 2012), Embase (1980 to August 2012), CINAHL (1981 to August 2012), the Cochrane database of systematic reviews, and the Cochrane database of registered clinical trials.   ",False,METHODS
1949,Vitamin D deficiency effects the term of delivery.,"STUDY SELECTION Studies reporting on the association between serum 25-OHD levels during pregnancy and the outcomes of interest (pre-eclampsia, gestational diabetes, bacterial vaginosis, caesarean section, small for gestational age infants, birth weight, birth length, and head circumference).   
",False,METHODS
1950,Vitamin D deficiency effects the term of delivery.,"DATA EXTRACTION Two authors independently extracted data from original research articles, including key indicators of study quality.",False,METHODS
1951,Vitamin D deficiency effects the term of delivery.,We pooled the most adjusted odds ratios and weighted mean differences.,False,METHODS
1952,Vitamin D deficiency effects the term of delivery.,"Associations were tested in subgroups representing different patient characteristics and study quality.   
",False,METHODS
1953,Vitamin D deficiency effects the term of delivery.,RESULTS 3357 studies were identified and reviewed for eligibility.,False,RESULTS
1954,Vitamin D deficiency effects the term of delivery.,31 eligible studies were included in the final analysis.,False,RESULTS
1955,Vitamin D deficiency effects the term of delivery.,"Insufficient serum levels of 25-OHD were associated with gestational diabetes (pooled odds ratio 1.49, 95% confidence interval 1.18 to 1.89), pre-eclampsia (1.79, 1.25 to 2.58), and small for gestational age infants (1.85, 1.52 to 2.26).",True,RESULTS
1956,Vitamin D deficiency effects the term of delivery.,"Pregnant women with low serum 25-OHD levels had an increased risk of bacterial vaginosis and low birthweight infants but not delivery by caesarean section.   
",True,RESULTS
1957,Vitamin D deficiency effects the term of delivery.,"CONCLUSION Vitamin D insufficiency is associated with an increased risk of gestational diabetes, pre-eclampsia, and small for gestational age infants.",True,CONCLUSIONS
1958,Vitamin D deficiency effects the term of delivery.,"Pregnant women with low 25-OHD levels had an increased risk of bacterial vaginosis and lower birth weight infants, but not delivery by caesarean section.",True,CONCLUSIONS
1959,Vitamin D deficiency is unrelated to birth weight.,"OBJECTIVE To assess the effect of 25-hydroxyvitamin D (25-OHD) levels on pregnancy outcomes and birth variables.   
",False,OBJECTIVE
1960,Vitamin D deficiency is unrelated to birth weight.,"DESIGN Systematic review and meta-analysis.   
",False,METHODS
1961,Vitamin D deficiency is unrelated to birth weight.,"DATA SOURCES Medline (1966 to August 2012), PubMed (2008 to August 2012), Embase (1980 to August 2012), CINAHL (1981 to August 2012), the Cochrane database of systematic reviews, and the Cochrane database of registered clinical trials.   ",False,METHODS
1962,Vitamin D deficiency is unrelated to birth weight.,"STUDY SELECTION Studies reporting on the association between serum 25-OHD levels during pregnancy and the outcomes of interest (pre-eclampsia, gestational diabetes, bacterial vaginosis, caesarean section, small for gestational age infants, birth weight, birth length, and head circumference).   
",False,METHODS
1963,Vitamin D deficiency is unrelated to birth weight.,"DATA EXTRACTION Two authors independently extracted data from original research articles, including key indicators of study quality.",False,METHODS
1964,Vitamin D deficiency is unrelated to birth weight.,We pooled the most adjusted odds ratios and weighted mean differences.,False,METHODS
1965,Vitamin D deficiency is unrelated to birth weight.,"Associations were tested in subgroups representing different patient characteristics and study quality.   
",False,METHODS
1966,Vitamin D deficiency is unrelated to birth weight.,RESULTS 3357 studies were identified and reviewed for eligibility.,False,RESULTS
1967,Vitamin D deficiency is unrelated to birth weight.,31 eligible studies were included in the final analysis.,False,RESULTS
1968,Vitamin D deficiency is unrelated to birth weight.,"Insufficient serum levels of 25-OHD were associated with gestational diabetes (pooled odds ratio 1.49, 95% confidence interval 1.18 to 1.89), pre-eclampsia (1.79, 1.25 to 2.58), and small for gestational age infants (1.85, 1.52 to 2.26).",False,RESULTS
1969,Vitamin D deficiency is unrelated to birth weight.,"Pregnant women with low serum 25-OHD levels had an increased risk of bacterial vaginosis and low birthweight infants but not delivery by caesarean section.   
",True,RESULTS
1970,Vitamin D deficiency is unrelated to birth weight.,"CONCLUSION Vitamin D insufficiency is associated with an increased risk of gestational diabetes, pre-eclampsia, and small for gestational age infants.",False,CONCLUSIONS
1971,Vitamin D deficiency is unrelated to birth weight.,"Pregnant women with low 25-OHD levels had an increased risk of bacterial vaginosis and lower birth weight infants, but not delivery by caesarean section.",True,CONCLUSIONS
1972,Women with a higher birth weight are more likely to develop breast cancer later in life.,"BACKGROUND Birth size, perhaps a proxy for prenatal environment, might be a correlate of subsequent breast cancer risk, but findings from epidemiological studies have been inconsistent.",False,BACKGROUND
1973,Women with a higher birth weight are more likely to develop breast cancer later in life.,"We re-analysed individual participant data from published and unpublished studies to obtain more precise estimates of the magnitude and shape of the birth size-breast cancer association.   
",False,BACKGROUND
1974,Women with a higher birth weight are more likely to develop breast cancer later in life.,"METHODS AND FINDINGS Studies were identified through computer-assisted and manual searches, and personal communication with investigators.",False,METHODS
1975,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Individual participant data from 32 studies, comprising 22,058 breast cancer cases, were obtained.",False,METHODS
1976,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Random effect models were used, if appropriate, to combine study-specific estimates of effect.",False,METHODS
1977,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Birth weight was positively associated with breast cancer risk in studies based on birth records (pooled relative risk [RR] per one standard deviation [SD] [= 0.5 kg] increment in birth weight: 1.06; 95% confidence interval [CI] 1.02-1.09) and parental recall when the participants were children (1.02; 95% CI 0.99-1.05), but not in those based on adult self-reports, or maternal recall during the woman's adulthood (0.98; 95% CI 0.95-1.01) (p for heterogeneity between data sources = 0.003).",True,RESULTS
1978,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Relative to women who weighed 3.000-3.499 kg, the risk was 0.96 (CI 0.80-1.16) in those who weighed < 2.500 kg, and 1.12 (95% CI 1.00-1.25) in those who weighed > or = 4.000 kg (p for linear trend = 0.001) in birth record data.",True,RESULTS
1979,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Birth length and head circumference from birth records were also positively associated with breast cancer risk (pooled RR per one SD increment: 1.06 [95% CI 1.03-1.10] and 1.09 [95% CI 1.03-1.15], respectively).",False,RESULTS
1980,Women with a higher birth weight are more likely to develop breast cancer later in life.,Simultaneous adjustment for these three birth size variables showed that length was the strongest independent predictor of risk.,False,RESULTS
1981,Women with a higher birth weight are more likely to develop breast cancer later in life.,The birth size effects did not appear to be confounded or mediated by established breast cancer risk factors and were not modified by age or menopausal status.,False,RESULTS
1982,Women with a higher birth weight are more likely to develop breast cancer later in life.,"The cumulative incidence of breast cancer per 100 women by age 80 y in the study populations was estimated to be 10.0, 10.0, 10.4, and 11.5 in those who were, respectively, in the bottom, second, third, and top fourths of the birth length distribution.   
",False,RESULTS
1983,Women with a higher birth weight are more likely to develop breast cancer later in life.,"CONCLUSIONS This pooled analysis of individual participant data is consistent with birth size, and in particular birth length, being an independent correlate of breast cancer risk in adulthood.",False,CONCLUSIONS
1984,Women with a higher birth weight are more likely to develop breast cancer later in life.,Breast cancer may originate in utero.,False,BACKGROUND
1985,Women with a higher birth weight are more likely to develop breast cancer later in life.,We reviewed the available evidence on the association between birthweight and the risk of breast cancer.,False,BACKGROUND
1986,Women with a higher birth weight are more likely to develop breast cancer later in life.,"To date, 26 research papers addressing this issue have been published.",False,RESULTS
1987,Women with a higher birth weight are more likely to develop breast cancer later in life.,"The majority of studies identified a positive link between birthweight and premenopausal, but not postmenopausal, breast cancer.",True,RESULTS
1988,Women with a higher birth weight are more likely to develop breast cancer later in life.,The relative risk estimate for breast cancer comparing women with high birthweight to women with low birthweight combining all studies including both pre- and postmenopausal breast cancer was 1.23 (95% confidence interval 1.13-1.34).,True,RESULTS
1989,Women with a higher birth weight are more likely to develop breast cancer later in life.,The mechanisms underlying this association likely include elevated levels of growth factors that may increase the number of susceptible stem cells in the mammary gland or initiate tumors through DNA mutations.,False,RESULTS
1990,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Loss of imprinting (LOI) of growth hormone genes relevant for intrauterine growth, such as insulin-like growth factor 2 (IGF2), leads to abnormally high levels of these hormones evidenced by high birthweight.",False,CONCLUSIONS
1991,Women with a higher birth weight are more likely to develop breast cancer later in life.,LOI of IGF2 has also been found in mammary tumor tissue.,False,CONCLUSIONS
1992,Women with a higher birth weight are more likely to develop breast cancer later in life.,The role of environmental factors that stimulate such epigenetic regulation of gene expression remains to be elucidated.,False,CONCLUSIONS
1993,Women with a higher birth weight are more likely to develop breast cancer later in life.,BACKGROUND Emerging evidence suggests an association between female prenatal experience and her subsequent risk of developing breast cancer.,False,OBJECTIVE
1994,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Potential underlying mechanisms include variation in amounts of maternal endogenous sex hormones and growth hormones, germ-cell mutations, formation of cancer stem-cells, and other genetic or epigenetic events.",False,OBJECTIVE
1995,Women with a higher birth weight are more likely to develop breast cancer later in life.,"We reviewed and summarised quantitatively the available data on intrauterine exposures and risk of breast cancer.   
",False,OBJECTIVE
1996,Women with a higher birth weight are more likely to develop breast cancer later in life.,METHODS We systematically searched for studies that assessed association between perinatal factors and risk of breast cancer.,False,METHODS
1997,Women with a higher birth weight are more likely to develop breast cancer later in life.,"We reviewed separately each of the perinatal factors, including birthweight, birth length, parental age at delivery, gestational age, intrauterine exposure to diethylstilbestrol, twin membership, maternal pre-eclampsia or eclampsia, and other factors.   
",False,METHODS
1998,Women with a higher birth weight are more likely to develop breast cancer later in life.,"FINDINGS We identified 57 studies published between Oct 1, 1980, and June 21, 2007.",False,RESULTS
1999,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Increased risk of breast cancer was noted with increased birthweight (relative risk [RR] 1.15 [95% CI 1.09-1.21]), birth length (1.28 [1.11-1.48]), higher maternal age (1.13 [1.02-1.25]), and paternal age (1.12 [1.05-1.19]).",True,RESULTS
2000,Women with a higher birth weight are more likely to develop breast cancer later in life.,Decreased risk of breast cancer was noted for maternal pre-eclampsia and eclampsia (0.48 [0.30-0.78]) and twin membership (0.93 [0.87-1.00]).,False,RESULTS
2001,Women with a higher birth weight are more likely to develop breast cancer later in life.,"No association was noted between risk of breast cancer and gestational age at birth (0.95 [0.71-1.26]) or maternal diethylstilbestrol treatment (1.40 [0.86-2.28]).   
",False,RESULTS
2002,Women with a higher birth weight are more likely to develop breast cancer later in life.,INTERPRETATION The intrauterine environment contributes to the predisposition of women to breast cancer in adulthood.,False,CONCLUSIONS
2003,Women with a higher birth weight are more likely to develop breast cancer later in life.,The in-utero mechanisms responsible for such predisposition need to be elucidated.,False,CONCLUSIONS
2004,Women with a higher birth weight are more likely to develop breast cancer later in life.,"INTRODUCTION Various perinatal factors, including birth weight, birth order, maternal age, gestational age, twin status, and parental smoking, have been postulated to affect breast cancer risk in daughters by altering the hormonal environment of the developing fetal mammary glands.",False,BACKGROUND
2005,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Despite ample biologic plausibility, epidemiologic studies to date have yielded conflicting results.",False,BACKGROUND
2006,Women with a higher birth weight are more likely to develop breast cancer later in life.,"We investigated the associations between perinatal factors and subsequent breast cancer risk through meta-analyses.   
",False,BACKGROUND
2007,Women with a higher birth weight are more likely to develop breast cancer later in life.,"METHODS We reviewed breast cancer studies published from January 1966 to February 2007 that included data on birth weight, birth order, maternal age, gestational age, twin status, and maternal or paternal smoking.",False,METHODS
2008,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Meta-analyses using random effect models were employed to summarize the results.   
",False,METHODS
2009,Women with a higher birth weight are more likely to develop breast cancer later in life.,"RESULTS We found that heavier birth weights were associated with increased breast cancer risk, with studies involving five categories of birth weight identifying odds ratios (ORs) of 1.24 (95% confidence interval [CI] 1.04 to 1.48) for 4,000 g or more and 1.15 (95% CI 1.04 to 1.26) for 3,500 g to 3,999 g, relative to a birth weight of 2,500 to 2,599 g. These studies provided no support for a J-shaped relationship of birthweight to risk.",True,RESULTS
2010,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Support for an association with birthweight was also derived from studies based on three birth weight categories (OR 1.15 [95% CI 1.01 to 1.31] for > or =4,000 g relative to <3,000 g) and two birth weight categories (OR 1.09 [95% CI 1.02 to 1.18] for > or =3,000 g relative to <3,000 g).",False,RESULTS
2011,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Women born to older mothers and twins were also at some increased risk, but the results were heterogeneous across studies and publication years.",False,RESULTS
2012,Women with a higher birth weight are more likely to develop breast cancer later in life.,"Birth order, prematurity, and maternal smoking were unrelated to breast cancer risk.   
",False,CONCLUSIONS
2013,Women with a higher birth weight are more likely to develop breast cancer later in life.,CONCLUSION Our findings provide some support for the hypothesis that in utero exposures reflective of higher endogenous hormone levels could affect risk for development of breast cancer in adulthood.,False,CONCLUSIONS
2014,aPKCz causes tumour enhancement by affecting glutamine metabolism.,Tumor cells have high-energetic and anabolic needs and are known to adapt their metabolism to be able to survive and keep proliferating under conditions of nutrient stress.,False,BACKGROUND
2015,aPKCz causes tumour enhancement by affecting glutamine metabolism.,We show that PKCζ deficiency promotes the plasticity necessary for cancer cells to reprogram their metabolism to utilize glutamine through the serine biosynthetic pathway in the absence of glucose.,False,BACKGROUND
2016,aPKCz causes tumour enhancement by affecting glutamine metabolism.,"PKCζ represses the expression of two key enzymes of the pathway, PHGDH and PSAT1, and phosphorylates PHGDH at key residues to inhibit its enzymatic activity.",False,BACKGROUND
2017,aPKCz causes tumour enhancement by affecting glutamine metabolism.,"Interestingly, the loss of PKCζ in mice results in enhanced intestinal tumorigenesis and increased levels of these two metabolic enzymes, whereas patients with low levels of PKCζ have a poor prognosis.",True,BACKGROUND
2018,aPKCz causes tumour enhancement by affecting glutamine metabolism.,"Furthermore, PKCζ and caspase-3 activities are correlated with PHGDH levels in human intestinal tumors.",False,BACKGROUND
2019,aPKCz causes tumour enhancement by affecting glutamine metabolism.,"Taken together, this demonstrates that PKCζ is a critical metabolic tumor suppressor in mouse and human cancer.",True,BACKGROUND
2020,cSMAC formation enhances weak ligand signalling.,T cell activation is predicated on the interaction between the T cell receptor and peptide-major histocompatibility (pMHC) ligands.,False,BACKGROUND
2021,cSMAC formation enhances weak ligand signalling.,The factors that determine the stimulatory potency of a pMHC molecule remain unclear.,False,BACKGROUND
2022,cSMAC formation enhances weak ligand signalling.,We describe results showing that a peptide exhibiting many hallmarks of a weak agonist stimulates T cells to proliferate more than the wild-type agonist ligand.,False,BACKGROUND
2023,cSMAC formation enhances weak ligand signalling.,An in silico approach suggested that the inability to form the central supramolecular activation cluster (cSMAC) could underlie the increased proliferation.,False,BACKGROUND
2024,cSMAC formation enhances weak ligand signalling.,This conclusion was supported by experiments that showed that enhancing cSMAC formation reduced stimulatory capacity of the weak peptide.,True,BACKGROUND
2025,cSMAC formation enhances weak ligand signalling.,Our studies highlight the fact that a complex interplay of factors determines the quality of a T cell antigen.,False,BACKGROUND
2026,mTORC2 regulates intracellular cysteine levels through xCT inhibition.,"Mutations in cancer reprogram amino acid metabolism to drive tumor growth, but the molecular mechanisms are not well understood.",False,BACKGROUND
2027,mTORC2 regulates intracellular cysteine levels through xCT inhibition.,"Using an unbiased proteomic screen, we identified mTORC2 as a critical regulator of amino acid metabolism in cancer via phosphorylation of the cystine-glutamate antiporter xCT.",False,BACKGROUND
2028,mTORC2 regulates intracellular cysteine levels through xCT inhibition.,"mTORC2 phosphorylates serine 26 at the cytosolic N terminus of xCT, inhibiting its activity.",True,BACKGROUND
2029,mTORC2 regulates intracellular cysteine levels through xCT inhibition.,"Genetic inhibition of mTORC2, or pharmacologic inhibition of the mammalian target of rapamycin (mTOR) kinase, promotes glutamate secretion, cystine uptake, and incorporation into glutathione, linking growth factor receptor signaling with amino acid uptake and utilization.",True,BACKGROUND
2030,mTORC2 regulates intracellular cysteine levels through xCT inhibition.,"These results identify an unanticipated mechanism regulating amino acid metabolism in cancer, enabling tumor cells to adapt to changing environmental conditions.",False,BACKGROUND
